<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="CD015477" article-type="systematic-review" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="iso-abbrev">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3102</journal-id><journal-id journal-id-type="pmc-domain">cochrev</journal-id><journal-id journal-id-type="publisher-id">14651858</journal-id><journal-title-group><journal-title>The Cochrane Database of Systematic Reviews</journal-title></journal-title-group><issn pub-type="epub">1469-493X</issn><issn-l>1361-6137</issn-l><publisher><publisher-name>John Wiley and Sons, Inc. and the Cochrane Library</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9726273</article-id><article-id pub-id-type="pmcid-ver">PMC9726273.1</article-id><article-id pub-id-type="pmcaid">9726273</article-id><article-id pub-id-type="pmcaiid">9726273</article-id><article-id pub-id-type="pmid">36473651</article-id><article-id pub-id-type="doi">10.1002/14651858.CD015477</article-id><article-id pub-id-type="publisher-id">CD015477</article-id><article-id pub-id-type="other">CD015477</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Medicine General &amp; Introductory Medical Sciences</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of COVID&#8208;19 vaccines</article-title></title-group><contrib-group><contrib id="d24e261" contrib-type="editor"><collab collab-type="editors">Cochrane Emergency and Critical Care Group</collab></contrib><contrib id="d24e271" contrib-type="author"><name name-style="western"><surname>Gra&#241;a</surname><given-names initials="C">Carolina</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e275" contrib-type="author"><name name-style="western"><surname>Ghosn</surname><given-names initials="L">Lina</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e279" contrib-type="author"><name name-style="western"><surname>Evrenoglou</surname><given-names initials="T">Theodoros</given-names></name><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e283" contrib-type="author"><name name-style="western"><surname>Jarde</surname><given-names initials="A">Alexander</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e287" contrib-type="author"><name name-style="western"><surname>Minozzi</surname><given-names initials="S">Silvia</given-names></name><xref ref-type="aff" rid="CD015477-aff-0003"/></contrib><contrib id="d24e291" contrib-type="author"><name name-style="western"><surname>Bergman</surname><given-names initials="H">Hanna</given-names></name><xref ref-type="aff" rid="CD015477-aff-0004"/></contrib><contrib id="d24e295" contrib-type="author"><name name-style="western"><surname>Buckley</surname><given-names initials="BS">Brian S</given-names></name><xref ref-type="aff" rid="CD015477-aff-0004"/></contrib><contrib id="d24e299" contrib-type="author"><name name-style="western"><surname>Probyn</surname><given-names initials="K">Katrin</given-names></name><xref ref-type="aff" rid="CD015477-aff-0004"/></contrib><contrib id="d24e303" contrib-type="author"><name name-style="western"><surname>Villanueva</surname><given-names initials="G">Gemma</given-names></name><xref ref-type="aff" rid="CD015477-aff-0004"/></contrib><contrib id="d24e308" contrib-type="author"><name name-style="western"><surname>Henschke</surname><given-names initials="N">Nicholas</given-names></name><xref ref-type="aff" rid="CD015477-aff-0004"/></contrib><contrib id="d24e312" contrib-type="author"><name name-style="western"><surname>Bonnet</surname><given-names initials="H">Hillary</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e316" contrib-type="author"><name name-style="western"><surname>Assi</surname><given-names initials="R">Rouba</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e320" contrib-type="author"><name name-style="western"><surname>Menon</surname><given-names initials="S">Sonia</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/></contrib><contrib id="d24e324" contrib-type="author"><name name-style="western"><surname>Marti</surname><given-names initials="M">Melanie</given-names></name><xref ref-type="aff" rid="CD015477-aff-0005"/></contrib><contrib id="d24e328" contrib-type="author"><name name-style="western"><surname>Devane</surname><given-names initials="D">Declan</given-names></name><xref ref-type="aff" rid="CD015477-aff-0006"/></contrib><contrib id="d24e332" contrib-type="author"><name name-style="western"><surname>Mallon</surname><given-names initials="P">Patrick</given-names></name><xref ref-type="aff" rid="CD015477-aff-0007"/></contrib><contrib id="d24e336" contrib-type="author"><name name-style="western"><surname>Lelievre</surname><given-names initials="JD">Jean-Daniel</given-names></name><xref ref-type="aff" rid="CD015477-aff-0008"/></contrib><contrib id="d24e340" contrib-type="author"><name name-style="western"><surname>Askie</surname><given-names initials="LM">Lisa M</given-names></name><xref ref-type="aff" rid="CD015477-aff-0009"/></contrib><contrib id="d24e344" contrib-type="author"><name name-style="western"><surname>Kredo</surname><given-names initials="T">Tamara</given-names></name><xref ref-type="aff" rid="CD015477-aff-0010"/></contrib><contrib id="d24e348" contrib-type="author"><name name-style="western"><surname>Ferrand</surname><given-names initials="G">Gabriel</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/></contrib><contrib id="d24e353" contrib-type="author"><name name-style="western"><surname>Davidson</surname><given-names initials="M">Mauricia</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e357" contrib-type="author"><name name-style="western"><surname>Riveros</surname><given-names initials="C">Carolina</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e361" contrib-type="author"><name name-style="western"><surname>Tovey</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/></contrib><contrib id="d24e365" contrib-type="author"><name name-style="western"><surname>Meerpohl</surname><given-names initials="JJ">Joerg J</given-names></name><xref ref-type="aff" rid="CD015477-aff-0011"/><xref ref-type="aff" rid="CD015477-aff-0012"/></contrib><contrib id="d24e369" contrib-type="author"><name name-style="western"><surname>Grasselli</surname><given-names initials="G">Giacomo</given-names></name><xref ref-type="aff" rid="CD015477-aff-0013"/></contrib><contrib id="d24e373" contrib-type="author"><name name-style="western"><surname>Rada</surname><given-names initials="G">Gabriel</given-names></name><xref ref-type="aff" rid="CD015477-aff-0014"/><xref ref-type="aff" rid="CD015477-aff-0015"/></contrib><contrib id="d24e377" contrib-type="author"><name name-style="western"><surname>Hr&#243;bjartsson</surname><given-names initials="A">Asbj&#248;rn</given-names></name><xref ref-type="aff" rid="CD015477-aff-0016"/><xref ref-type="aff" rid="CD015477-aff-0017"/></contrib><contrib id="d24e381" contrib-type="author"><name name-style="western"><surname>Ravaud</surname><given-names initials="P">Philippe</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e385" contrib-type="author"><name name-style="western"><surname>Chaimani</surname><given-names initials="A">Anna</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib><contrib id="d24e389" contrib-type="author" corresp="yes"><name name-style="western"><surname>Boutron</surname><given-names initials="I">Isabelle</given-names></name><xref ref-type="aff" rid="CD015477-aff-0001"/><xref ref-type="aff" rid="CD015477-aff-0002"/></contrib></contrib-group><aff id="CD015477-aff-0001"><institution>Cochrane France</institution><city>Paris</city><country>France</country></aff><aff id="CD015477-aff-0002"><institution content-type="dept">Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE</institution><institution>Universit&#233; de Paris</institution><city>Paris</city><country>France</country></aff><aff id="CD015477-aff-0003"><institution>Cochrane Review Group on Drugs and Alcohol</institution><city>Rome</city><country>Italy</country></aff><aff id="CD015477-aff-0004"><institution content-type="dept">Cochrane Response</institution><institution>Cochrane</institution><city>London</city><country>UK</country></aff><aff id="CD015477-aff-0005"><institution content-type="dept">Department of Immunization, Vaccines and Biologicals</institution><institution>World Health Organization</institution><city>Geneva</city><country>Switzerland</country></aff><aff id="CD015477-aff-0006"><institution content-type="dept">Evidence Synthesis Ireland, Cochrane Ireland and HRB-Trials Methodology Research Network</institution><institution>National University of Ireland</institution><city>Galway</city><country>Ireland</country></aff><aff id="CD015477-aff-0007"><institution content-type="dept">UCD Centre for Experimental Pathogen Host Research and UCD School of Medicine</institution><institution>University College Dublin</institution><city>Dublin</city><country>Ireland</country></aff><aff id="CD015477-aff-0008"><institution content-type="dept">Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital</institution><institution>Vaccine Research Institute, Universit&#233; Paris Est Cr&#233;teil</institution><city>Paris</city><country>France</country></aff><aff id="CD015477-aff-0009"><institution content-type="dept">Quality Assurance Norms and Standards Department</institution><institution>World Health Organization</institution><city>Geneva</city><country>Switzerland</country></aff><aff id="CD015477-aff-0010"><institution content-type="dept">Cochrane South Africa</institution><institution>South African Medical Research Council</institution><city>Cape Town</city><country>South Africa</country></aff><aff id="CD015477-aff-0011"><institution content-type="dept">Institute for Evidence in Medicine, Medical Center &amp; Faculty of Medicine</institution><institution>University of Freiburg</institution><city>Freiburg</city><country>Germany</country></aff><aff id="CD015477-aff-0012"><institution content-type="dept">Cochrane Germany</institution><institution>Cochrane Germany Foundation</institution><city>Freiburg</city><country>Germany</country></aff><aff id="CD015477-aff-0013"><institution content-type="dept">Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation</institution><institution>University of Milan</institution><city>Milan</city><country>Italy</country></aff><aff id="CD015477-aff-0014"><institution>Epistemonikos Foundation</institution><city>Santiago</city><country>Chile</country></aff><aff id="CD015477-aff-0015"><institution content-type="dept">UC Evidence Center, Cochrane Chile Associated Center</institution><institution>Pontificia Universidad Cat&#243;lica de Chile</institution><city>Santiago</city><country>Chile</country></aff><aff id="CD015477-aff-0016"><institution content-type="dept">Centre for Evidence Based Medicine Odense (CEBMO) and Cochrane Denmark</institution><institution>University of Southern Denmark</institution><city>Odense</city><country>Denmark</country></aff><aff id="CD015477-aff-0017"><institution content-type="dept">Open Patient data Explorative Network (OPEN)</institution><institution>Odense University Hospital</institution><city>Odense</city><country>Denmark</country></aff><pub-date pub-type="epub"><day>7</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>2022</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">422713</issue-id><elocation-id>CD015477</elocation-id><pub-history><event event-type="pmc-release"><date><day>07</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>07</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-04 18:25:14.197"><day>04</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non-Commercial-No-Derivatives Licence</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CD015477.pdf"/><abstract><title>Abstract</title><sec id="CD015477-sec-0001"><title>Background</title><p>Different forms of vaccines have been developed to prevent the SARS&#8208;CoV&#8208;2 virus and subsequent COVID&#8208;19 disease. Several are in widespread use globally.&#160;</p></sec><sec id="CD015477-sec-0002"><title>Objectives</title><p>To assess the efficacy and safety of COVID&#8208;19 vaccines (as a full primary vaccination series or a booster dose) against SARS&#8208;CoV&#8208;2.</p></sec><sec id="CD015477-sec-0003"><title>Search methods</title><p>We searched the Cochrane COVID&#8208;19 Study Register and the COVID&#8208;19 L&#183;OVE platform (last search date 5 November 2021). We also searched the WHO International Clinical Trials Registry Platform, regulatory agency websites, and Retraction Watch.</p></sec><sec id="CD015477-sec-0004"><title>Selection criteria</title><p>We included randomized controlled trials (RCTs) comparing COVID&#8208;19 vaccines to placebo, no vaccine, other active vaccines, or other vaccine schedules.</p></sec><sec id="CD015477-sec-0005"><title>Data collection and analysis</title><p>We used standard Cochrane methods. We used GRADE to assess the certainty of evidence for all except immunogenicity outcomes.&#160;</p><p>We synthesized data for each vaccine separately and presented summary effect estimates with 95% confidence intervals (CIs).&#160;</p></sec><sec id="CD015477-sec-0006"><title>Main results</title><p>We included and analyzed 41 RCTs assessing 12 different vaccines, including homologous and heterologous vaccine schedules and the effect of booster doses. Thirty&#8208;two RCTs were multicentre and five were multinational. The sample sizes of RCTs were 60 to 44,325 participants. Participants were aged: 18 years or older in 36 RCTs; 12 years or older in one RCT; 12 to 17 years in two RCTs; and three to 17 years in two RCTs. Twenty&#8208;nine RCTs provided results for individuals aged over 60 years, and three RCTs included immunocompromized patients. No trials included pregnant women. Sixteen RCTs had two&#8208;month follow&#8208;up or less, 20 RCTs had two to six months, and five RCTs had greater than six to 12 months or less. Eighteen reports were based on preplanned interim analyses.</p><p>Overall risk of bias was low for all outcomes in eight RCTs, while 33 had concerns for at least one outcome.</p><p>We identified 343 registered RCTs with results not yet available.&#160;</p><p>This abstract reports results for the <italic toggle="yes">critical outcomes</italic> of confirmed symptomatic COVID&#8208;19, severe and critical COVID&#8208;19, and serious adverse events only for the 10 WHO&#8208;approved vaccines. For remaining outcomes and vaccines, see main text. The evidence for mortality was generally sparse and of low or very low certainty for all WHO&#8208;approved vaccines, except AD26.COV2.S (Janssen), which probably reduces the risk of all&#8208;cause mortality (risk ratio (RR) 0.25, 95% CI 0.09 to 0.67; 1 RCT, 43,783 participants; high&#8208;certainty evidence).</p><p><bold>Confirmed symptomatic COVID&#8208;19</bold></p><p>High&#8208;certainty evidence found that BNT162b2 (BioNtech/Fosun Pharma/Pfizer), mRNA&#8208;1273 (ModernaTx), ChAdOx1 (Oxford/AstraZeneca), Ad26.COV2.S, BBIBP&#8208;CorV (Sinopharm&#8208;Beijing), and BBV152 (Bharat Biotect) reduce the incidence of symptomatic COVID&#8208;19 compared to placebo (vaccine efficacy (VE): BNT162b2: 97.84%, 95% CI 44.25% to 99.92%; 2 RCTs, 44,077 participants; mRNA&#8208;1273: 93.20%, 95% CI 91.06% to 94.83%; 2 RCTs, 31,632 participants; ChAdOx1: 70.23%, 95% CI 62.10% to 76.62%; 2 RCTs, 43,390 participants; Ad26.COV2.S: 66.90%, 95% CI 59.10% to 73.40%; 1 RCT, 39,058 participants; BBIBP&#8208;CorV: 78.10%, 95% CI 64.80% to 86.30%; 1 RCT, 25,463 participants; BBV152: 77.80%, 95% CI 65.20% to 86.40%; 1 RCT, 16,973 participants).</p><p>Moderate&#8208;certainty evidence found that NVX&#8208;CoV2373 (Novavax) probably reduces the incidence of symptomatic COVID&#8208;19 compared to placebo (VE 82.91%, 95% CI 50.49% to 94.10%; 3 RCTs, 42,175 participants).</p><p>There is low&#8208;certainty evidence for CoronaVac (Sinovac) for this outcome (VE 69.81%, 95% CI 12.27% to 89.61%; 2 RCTs, 19,852 participants).</p><p><bold>Severe or critical COVID&#8208;19</bold></p><p>High&#8208;certainty evidence found that BNT162b2, mRNA&#8208;1273, Ad26.COV2.S, and BBV152 result in a large reduction in incidence of severe or critical disease due to COVID&#8208;19 compared to placebo (VE: BNT162b2: 95.70%, 95% CI 73.90% to 99.90%; 1 RCT, 46,077 participants; mRNA&#8208;1273: 98.20%, 95% CI 92.80% to 99.60%; 1 RCT, 28,451 participants; AD26.COV2.S: 76.30%, 95% CI 57.90% to 87.50%; 1 RCT, 39,058 participants; BBV152: 93.40%, 95% CI 57.10% to 99.80%; 1 RCT, 16,976 participants).</p><p>Moderate&#8208;certainty evidence found that NVX&#8208;CoV2373 probably reduces the incidence of severe or critical COVID&#8208;19 (VE 100.00%, 95% CI 86.99% to 100.00%; 1 RCT, 25,452 participants).</p><p>Two trials reported high efficacy of CoronaVac for severe or critical disease with wide CIs, but these results could not be pooled.</p><p><bold>Serious adverse events (SAEs)</bold></p><p>mRNA&#8208;1273, ChAdOx1 (Oxford&#8208;AstraZeneca)/SII&#8208;ChAdOx1 (Serum Institute of India), Ad26.COV2.S, and BBV152 probably result in little or no difference in SAEs compared to placebo (RR: mRNA&#8208;1273: 0.92, 95% CI 0.78 to 1.08; 2 RCTs, 34,072 participants; ChAdOx1/SII&#8208;ChAdOx1: 0.88, 95% CI 0.72 to 1.07; 7 RCTs, 58,182 participants; Ad26.COV2.S: 0.92, 95% CI 0.69 to 1.22; 1 RCT, 43,783 participants); BBV152: 0.65, 95% CI 0.43 to 0.97; 1 RCT, 25,928 participants). In each of these, the likely absolute difference in effects was fewer than 5/1000 participants.</p><p>Evidence for SAEs is uncertain for BNT162b2, CoronaVac, BBIBP&#8208;CorV, and NVX&#8208;CoV2373 compared to placebo (RR: BNT162b2: 1.30, 95% CI 0.55 to 3.07; 2 RCTs, 46,107 participants; CoronaVac: 0.97, 95% CI 0.62 to 1.51; 4 RCTs, 23,139 participants; BBIBP&#8208;CorV: 0.76, 95% CI 0.54 to 1.06; 1 RCT, 26,924 participants; NVX&#8208;CoV2373: 0.92, 95% CI 0.74 to 1.14; 4 RCTs, 38,802 participants).</p><p>For the evaluation of heterologous schedules, booster doses, and efficacy against variants of concern, see main text of review.</p></sec><sec id="CD015477-sec-0007"><title>Authors' conclusions</title><p>Compared to placebo, most vaccines reduce, or likely reduce, the proportion of participants with confirmed symptomatic COVID&#8208;19, and for some, there is high&#8208;certainty evidence that they reduce severe or critical disease. There is probably little or no difference between most vaccines and placebo for serious adverse events. Over 300 registered RCTs are evaluating the efficacy of COVID&#8208;19 vaccines, and this review is updated regularly on the COVID&#8208;NMA platform (<uri>covid-nma.com</uri>).</p><p><bold>Implications for practice</bold></p><p>Due to the trial exclusions, these results cannot be generalized to pregnant women, individuals with a history of SARS&#8208;CoV&#8208;2 infection, or immunocompromized people. Most trials had a short follow&#8208;up and were conducted before the emergence of variants of concern.</p><p><bold>Implications for research</bold></p><p>Future research should evaluate the long&#8208;term effect of vaccines, compare different vaccines and vaccine schedules, assess vaccine efficacy and safety in specific populations, and include outcomes such as preventing long COVID&#8208;19. Ongoing evaluation of vaccine efficacy and effectiveness against emerging variants of concern is also vital.&#160;</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain language summary</title><p><bold>What are the benefits and risks of vaccines for preventing COVID&#8208;19?</bold></p><p><bold>Key messages</bold></p><p>&#8211; Most vaccines reduce, or probably reduce, the number of people who get COVID&#8208;19 disease and severe COVID&#8208;19 disease.</p><p>&#8211; Many vaccines likely increase number of people experiencing events such as fever or headache compared to placebo (sham vaccine that contains no medicine but looks identical to the vaccine being tested). This is expected because these events are mainly due to the body's response to the vaccine; they are usually mild and short&#8208;term.</p><p>&#8211; Many vaccines have little or no difference in the incidence of serious adverse events compared to placebo.&#160;</p><p>&#8211; There is insufficient evidence to determine whether there was a difference between the vaccine and placebo in terms of death because the numbers of deaths were low in the trials.</p><p>&#8211; Most trials assessed vaccine efficacy over a short time, and did not evaluate efficacy to the COVID variants of concern.&#160;</p><p><bold>What is SARS&#8208;CoV&#8208;2 and COVID&#8208;19?</bold></p><p>SARS&#8208;CoV&#8208;2 (severe acute respiratory syndrome coronavirus 2) is the virus that causes COVID&#8208;19 disease. Not everyone infected with SARS&#8208;CoV&#8208;2 will develop symptoms of COVID&#8208;19. Symptoms can be mild (e.g. fever and headaches) to life&#8208;threatening (e.g. difficulty breathing), or death.</p><p><bold>How do vaccines prevent COVID&#8208;19?</bold></p><p>While vaccines work slightly differently, they all prepare the body's immune system to prevent people from getting infected with SARS&#8208;CoV&#8208;2 or, if they do get infected, to prevent severe disease.</p><p><bold>What did we want to find out?</bold></p><p>We wanted to find out how well each vaccine works in reducing SARS&#8208;CoV&#8208;2 infection, COVID&#8208;19 disease with symptoms, severe COVID&#8208;19 disease, and total number of deaths (including any death, not only those related to COVID&#8208;19).</p><p>We wanted to find out about serious adverse events that might require hospitalization, be life&#8208;threatening, or both; systemic reactogenicity events (immediate short&#8208;term reactions to vaccines mainly due to immunological responses; e.g. fever, headache, body aches, fatigue); and any adverse events (which include non&#8208;serious adverse events).</p><p><bold>What did we do?&#160;</bold></p><p>We searched for studies that examined any COVID&#8208;19 vaccine compared to placebo, no vaccine, or another COVID&#8208;19 vaccine.</p><p>We selected only randomized trials (a study design that provides the most robust evidence because they evaluate interventions under ideal conditions among participants assigned by chance to one of two or more groups). We compared and summarized the results of the studies, and rated our confidence in the evidence based on factors such as how the study was conducted.</p><p><bold>What did we find?&#160;</bold></p><p>We found 41 worldwide studies involving 433,838 people assessing 12 different vaccines. Thirty&#8208;five studies included only healthy people who had never had COVID&#8208;19. Thirty&#8208;six studies included only adults, two only adolescents, two children and adolescents, and one included adolescents and adults. Three studied people with weakened immune systems, and none studied pregnant women.</p><p>Most cases assessed results less than six months after the primary vaccination. Most received co&#8208;funding from academic institutions and pharmaceutical companies. Most studies compared a COVID&#8208;19 vaccine with placebo. Five evaluated the addition of a 'mix and match' booster dose.</p><p><bold>Main results&#160;</bold></p><p>We report below results for three main outcomes and for 10 World Health Organization (WHO)&#8208;approved vaccines (for the remaining outcomes and vaccines, see main text). There is insufficient evidence regarding deaths between vaccines and placebo (mainly because the number of deaths was low), except for the Janssen vaccine, which probably reduces the risk of all&#8208;cause deaths.&#160;</p><p><italic toggle="yes">People with symptoms</italic></p><p>The Pfizer, Moderna, AstraZeneca, Sinopharm&#8208;Beijing, and Bharat vaccines produce a large reduction in the number of people with symptomatic COVID&#8208;19.</p><p>The Janssen vaccine reduces the number of people with symptomatic COVID&#8208;19.</p><p>The Novavax vaccine probably has a large reduction in the number of people with symptomatic COVID&#8208;19.</p><p>There is insufficient evidence to determine whether CoronaVac vaccine affects the number of people with symptomatic COVID&#8208;19 because results differed between the two studies (one involved only healthcare workers with a higher risk of exposure).</p><p><italic toggle="yes">Severe disease</italic></p><p>The Pfizer, Moderna, Janssen, and Bharat vaccines produce a large reduction in the number of people with severe disease.</p><p>There is insufficient evidence about CoronaVac vaccine on severe disease because results differed between the two studies (one involved only healthcare workers with a higher risk of exposure).</p><p><italic toggle="yes">Serious adverse events</italic></p><p>For the Pfizer, CoronaVac, Sinopharm&#8208;Beijing, and Novavax vaccines, there is insufficient evidence to determine whether there was a difference between the vaccine and placebo mainly because the number of serious adverse events was low.</p><p>Moderna, AstraZeneca, Janssen, and Bharat vaccines probably result in no or little difference in the number of serious adverse events.&#160;</p><p><bold>What are the limitations of the evidence?</bold></p><p>Most studies assessed the vaccine for a short time after injection, and it is unclear if and how vaccine protection wanes over time. Due to the exclusion criteria of COVID&#8208;19 vaccine trials, results cannot be generalized to pregnant women, people with a history of SARS&#8208;CoV&#8208;2 infection, or people with weakened immune systems. More research is needed comparing vaccines and vaccine schedules, and effectiveness and safety in specific populations and outcomes (e.g. preventing long COVID&#8208;19). Further, most studies were conducted before the emergence of variants of concerns.</p><p><bold>How up to date is this evidence?</bold></p><p>The evidence is up to date to November 2021. This is a living systematic review. Our results are available and updated bi&#8208;weekly on the COVID&#8208;NMA platform at covid&#8208;nma.com.</p></abstract><kwd-group kwd-group-type="mesh"><kwd>Adolescent</kwd><kwd>Aged</kwd><kwd>Humans</kwd><kwd>Middle Aged</kwd><kwd>2019-nCoV Vaccine mRNA-1273</kwd><kwd>COVID-19</kwd><kwd>COVID-19/prevention &amp; control</kwd><kwd>SARS-CoV-2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="status-note"><p>Edited (no change to conclusions)</p></notes></front><body id="CD015477-body"><sec id="CD015477-sec-0008"><title>Summary of findings</title><table-wrap id="CD015477-tbl-0001" position="anchor" orientation="portrait"><label>Summary of findings 1</label><caption><title>BNT162b2 &#8211; Pfizer/BioNTech + Fosun Pharma compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="top" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="top" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with BNT162b2&#160;</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection&#160;</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">3923 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>85 per 100,000</bold>&#8232;(3 to 2187)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 97.84</bold><break/>(44.25 to 99.92)</td><td valign="bottom" colspan="1" rowspan="1">44,077&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">100 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>4 per 100,000</bold>&#8232;(0 to 26)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 95.70</bold>&#8232;(73.90 to 99.90)</td><td valign="bottom" colspan="1" rowspan="1">46,077&#8232;(1 RCT)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">64 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>68 per 100,000</bold>&#8232;(33 to 142)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.07</bold>&#8232;(0.52 to 2.22)</td><td valign="bottom" colspan="1" rowspan="1">43,847&#8232;(1 RCT)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">2 additional studies (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;(adolescents aged 12&#8211;15 years);&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>&#160;(adults aged 18&#8211;85 years)) reported this outcome in 2302 participants (1131 versus 1129 participants and 24 versus 18 participants in the BNT162b2 versus placebo groups, respectively). There were no events in either group and the trials did not contribute to the effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>i</sup></td><td colspan="2" valign="bottom" rowspan="1">Outcome not pooled due to considerable heterogeneity (I&#178; = 90%) between included studies:&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;(&#8805; 16 years): RR 2.17, 95% CI 2.09 to 2.26; n = 43,847;&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;(12&#8211;15 years): RR 1.01, 95% CI 0.73 to 1.41; n = 2260;&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>&#160;(&#8805; 18 years): RR 1.50, 95% CI 0.53 to 4.21; n = 42</td><td valign="bottom" colspan="1" rowspan="1">&#160;</td><td valign="bottom" colspan="1" rowspan="1">46,149&#8232;(3 RCTs)<sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">508 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>660 per 100,000</bold>&#8232;(279 to 1558)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.30</bold>&#8232;(0.55 to 3.07)</td><td valign="bottom" colspan="1" rowspan="1">46,107&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>l,m</sup></td><td valign="bottom" colspan="1" rowspan="1">1 additional trial (<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>&#160;(adults aged 18&#8211;85 years)) reported this outcome in 42 participants (24 BNT162b2 versus 18 placebo). There were no events in either group and the trial did not contribute to the effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% CI) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019; <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0001" fn-type="fn"><p><sup>a</sup>Last updated: 3 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from 7 days following the second dose to 1.81 months and six months.&#8232;<sup>c</sup>BioNTech/Fosun Pharma/Pfizer:&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;(adolescents and adults aged from 16 years);&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;(adolescents aged 12&#8211;15 years)&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Follow&#8208;up: from seven days following the second dose to six months.&#8232;<sup>f</sup>BioNTech/Fosun Pharma/Pfizer:&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;(adolescents and adults aged from 16 years)&#8232;<sup>g</sup>Follow&#8208;up: six months&#8232;<sup>h</sup>Imprecision: downgraded two levels due to small number of events observed and a wide CIs that encompasses a potential benefit and a potential harm with the intervention.&#8232;<sup>i</sup>Follow&#8208;up: 1.7 months&#8232;<sup>j</sup>BioNTech/Fosun Pharma/Pfizer:&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;(adolescents and adults aged from 16 years);&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;(adolescents aged 12&#8211;15 years);&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>&#160;(adults aged 18&#8211;85 years)&#8232;<sup>k</sup>Inconsistency: downgraded two levels (I&#178; = 90%)&#8232;<sup>l</sup>Inconsistency: downgraded one level (I&#178; = 76%)&#8232;<sup>m</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm. This outcome was not downgraded an additional level for imprecision because it was downgraded one level for inconsistency, which is related to and would have contributed to the severity of the imprecision.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0002" position="anchor" orientation="portrait"><label>Summary of findings 2</label><caption><title>mRNA&#8208;1273 &#8211; ModernaTX compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Anticipated absolute effects<sup>*</sup></bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with mRNA&#8208;1273&#160;</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection<sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">8957 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>2394 per 100,000</bold>&#8232;(997 to 5749)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 73.27</bold>&#8232;(35.82 to 88.87)</td><td valign="bottom" colspan="1" rowspan="1">31,632&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#10753;&#9711;&#8232;Moderate<sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">Substantial heterogeneity (I&#178; = 66%) between included studies:&#160;<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;(adolescents aged 12&#8211;17 years, median 2.3 months' follow&#8208;up): VE 55.7% (95% CI 16.8 to 76.4), n = 3181;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>&#160;(adults aged 18&#8211;95 years, 5.3 months' follow&#8208;up): VE 82% (95% CI 79.5 to 84.2), n = 28,451</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 <sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">4939 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>336 per 100,000</bold>&#8232;(255 to 442)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 93.20</bold><break/>(91.06 to 94.83)</td><td valign="bottom" colspan="1" rowspan="1">31,632&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#10753;&#10753;&#8232;High<sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Severe or critical COVID&#8208;19<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">748 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>13 per 100,000</bold>&#8232;(3 to 54)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 98.20</bold><break/>(92.80 to 99.60)</td><td valign="bottom" colspan="1" rowspan="1">28,451&#8232;(1 RCT)<sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#10753;&#10753;&#8232;High<sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">All&#8208;cause mortality<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">106 per 100,000</td><td valign="bottom" colspan="1" rowspan="1">&#160;<break/><bold>112 per 100,000</bold>&#8232;(57 to 222)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.06</bold>&#8232;(0.54 to 2.10)</td><td valign="bottom" colspan="1" rowspan="1">30,346&#8232;(1 RCT)<sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#9711;&#9711;&#8232;Low<sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">1 additional trial: (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;(adolescents aged 12&#8211;17 years)) reported on this outcome in 3726 participants (2486 mRNA&#8208;1273 and 1240 placebo). There were no events in either group and the trial did not contribute to the pooled effect estimate</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Systemic reactogenicity events<sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">432 per 1000</td><td valign="top" colspan="1" rowspan="1"><bold>553 per 1000</bold>&#8232;(527 to 579)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.28</bold>&#8232;(1.22 to 1.34)</td><td valign="bottom" colspan="1" rowspan="1">34,037&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#10753;&#10753;&#8232;High<sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Any adverse event<sup>k</sup></td><td colspan="2" valign="top" rowspan="1">Outcome not pooled due to considerable heterogeneity (I&#178; = 100%) between included studies:&#160;<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;(all solicited adverse events, adolescents aged 12&#8211;17 years, median 2.8 months' follow&#8208;up): RR 1.47 (95% CI 1.41 to 1.54), n = 3726;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>&#160;(all solicited adverse events, adults aged 18&#8211;95 years, 5.3 months' follow&#8208;up): RR 2.15 (95% CI 2.11 to 2.19), n = 29,269</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">32,995&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#9711;&#9711;&#8232;Low<sup>l</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Serious adverse events<sup>l</sup></td><td valign="bottom" colspan="1" rowspan="1">1792 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>1649 per 100,000</bold>&#8232;(1398 to 1936)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.92</bold>&#8232;(0.78 to 1.08)</td><td valign="bottom" colspan="1" rowspan="1">34,072&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#10753;&#9711;&#8232;Moderate<sup>m</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Local reactogenicity events<sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">211 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>697 per 1000</bold>&#8232;(427 to 1000)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 3.30</bold>&#8232;(2.02 to 5.40)</td><td valign="bottom" colspan="1" rowspan="1">34,037&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#10753;&#10753;&#10753;&#10753;&#8232;High<sup>n</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).&#8232;&#8232;<bold>COVID&#8208;19:</bold> coronavirus disease 2019; <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0002" fn-type="fn"><p>a. Last updated: 01 March 2023</p><p>b. Follow&#8208;up: from 14 days after dose 2 to 2.3 months (median) and 5.3 months&#160;</p><p>c. Moderna TX:&#160;<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;(adolescents aged 12&#8211;17 years);&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>&#160;(adults aged 18&#8211;95 years)</p><p>d. Despite some concerns with deviations from intervention, not downgraded for risk of bias</p><p>e. Inconsistency: downgraded one level: I&#178; = 66.37%&#160;</p><p>f. Follow&#8208;up: 5.3 months</p><p>g. Moderna TX:&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>&#160;(adults aged 18&#8211;95 years)</p><p>h. Imprecision downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention</p><p>i. Follow&#8208;up: seven days</p><p>j. Despite inconsistency (I&#178; = 61%) not downgraded for inconsistency, as the same direction of effect in both effect estimates&#160;</p><p>k. Follow&#8208;up: 2.8 months (median) and 5.3 months</p><p>l. Inconsistency: downgraded two levels (I&#178; = 100%)&#160;</p><p>m. Imprecision: downgraded one level due to wide CIs that encompass a potential benefit and a potential harm with the intervention.</p><p>n. Despite inconsistency (I&#178; = 99%), not downgraded for inconsistency, as the same direction of effect in both effect estimates&#160;</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0003" position="anchor" orientation="portrait"><label>Summary of findings 3</label><caption><title>CVnCoV &#8211; CureVac AG compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence (GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Risk with CVnCOV</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">1187 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>615 per 100,000</bold>&#8232;(464 to 811)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 48.20</bold><break/>(31.70 to 60.90)</td><td valign="bottom" colspan="1" rowspan="1">25,062&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">82 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>30 per 100,000</bold>&#8232;(7 to 82)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 63.80</bold><break/>(0.00 to 91.70)</td><td valign="bottom" colspan="1" rowspan="1">25,062&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8854;&#8854;&#8854;&#8232;<bold>Very low</bold><sup>d,e,g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">30 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>40 per 100,000</bold>&#8232;(14 to 116)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.33</bold>&#8232;(0.46 to 3.83)</td><td valign="bottom" colspan="1" rowspan="1">39,529&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8854;&#8854;&#8854;&#8232;<bold>Very low</bold><sup>e,g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">635 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>940 per 1000</bold>&#8232;(908 to 971)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.48</bold>&#8232;(1.43 to 1.53)</td><td valign="bottom" colspan="1" rowspan="1">3982&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">679 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>965 per 1000</bold>&#8232;(937 to 999)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.42</bold>&#8232;(1.38 to 1.47)</td><td valign="bottom" colspan="1" rowspan="1">3982&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">334 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>414 per 100,000</bold>&#8232;(301 to 572)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.24</bold>&#8232;(0.90 to 1.71)</td><td valign="bottom" colspan="1" rowspan="1">39,529&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>e,l</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">241 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>847 per 1000</bold>&#8232;(782 to 920)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 3.51</bold>&#8232;(3.24 to 3.81)</td><td valign="bottom" colspan="1" rowspan="1">3982&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0003" fn-type="fn"><p><sup>a</sup>Last updated: 10 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from 14 days following the second dose to 6.23 months&#8232;<sup>c</sup>CureVac AG:&#160;<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>&#160;(adults aged 18&#8211;98 years)&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Indirectness: downgraded one level as data are from interim analyses of the trial and from the available information it is unclear whether these were preplanned.&#8232;<sup>f</sup>Follow&#8208;up: from seven days following the second dose to six months&#8232;<sup>g</sup>Imprecision: downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention.&#8232;<sup>h</sup>Follow&#8208;up: 6.23 months&#8232;<sup>i</sup>Follow&#8208;up: seven days&#8232;<sup>j</sup>Follow&#8208;up: one month&#8232;<sup>k</sup>Follow&#8208;up: 1.7 months&#8232;<sup>l</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0004" position="anchor" orientation="portrait"><label>Summary of findings 4</label><caption><title>ChAdOx1 &#8211; AstraZeneca + University of Oxford &#160;compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with ChAdOx1</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">3199 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>1300 per 100,000</bold>&#8232;(1017 to 1663)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 59.35</bold><break/>(48.00 to 68.22)</td><td valign="bottom" colspan="1" rowspan="1">43,390&#8232;(5 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">Substantial heterogeneity (I&#178; = 68%) between included studies:&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;(VE 64.35%, 95% CI 56.10% to 71.00%; n = 26,212);&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(VE 54.10%, 95% CI 44.70% to 61.90%; n = 17,178)</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">2207 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>657 per 100,000</bold>&#8232;(516 to 836)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 70.23</bold><break/>(62.10 to 76.62)</td><td valign="bottom" colspan="1" rowspan="1">43,390&#8232;(5 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">52 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>25 per 100,000</bold>&#8232;(10 to 59)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.48</bold>&#8232;(0.20 to 1.14)</td><td valign="bottom" colspan="1" rowspan="1">56,727&#8232;(5 RCTs)<sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">2 additional trials (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>) reported this outcome in 1392 participants (192 ChAdOx1 versus 64 placebo and 900 SII&#8208;ChAdOx1 versus 300 placebo, respectively). There were no events in either group in either trial and they did not contribute to the pooled effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">141 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>553 per 1000</bold>&#8232;(297 to 1000)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 3.93</bold>&#8232;(2.11 to 7.29)</td><td valign="bottom" colspan="1" rowspan="1">256&#8232;(1 RCT)<sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>l</sup></td><td colspan="2" valign="bottom" rowspan="1">Outcome not pooled due to considerable heterogeneity (I&#178; = 90%) between included studies:&#160;<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>&#160;(RR 2.54, 95% CI 1.73 to 3.74; n = 256);&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;(RR 1.37, 95% CI 1.33 to 1.42; n = 32,379);&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;(RR 1.39, 95% CI 1.12 to 1.74; n = 1200);&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(RR 0.74, 95% CI 0.56 to 0.96; n = 23,745)</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">57,580&#8232;(7 RCTs)<sup>m</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>n</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>o</sup></td><td valign="bottom" colspan="1" rowspan="1">794 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>699 per 100,000</bold>&#8232;(572 to 850)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.88</bold>&#8232;(0.72 to 1.07)</td><td valign="bottom" colspan="1" rowspan="1">58,182&#8232;(7 RCTs)<sup>p</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>q</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">94 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>604 per 1000</bold>&#8232;(279 to 1000)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 6.44</bold>&#8232;(2.98 to 13.92)</td><td valign="bottom" colspan="1" rowspan="1">256&#8232;(1 RCT)<sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>k,r</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0004" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from 14 days after second dose up to 1.34 months (median) and 2 months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(data from four pooled RCTs)&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Inconsistency: downgraded one level (I&#178; = 68%).&#8232;<sup>f</sup>Follow&#8208;up: 2 months, 4.2 months and 2 months (median)&#8232;<sup>g</sup><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(data from four pooled RCTs);&#160;<xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;(participants with HIV, trial already counted in&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>)&#8232;<sup>h</sup>Imprecision: downgraded two levels due to small number of events observed and wide CIs that encompass a potential benefit and a potential harm with the intervention.&#8232;<sup>i</sup>Follow&#8208;up: seven days&#8232;<sup>j</sup><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>&#8232;<sup>k</sup>Imprecision: downgraded one level due to low number of participants/few events observed.&#8232;<sup>l</sup>Follow&#8208;up: 1 month, 1.16 months, 1.9 months, and 3.4 months&#8232;<sup>m</sup><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(data from four pooled RCTs)&#8232;<sup>n</sup>Inconsistency: downgraded two levels (I&#178; = 90%).&#8232;<sup>o</sup>Follow&#8208;up: 1 month, 1.9 months, 6 months, and 3.64 months (median)&#8232;<sup>p</sup><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(data from four pooled RCTs).&#160;<xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;(participants with HIV, trial already counted in&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>)&#8232;<sup>q</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of no effect.&#8232;<sup>r</sup>Despite some concerns with selection of reported results, not downgraded for risk of bias.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0005" position="anchor" orientation="portrait"><label>Summary of findings 5</label><caption><title>SII&#8208;ChAdOx1 &#8211; Serum Institute of India/AstraZeneca + University of Oxford compared to ChAdOx1 &#8211; University of Oxford for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with ChAdOx1</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with SII&#8208;ChAdOx1</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection&#160;</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">1 study reported this outcome in 400 participants (<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>). There were no events in either group and no effect estimate could be calculated.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">390 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>285 per 1000</bold>&#8232;(211 to 382)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.73</bold>&#8232;(0.54 to 0.98)</td><td valign="bottom" colspan="1" rowspan="1">400&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">200 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>166 per 1000</bold>&#8232;(104 to 266)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.83</bold>&#8232;(0.52 to 1.33)</td><td valign="bottom" colspan="1" rowspan="1">400&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">2000 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>1000 per 100,000</bold>&#8232;(160 to 5900)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.50</bold>&#8232;(0.08 to 2.95)</td><td valign="bottom" colspan="1" rowspan="1">400&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">360 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>274 per 1000</bold>&#8232;(198 to 378)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.76</bold>&#8232;(0.55 to 1.05)</td><td valign="bottom" colspan="1" rowspan="1">400&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="top" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2.</td></tr><tr><td colspan="7" valign="top" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0005" fn-type="fn"><p><sup>a</sup>Last updated: 10 May 2022&#8232;<sup>b</sup>Follow&#8208;up: seven days&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#8232;<sup>d</sup>Imprecision: downgraded one level due to low number of events/participants.&#8232;<sup>e</sup>Follow&#8208;up: 1.9 months&#8232;<sup>f</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and low number of events/participants.&#8232;<sup>g</sup>Follow&#8208;up: six months&#8232;<sup>h</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and low number of events/participants.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0006" position="anchor" orientation="portrait"><label>Summary of findings 6</label><caption><title>AD26.COV2.S &#8211; Janssen Pharmaceutical Companies compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with AD26.COV2.S</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">1796 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>594 per 100,000</bold>&#8232;(478 to 735)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 66.90</bold><break/>(59.10 to 73.40)</td><td valign="bottom" colspan="1" rowspan="1">39,058&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">409 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>97 per 100,000</bold>&#8232;(51 to 172)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 76.30</bold><break/>(57.90 to 87.50)</td><td valign="bottom" colspan="1" rowspan="1">39,058&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">91 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>23 per 100,000</bold>&#8232;(8 to 61)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.25</bold>&#8232;(0.09 to 0.67)</td><td valign="bottom" colspan="1" rowspan="1">43,783&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">448 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>412 per 100,000</bold>&#8232;(309 to 546)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.92</bold>&#8232;(0.69 to 1.22)</td><td valign="bottom" colspan="1" rowspan="1">43,783&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">34,575 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>63,273 per 100,000</bold>&#8232;(44,602 to 89,896)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.83</bold>&#8232;(1.29 to 2.60)</td><td valign="bottom" colspan="1" rowspan="1">7222&#8232;(2 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d,g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>h</sup></td><td colspan="2" valign="bottom" rowspan="1">Outcome not pooled due to considerable heterogeneity (I&#178; = 96%) between included studies:&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>&#160;(RR 1.09, 95% CI 0.96 to 1.24; n = 6736);&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#160;(RR 2.31, 95% CI 1.80 to 2.97; n = 486)</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">7222&#8232;(2 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d,i</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="top" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% CI) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE</bold>: vaccine efficacy.</td></tr><tr><td colspan="7" valign="top" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0006" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: 1.9 months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Follow&#8208;up: seven days and 14 days&#8232;<sup>f</sup><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#8232;<sup>g</sup>Despite I&#178; = 83%, not downgraded for inconsistency, as the same direction of effect in both effect estimates.&#8232;<sup>h</sup>Follow&#8208;up: 0.23 months and 0.92 months&#8232;<sup>i</sup>Inconsistency: downgraded two levels (I&#178; = 96%).&#8232;<sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of benefit.&#8232;<sup>k</sup>Follow&#8208;up: seven days&#8232;<sup>l</sup>Despite I&#178; = 84%, not downgraded for inconsistency, as the same direction of effect in both effect estimates.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0007" position="anchor" orientation="portrait"><label>Summary of findings 7</label><caption><title>Gam&#8208;COVID&#8208;VAC &#8211; Sputnik V compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with Gam&#8208;COVID&#8208;VAC</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">1022 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>92 per 100,000</bold>&#8232;(51 to 167)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 91.10</bold><break/>(83.80 to 95.10)</td><td valign="bottom" colspan="1" rowspan="1">18,695&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">408 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>0 per 100,000</bold>&#8232;(0 to 23)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 100.00</bold><break/>(94.40 to 100.00)</td><td valign="bottom" colspan="1" rowspan="1">19,866&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">18 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>18 per 100,000</bold>&#8232;(2 to 176)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.99</bold>&#8232;(0.10 to 9.54)</td><td valign="bottom" colspan="1" rowspan="1">21,862&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8854;&#8854;&#8854;&#8232;<bold>Very low</bold><sup>d,e,g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">423 per 100,000</td><td valign="top" colspan="1" rowspan="1"><bold>275 per 100,000</bold>&#8232;(165 to 453)</td><td valign="top" colspan="1" rowspan="1"><bold>RR 0.65</bold>&#8232;(0.39 to 1.07)</td><td valign="top" colspan="1" rowspan="1">21,862&#8232;(1 RCT)<sup>c</sup></td><td valign="top" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d,e,h</sup></td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% CI) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019; <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0007" fn-type="fn"><p><sup>a</sup>Last updated: 27 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from seven days after second dose&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>&#8232;<sup>d</sup>Indirectness: downgraded one level as data are from interim analyses of the trial and from the available information it is unclear whether these were preplanned.&#8232;<sup>e</sup>Concern regarding the internal validity of the trial.&#8232;<sup>f</sup>Follow&#8208;up: 1.6 months (median)&#8232;<sup>g</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.&#8232;<sup>h</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of benefit.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0008" position="anchor" orientation="portrait"><label>Summary of findings 8</label><caption><title>CoronaVac &#8211; Sinovac compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with CoronaVac</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection&#160;</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">2398 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>724 per 100,000</bold>&#8232;(249 to 2104)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 69.81</bold><break/>(12.27 to 89.61)</td><td valign="bottom" colspan="1" rowspan="1">19,852&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d,e,f</sup></td><td valign="bottom" colspan="1" rowspan="1">Considerable heterogeneity (I&#178; = 92%) between included studies:&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>&#160;(VE 83.50%, 95% CI 65.40% to 92.10%; n = 10,029);&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>&#160;(VE 50.70%, 95% CI 35.90 to 62.00%; n = 9823)</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold><sup>b</sup></td><td colspan="2" valign="bottom" rowspan="1">2 studies report on severe or critical disease due to COVID&#8208;19:&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>, with 0/6559 events in the CoronaVac group versus 1/3470 events in the placebo group and a VE of 100%, 95% CI (20.40% to 100.00%); and&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>, with 0/4953 events in the CoronaVac group and 6/4870 events in the placebo group and a VE of 100%, 95% CI (16.90% to 100.00%). (Note: estimates could not be pooled due to asymmetry in the CIs)</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">19,852&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d,g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">20 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>10 per 100,000</bold>&#8232;(1 to 113)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.50</bold>&#8232;(0.05 to 5.52)</td><td valign="bottom" colspan="1" rowspan="1">22,610&#8232;(2 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">409 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>487 per 1000</bold>&#8232;(409 to 581)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.19</bold>&#8232;(1.00 to 1.42)</td><td valign="bottom" colspan="1" rowspan="1">23,966&#8232;(6 RCTs)<sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>l,m,n</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>o</sup></td><td valign="bottom" colspan="1" rowspan="1">531 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>579 per 1000</bold>&#8232;(568 to 590)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.09</bold>&#8232;(1.07 to 1.11)</td><td valign="bottom" colspan="1" rowspan="1">23,367&#8232;(6 RCTs)<sup>p</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>q</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>r</sup></td><td valign="bottom" colspan="1" rowspan="1">372 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>361 per 100,000</bold>&#8232;(231 to 562)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.97</bold>&#8232;(0.62 to 1.51)</td><td valign="bottom" colspan="1" rowspan="1">23,139&#8232;(4 RCTs)<sup>s</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>i,q</sup></td><td valign="bottom" colspan="1" rowspan="1">2 additional trials (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>) reported this outcome in 482 participants (270 versus 164 and 24 versus 24 respectively, receiving CoronaVac versus placebo). There were no events in either group and the trials did not contribute to the pooled effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">227 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>400 per 1000</bold>&#8232;(384 to 414)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.76</bold>&#8232;(1.69 to 1.82)</td><td valign="bottom" colspan="1" rowspan="1">23,962&#8232;(6 RCTs)<sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>l</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0008" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from 14 days after the second dose up to two months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Inconsistency: downgraded one level (I&#178; = 92%).&#8232;<sup>f</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm.&#8232;<sup>g</sup>Imprecision: downgraded two levels due to low number of events and wide CIs.&#8232;<sup>h</sup>Follow&#8208;up: 1.4 and 2 months (median)&#8232;<sup>i</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.&#8232;<sup>j</sup>Follow&#8208;up: 7&#8211;28 days&#8232;<sup>k</sup><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>&#8232;<sup>l</sup>Despite some concerns with adequate randomisation, deviation from intended intervention, missing data, and selection of reported results not downgraded for risk of bias.&#8232;<sup>m</sup>Inconsistency: downgraded one level (I&#178; = 55%).&#8232;<sup>n</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of harm.&#8232;<sup>o</sup>Follow&#8208;up: one to three months (median)&#8232;<sup>p</sup><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>&#8232;<sup>q</sup>Despite some concerns with adequate randomisation, not downgraded for risk of bias.&#8232;<sup>r</sup>Follow&#8208;up: 4.1 months, 2 months (median), 3 months (median)&#8232;<sup>s</sup><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0009" position="anchor" orientation="portrait"><label>Summary of findings 9</label><caption><title>WIBP&#8208;CorV &#8211; Sinopharm&#8208;Wuhan compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects<sup>*</sup></bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Risk with WIBP&#8208;CorV</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">912 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>328 per 100,000</bold>&#8232;(231 to 467)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 64.00</bold><break/>(48.80 to 74.70)</td><td valign="bottom" colspan="1" rowspan="1">25,449&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">746 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>203 per 100,000</bold>&#8232;(131 to 313)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 72.80</bold><break/>(58.10 to 82.40)</td><td valign="bottom" colspan="1" rowspan="1">25,480&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">1 trial reported on this outcome in 26,917 participants (13,464 WIBP&#8208;CorV versus 13,453 placebo) (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). There were no events in either group and no effect estimate could be calculated for this outcome.</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">278 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>275 per 1000</bold>&#8232;(264 to 286)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.99</bold>&#8232;(0.95 to 1.03)</td><td valign="bottom" colspan="1" rowspan="1">27,029&#8232;(2 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">504 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>484 per 1000</bold>&#8232;(469 to 494)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.96</bold>&#8232;(0.93 to 0.98)</td><td valign="bottom" colspan="1" rowspan="1">27,029&#8232;(2 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">579 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>480 per 100,000</bold>&#8232;(347 to 665)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.83</bold>&#8232;(0.60 to 1.15)</td><td valign="bottom" colspan="1" rowspan="1">27,029&#8232;(2 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>g,j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">290 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>255 per 1000</bold>&#8232;(247 to 267)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.88</bold>&#8232;(0.85 to 0.92)</td><td valign="bottom" colspan="1" rowspan="1">27,029&#8232;(2 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% CI) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0009" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from 2 weeks after the second dose up to 2.6 months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Follow&#8208;up: seven days and 28 days&#8232;<sup>f</sup><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>&#8232;<sup>g</sup>Despite some concerns with adequate randomisation, not downgraded for risk of bias.&#8232;<sup>h</sup>Follow&#8208;up: one month&#8232;<sup>i</sup>Follow&#8208;up: 1.6 and 2.6 months (median)&#8232;<sup>j</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and few events.&#8232;<sup>k</sup>Follow&#8208;up: seven days</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0010" position="anchor" orientation="portrait"><label>Summary of findings 10</label><caption><title>BBIBP&#8208;CorV &#8211; Sinopharm&#8208;Beijing &#160;compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects<sup>*</sup></bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with BBIBP&#8208;CorV</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">912 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>242 per 100,000</bold>&#8232;(162 to 359)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 73.50</bold><break/>(60.60 to 82.20)</td><td valign="bottom" colspan="1" rowspan="1">25,435&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">746 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>163 per 100,000</bold>&#8232;(102 to 263)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 78.10</bold><break/>(64.80 to 86.30)</td><td valign="bottom" colspan="1" rowspan="1">25,463&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">1 study reported this outcome in 26,924 participants (13,471 BBIBP&#8208;CorV versus 13,453 placebo) (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). There were no events in either group and no effect estimate could be calculated for this outcome.</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">274 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>288 per 1000</bold>&#8232;(236 to 351)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.05</bold>&#8232;(0.86 to 1.28)</td><td valign="bottom" colspan="1" rowspan="1">27,540&#8232;(3 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>h</sup></td><td colspan="2" valign="bottom" rowspan="1">3 studies (n = 27,540) reported any adverse event with 1 month or 2.9 months' follow&#8208;up. 2 of the studies reported an effect estimate in favour of BBIBP&#8208;CorV: 1 with RR 0.91, 95% CI 0.89 to 0.94; n = 26,924; and 1 with CIs crossing the line of no effect (RR 0.83, 95% CI 0.36 to 1.95; n = 112). 1 study reported an effect estimate in favour of placebo with CIs not crossing the line of null effect (RR 2.05, 95% CI 1.47 to 2.87; n = 504)&#160;</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">26,924&#8232;(3 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>i,j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">580 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>441 per 100,000</bold>&#8232;(313 to 615)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.76</bold>&#8232;(0.54 to 1.06)</td><td valign="bottom" colspan="1" rowspan="1">26,924&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>l</sup></td><td valign="bottom" colspan="1" rowspan="1">1 additional study reported this outcome in 112 participants (84 BBIBP&#8208;CorV versus 28 placebo) (<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>). There were no events in either group and the trial did not contribute to the effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>e</sup></td><td colspan="2" valign="bottom" rowspan="1">3 studies (n = 27,540) reported local adverse events with 7 days' follow&#8208;up. 1 study reported an effect estimate in favour of BBIBP&#8208;CorV: RR 0.71, 95% CI 0.68 to 0.74; n = 26,924. 2 studies reported an effect estimate in favour of placebo with CIs not crossing the line of null effect (RR 10.00, 95% CI 2.36 to 42.34; n = 504 and RR 3.33, 95% CI 0.45 to 24.89; n = 112).</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">26,924&#8232;(3 RCTs)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>i,j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0010" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from 2 weeks after second dose up to 2.6 months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Follow&#8208;up: seven days&#8232;<sup>f</sup><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>&#160;(children);&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>&#8232;<sup>g</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and the possibility of harm.&#8232;<sup>h</sup>Follow&#8208;up: one month and 2.9 months&#8232;<sup>i</sup>Inconsistency: downgraded one level as studies are not pooled, effect estimates and direction of effect inconsistent between included studies.&#8232;<sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of benefit and the possibility of harm.&#8232;<sup>k</sup>Follow&#8208;up: 2.6 months (median)&#8232;<sup>l</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of no effect and the possibility of benefit and few events.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0011" position="anchor" orientation="portrait"><label>Summary of findings 11</label><caption><title>BBV152 &#8211; Bharat Biotech compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect</bold>&#8232;<bold>(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants</bold>&#8232;<bold>(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence</bold>&#8232;<bold>(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with BBV152&#160;</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">1841 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>575 per 100,000</bold>&#8232;(322 to 982)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 68.80</bold><break/>(46.70 to 82.50)</td><td valign="bottom" colspan="1" rowspan="1">6289&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">1247 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>277 per 100,000</bold>&#8232;(170 to 434)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 77.80</bold><break/>(65.20 to 86.40)</td><td valign="bottom" colspan="1" rowspan="1">16,973&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">176 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>12 per 100,000</bold>&#8232;(0 to 76)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 93.40</bold><break/>(57.10 to 99.80</td><td valign="bottom" colspan="1" rowspan="1">16,976&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">78 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>39 per 100,000</bold>&#8232;(13 to 113)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.50</bold>&#8232;(0.17 to 1.46)</td><td valign="bottom" colspan="1" rowspan="1">25,753&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">20 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>26 per 1000</bold>&#8232;(23 to 31)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.34</bold>&#8232;(1.15 to 1.58)</td><td valign="bottom" colspan="1" rowspan="1">25,925&#8232;(2 RCTs)<sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">124 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>124 per 1000</bold>&#8232;(117 to 133)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.00</bold>&#8232;(0.94 to 1.07)</td><td valign="bottom" colspan="1" rowspan="1">25,753&#8232;(1 RCT)<sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>i</sup></td><td valign="bottom" colspan="1" rowspan="1">463 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>301 per 100,000</bold>&#8232;(199 to 449)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.65</bold>&#8232;(0.43 to 0.97)</td><td valign="bottom" colspan="1" rowspan="1">25,928&#8232;(1 RCT)<sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">1 additional trial reported this outcome in 175 participants (100 BBV152 versus 75 placebo) (<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>). There were no events in either group and the trial did not contribute to the pooled effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">31 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>34 per 1000</bold>&#8232;(30 to 39)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.08</bold>&#8232;(0.95 to 1.24)</td><td valign="bottom" colspan="1" rowspan="1">25,750&#8232;(2 RCTs)<sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0011" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from two weeks after second dose to 3.3 months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Follow&#8208;up: 3.3 months (median)&#8232;<sup>f</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and low number of events.&#8232;<sup>g</sup>Follow&#8208;up: seven days&#8232;<sup>h</sup><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>&#8232;<sup>i</sup>Follow&#8208;up: 4.9 months (median)&#8232;<sup>j</sup><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0012" position="anchor" orientation="portrait"><label>Summary of findings 12</label><caption><title>NVX&#8208;CoV2373 &#8211; Novavax compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with NVX&#8208;CoV2373</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">1140 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>195 per 100,000</bold>&#8232;(67 to 564)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 82.91</bold><break/>(50.49 to 94.10)</td><td valign="bottom" colspan="1" rowspan="1">42,175&#8232;(3 RCTs)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">Substantial heterogeneity (I&#178; = 65%) between included studies:&#160;<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>&#160;(VE 90.40%, 95% CI 82.88 to 94.62%; n = 25,452);&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>&#160;(VE 89.70%, 95% CI 80.20% to 94.60%; n = 14,039);&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#160;(VE 49.40%, 95% CI 6.10% to 72.80%; n = 2684)</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1">172 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>0 per 100,000</bold>&#8232;(0 to 22)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 100.00</bold>&#8232;(86.99 to 100.00)</td><td valign="bottom" colspan="1" rowspan="1">25,452&#8232;(1 RCT)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d,g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">51 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>46 per 100,000</bold>&#8232;(15 to 136)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.90</bold> (0.30 to 2.68)</td><td valign="bottom" colspan="1" rowspan="1">29,582&#8232;(1 RCT)<sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d,i</sup></td><td valign="bottom" colspan="1" rowspan="1">1 additional study reported on this outcome in 14,039 participants (7020 NVX&#8208;CoV2373 versus 7019 placebo) (<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>). There were no events in either group and the trial did not contribute to the pooled effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">363 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>439 per 1000</bold>&#8232;(425 to 454)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.21</bold>&#8232;(1.17 to 1.25)</td><td valign="bottom" colspan="1" rowspan="1">31,063&#8232;(3 RCTs)<sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>l</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>m</sup></td><td valign="bottom" colspan="1" rowspan="1">173 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>199 per 1000</bold>&#8232;(182 to 218)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.15</bold>&#8232;(1.05 to 1.26)</td><td valign="bottom" colspan="1" rowspan="1">46,231&#8232;(5 RCTs)<sup>n</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>l,o</sup></td><td valign="bottom" colspan="1" rowspan="1">Substantial heterogeneity (I&#178; = 57%) between the 5 included studies.</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>m</sup></td><td valign="bottom" colspan="1" rowspan="1">777 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>715 per 100,000</bold>&#8232;(575 to 886)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.92</bold>&#8232;(0.74 to 1.14)</td><td valign="bottom" colspan="1" rowspan="1">38,802&#8232;(4 RCTs)<sup>p</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>i,q</sup></td><td valign="bottom" colspan="1" rowspan="1">1 additional trial reported on this outcome in 52 participants (29 NVX&#8208;CoV2373 versus 23 placebo) &#160;(<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>). There were no events in either group and the trial did not contribute to the pooled effect estimate.&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>j</sup></td><td valign="bottom" colspan="1" rowspan="1">191 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>532 per 1000</bold>&#8232;(381 to 742)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 2.78</bold>&#8232;(1.99 to 3.88)</td><td valign="bottom" colspan="1" rowspan="1">31,063&#8232;(3 RCTs)<sup>k</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8853;&#8232;<bold>High</bold><sup>l,r</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0012" fn-type="fn"><p><sup>a</sup>Last updated: 2 June 2022&#8232;<sup>b</sup>Follow&#8208;up: from seven days after second dose up to three months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#8232;<sup>d</sup>Despite some concerns with deviations from intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Inconsistency: downgraded one level (I&#178; = 65%).&#8232;<sup>f</sup><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>&#8232;<sup>g</sup>Indirectness: downgraded one level as outcome in this trial included participants with moderate severity.&#8232;<sup>h</sup>Follow&#8208;up: two months (median)&#8232;<sup>i</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.&#8232;<sup>j</sup>Follow&#8208;up: seven days&#8232;<sup>k</sup><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#8232;<sup>l</sup>Despite some concerns with adequate randomisation and missing data, not downgraded for risk of bias.&#8232;<sup>m</sup>Unsolicited adverse events, follow&#8208;up to three months (median)&#8232;<sup>n</sup><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#8232;<sup>o</sup>Inconsistency: downgraded one level (I&#178; = 57%).&#8232;<sup>p</sup><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#8232;<sup>q</sup>Despite some concerns with adequate randomisation, deviation from intended intervention and missing data, not downgraded for risk of bias.&#8232;<sup>r</sup>Despite I&#178; = 86%, not downgraded for inconsistency, as the same direction of effect in both effect estimates.</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0013" position="anchor" orientation="portrait"><label>Summary of findings 13</label><caption><title>FINLAY&#8208;FR&#8208;2 &#8211; Instituto Finlay de Vacunas compared to placebo for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants&#8232;(studies)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with FINLAY&#8208;FR&#8208;2</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">1084 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>314 per 100,000</bold>&#8232;(226 to 445)</td><td valign="bottom" colspan="1" rowspan="1"><bold>VE 71.00</bold><break/>(58.90 to 79.10)</td><td valign="bottom" colspan="1" rowspan="1">28,674&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>e</sup></td><td valign="bottom" colspan="1" rowspan="1">168 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>62 per 100,000</bold>&#8232;(29 to 134)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 0.37</bold>&#8232;(0.17 to 0.80)</td><td valign="bottom" colspan="1" rowspan="1">28,674&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td colspan="7" valign="top" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% CI) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2; <bold>VE:</bold> vaccine efficacy.</td></tr><tr><td colspan="7" valign="top" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0013" fn-type="fn"><p><sup>a</sup>Last updated: 6 May 2022&#8232;<sup>b</sup>Follow&#8208;up: from seven days after second dose up to three months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>&#8232;<sup>d</sup>Risk of bias downgraded one level: some concerns regarding adequate randomisation and deviation from intended intervention.&#8232;<sup>e</sup>Follow&#8208;up: 1.7 months (median)</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0014" position="anchor" orientation="portrait"><label>Summary of findings 14</label><caption><title>Heterologous vaccination scheme compared to homologous vaccination scheme for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#8232;(GRADE)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with homologous vaccination scheme</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with heterologous vaccination scheme</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality&#160;</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">60 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>118 per 1000</bold>&#8232;(31 to 445)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.96</bold>&#8232;(0.52 to 7.41)</td><td valign="bottom" colspan="1" rowspan="1">101&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold><sup>f</sup></td><td colspan="2" valign="bottom" rowspan="1">3 studies (n = 564) that compared heterologous versus homologous vaccination schemes reported any adverse event with 1 or 2 months' follow&#8208;up. 2 of the studies reported an effect estimate in favour of homologous scheme but with CIs crossing the line of no effect (RR 1.21, 95% CI 0.87 to 1.68; n = 234; and RR 1.03, 95% CI 0.75 to 1.43; n = 229). 1 study reported an effect estimate in favour of homologous scheme with CIs not crossing the line of null effect (RR 3.19, 95% CI 1.11 to 9.11; n = 101)</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">(3 RCTs)<sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8854;&#8854;&#8854;&#8232;<bold>Very low</bold><sup>h,i,j</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold><sup>k</sup></td><td colspan="2" valign="bottom" rowspan="1">1 study (<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1) that compared heterologous versus homologous vaccination schemes reported no serious adverse events in the heterologous scheme (0/114) versus 1 serious adverse event (1/115) in the homologous scheme (RR 0.34, 95% CI 0.01 to 8.17). 2 more studies reported the outcome, with 0 events in both groups:&#160;<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>: CoronaVac/Ad5 versus CoronaVac/CoronaVac in n = 51 versus n = 50 and&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>: BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2 in n = 115 versus n = 119 respectively, in heterologous versus homologous scheme</td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td><td valign="bottom" colspan="1" rowspan="1">229&#8232;(1 RCT)<sup>l</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8854;&#8854;&#8854;&#8232;<bold>Very low</bold><sup>h,m</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">20 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>235 per 1000</bold>&#8232;(32 to 1000)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 11.76</bold>&#8232;(1.59 to 87.14)</td><td valign="bottom" colspan="1" rowspan="1">101&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d,n</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="bottom" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2.</td></tr><tr><td colspan="7" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0014" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: 28 days&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>: CoronaVac/Ad5 versus CoronaVac/CoronaVac&#8232;<sup>d</sup>Despite some concerns with deviation from intended intervention, not downgraded for risk of bias.&#8232;<sup>e</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit for heterologous and benefit for homologous vaccination scheme and the low number of events/participants.&#8232;<sup>f</sup>Follow&#8208;up: one and two months&#8232;<sup>g</sup><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>: CoronaVac/Ad5 versus CoronaVac/CoronaVac;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>: BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1&#8232;<sup>h</sup>Risk of bias downgraded one level: some concerns regarding outcome measurement.&#8232;<sup>i</sup>Inconsistency: downgraded one level as studies are not pooled, effect estimates and direction of effect inconsistent between included studies.&#8232;<sup>j</sup>Imprecision: downgraded one level due to wide CIs consistent with the possibility of no effect and benefit for homologous vaccination scheme and the low number of events/participants.&#8232;<sup>k</sup>Follow&#8208;up: one month&#8232;<sup>l</sup><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>: ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1&#8232;<sup>m</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit for the heterologous and benefit for homologous vaccination scheme and the low number of events/participants.&#8232;<sup>n</sup>Imprecision: downgraded two levels due to very few events or participants (or both).</p></fn></table-wrap-foot></table-wrap><table-wrap id="CD015477-tbl-0015" position="anchor" orientation="portrait"><label>Summary of findings 15</label><caption><title>Booster compared to placebo/no booster for vaccination against COVID&#8208;19<sup>a</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Outcomes</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Anticipated absolute effects*</bold> (95% CI)</td><td rowspan="2" valign="bottom" colspan="1"><bold>Relative effect&#8232;(95% CI)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#8470; of participants</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Certainty of the evidence&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Comments</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with placebo/no booster</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Risk with booster</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold><sup>b</sup></td><td valign="bottom" colspan="1" rowspan="1">63 per 100,000</td><td valign="bottom" colspan="1" rowspan="1"><bold>80 per 100,000</bold>&#8232;(33 to 191)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.27</bold>&#8232;(0.52 to 3.05)</td><td valign="bottom" colspan="1" rowspan="1">28,254&#8232;(1 RCT)<sup>c</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8854;&#8854;&#8854;&#8232;<bold>Very low</bold><sup>d,e</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">102 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>183 per 1000</bold>&#8232;(72 to 464)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 1.80</bold>&#8232;(0.71 to 4.56)</td><td valign="bottom" colspan="1" rowspan="1">119&#8232;(1 RCT)<sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8854;&#8854;&#8232;<bold>Low</bold><sup>d</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Any adverse event</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Serious adverse events</bold></td><td colspan="6" valign="bottom" rowspan="1">Outcome not yet measured or reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold><sup>f</sup></td><td valign="bottom" colspan="1" rowspan="1">119 per 1000</td><td valign="bottom" colspan="1" rowspan="1"><bold>766 per 1000</bold>&#8232;(377 to 1000)</td><td valign="bottom" colspan="1" rowspan="1"><bold>RR 6.46</bold>&#8232;(3.18 to 13.13)</td><td valign="bottom" colspan="1" rowspan="1">119&#8232;(1 RCT)<sup>g</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8853;&#8853;&#8853;&#8854;&#8232;<bold>Moderate</bold><sup>h</sup></td><td valign="bottom" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="7" valign="top" rowspan="1">*<bold>The risk in the intervention group</bold> (and its 95% CI) is based on the assumed risk in the comparison group and the <bold>relative effect</bold> of the intervention (and its 95% CI).<break/><bold>COVID&#8208;19:</bold> coronavirus disease 2019 <bold>CI:</bold> confidence interval; <bold>RCT:</bold> randomized controlled trial; <bold>RR:</bold> risk ratio; <bold>SARS&#8208;CoV&#8208;2:</bold> severe acute respiratory syndrome coronavirus 2.</td></tr><tr><td colspan="7" valign="top" rowspan="1"><bold>GRADE Working Group grades of evidence</bold>&#8232;<bold>High certainty:</bold> we are very confident that the true effect lies close to that of the estimate of the effect.&#8232;<bold>Moderate certainty:</bold> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&#8232;<bold>Low certainty:</bold> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.&#8232;<bold>Very low certainty:</bold> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0015" fn-type="fn"><p><sup>a</sup>Last updated: 4 May 2022&#8232;<sup>b</sup>Follow&#8208;up: 1.7 months (median)&#8232;<sup>c</sup><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>: FINLAY&#8208;FR&#8208;2/booster FR&#8208;1 versus FINLAY&#8208;FR&#8208;2&#8232;<sup>d</sup>Imprecision: downgraded two levels due to wide CIs consistent with the possibility of benefit and the possibility of harm and few events.&#8232;<sup>e</sup>Risk of bias downgraded one level: some concerns regarding adequate randomization and deviation from intended intervention.&#8232;<sup>f</sup>Follow&#8208;up: seven days&#8232;<sup>g</sup><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>: mRNA&#8208;1273 booster versus placebo (solid organ transplant recipients).&#8232;<sup>h</sup>Imprecision: downgraded one level due to low number of participants.</p></fn></table-wrap-foot></table-wrap></sec><sec id="CD015477-sec-0009"><title>Background</title><sec id="CD015477-sec-0010"><title>Description of the condition</title><p>In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus&#8208;2 (SARS&#8208;CoV&#8208;2) outbreak began in Wuhan, Hubei Province, China. SARS&#8208;CoV&#8208;2 began to spread worldwide, and on 11 March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID&#8208;19) a pandemic (<xref rid="CD015477-bbs2-0164" ref-type="ref-list">WHO 2020a</xref>).</p><p>In many countries, the number of cases increased exponentially during the first and subsequent waves (<xref rid="CD015477-bbs2-0170" ref-type="ref-list">Worldometer 2022</xref>). The clinical spectrum of COVID&#8208;19 ranges from mild to critical, and approximately 15% to 30% of patients infected with the wild&#8208;type variant of SARS&#8208;CoV&#8208;2 experienced acute respiratory distress syndrome (<xref rid="CD015477-bbs2-0056" ref-type="ref-list">Attaway 2021</xref>). Persons with underlying conditions and weakened immune systems were at higher risk of becoming severely sick (<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>).&#160;</p><p>Further, genetic variants of SARS&#8208;CoV&#8208;2 have been emerging and circulating at a global level: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) variants, and more recently B.1.1.529 (Omicron) (<xref rid="CD015477-bbs2-0167" ref-type="ref-list">WHO 2022a</xref>). Consequently, the WHO has developed a definition of variants of concern for molecular surveillance (<xref rid="CD015477-bbs2-0167" ref-type="ref-list">WHO 2022a</xref>).</p><p>Intensive research and development of vaccines is currently underway to curtail the pandemic and prevent disease outbreaks that could overwhelm health systems worldwide (<xref rid="CD015477-bbs2-0158" ref-type="ref-list">van Riel 2020</xref>;&#160;<xref rid="CD015477-bbs2-0168" ref-type="ref-list">WHO 2022b</xref>).</p></sec><sec id="CD015477-sec-0011"><title>Description of the intervention</title><p>Vaccines exploit the ability of the immune system to respond to and remember encounters with pathogenic antigens. COVID&#8208;19 vaccine development, aimed at conferring protection against infection, or symptomatic disease, or both, has been accelerated due to priority funding over other diseases.</p><p>Different vaccine platform technologies (i.e. technologies that have in common the use of a &#8216;backbone&#8217; carrier or vector) are being, and have been tested: live attenuated virus vaccines or inactivated virus vaccines (either inactivated whole or altered pathogens); protein&#8208;based vaccines (protein subunits or virus&#8208;like particles); viral vector vaccines (non&#8208;replicating viral vector, replicating viral vector); and nucleic acid&#8208;based vaccines (DNA&#8208; and RNA&#8208;based vaccines)(<xref rid="CD015477-bbs2-0054" ref-type="ref-list">Abbasi 2020</xref>).&#160;</p><p>Vaccines may be categorized as either live or non&#8208;live (<xref rid="CD015477-bbs2-0066" ref-type="ref-list">CDC 2021</xref>), distinguishing those vaccines that contain an attenuated (live) form of the pathogen from those that harbour the killed (inactivated, non&#8208;live) version of the pathogen. Non&#8208;live vaccines predominantly induce humoral immunity, whereas live vaccines create a robust cellular and humoral response. The present review includes 12 vaccines within four different non&#8208;live vaccine platform technologies.</p><p><list id="CD015477-list-0001" list-type="bullet"><list-item><p>Inactivated virus vaccines</p><list id="CD015477-list-0002" list-type="bullet"><list-item><p>CoronaVac</p></list-item><list-item><p>WIBP&#8208;CorV</p></list-item><list-item><p>BBIBP&#8208;CorV</p></list-item><list-item><p>BBV152</p></list-item></list></list-item><list-item><p>Protein subunit vaccines</p><list id="CD015477-list-0003" list-type="bullet"><list-item><p>NVX&#8208;CoV2373</p></list-item><list-item><p>FINLAY&#8208;FR&#8208;2</p></list-item></list></list-item><list-item><p>Viral vector (non&#8208;replicating) vaccines</p><list id="CD015477-list-0004" list-type="bullet"><list-item><p>ChAdOx1</p></list-item><list-item><p>Ad26.COV2.S</p></list-item><list-item><p>Gam&#8208;COVID&#8208;Vac</p></list-item></list></list-item><list-item><p>Nucleic acid&#8208;based (RNA) vaccines</p><list id="CD015477-list-0005" list-type="bullet"><list-item><p>BNT162b2</p></list-item><list-item><p>mRNA&#8208;1273</p></list-item><list-item><p>CVnCoV</p></list-item></list></list-item></list></p></sec><sec id="CD015477-sec-0012"><title>How the intervention might work</title><p>Vaccines aim to generate an immune response that prevents SARS&#8208;CoV&#8208;2 infection or reduces the risk of severe disease or death.</p><sec id="CD015477-sec-0013"><title>Live attenuated virus vaccines</title><p>Live attenuated virus vaccines use a weakened form of the virus and are developed so that in an immunocompetent host, they replicate sufficiently to generate a robust immune response (<xref rid="CD015477-bbs2-0134" ref-type="ref-list">Pollard 2021</xref>). Live attenuated vaccines may potentially replicate in an uncontrolled manner in immunosuppressed individuals, thus rendering them less suitable for use within this population (<xref rid="CD015477-bbs2-0144" ref-type="ref-list">Rubin 2013</xref>).</p></sec><sec id="CD015477-sec-0014"><title>Inactivated virus vaccines</title><p>In contrast, inactivated vaccines contain either inactivated whole or altered pathogens, thus precluding their replication; however, inactivated vaccines do not always induce as strong or long&#8208;lasting an immune response as live attenuated vaccines.</p><p>Inactivated virus technologies present multiple viral proteins for immune recognition. They have a stable expression of conformation&#8208;dependent antigenic epitopes (<xref rid="CD015477-bbs2-0142" ref-type="ref-list">Roper 2009</xref>). Pitfalls include their potential to alter viral epitopes, which may adversely affect immunogenicity if the native structure of the viral antigen is not maintained (<xref rid="CD015477-bbs2-0075" ref-type="ref-list">DeZure 2016</xref>). As a result, the administration of multiple doses, booster injections, or adjuvant addition is often needed to elicit protective humoral immune responses(<xref rid="CD015477-bbs2-0134" ref-type="ref-list">Pollard 2021</xref>).</p><p><italic toggle="yes">Protein subunit vaccines</italic> are composed of fragments of the virus. Akin to inactivated whole&#8208;cell vaccines, protein subunit vaccines do not harbour live components of the pathogen. They are distinguished from inactivated whole&#8208;cell vaccines by containing only the necessary antigenic parts of the pathogen for mounting a protective immune response. As the subunit vaccine only relies on the antigen of interest made using recombinant technology, it is considered a more reliable and safer technique than inactivated vaccines(<xref rid="CD015477-bbs2-0077" ref-type="ref-list">Dong 2020</xref>). Nevertheless, this advantage may be offset by its inability to display the virus's full antigenic complexity. This may cause an unbalanced immune response and lower its protective effect (<xref rid="CD015477-bbs2-0081" ref-type="ref-list">Enjuanes 2016</xref>). Consequently, adjuvants may be required to boost immune responses and increase immunogenicity.&#160;</p><p>Several other platforms have developed over the past few decades. These include virus&#8208;like particles, viral vectors, nucleic acid&#8208;based RNA and DNA vaccines (<xref rid="CD015477-bbs2-0134" ref-type="ref-list">Pollard 2021</xref>), all of which have been employed in COVID&#8208;19 vaccine development.&#160;</p><p><italic toggle="yes">Virus&#8208;like particle (VLP) vaccines</italic> contain virus&#8208;like particles which closely resemble viruses, but are non&#8208;infectious as they contain no viral genetic material (<xref rid="CD015477-bbs2-0126" ref-type="ref-list">Oxford Vaccine Group 2020</xref>). This platform has been used against hepatitis B and human papillomavirus (HPV), and constitutes another protein&#8208;based vaccine composed of proteins from the viral capsid (<xref rid="CD015477-bbs2-0091" ref-type="ref-list">Fuenmayor 2017</xref>). VLP vaccines consist of self&#8208;assembled viral structural proteins that mimic the conformation of native SARS&#8208;CoV virions (<xref rid="CD015477-bbs2-0119" ref-type="ref-list">Mortola 2004</xref>), making them immunogenic and inducing highly neutralizing&#8208;antibody titres. In light of their non&#8208;replicating and non&#8208;infectious constructs, VLPs may have an enhanced safety profile.&#160;</p><p>Unlike previous vaccines, viral vectors and nucleic acid&#8208;based RNA and DNA vaccines do not contain antigens, but rather nucleic acid sequences (RNA or DNA) that code for the proteins of interest inside the organism (<xref rid="CD015477-bbs2-0134" ref-type="ref-list">Pollard 2021</xref>).</p><sec id="CD015477-sec-0015"><title>Viral vector vaccines&#160;</title><p>They differ from most conventional vaccines because they do not contain antigens (<xref rid="CD015477-bbs2-0092" ref-type="ref-list">Gavi 2020</xref>). They are generally constructed from a carrier virus, such as an adeno&#8208; or pox&#8208;virus, and are engineered to carry the key target for COVID&#8208;19 vaccines (<xref rid="CD015477-bbs2-0077" ref-type="ref-list">Dong 2020</xref>). Whilst vector vaccines confer the key advantage of including the innate immune responses required for eliciting adaptive immune responses, a potential disadvantage is that the host may already possess immunity against the vector due to prior exposure, thus reducing its effect (<xref rid="CD015477-bbs2-0134" ref-type="ref-list">Pollard 2021</xref>). However, this disadvantage does not exist for all vectors. If the anti&#8208;vector response is likely to interfere with the efficacy induced by adenovirus vectors widely used for SARS&#8208;CoV&#8208;2 vaccines, this is not the case with Pox virus vectors (<xref rid="CD015477-bbs2-0077" ref-type="ref-list">Dong 2020</xref>).</p></sec><sec id="CD015477-sec-0016"><title>Nucleic acid&#8208;based vaccine &#8211; mRNA vaccine&#160;</title><p>Whilst mRNA vaccines are considered a new type of vaccine (<xref rid="CD015477-bbs2-0066" ref-type="ref-list">CDC 2021</xref>), this platform has garnered interest among researchers for decades. The mechanism of action of mRNA vaccines is to instruct cells how to make a protein that may trigger an immune response (<xref rid="CD015477-bbs2-0066" ref-type="ref-list">CDC 2021</xref>). mRNA translation occurs in the host cell's cytosol, circumventing the risk of integration into the host genome (<xref rid="CD015477-bbs2-0066" ref-type="ref-list">CDC 2021</xref>). Like viral vectors, mRNA vaccines induce dendritic cell sensing &#8211; mRNA can stimulate TLR7, thus avoiding the use of adjuvants. Like viral vectors, attenuated vaccines and DNA vaccines, these vaccines can induce a CD8 T cell response. Finally, RNAs rapidly destroy mRNAs in the extracellular medium; these vaccines must be encapsulated.</p></sec><sec id="CD015477-sec-0017"><title>Nucleic acid&#8208;based vaccine &#8211; DNA vaccine&#160;</title><p>DNA vaccine candidates function by injecting a plasmid containing the DNA sequence encoding a SARS&#8208;CoV&#8208;2 antigen which will stimulate the immune response. Due to the biocompatibility of plasmid DNA, their cost&#8208;efficient production and long shelf life, DNA vaccine&#8208;based immunotherapeutic strategies have been developed for treatment of infections (<xref rid="CD015477-bbs2-0102" ref-type="ref-list">Hobernik 2018</xref>). However, their disadvantage is that the DNA molecules must cross the nuclear membrane to be transcribed, and they generally have low immunogenicity (<xref rid="CD015477-bbs2-0077" ref-type="ref-list">Dong 2020</xref>).</p><p>These vaccines are used systemically (usually intramuscular injection), but mucosal SARS&#8208;CoV&#8208;2 vaccines are under development. This type of vaccine is predicted to have a better efficacy against infection. Apart from COVID&#8208;19, only one vaccine used via the nasal route has been approved to date: an attenuated vaccine against the influenza virus.</p></sec></sec></sec><sec id="CD015477-sec-0018"><title>Why it is important to do this review</title><p>Given the importance to global health and the increasing number of vaccine candidates now being tested in phase 2 and phase 3 trials, there is a need to produce and maintain a living synthesis of the efficacy and safety of COVID&#8208;19 vaccines.</p><p>This review is part of a larger project: the COVID&#8208;NMA initiative (<xref rid="CD015477-bbs2-0060" ref-type="ref-list">Boutron 2020a</xref>). The COVID&#8208;NMA initiative provides decision&#8208;makers with a complete, high&#8208;quality, and up&#8208;to&#8208;date mapping and synthesis of evidence on interventions for preventing and treating COVID&#8208;19. We developed a master protocol on the effect of all interventions for preventing and treating COVID&#8208;19 (<xref rid="CD015477-bbs2-0061" ref-type="ref-list">Boutron 2020b</xref>), followed by specific protocols for more specific questions. Our results are made available and updated bi&#8208;weekly on the COVID&#8208;NMA platform at <uri>covid-nma.com</uri>.&#160;</p><p>We followed the PRISMA guidelines (<xref rid="CD015477-bbs2-0127" ref-type="ref-list">Page 2021</xref>). The protocol is available at <uri>doi.org/10.5281/zenodo.6458272</uri> and registered on PROSPERO (<uri>www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271897</uri>). It was peer&#8208;reviewed and processed by Cochrane's Central Editorial Service.&#160;</p><p>This review will be updated as soon as new evidence changes the conclusions or certainty of the evidence of the review, or at least twice a year if no substantial changes occur.</p></sec></sec><sec id="CD015477-sec-0019"><title>Objectives</title><p>To assess the efficacy and safety of COVID&#8208;19 vaccines (as a full primary vaccination series or as a booster dose) against SARS&#8208;CoV&#8208;2.</p></sec><sec id="CD015477-sec-0020"><title>Methods</title><sec id="CD015477-sec-0021"><title>Criteria for considering studies for this review</title><sec id="CD015477-sec-0022"><title>Types of studies</title><p>We included parallel individually or cluster&#8208;randomized controlled trials (RCTs) evaluating COVID&#8208;19 vaccines in humans with no restrictions on language. Single&#8208;arm studies, non&#8208;randomized studies, and modelling studies of interventions for COVID&#8208;19 were not eligible to be included in the review.&#160;</p></sec><sec id="CD015477-sec-0023"><title>Types of participants</title><p>We included individuals with no restriction on age and comorbidities, irrespective of their serological status at baseline.</p></sec><sec id="CD015477-sec-0024"><title>Types of interventions</title><p>Eligible interventions included any COVID&#8208;19 vaccines, particularly:</p><p><list id="CD015477-list-0006" list-type="bullet"><list-item><p>live attenuated virus vaccine;</p></list-item><list-item><p>inactivated virus vaccine;</p></list-item><list-item><p>protein subunit vaccine;</p></list-item><list-item><p>virus&#8208;like particle (VLP) vaccine;</p></list-item><list-item><p>non&#8208;replicating viral vector (e.g. recombinant adenovirus) vaccine;</p></list-item><list-item><p>replicating viral vector vaccine;</p></list-item><list-item><p>RNA&#8208;based vaccine.</p></list-item><list-item><p>DNA&#8208;based vaccine;&#160;</p></list-item><list-item><p>Other vaccine types for COVID&#8208;19, if any.</p></list-item></list></p><p>In the analysis, we included only results for vaccine candidates with a selected dose evaluated in phases 2&#8208;3 or phase 3 trials and their corresponding early phases.&#160;</p><p>Comparators included placebo (placebo could consist of saline placebo, injecting only the vaccine adjuvant or injecting a vaccine protecting against other diseases, such as meningococcal conjugate vaccine), no vaccine, or another COVID&#8208;19 vaccine.</p></sec><sec id="CD015477-sec-0025"><title>Types of outcome measures</title><p>Our outcomes were identified with content experts, considering the outcomes most frequently evaluated in the registered RCTs, and after consulting the main outcomes recommended by the US Food and Drug Administration (FDA) guidance for developing a vaccine (<xref rid="CD015477-bbs2-0083" ref-type="ref-list">FDA 2020a</xref>).</p><sec id="CD015477-sec-0026"><title>Efficacy outcomes</title><p><list id="CD015477-list-0007" list-type="bullet"><list-item><p>Incidence of confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination (all doses of the primary vaccination schedule)*&#160;</p></list-item><list-item><p>Incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination</p></list-item><list-item><p>Severe or critical COVID&#8208;19 after complete vaccination, as reported by authors (a table summarising the definitions used in each study can be found in&#160;<xref rid="CD015477-sec-0301" ref-type="app">Appendix 1</xref>)</p></list-item><list-item><p>All&#8208;cause mortality&#160;</p></list-item></list></p><p><italic toggle="yes">*confirmed by reverse transcription polymerase chain reaction (RT&#8208;PCR), nucleic acid amplification testing (NAAT), or any other validated test.</italic></p></sec><sec id="CD015477-sec-0027"><title>Safety outcomes</title><p><list id="CD015477-list-0008" list-type="bullet"><list-item><p>Incidence of systemic reactogenicity events (i.e. the immediate short&#8208;term reactions of a system to vaccines mainly due to immunological responses, such as fever) reported at day 14 after first dose.</p></list-item></list></p><p>When the number of participants with at least one systemic reactogenicity event is not reported, we used proxy measures as follows.</p><p><list id="CD015477-list-0009" list-type="bullet"><list-item><p>For adults: the number of participants with malaise as first choice, headache as second choice, and fever 37.5 &#176;C or greater as third choice;&#160;</p></list-item><list-item><p>For children: irritability as first choice, decreased activity/weakness as second choice, and fever 37.5 &#176;C or greater as third choice.&#160;</p></list-item><list-item><p>Incidence of any adverse event (including non&#8208;serious adverse events). We considered any adverse event reported by authors, prioritizing 'solicited' adverse events. However, when these were not available, we collected 'unsolicited' adverse events.</p></list-item><list-item><p>Incidence of any serious adverse events (SAEs) as reported by authors (a table reporting the definitions used in each study can be found in&#160;<xref rid="CD015477-sec-0301" ref-type="app">Appendix 1</xref>).</p></list-item></list></p></sec><sec id="CD015477-sec-0028"><title>Immunogenicity outcomes</title><p><list id="CD015477-list-0010" list-type="bullet"><list-item><p>Geometric mean titre (GMT) of a specific antibody against SARS&#8208;CoV&#8208;2 (two weeks after the first dose or nearest follow&#8208;up, as mentioned in the manuscript)</p></list-item><list-item><p>GMT of a neutralizing antibody against SARS&#8208;CoV&#8208;2 (two weeks after second dose or nearest follow&#8208;up, as mentioned in the manuscript)</p></list-item><list-item><p>Cellular immune responses (i.e. interferon gamma (IFN&#8208;&#947;) enzyme&#8208;linked immunospot (ELISpot)) (any time point reported by authors)</p></list-item></list></p></sec><sec id="CD015477-sec-0029"><title>Specific safety outcomes</title><p><list id="CD015477-list-0011" list-type="bullet"><list-item><p>Incidence of local reactogenicity events (i.e. the immediate local short&#8208;term reactions of a system to vaccines mainly due to immunological responses, such as pain and swelling) reported at day seven after first dose.</p></list-item></list></p><p>When the number of participants with at least one local adverse event is not reported, we used as a proxy measure pain as the first choice, local swelling/induration as the second choice, and erythema (redness) as the third choice.</p><p><list id="CD015477-list-0012" list-type="bullet"><list-item><p>Incidence of specific safety outcomes&#160;</p></list-item><list-item><p>Cardioembolic events (i.e. pulmonary embolism, stroke, venous thrombosis, cavernous sinus thrombosis, pericarditis, myocardial infarction)&#160;</p></list-item><list-item><p>Haematological events (i.e. thrombocytopenia, haemorrhage, neutropenia, anaemia, lymphadenopathy)</p></list-item><list-item><p>Neurological events (i.e. nervous system diseases)</p></list-item><list-item><p>Vaccine&#8208;enhanced disease</p></list-item></list></p><p>Note: as the start of follow&#8208;up (T0) varies (e.g. follow&#8208;up starts "14 days after the last dose" or "21 days after the first dose"), we systematically recorded the T0 considered in the study report. For safety outcomes, we considered T0 = time the first dose is injected when the comparison is vaccine versus placebo/no vaccine; T0 = time after the second dose when the comparison focuses on heterologous vaccination; and T0 = time after the booster or placebo when the comparison assessed the booster dose. We systematically recorded the follow&#8208;up duration for the outcomes considered. When the same outcome was recorded at several time points, we recorded the latest.&#160;</p><p>For specific antibodies against SARS&#8208;CoV&#8208;2, we considered T0 = 2 weeks after the first dose where available, or the nearest time point.</p><p>For neutralizing antibodies against SARS&#8208;CoV&#8208;2, we considered T0 = 2 weeks after the second dose where available, or the nearest time point.</p></sec></sec></sec><sec id="CD015477-sec-0030"><title>Search methods for identification of studies</title><p>We used the search strategies defined in the protocol of the larger COVID&#8208;NMA initiative (<uri>covid-nma.com</uri>) (<xref rid="CD015477-bbs2-0061" ref-type="ref-list">Boutron 2020b</xref>), and outlined in&#160;<xref rid="CD015477-sec-0302" ref-type="app">Appendix 2</xref>&#160;to identify randomized trials evaluating vaccines for COVID&#8208;19. The search methods and strategies to identify records for this review are being revised approximately yearly, to ensure that they reflect any terminology changes in the topic area, or in the databases.&#160;</p><sec id="CD015477-sec-0031"><title>Electronic searches</title><p>The&#160;Epistemonikos&#160;L&#183;OVE COVID&#8208;19 platform was searched regularly from 4 September 2020 until 5 November 2021 (<xref rid="CD015477-bbs2-0082" ref-type="ref-list">Epistemonikos</xref>) (<uri>app.iloveevidence.com/covid19</uri>). This platform is a digital repository built by systematic searches in multiple databases, trial registries and preprint servers. Complete data sources and search methods are available at: <uri>app.iloveevidence.com/covid19/methods</uri>.</p><p>The&#160;Cochrane<bold>&#160;</bold>COVID&#8208;19 Study Register has been searched on a regular basis (<uri>covid-19.cochrane.org/</uri>; last searched 5 November 2021). The&#160;Cochrane&#160;COVID&#8208;19 Study Register is a specialized register built within the&#160;Cochrane&#160;Register of Studies (CRS) and is maintained by&#160;Cochrane&#160;Information Specialists. The register contains study reports from several sources, including:&#160;</p><p><list id="CD015477-list-0013" list-type="bullet"><list-item><p>daily searches of PubMed;</p></list-item><list-item><p>daily searches of ClinicalTrials.gov;</p></list-item><list-item><p>weekly searches of Embase.com;</p></list-item><list-item><p>weekly searches of the WHO International Clinical Trials Registry Platform (ICTRP);</p></list-item><list-item><p>weekly searches of medRxiv;</p></list-item><list-item><p>monthly searches of the&#160;Cochrane&#160;Central Register of Controlled Trials (CENTRAL).</p></list-item></list></p><p>Complete data sources and search methods for the register are available at: <uri>community.cochrane.org/about-covid-19-study-register</uri>.</p><p>We also searched the Retraction Watch Database for retracted studies (<uri>retractionwatch.com/retracted-coronavirus-covid-19-papers/</uri>; last searched 5 November 2021).</p><p>We also systematically searched for updates or publications of preprints using a preprint tracker, developed in collaboration with a research team from the French National Centre for Scientific Research (CNRS) (<xref rid="CD015477-bbs2-0064" ref-type="ref-list">Cabanac 2021</xref>).&#160;</p></sec><sec id="CD015477-sec-0032"><title>Searching other resources</title><p>We searched the following trial registries for unpublished and ongoing studies.</p><p><list id="CD015477-list-0014" list-type="bullet"><list-item><p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<uri>trialsearch.who.int/</uri>), to identify ongoing and completed clinical trials on COVID&#8208;19 (last searched 3 November 2021). We used the <italic toggle="yes">List by Health Topic</italic>: 2019&#8208;nCoV / COVID&#8208;19 filter to retrieve all studies identified.&#160;</p></list-item><list-item><p>European Medicines Agency (EMA) clinical data website (<uri>clinicaldata.ema.europa.eu/web/cdp/home</uri>) to identify trials submitted to the EMA and also for the clinical study report (CSR) of eligible studies (last searched 5 November 2021).&#160;</p></list-item><list-item><p>FDA website (<uri>www.fda.gov</uri>) to identify FDA approval trials (last searched 5 November 2021).</p></list-item></list></p></sec></sec><sec id="CD015477-sec-0033"><title>Data collection and analysis</title><p>We search, screen and extract data weekly. The analysis is updated online every 2 weeks (<uri>covid-nma.com</uri>). The next update will be conducted soon after the publication of this review.</p><sec id="CD015477-sec-0034"><title>Selection of studies</title><p>&#160;We searched and screened the citations retrieved and used a spreadsheet to document search dates and citations identified. We identified duplicates in Rayyan (<xref rid="CD015477-bbs2-0125" ref-type="ref-list">Ouzzani 2016</xref>), and then in a spreadsheet to enhance sensitivity. Two review authors (CR, HB) independently screened records and abstracts; a third review author (RA) resolved any disagreements.</p><p>We did not check the references of included reports as the living search process identifies COVID&#8208;19 trial records prospectively from the point of trial registration.&#160;</p><p>Whenever both preprints and subsequent peer&#8208;reviewed publications were available, we favoured the latter as they are the latest documents of trial findings (<xref rid="CD015477-bbs2-0061" ref-type="ref-list">Boutron 2020b</xref>).</p><p>We retrieved CSRs for four vaccines (BNT162b2 &#8211; BioNtech/Fosun Pharma/Pfizer; mRNA&#8208;123 &#8211; ModernaTX; ChAdOx1 &#8211; Astra Zeneca+University of Oxford; and AD26.COV2.S &#8211; Janssen Pharmaceutical Companies) from the EMA website (<uri>www.ema.europa.eu/en</uri>). For three vaccines (BNT162b2, mRNA&#8208;123 &#8211; ModernaTX and Ad26.COV2.S), we found minor discrepancies when compared to the data reported in the peer&#8208;reviewed publication. Discrepancies were due to different cut&#8208;off dates and follow&#8208;up lengths. We were unable to compare data between the CSR and the peer&#8208;reviewed publication for one vaccine (ChAdOx1) since the publication reports pooled results for four trials (COV001, COV002, COV003, and COV005) and the CSR contains data for only two of them (COV002 and COV003).&#160;</p></sec><sec id="CD015477-sec-0035"><title>Data extraction and management</title><p>All data were extracted in duplicate. Two review authors (HB, BB) independently read each preprint, publication, protocol, or other study reports, evaluated the completeness of the data, and assessed the risk of bias. Based on a pilot data extraction form, we designed, evaluated and modified a specific structured data extraction form whenever needed to ensure consistency in the extraction of information. The form was implemented on the COVID&#8208;NMA platform on the extraction module explicitly developed for this purpose (<uri>covid-nma.com</uri>). All discrepancies automatically identified by the platform data extraction module were discussed by the two review authors to reach a consensus.</p><p>Information extracted included study characteristics (such as first author, publication year and journal), number of participants randomized, patient characteristics (age, sex, pre&#8208;existing neutralizing or specific antibodies or participants seropositive, comorbidities), intervention details (type of vaccines, dosing, schedule and route of administration), outcome measures, and risk of bias assessment.&#160;</p><p>For dichotomous outcomes, we extracted the number of events and number of total participants in each study arm.&#160;</p><p>For <italic toggle="yes">efficacy outcomes</italic>, we extracted vaccine efficacy as reported by the authors and 95% confidence interval (CI) for each outcome, when available. Vaccine efficacy measures the percentage reduction in incidence of cases among vaccinated persons compared to unvaccinated persons. It is usually calculated as the incidence rate among unvaccinated &#8211; incidence rate among vaccinated / the incidence rate among unvaccinated.&#160;</p><p>For <italic toggle="yes">immunogenicity outcomes</italic>, we recorded GMTs and 95% CIs for specific and neutralizing antibodies in the control and intervention. We extracted results related to cellular response as reported by authors.</p><p>For <italic toggle="yes">safety outcomes,</italic> we extracted the data as analyzed by the authors.</p><p>We extracted the data as analyzed by the trial authors.&#160;</p><p>To explore vaccine efficacy on variants of concern, such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), we also took into account that:</p><p><list id="CD015477-list-0015" list-type="bullet"><list-item><p>vaccine efficacy on variants of concern is determined by sequencing all available cases where available;</p></list-item><list-item><p>study authors extrapolated vaccine efficacy on variants of concern&#160;</p><list id="CD015477-list-0016" list-type="bullet"><list-item><p>considering the prevalent variant during the study period</p></list-item><list-item><p>from other sources: the information was extrapolated from data on the prevalence of the variant in the population during the study period. This information was obtained from <uri>outbreak.info</uri> or other sources.</p></list-item></list></list-item></list></p><p>This was done only for critical outcomes of efficacy.&#160;</p></sec><sec id="CD015477-sec-0036"><title>Assessment of risk of bias in included studies</title><p>We assessed each study with the&#160;Cochrane&#160;RoB 2 tool for randomized controlled trials (<xref rid="CD015477-bbs2-0155" ref-type="ref-list">Sterne 2019</xref>). We assessed risk of bias for the critical outcomes of the review. We recorded judgements for each domain using the online data extraction tool we developed. Risk of bias was assessed independently, in duplicate with consensus by researchers with epidemiological training (currently 4 people) or&#160;Cochrane&#160;Response members (the number of people involved varies). All have been previously trained in clinical epidemiology and systematic reviews. All have participated in a training programme where they had to read the training material and perform data extraction and RoB assessments with a team of experienced researchers. The data quality was assessed by the&#160;Cochrane&#160;Bias Methods Group, who checked a random sample of 10% of the extracted reports.</p><p>The&#160;Cochrane&#160;RoB 2 tool is structured into five domains: 1) risk of bias arising from the randomisation process; 2) risk of bias due to deviations from intended interventions; 3) risk of bias due to missing outcome data; 4) risk of bias in the measurement of the outcome; and 5) risk of bias in the selection of the reported result. Within each domain, a series of 'signalling questions' elicit information relevant to the risk of bias assessment. The response options to the signalling questions are: "yes"; "probably yes"; "probably no"; "no"; and "no information." A risk of bias judgement for each domain is generated by an algorithm, based on answers to the signalling questions. Judgement can be 'low', &#8216;some concerns&#8217; or 'high' risk of bias. Overall, risk of bias will be considered as "low risk of bias" if all domains are at 'low risk;' "some concerns" if at least one domain is of &#8216;some concern&#8217; and no domains are 'high risk of bias;' and "high risk of bias" if there is at least one domain assessed as 'high risk,' or several domains with 'some concerns.' In the context of this review, we are interested in quantifying the effect of assignment to the interventions at baseline, regardless of whether the interventions are received as intended (i.e. the intention&#8208;to&#8208;treat effect).</p><p>For cluster&#8208;randomized trials, if any, we planned to rely on the extension of the RoB tool 2 for cluster&#8208;randomized trials. Particularly, we planned to add the domain 1b: risk of bias arising from the timing of identification or recruitment of participants in a cluster&#8208;randomized trial. There were no cluster&#8208;RCTs reported by the date of the last search.</p><p>While we relied on the signalling questions to assess each domain and justify our assessment, we did not record the answers of systematic reviewers or how consensus was obtained for the signalling questions; this was done only at the domain level.</p><p>The risk of bias assessment was considered part of an evaluation of the certainty of the evidence and sensitivity analysis.</p></sec><sec id="CD015477-sec-0037"><title>Measures of treatment effect</title><p>For dichotomous outcomes, we used vaccine efficacy and risk ratio accompanied by the 95% CI as a measure of effect. For outcomes measured with GMTs, we calculated the geometric mean ratios (GMRs) by taking the anti&#8208;log of the mean difference of the log transformed data between arms.</p><p>To date, all trials reported vaccine efficacy. In the future if we identify trials reporting only rate ratio, we will calculate vaccine efficacy using the formula rate ratio = 1 &#8722; VE/100.</p></sec><sec id="CD015477-sec-0038"><title>Unit of analysis issues</title><p>We analyzed separately different comparisons from multiple&#8208;arm trials for all pairwise meta&#8208;analyses.&#160;</p></sec><sec id="CD015477-sec-0039"><title>Dealing with missing data</title><p>For missing outcome data, we extracted the number of participants who dropped out before the completion of the study, and how the study authors handled missing data. We assessed the appropriateness of any imputation methods used to account for early dropouts in our risk of bias assessments. We conducted sensitivity analysis to assess the potential impact of missing outcome data on the results.</p></sec><sec id="CD015477-sec-0040"><title>Assessment of heterogeneity</title><p>We first generated descriptive statistics for study and population characteristics, and we examined the distribution of important clinical and methodological variables (such as age, immunocompromized status, location etc.). We have considered the variability in point estimates and the overlap in CIs in addition to the I<sup>2</sup> statistic to assess the level of statistical heterogeneity (<xref rid="CD015477-bbs2-0139" ref-type="ref-list">Riley 2011</xref>).&#160;</p></sec><sec id="CD015477-sec-0041"><title>Assessment of reporting biases</title><p>We assessed the selective non&#8208;reporting or under&#8208;reporting of results in the trials identified according to the framework proposed in Chapter 13 of the&#160;<italic toggle="yes">Cochrane Handbook for Systematic Reviews of Interventions</italic> (<xref rid="CD015477-bbs2-0101" ref-type="ref-list">Higgins 2021</xref>).</p></sec><sec id="CD015477-sec-0042"><title>Assessment of risk of bias due to missing results in the included studies</title><p>We checked whether the results of all our critical and important outcomes were reported as prespecified in the first version of the trial registry. When more than one version was available and the outcomes were modified, we checked the date of the modification using &#8220;history of changes.&#8221; Of note, some platforms do not provide information about previous versions of the registers. In these cases, we could not know whether we were assessing the original. When registration was not prospective, we also checked the protocol or statistical analysis plan if available.</p><p>We used a matrix indicating the availability of study results as recommended in the&#160;<italic toggle="yes">Cochrane Handbook for Systematic Reviews of Interventions</italic> (<xref rid="CD015477-bbs2-0101" ref-type="ref-list">Higgins 2021</xref>;&#160;<xref rid="CD015477-bbs2-0104" ref-type="ref-list">Kirkham 2018</xref>).</p><p>We evaluated whether results were unavailable because of the results' P value, magnitude, or direction. We considered the risk of bias due to missing results if an outcome specified in the registry was missing from the main report.</p><p>Due to the small number of trials, we could not assess the potential for reporting bias across studies graphically or statistically.</p></sec><sec id="CD015477-sec-0043"><title>Data synthesis</title><p>We analyzed each type of vaccine separately. We combined trials with comparators as placebo or adjuvant or other control together under the same comparison at the specific vaccine level. We included all eligible RCTs in the primary analysis, whatever the risk of bias assessment. We included early&#8208;phase trials in the analysis only when the selected dose was clearly defined and efficacy outcomes (usually assessed in Phase 3 trials) were available.</p><p>We performed a pairwise meta&#8208;analysis and presented summary effect estimates with 95% CIs for each direct comparison, with at least two studies providing data. We used the random&#8208;effects model to incorporate the anticipated clinical and methodological heterogeneity across studies. We presented trials reporting zero events in both arms in the forest plot but did not incorporate these in the analysis.</p><p>In the presence of excessive heterogeneity across studies (i.e. diverse forest plots or Tau<sup>2</sup> &gt; 75% quartile of empirical distributions, or both) (<xref rid="CD015477-bbs2-0157" ref-type="ref-list">Turner 2012</xref>), we did not synthesize the trial data quantitatively but qualitatively unless we could set up homogeneous subsets of the available trials.</p><p>All analyses were undertaken with the statistical software environment R (version 4.0.3) using the packages metafor and meta (<xref rid="CD015477-bbs2-0058" ref-type="ref-list">Balduzzi 2019</xref>;&#160;<xref rid="CD015477-bbs2-0159" ref-type="ref-list">Viechtbauer 2010</xref>).</p><p>We initially planned to conduct a network meta&#8208;analysis (NMA); however, the network of vaccines appeared very sparse, included mainly comparisons of vaccines against placebo, and only one or two studies informed most of the available comparisons (<xref rid="CD015477-fig-0001" ref-type="fig">Figure 1</xref>). A network of such structure does not allow proper evaluation of the synthesis assumptions. Additionally, the NMA estimates from this network would not be substantially more precise (and could even be less precise for some comparisons) than the direct ones. We will reassess the feasibility of conducting an NMA regularly as part of the living systematic review process (details of the NMA methods considered for future update versions are available in&#160;<xref rid="CD015477-sec-0305" ref-type="app">Appendix 3</xref>).</p><fig id="CD015477-fig-0001" position="float" orientation="portrait"><label>1</label><caption><p>Network graph. The size of the nodes is proportional to the number of participants randomized and the thickness of the lines to the number of studies in each comparison.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-01.jpg"/></fig></sec><sec id="CD015477-sec-0044"><title>Subgroup analysis and investigation of heterogeneity</title><p>We had planned to perform subgroup analyses for critical outcomes only (<xref rid="CD015477-bbs2-0061" ref-type="ref-list">Boutron 2020b</xref>). For future updates, we will pursue our prespecified subgroup analyses to explore whether the following population characteristics explain sources of heterogeneity.</p><p><list id="CD015477-list-0017" list-type="bullet"><list-item><p>Age:</p><list id="CD015477-list-0018" list-type="bullet"><list-item><p>children or adolescents (aged less than 18 years);</p></list-item><list-item><p>adults (aged 18 to 59 years);</p></list-item><list-item><p>older adults (aged greater than 60 years).</p></list-item></list></list-item><list-item><p>Specific populations:</p><list id="CD015477-list-0019" list-type="bullet"><list-item><p>immunocompromized people;</p></list-item><list-item><p>pregnant women.</p></list-item></list></list-item></list></p><p>It should be noted that, as the evidence base on COVID&#8208;19/SARS&#8208;CoV&#8208;2 and its variants continues to evolve, we will reassess the feasibility of performing these subgroup analyses in future updates of the review when we could also evaluate the impact of the different SARS&#8208;CoV&#8208;2 variants in a meta&#8208;regression model.</p><p>For the current review, we assessed the level of heterogeneity by visual inspection of forest plots, the I<sup>2</sup> statistic, the between&#8208;study variance (Tau<sup>2</sup>), and prediction intervals.&#160;</p></sec><sec id="CD015477-sec-0045"><title>Sensitivity analysis</title><p>We performed sensitivity analyses for critical outcomes only. We performed sensitivity analyses by excluding RCTs reported in preprint only and early&#8208;phase trials (1 and 2). We also ran the analyses using the number of participants randomized instead of those analyzed for safety outcomes to assess the potential impact of missing outcome data on the results. For efficacy outcomes, it was not possible to calculate the effect estimate (vaccine efficacy) using the number of participants randomized. We did not perform the planned sensitivity analysis that excluded RCTs with an overall high risk of bias since no RCTs were considered at high risk of bias.&#160;</p></sec><sec id="CD015477-sec-0046"><title>Summary of findings and assessment of the certainty of the evidence</title><p>To evaluate the certainty of the evidence in the results of the pairwise comparisons for all outcomes except immunogenetic outcomes, overall certainty of the evidence for each outcome was assessed by one review author (KP) and cross&#8208;checked by another review author (AJ) using the GRADE approach (<xref rid="CD015477-bbs2-0149" ref-type="ref-list">Sch&#252;nemann 2021</xref>). We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence. The assessment of imprecision was based on a non&#8208;contextualized approach i.e. rating the certainty that there is any effect (<xref rid="CD015477-bbs2-0103" ref-type="ref-list">Hultcrantz 2017</xref>;&#160;<xref rid="CD015477-bbs2-0176" ref-type="ref-list">Zeng 2021a</xref>), with the null effect as the threshold for the critical outcomes of mortality and SAEs (<xref rid="CD015477-bbs2-0096" ref-type="ref-list">Guyatt 2011</xref>). In the description of the results for each outcome, we use different thresholds for the size of the effects.</p><p>For outcomes reported as vaccine efficacy, we used a threshold of 30%, based on the WHO guidance document which indicated that the primary efficacy endpoint estimate for a placebo&#8208;controlled trial should be at least 50%, with a statistical success criterion that the lower bound of the confidence interval be more than 30% (<xref rid="CD015477-bbs2-0165" ref-type="ref-list">WHO 2020b</xref>;&#160;<xref rid="CD015477-bbs2-0166" ref-type="ref-list">WHO 2020c</xref>). For additional adverse event outcomes (i.e. any adverse event, systemic reactogenicity events, and local reactogenicity events), we considered the thresholds for an effect to be RRs of 0.75 and 1.25 for downgrading imprecision.&#160;</p><p>For all&#8208;cause mortality and SAEs, we considered the effect was "large" when the absolute difference was greater than 5%; there was a "slight" effect when the absolute difference was from 1% to 5%, and there was "little or no effect" when the absolute difference was less than 1%.&#160;</p><p>For vaccine efficacy outcomes, when the effect estimate was 70% or greater we considered the vaccine to have a "large effect" (<xref rid="CD015477-bbs2-0165" ref-type="ref-list">WHO 2020b</xref>;&#160;<xref rid="CD015477-bbs2-0166" ref-type="ref-list">WHO 2020c</xref>).</p><p>For any adverse event, systemic reactogenicity events, and local reactogenicity events, we considered the effect as a "large effect" when the absolute difference was greater than 25%; a "slight effect" when the absolute difference was from 10% to 25%, and "little or no effect" when the absolute difference was less than 10%.&#160;</p><p>We prepared summary of findings tables to present estimated relative and absolute risks for critical and important outcomes, except for immunogenicity outcomes. We calculated absolute effects with&#160;<xref rid="CD015477-bbs2-0095" ref-type="ref-list">GRADEpro GDT</xref>&#160;using the pooled baseline risks from the control groups of the included studies. Absolute effects are presented per 1000 for the outcomes 'any adverse event,' 'systemic adverse events,' and 'local adverse events,' and in remaining outcomes with low baseline risk (control group event rates less than 1%) per 100,000. We did not report absolute effect for results with low or very low certainty. For outcomes where vaccine efficacy is presented as the effect measure in the summary of findings tables, we used the corresponding RR to calculate the absolute effect. The rationale for using a footnote for the length of follow&#8208;up was to add the specific time per individual study for each outcome.&#160;</p></sec></sec></sec><sec id="CD015477-sec-0047"><title>Results</title><sec id="CD015477-sec-0048"><title>Description of studies</title><p>The full description of included studies is available at <uri>zenodo.org/record/6963352#.YuvhdhzP3RY</uri>. Characteristics of excluded studies and unpublished registered studies are summarized in&#160;the&#160;<xref rid="CD015477-sec-0491" ref-type="sec">Characteristics of excluded studies</xref>&#160;section and&#160;in&#160;<xref rid="CD015477-sec-0313" ref-type="app">Appendix 4</xref>, respectively.</p><sec id="CD015477-sec-0049"><title>Results of the search</title><p>The results of the searches are detailed in&#160;<xref rid="CD015477-fig-0002" ref-type="fig">Figure 2</xref>. On 5 November 2021, after excluding duplicates, we screened 48,047 records: 701 were eligible for full&#8208;text screening; we included 111 reports of 76 studies evaluating vaccine candidates against SARS&#8208;CoV&#8208;2. Thirty early&#8208;phase randomized trials (36 reports) are pending due to uncertainty regarding concentration of the vaccine candidate to be selected for the phase 3 trial or lack of results on efficacy for the selected dose reported in a phase 3 trial (<xref rid="CD015477-sec-0314" ref-type="app">Appendix 5</xref>). In seven reports of trials already included in the analysis and in five other reports of trials not included in the analysis, we did not find any outcomes of interest or we were unable to extract the data (i.e. results reported only as figures or in graphs) (<xref rid="CD015477-sec-0315" ref-type="app">Appendix 6</xref>). Overall, we included 41 studies in the analyses. These studies assessed four different types of vaccine platforms: RNA&#8208;based vaccines (six studies), non&#8208;replicating viral vector vaccines (10 studies), inactivated virus vaccines (13 studies), and protein subunit vaccines (six studies). They also assessed heterologous vaccine schedules and the effect of booster doses (six studies). Of note, we did not identify any trials reporting the efficacy outcome of interest for the vaccine Ad5&#8208;vectored (non&#8208;replicant viral vector) (<xref rid="CD015477-bbs2-0180" ref-type="ref-list">Zhu 2021a</xref>); however, its efficacy as part of a heterologous scheme is assessed in a trial included in the analysis (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>).&#160;</p><fig id="CD015477-fig-0002" position="float" orientation="portrait"><label>2</label><caption><p>PRISMA flow diagram of included randomized controlled trials (RCTs) (last search date 5 November 2021). COVID&#8208;NMA is a living systematic review of all trials assessing treatment and preventive interventions for COVID&#8208;19 (<xref rid="CD015477-bbs2-0060" ref-type="ref-list">Boutron 2020a</xref>). This review is a subreview of the COVID&#8208;NMA.</p><p>FDA: Food and Drug Administration; ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="tCD015477-FIG-02.jpg"/></fig></sec><sec id="CD015477-sec-0050"><title>Included studies</title><sec id="CD015477-sec-0051"><title>Source of the data</title><p>We identified 41 trials overall. There were 37 primary analyses (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;&#160;<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>;&#160;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>;&#160;<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>;&#160;<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>;&#160;<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>;&#160;&#160;<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>;&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>;&#160;<xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>;&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>), and&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>,&#160;which was a combined analysis of four trials ((COV001 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>), COV002 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>), COV003 (ISRCTN89951424), COV005 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>)).</p><p>We also identified four articles reporting secondary analyses of the four trials included in&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>.&#160;<xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref>&#160;reported results by variants for COV002 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>);&#160;<xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref>&#160;reported results by variants for COV003 (ISRCTN89951424);&#160;<xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>&#160;reported results by variants for COV005 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>); and&#160;<xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;reported results for participants with HIV included in COV005 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>).</p><p>The 41 included trials were reported in 63 reports (34 peer&#8208;reviewed publications, 22 reports of preprints, four clinical study reports, and three FDA briefings). Of the 34 peer&#8208;reviewed publications, 17 were published with earlier versions&#160;(<xref rid="CD015477-sec-0316" ref-type="app">Appendix 7</xref>). Data were initially extracted from these reports and then updated with subsequent publications. Only the latest versions of the reports are referenced. Most of the trials included were performed and results were retrieved before the detection of variants of concern. Overall, 10 trials reported results for a specific SARS&#8208;CoV&#8208;2 variant of concern; four trials presented results on the Alpha variant (B.1.1.7) (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>), four on Beta variant (B.1.351) (<xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>), two on Gamma variant (P.1) (<xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref>;&#160;<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>), and one on Delta (B.1.617.2) (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>).</p></sec><sec id="CD015477-sec-0052"><title>Study design</title><p>All trials used a parallel&#8208;group individually randomized design. Twenty&#8208;six of the RCTs included in the analysis had two arms (63.4%) and 15 (36.6%) were multiple&#8208;arm trials. There were 13 early&#8208;phase trials: three phase 1 (<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>;&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>), seven phase 1&#8208;2 (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>), and three phase 2 (<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>). In 40 trials (97.5%) the outcome assessor was blinded. All trials evaluating BNT162b2 (three), mRNA&#8208;1273 (two), CVnCoV RNA (one), Ad26.COV2.S (two), and NVX&#8208;CoV2373 (five) used placebo (normal saline) in the control arm. All trials assessing Gam&#8208;COVID&#8208;Vac (one), CoronaVac (six), WIBP&#8208;CorV (two), BBIBP&#8208;CorV (three), BBV152 (two), and FINLAY&#8208;FR&#8208;2 (one) used adjuvant in the control arm. In the case of ChAdOx1/SII&#8208;ChAdOx1, three trials used placebo (normal saline) in the control arm (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>), three used a non&#8208;COVID&#8208;19 vaccine (MenACWY) (COV001, COV002 and COV003 included in&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>), and one used adjuvant (<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>). Two trials assessing heterologous vaccine schedules used regular homologous vaccine schedules as control (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>), and four trials compared the effect of different vaccine booster schedules (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>).</p><p>Recruitment was completed for 33 trials (80.4%), ongoing for seven trials that reported results of prespecified interim analyses (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>), and one trial was terminated due to an emergency use authorization for the vaccine candidate (<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>). The mean sample size was 10,581 participants with median of 504 (interquartile range (IQR) 180 to 21,977; range: minimum 42 to maximum 44,325).</p></sec><sec id="CD015477-sec-0053"><title>Study registration</title><p>All trial registration records were available; three trials were registered retrospectively (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>).</p></sec><sec id="CD015477-sec-0054"><title>Settings</title><p>Overall, 32 RCTs were multicentre and nine were single&#8208;centre trials (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>). The trials took place in Asia (14 trials, 34.1%), Europe (eight trials, 19.5%), North America (seven trials, 17.0%), worldwide (five trials, 12.1%), South America (four trials, 9.7%), Africa (two trials, 4.8%), and Oceania (one trial, 2.4%).</p></sec><sec id="CD015477-sec-0055"><title>Characteristics of participants</title><p>There were 433,838 participants randomized; 250,200 (57.7%) were assigned to the intervention and 183,638 (42.3%) to the control arm. The number of participants analyzed varied by outcome, from 408 to 418,803 participants. The age range was between three and 100 years; 26 trials included participants 18 years of age or older, seven trials included adults between 18 and 65 years of age, two trials included participants 50 years or older (<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>), two trials included participants 12 years old or older (<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>;&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>), two trials included only adolescents 12 to 17 years old (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>). Two trials included children and adolescents three to 17 years of age (<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>). Overall, 54.0% of participants were male and the mean age ranged between 14 years (minimum) to 61 years (maximum).</p><p>Most trials (n = 35, 85.3%) enrolled healthy or clinically stable participants with no history of SARS&#8208;CoV&#8208;2 infection or COVID&#8208;19 diagnosis, four trials enrolled healthcare workers or individuals considered at substantial risk of exposure to and infection with SARS&#8208;CoV&#8208;2 (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>), and two trials included immunocompromized participants in trials assessing booster dose; transplant recipients (<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>) and adults under current rituximab therapy (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>). Thirty&#8208;seven of 41 trials reported that pregnancy was an exclusion criterion. No trials reported data on vaccine efficacy and safety in pregnant women.</p></sec><sec id="CD015477-sec-0056"><title>Details of the intervention</title><p>The included trials reported on four types of vaccine platforms and 12 vaccine candidates: three RNA&#8208;based vaccines (BNT162b2, mRNA&#8208;1273 and CVnCoV), three non&#8208;replicating viral vector vaccines (Ad26.COV2.S, ChAdOx1/SII&#8208;ChAdOx1 and Gam&#8208;COVID&#8208;Vac), four inactivated virus vaccines (CoronaVac, WIBP&#8208;CorV, BBIBP&#8208;CorV and BBV152), and two protein subunit vaccines (NVX&#8208;CoV2373 and FINLAY&#8208;FR&#8208;2). As SII&#8208;ChAdOx1, manufactured in India at Serum Institute of India, is the equivalent of ChAdOx1, we pooled the results for both vaccines in the analysis.</p><p>All COVID&#8208;19 vaccine candidates are to be administered through an intramuscular injection. Most of the vaccine candidates full vaccination schedules relied on two doses with a between&#8208;dose time interval varying from 14 to 28 days; however, four trials reported a time interval between doses of less than six weeks to 12 weeks or greater for ChAdOx1 (<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>), and one trial one to three months for heterologous compared to a homologous scheme (CoronaVac/Ad5 versus CoronaVac/CoronaVac) (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>). One vaccine candidate had a two&#8208;dose schedule in adults and three&#8208;dose schedule in children and adolescents (BBIBP&#8208;CorV); one vaccine candidate necessitates a single dose (Ad26.COV2.S), and six studies evaluated the effect of a homologous compared to a heterologous booster dose; the time intervals between complete vaccination and boosters are 28 days (<xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>), one month (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>), two months (<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>), three months (<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>), four months (mean) (<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>), and three to six months (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>). There were no studies on variant&#8208;adapted booster doses.</p></sec><sec id="CD015477-sec-0057"><title>Outcome measurement</title><p>There was some heterogeneity in the way outcomes were assessed.&#160;</p><p>The definition of 'severe or critical disease' was most often based on the WHO clinical progression scale (<xref rid="CD015477-bbs2-0116" ref-type="ref-list">Marshall 2020</xref>). 'Serious adverse events' were assessed using different grading scales such as ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for Human Use (<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>), Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>), and toxicity grading scales adapted from Food and Drug Administration (FDA) grading guidance (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>). The list of definitions used for both outcomes is in&#160;<xref rid="CD015477-sec-0301" ref-type="app">Appendix 1</xref>.&#160;</p></sec><sec id="CD015477-sec-0058"><title>Funding and conflict of interest</title><p>Trials received mixed (private and public) funding (20 trials, 48.78%), public/non&#8208;profit funding (14 trials, 34.14%), and private funding (seven trials, 17.07%). Overall, 37 trials declared competing interests and four trials declared no competing interests (<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>).</p></sec></sec><sec id="CD015477-sec-0059"><title>Excluded studies</title><p>We excluded 590 reports; 579 were RCTs evaluating other interventions and were consequently included in the COVID&#8208;NMA platform (<uri>covid-nma.com</uri>); 11 reports evaluated vaccines but were not eligible for the review (<xref rid="CD015477-bbs2-0043" ref-type="ref-list">Baden 2021</xref>;&#160;<xref rid="CD015477-bbs2-0044" ref-type="ref-list">Barrett 2021</xref>;&#160;<xref rid="CD015477-bbs2-0045" ref-type="ref-list">Ewer 2021</xref>;&#160;<xref rid="CD015477-bbs2-0046" ref-type="ref-list">Flaxman 2021</xref>;&#160;<xref rid="CD015477-bbs2-0047" ref-type="ref-list">Hsieh 2021</xref>;&#160;<xref rid="CD015477-bbs2-0048" ref-type="ref-list">Irfan 2021</xref>;&#160;<xref rid="CD015477-bbs2-0049" ref-type="ref-list">Lazarus 2021</xref>;&#160;<xref rid="CD015477-bbs2-0050" ref-type="ref-list">Patamatamkul 2021</xref>;&#160;<xref rid="CD015477-bbs2-0051" ref-type="ref-list">Ward 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0052" ref-type="ref-list">Wu 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0053" ref-type="ref-list">Zdanowski 2021</xref>). Reasons for exclusion included: not randomized (five reports), secondary analysis (two reports), intervention not relevant to the review (two reports), exploratory analysis (one report), and comment (one report). See&#160;<xref rid="CD015477-sec-0491" ref-type="sec">Characteristics of excluded studies</xref>&#160;table.</p><sec id="CD015477-sec-0060"><title>Ongoing studies</title><p>We identified 343 trials from registries; 10 were completed, two were terminated, 172 were not recruiting, 155 were ongoing and four were cancelled (<xref rid="CD015477-sec-0313" ref-type="app">Appendix 4</xref>).&#160;</p><sec id="CD015477-sec-0061"><title>RNA&#8208;based vaccine</title><p>We identified 73 unpublished trials; 34 were not recruiting (67,412 participants planned) and 39 were ongoing (192 participants planned).</p></sec><sec id="CD015477-sec-0062"><title>Non&#8208;replicating viral vector</title><p>We identified 73 unpublished trials; there was one completed trial without results available (27 participants planned), 39 not recruiting (60,018 participants planned), 32 ongoing (157,387 participants planned), and one cancelled (1210 participants planned).</p></sec><sec id="CD015477-sec-0063"><title>Replicating viral vector</title><p>We identified 10 unpublished trials; one completed trial without results available (90 participants planned), four not recruiting (40,950 participants planned), three ongoing (6434 participants planned), and two terminated (495 participants planned).</p></sec><sec id="CD015477-sec-0064"><title>Inactivated virus</title><p>We identified 61 unpublished trials; four completed trials without results available (19,512 participants planned), 25 not recruiting (146,312 participants planned), and 32 ongoing (122,182 participants planned).</p></sec><sec id="CD015477-sec-0065"><title>Protein subunit</title><p>We identified 91 unpublished trials; two completed trials without results available (173 participants planned), 56 not recruiting (605,200 participants planned), 31 ongoing (260,273 participants planned), and two terminated (no participants).</p></sec><sec id="CD015477-sec-0066"><title>Live attenuated virus</title><p>We identified two studies not recruiting (163 participants planned).</p></sec><sec id="CD015477-sec-0067"><title>DNA&#8208;based vaccine</title><p>We identified 18 unpublished trials; two completed trials without results available (30 participants planned), nine not recruiting (16,238 participants planned), and seven ongoing (997 participants planned).</p></sec><sec id="CD015477-sec-0068"><title>Virus&#8208;like particles</title><p>We identified 12 unpublished trials; two not recruiting (1818 participants planned), nine ongoing (2546 participants planned), and one terminated (997 participants planned).</p></sec><sec id="CD015477-sec-0069"><title>Any SARS&#8208;CoV&#8208;2 vaccine</title><p>We identified three trials; two recruiting (2300 participants planned) and one not recruiting (1314 participants planned).&#160;</p></sec></sec></sec></sec><sec id="CD015477-sec-0070"><title>Risk of bias in included studies</title><p>For the overall risk of bias across trials, we judged 34 trials to have 'some concerns' for at least one outcome; eight trials were at low risk of bias for all outcomes (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>;&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>; <xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>). Further details of these assessments are available in the risk of bias assessment tables (<xref rid="CD015477-sec-0317" ref-type="app">Appendix 8</xref>).</p><sec id="CD015477-sec-0071"><title>Risk of bias arising from the randomisation process</title><p>We judged the risk of bias due to randomization to be appropriate and adequately done in 32 trials. In other trials, the allocation concealment was either unclear (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>), or not reported (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>;&#160;<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>);&#160;we downgraded&#160;<xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>&#160;due to imbalances in baseline characteristics.</p></sec><sec id="CD015477-sec-0072"><title>Risk of bias due to deviations from intended interventions</title><p>Thirty&#8208;four trials were blinded for participants, outcome assessors or healthcare providers, or both. Participants were blinded in six trials (<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(which reported pooled results for four trials)), and blinding was unclear in one (<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>). Nevertheless, no deviations from the intended intervention occurred due to awareness of the intervention received, and we did not downgrade the trials for this reason.</p><p>For efficacy outcomes, we judged the risk of bias due to deviation from intended interventions to be low in 13 trials and have 'some concerns' in 28 trials, mainly because analyses used to estimate the effect of assignment to intervention was inappropriate as most analyses were per protocol for efficacy outcomes. Participants were excluded for positive or unknown baseline SARS&#8208;CoV&#8208;2 status, not receiving a scheduled injection, not receiving the correct injection or major protocol deviation. We considered there would be no substantial impact of failure to analyse participants according to their randomized assignment due to the relatively small number of exclusions or a balanced number of exclusions between arms. In contrast, safety outcomes mainly were analyzed using intention&#8208;to&#8208;treat analysis. We considered this method appropriate to estimate the effect of assignment to intervention.</p></sec><sec id="CD015477-sec-0073"><title>Risk of bias due to missing outcome data</title><p>We judged the risk of bias due to missing outcome data as low for all outcomes for 33 trials. There were no missing data or any missing outcome data were reasonably well&#8208;balanced across intervention groups, with similar reasons for missing data across the groups. Additionally, when missingness was related to deviations from the protocol, it was accounted for in the assessment of bias due to deviations from intended interventions and we did not downgrade the trial due to missing outcome data. For eight trials (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>), we judged the risk of bias as having 'some concerns' since trialists failed to report data for all or nearly all participants for at least one outcome, and missingness could depend on the true value of the outcome, for instance, unbalanced loss to follow&#8208;up due to adverse events or deceased participants not included in the analysis.&#160;</p></sec><sec id="CD015477-sec-0074"><title>Risk of bias in the measurement of the outcome</title><p>We judged the risk of bias as low for all outcomes in 38 trials. We judged three trials as having 'some concerns' due to unclear or not blinded assessment of the safety outcomes whose evaluation can be influenced by knowledge of the intervention assignment (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>;&#160;<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>).</p></sec><sec id="CD015477-sec-0075"><title>Risk of bias in the selection of the reported results</title><p>Thirty&#8208;three trials had prospective registrations or protocols (or both) available with no discrepancies between prespecified and reported outcomes; we judged these trials to be at low risk of bias. Six trials had risk of bias concerns due to reported outcomes that were not prespecified or had discrepancies in time points (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>).&#160;</p></sec><sec id="CD015477-sec-0076"><title>Bias due to missing results in the synthesis</title><p>We present matrices indicating the availability of trial results for critical and important review outcomes in&#160;<xref rid="CD015477-sec-0416" ref-type="app">Appendix 9</xref>. There was evidence of bias due to missing results in four trials:&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>,&#160;<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>,&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>, and&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#160;planned to assess 'GMTs of neutralizing and specific antibodies' but did not report on them.&#160;<xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>&#160;reported 'total adverse events', but only reported on 'local and systemic reactogenicity events', in addition to outcomes 'confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination' and 'GMTs of neutralizing and specific antibodies', which were not reported as well.&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;did not report on the preplanned analysis for 'GMTs of neutralizing and specific antibodies' as well as 'systemic and local reactogenicity events' when compared to placebo.&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>&#160;planned to assess 'GMTs of neutralizing and specific antibodies' and 'confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination' but did not report on them.&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>&#160;in phase 2 did not report on the results of 'serious adverse events'.&#160;<xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref>&#160;did not report on the prespecified outcomes 'systemic and serious adverse events'.&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>&#160;did not report on the prespecified 'local and systemic reactogenicity events'.&#160;<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>&#160;and&#160;<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>&#160;did not report on the prespecified outcome 'confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination'. Finally,&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;reporting on results of four trials did not report on results of 'local adverse events'. Ten registered trials are completed but not yet published (19,832 participants planned); the dates of completion range between 15 January 2021 and 13 October 2021. Publication delay since study completion ranged between 23 days and 295 days.</p></sec><sec id="CD015477-sec-0077"><title>Overview of the risk of bias assessments by outcome</title><p>The outcome 'SARS&#8208;CoV&#8208;2 infection after complete vaccination' was reported in seven trials; in all trials we assessed the overall risk of bias to have 'some concerns'.&#160;</p><p>The outcome 'confirmed symptomatic COVID&#8208;19 after complete vaccination' was reported in 18 trials; in all trials we assessed the overall risk of bias to have 'some concerns'.</p><p>The outcome 'severe or critical COVID&#8208;19 after complete vaccination' was reported in 11 trials. In one of them, we assessed the overall risk of bias for this outcome to be 'low' (<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>). In 10 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'.</p><p>The outcome 'all&#8208;cause mortality' was reported in 22 trials. In 17 trials, we assessed the overall risk of bias for this outcome to be 'low'. In five trials, we assessed the overall risk of bias for this outcome to have 'some concerns'.</p><p>The outcome 'serious adverse events' was reported in 32 trials. In 21 of them, we assessed the overall risk of bias for this outcome to be low. In 11 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'.&#160;</p><p>The outcome 'any adverse event' was reported in 35 trials. In 24 of them, we assessed the overall risk of bias for this outcome to be 'low'. In 11 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'.</p><p>The outcome 'systemic adverse events' was reported in 31 trials. In 15 of them, we assessed the overall risk of bias for this outcome to be 'low'. In 16 trials, we assessed the overall risk of bias for this outcome to have 'some concerns'.&#160;</p></sec></sec><sec id="CD015477-sec-0078"><title>Effects of interventions</title><p>See: <xref rid="CD015477-tbl-0001" ref-type="table">Table 1</xref>; <xref rid="CD015477-tbl-0002" ref-type="table">Table 2</xref>; <xref rid="CD015477-tbl-0003" ref-type="table">Table 3</xref>; <xref rid="CD015477-tbl-0004" ref-type="table">Table 4</xref>; <xref rid="CD015477-tbl-0005" ref-type="table">Table 5</xref>; <xref rid="CD015477-tbl-0006" ref-type="table">Table 6</xref>; <xref rid="CD015477-tbl-0007" ref-type="table">Table 7</xref>; <xref rid="CD015477-tbl-0008" ref-type="table">Table 8</xref>; <xref rid="CD015477-tbl-0009" ref-type="table">Table 9</xref>; <xref rid="CD015477-tbl-0010" ref-type="table">Table 10</xref>; <xref rid="CD015477-tbl-0011" ref-type="table">Table 11</xref>; <xref rid="CD015477-tbl-0012" ref-type="table">Table 12</xref>; <xref rid="CD015477-tbl-0013" ref-type="table">Table 13</xref>; <xref rid="CD015477-tbl-0014" ref-type="table">Table 14</xref>; <xref rid="CD015477-tbl-0015" ref-type="table">Table 15</xref></p><p>We report the network structure, irrespective of the outcomes in&#160;<xref rid="CD015477-fig-0001" ref-type="fig">Figure 1</xref>&#160;and the certainty of evidence for all critical outcomes in the summary of findings tables.&#160;</p><sec id="CD015477-sec-0079"><title>RNA&#8208;based vaccines</title><sec id="CD015477-sec-0080"><title>BNT162b2 &#8211; BioNtech/Fosun Pharma/Pfizer versus placebo (normal saline)</title><p>See&#160;<xref rid="CD015477-tbl-0001" ref-type="table">Table 1</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0448" ref-type="app">Appendix 10</xref>.</p><p>We identified and included three trials in the analysis assessing BNT162b2. The outcomes 'confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination', 'systemic reactogenicity events', 'GMT of specific antibodies against SARS&#8208;CoV&#8208;2' and 'cellular immune response' were not reported for this comparison.</p><sec id="CD015477-sec-0081"><title>Critical outcomes</title><sec id="CD015477-sec-0082"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>). BNT162b2 results in a large reduction in the incidence of symptomatic COVID&#8208;19 after complete vaccination compared to placebo measured at 1.8 months' and six months' follow&#8208;up (vaccine efficacy (VE) 97.84%, 95% confidence interval (CI) 44.25% to 99.92%; I&#178; = 66%; 2 RCTs, 44,077 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0003" ref-type="fig">Figure 3</xref>).<bold>&#160;</bold></p><fig id="CD015477-fig-0003" position="float" orientation="portrait"><label>3</label><caption><p>Analysis 1.1.2: RNA&#8208;based vaccine. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p><p><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;included only participants 12 to 15 years of age.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-03.jpg"/></fig></sec><sec id="CD015477-sec-0083"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p>One trial reported severe or critical COVID&#8208;19 (<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>). BNT162b2 results in a large reduction in the incidence of severe or critical disease due to COVID&#8208;19 compared to placebo measured at six months' follow&#8208;up (VE 95.70%, 95% CI 73.90% to 99.90%; 1 RCT, 46,077 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0004" ref-type="fig">Figure 4</xref>).</p><fig id="CD015477-fig-0004" position="float" orientation="portrait"><label>4</label><caption><p>Analysis 1.1.3: RNA&#8208;based vaccine. Outcome: severe or critical COVID&#8208;19 after complete vaccination.</p><p>*<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;reports pooled results including adults' participants from&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;and adolescent participants from&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-04.jpg"/></fig></sec><sec id="CD015477-sec-0084"><title>All&#8208;cause mortality</title><p>Two trials reported the outcome in 2302 participants at 1.7 months and 4.7 months' follow&#8208;up (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>); there were no events and the trials did not contribute to the effect estimate. Only one study contributed to the analysis (<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>), with a follow&#8208;up of six months. The evidence is uncertain for an effect of BNT162b2 on all&#8208;cause mortality compared to placebo due to very serious imprecision (risk ratio (RR) 1.07, 95% CI 0.52 to 2.22; 1 RCT, 43,847 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0005" ref-type="fig">Figure 5</xref>).</p><fig id="CD015477-fig-0005" position="float" orientation="portrait"><label>5</label><caption><p>Analysis 1.1.4: RNA&#8208;based vaccine. Outcome: all&#8208;cause mortality.</p><p><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;included only participants 12 to 15 years of age.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-05.jpg"/></fig></sec><sec id="CD015477-sec-0085"><title>Serious adverse events</title><p>One trial reported the outcome in 42 participants at 1.7 months' follow&#8208;up (<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>); there were no events and the trial did not contribute to the effect estimate. Two trials contributed to the analysis at 1.7 months' follow&#8208;up (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>). The evidence is uncertain for an effect of BNT162b2 on SAEs compared to placebo due to serious inconsistency and serious imprecision (RR 1.30, 95% CI 0.55 to 3.07; I&#178; = 76%; 2 RCTs, 46,107 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0006" ref-type="fig">Figure 6</xref>).</p><fig id="CD015477-fig-0006" position="float" orientation="portrait"><label>6</label><caption><p>Analysis 1.1.5: RNA&#8208;based vaccine. Outcome: serious adverse events (SAEs).</p><p><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;included only participants 12 to 15 years of age.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-06.jpg"/></fig></sec><sec id="CD015477-sec-0086"><title>Any adverse event</title><p>Three RCTs reported the outcome at 1.7 months' follow&#8208;up (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>;&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>). We decided not to pool the results due to considerable heterogeneity (I&#178; = 90%) probably caused by studies assessing participants in different age groups;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;included adults while&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;included adolescents.</p><p>One trial reported results for 43,847 participants 16 years and older (<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>), the RR for any adverse event was 2.17 (95% CI 2.09 to 2.26). Another trial reported results for 2260 participants between 12 and 15 years of age (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>); the RR for any adverse event was 1.01 (95% CI 0.73 to 1.41). A third trial reported results for 42 participants 18 years or older (<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>); the RR for any adverse event in the study was 1.50 (95% CI 0.53 to 4.21) (<xref rid="CD015477-fig-0007" ref-type="fig">Figure 7</xref>).</p><fig id="CD015477-fig-0007" position="float" orientation="portrait"><label>7</label><caption><p>Analysis 1.1.7: RNA&#8208;based vaccine. Outcome: any adverse event (AE).</p><p><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;included only participants 12 to 15 years of age.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-07.jpg"/></fig></sec></sec><sec id="CD015477-sec-0087"><title>Important outcomes</title><sec id="CD015477-sec-0088"><title>GMTs of a neutralizing antibody against SARS&#8208;COV&#8208;2</title><p>Two trials reported GMTs of neutralizing antibodies against SARS&#8208;COV&#8208;2 (<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>). Results are detailed in&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>.&#160;</p></sec><sec id="CD015477-sec-0089"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials.&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;reported the number of participants with stroke and myocardial infarction,&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;reported the number of participants with cavernous sinus thrombosis, venous thrombosis and lymphadenopathy, and&#160;<xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>&#160;did not report any specific safety outcome of interest. These outcomes are summarized in detail in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.</p></sec><sec id="CD015477-sec-0090"><title>Vaccine&#8208;enhanced disease</title><p>This outcome was reported in a single trial which reported no vaccine&#8208;enhanced disease effect (<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>).</p></sec></sec></sec><sec id="CD015477-sec-0091"><title>mRNA&#8208;1273 &#8211; ModernaTX versus placebo (normal saline)&#160;</title><p>See&#160;<xref rid="CD015477-tbl-0002" ref-type="table">Table 2</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0460" ref-type="app">Appendix 13</xref>.</p><p>We identified and included two trials in the analysis assessing mRNA&#8208;1273. The outcomes 'GMT of specific antibodies against SARS&#8208;CoV&#8208;2', 'GMT of neutralizing antibodies against SARS&#8208;CoV&#8208;2' and 'cellular immune response' were not reported for this comparison.</p><sec id="CD015477-sec-0092"><title>Critical outcomes</title><sec id="CD015477-sec-0093"><title>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). mRNA&#8208;1273 probably results in a large reduction in the incidence of SARS&#8208;CoV&#8208;2 infection compared to placebo at 2.3 months (median) and 5.3 months' follow&#8208;up (VE 73.27%, 95% CI 35.82% to 88.87%; I&#178; = 66%; 2 RCTs, 31,632 participants; moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0008" ref-type="fig">Figure 8</xref>).</p><fig id="CD015477-fig-0008" position="float" orientation="portrait"><label>8</label><caption><p>Analysis 1.1.1: RNA&#8208;based vaccine. Outcome: confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination.</p><p><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-08.jpg"/></fig></sec><sec id="CD015477-sec-0094"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>Two trials reported on this outcome (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). mRNA&#8208;1273 results in a large reduction in the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to placebo at 2.3 months (median) and 5.3 months' follow&#8208;up (VE 93.20%, 95% CI 91.06% to 94.83%; I&#178; = 0%; 2 RCTs, 31,632 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="CD015477-sec-0095"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p>The outcome was reported in one trial (<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). mRNA&#8208;1273 results in a large reduction of the incidence of severe or critical disease due to COVID&#8208;19 compared to placebo at 5.3 months' follow&#8208;up (VE 98.20%, 95% CI 92.80% to 99.60%; 1 RCT, 28,451 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="CD015477-sec-0096"><title>All&#8208;cause mortality</title><p>One study reported the outcome in 3726 participants at 2.3 months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>); there were no events and the trial did not contribute to the effect estimate. One trial contributed to the analysis with follow&#8208;up of 5.3 months (<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). The evidence is uncertain for an effect of mRNA&#8208;1273 on all&#8208;cause mortality compared to placebo due to very serious imprecision (RR 1.06, 95% CI 0.54 to 2.10; 1 RCT, 30,346 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0005" ref-type="fig">Figure 5</xref>).</p></sec><sec id="CD015477-sec-0097"><title>Serious adverse events</title><p>Two trials reported SAEs (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). mRNA&#8208;1273 probably results in no or little difference in the incidence of SAEs compared to placebo at 2.8 months (median) and 5.3 months' follow&#8208;up (RR 0.92, 95% CI 0.78 to 1.08; I&#178; = 0%; 2 RCTs, 34,072 participants; absolute effect: 143 fewer per 100,000 (from 394 fewer to 143 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0006" ref-type="fig">Figure 6</xref>).</p></sec><sec id="CD015477-sec-0098"><title>Systemic reactogenicity events</title><p>Two trials reported the outcome (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). mRNA&#8208;1273 results in a slight increase in the occurrence of any systemic reactogenicity event compared to placebo (RR 1.28, 95% CI 1.22 to 1.34; I&#178; = 61%; 2 RCTs, 34,037 participants; absolute effect: 121 more with systemic reactogenicity events per 1000 (from 95 fewer to 147 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0009" ref-type="fig">Figure 9</xref>).</p><fig id="CD015477-fig-0009" position="float" orientation="portrait"><label>9</label><caption><p>Analysis 1.1.6: RNA&#8208;based vaccine. Outcome: systemic reactogenicity events.</p><p><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-09.jpg"/></fig></sec><sec id="CD015477-sec-0099"><title>Any adverse event</title><p>Two RCTs reported the outcome at 2.8 months (median) and 5.3 months' follow&#8208;up (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). We decided not to pool the results due to considerable heterogeneity (I&#178; = 100%) probably caused by studies assessing participants in different age groups;&#160;<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included participants aged three years to 17 years while&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>&#160;included adults. One trial reported results for 3726 participants between 12 and 17 years of age (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>); the risk for any adverse event in the study was 1.47 (95% CI 1.41 to 1.54), the other study reported results for 29,269 participants 18 years and older (<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>), the risk for any adverse event in this study was 2.15 (95% CI 2.11 to 2.19) (<xref rid="CD015477-fig-0007" ref-type="fig">Figure 7</xref>).</p></sec></sec><sec id="CD015477-sec-0100"><title>Important outcomes</title><sec id="CD015477-sec-0101"><title>Local reactogenicity events</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>). mRNA&#8208;1273 results in a large increase of local reactogenicity events compared to placebo (RR 3.30, 95% CI 2.02 to 5.40; I&#178; = 99%; 2 RCTs, 34,037 participants; absolute effect: 486 more with local reactogenicity events per 1000 (from 216 more to 930 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0010" ref-type="fig">Figure 10</xref>).</p><fig id="CD015477-fig-0010" position="float" orientation="portrait"><label>10</label><caption><p>Analysis 1.1.8: RNA&#8208;based vaccine. Outcome: local reactogenicity events.&#160;</p><p><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-10.jpg"/></fig></sec><sec id="CD015477-sec-0102"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials. One trial reported number of participants with pulmonary embolism, pericarditis, venous thrombosis, myocardial infarction, thrombocytopaenia, anaemia and nervous system diseases (<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>); the other trial reported number of participants with pericarditis myocardial infarction and lymphadenopathy (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>). Outcomes were summarized in detail in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.&#160;</p></sec><sec id="CD015477-sec-0103"><title>Vaccine&#8208;enhanced disease</title><p>One trial reported no vaccine&#8208;enhanced disease effect (<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>).</p></sec></sec></sec><sec id="CD015477-sec-0104"><title>CVnCoV &#8211; CureVac AG versus placebo (normal saline)</title><p>See&#160;<xref rid="CD015477-tbl-0003" ref-type="table">Table 3</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0461" ref-type="app">Appendix 14</xref>.</p><p>We identified and included in the analysis one trial assessing CVnCoV. The outcomes 'SARS&#8208;CoV&#8208;2 infection after complete vaccination', 'GMT of specific antibodies against SARS&#8208;CoV&#8208;2', 'GMT of neutralizing antibodies against SARS&#8208;CoV&#8208;2', 'cellular immune response', 'incidence of specific safety outcomes' and 'vaccine&#8208;enhanced disease' were not reported for this comparison.</p><sec id="CD015477-sec-0105"><title>Critical outcomes</title><sec id="CD015477-sec-0106"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>One trial reported this outcome at 6.2 months' follow&#8208;up (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>). CVnCoV probably results in a small reduction of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to placebo (VE 48.20%, 95% CI 31.70% to 60.90%; 1 RCT, 25,062 participants; moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="CD015477-sec-0107"><title>Severe or critical COVID&#8208;19 after complete vaccination&#160;</title><p>One trial reported the outcome at six months' follow&#8208;up (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>). The evidence is very uncertain for an effect of CVnCoV in reducing severe or critical COVID&#8208;19 compared to placebo due to serious indirectness and very serious imprecision (VE 63.80%, 95% CI 0.00% to 91.70%; 1 RCT, 25,062 participants; very low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="CD015477-sec-0108"><title>All&#8208;cause mortality</title><p>One trial reported this outcome at six months' follow&#8208;up (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>). The evidence is very uncertain for an effect of CVnCoV on all&#8208;cause mortality compared to placebo due to serious indirectness and very serious imprecision (RR 1.33, 95% CI 0.46 to 3.83; 1 RCT, 39,529 participants; very low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0005" ref-type="fig">Figure 5</xref>).</p></sec><sec id="CD015477-sec-0109"><title>Serious adverse events</title><p>One trial reported this outcome (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>). The evidence is very uncertain for an effect of CVnCoV on SAEs compared to placebo at 1.7 months' follow&#8208;up (RR 1.24, 95% CI 0.90 to 1.71; 1 RCT, 39,529 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0006" ref-type="fig">Figure 6</xref>).</p></sec><sec id="CD015477-sec-0110"><title>Systemic reactogenicity events</title><p>One trial reported this outcome (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>). CVnCoV results in a large increase in the incidence of systemic reactogenicity events compared to placebo at 6.2 months' follow&#8208;up (RR 1.48, 95% CI 1.43 to 1.53; 1 RCT, 3982 participants; absolute effect: 305 more with systemic reactogenicity events per 1000 (from 273 more to 336 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0009" ref-type="fig">Figure 9</xref>).</p></sec><sec id="CD015477-sec-0111"><title>Any adverse event</title><p>One trial reported this outcome (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>). CVnCoV probably results in a large increase in the incidence of any adverse event compared to placebo at one&#8208;month follow&#8208;up (RR 1.42, 95% CI 1.38 to 1.47; 1 RCT, 3982 participants; absolute effect: 285 more with any adverse event per 1000 (from 258 more to 319 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0007" ref-type="fig">Figure 7</xref>).&#160;</p></sec></sec><sec id="CD015477-sec-0112"><title>Important outcomes</title><sec id="CD015477-sec-0113"><title>Local reactogenicity events</title><p>One trial reported this outcome (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>). CVnCoV results in a large increase in the incidence of local reactogenicity events compared to placebo (RR 3.51, 95% CI 3.24 to 3.81; 1 RCT, 3982 participants; absolute effect: 606 more with local reactogenicity events per 1000 (from 541 more to 678 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0010" ref-type="fig">Figure 10</xref>).</p></sec></sec></sec></sec><sec id="CD015477-sec-0114"><title>Non&#8208;replicant viral vector vaccines</title><sec id="CD015477-sec-0115"><title>ChAdOx1/SII&#8208;ChAdOx1 &#8211; AstraZeneca+University of Oxford/Serum Institute of India versus placebo (normal saline/adjuvant/MenACWY)</title><p>See&#160;<xref rid="CD015477-tbl-0004" ref-type="table">Table 4</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0462" ref-type="app">Appendix 15</xref>.</p><p>We identified and included in the analysis seven trials assessing ChAdOx1 &#8211; AstraZeneca/University of Oxford and one trial assessing SII&#8208;ChAdOx1, the equivalent of ChAdOx1 manufactured in India at Serum Institute of India (<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>). The latter did not report efficacy outcomes.</p><p>The outcomes 'severe or critical COVID&#8208;19 after complete vaccination', 'GMT of neutralizing antibodies against SARS&#8208;CoV&#8208;2' and 'cellular immune response' were not reported for this comparison.</p><sec id="CD015477-sec-0116"><title>Critical outcomes</title><sec id="CD015477-sec-0117"><title>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p>This outcome was reported in five RCTs (<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(which&#160;reported pooled results for four trials)). ChAdOx1 probably reduces SARS&#8208;CoV&#8208;2 infection compared to placebo and MenACWY vaccine at 1.3 months (median) and two months (median) follow&#8208;up (VE 59.35%, 95% CI 48.00% to 68.22%; I&#178; = 68%; 5 RCTs, 43,390 participants; moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0011" ref-type="fig">Figure 11</xref>).</p><fig id="CD015477-fig-0011" position="float" orientation="portrait"><label>11</label><caption><p>Analysis 2.1.1: Non&#8208;replicating viral vector vaccine. Outcome: confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination.</p><p><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>: data pooled from four trials.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-11.jpg"/></fig></sec><sec id="CD015477-sec-0118"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>Five RCTs reported this outcome (<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>) (<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(which reported pooled results for four trials)). ChAdOx1 results in a large reduction of the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to placebo and MenACWY vaccine at 1.3 months (median) and two months (median) follow&#8208;up (VE 70.23%, 95% CI 62.10% to 76.62%; I&#178; = 38%; 5 RCTs, 43,390 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0012" ref-type="fig">Figure 12</xref>).</p><fig id="CD015477-fig-0012" position="float" orientation="portrait"><label>12</label><caption><p>Analysis 2.1.2: non&#8208;replicating viral vector vaccine. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p><p><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>: data pooled from four trials.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-12.jpg"/></fig></sec><sec id="CD015477-sec-0119"><title>All&#8208;cause mortality</title><p>Two trials reported this outcome in 1456 participants at 2&#8208;month follow&#8208;up (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>); there were no events and the trials did not contribute to the effect estimate. Five trials contributed to the analysis with follow&#8208;up from 2.0 months to 4.2 months (<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;(which&#160;reported on HIV&#8208;positive participants who were not included in this pooled analysis);&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(which reported pooled results for four trials)). The evidence is uncertain for an effect of ChAdOx1 on all&#8208;cause mortality compared to placebo and MenACWY vaccine due to very serious imprecision (RR 0.48, 95% CI 0.20 to 1.14; I&#178; = 0%; 5 RCTs, 56,727 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0013" ref-type="fig">Figure 13</xref>).</p><fig id="CD015477-fig-0013" position="float" orientation="portrait"><label>13</label><caption><p>Analysis 2.1.4: non&#8208;replicating viral vector vaccine. Outcome: all&#8208;cause mortality.</p><p>In&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>, the control arm received adjuvant.&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>: data pooled from four trials.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-13.jpg"/></fig></sec><sec id="CD015477-sec-0120"><title>Serious adverse events</title><p>Seven trials reported this outcome (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>;&#160;<xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;(which reported on HIV&#8208;positive participants who were not included in this pooled analysis);&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(which reported pooled results for four trials)). ChAdOx1 probably results in no or little increase in the incidence of SAEs compared to placebo and at one month' to 6 months' follow&#8208;up (RR 0.88, 95% CI 0.72 to 1.07; I&#178; = 6%; 7 RCTs, 58,182 participants; absolute effect: 1 fewer with SAEs per 1000 (from 2 fewer to 1 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0014" ref-type="fig">Figure 14</xref>).</p><fig id="CD015477-fig-0014" position="float" orientation="portrait"><label>14</label><caption><p>Analysis 2.1.5: non&#8208;replicating viral vector vaccine. Outcome: serious adverse events (SAEs).</p><p>In&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>, the control arm received adjuvant.&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>: data pooled from four trials.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-14.jpg"/></fig></sec><sec id="CD015477-sec-0121"><title>Systemic reactogenicity events</title><p>This outcome was reported in one trial (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>). ChAdOx1 probably results in a large increase of systemic reactogenicity events compared to placebo (RR 3.93, 95% CI 2.11 to 7.29; 1 RCT, 256 participants; absolute effect: 412 more with systemic reactogenicity events per 1000 (from 156 more to 885 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0015" ref-type="fig">Figure 15</xref>).</p><fig id="CD015477-fig-0015" position="float" orientation="portrait"><label>15</label><caption><p>Analysis 2.1.6: non&#8208;replicating viral vector vaccine. Outcome: systemic reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-15.jpg"/></fig></sec><sec id="CD015477-sec-0122"><title>Any adverse event</title><p>Seven trials reported this outcome (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>;&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>;&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>;&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(which reported pooled results for four trials). Due to considerable heterogeneity, we decided not to pool the results (I&#178; = 90%).&#160;<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>&#160;reported results for 256 participants at 1.2 months' follow&#8208;up; the risk of any adverse event in the study was 2.54 (95% CI 1.73 to 3.74).&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;reported results for 32,379 participants at one&#8208;month follow&#8208;up; the risk for any adverse event was 1.37 (95% CI 1.33 to 1.42).&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported results for 1200 participants at 1.9 months' follow&#8208;up; the risk for any adverse event was 1.39 (95% CI 1.12 to 1.74). Lastly, a report pooling four trials presented results for 23,745 participants, the risk for any adverse event was 0.74 (95% CI 0.56 to 0.96) at 3.4 months' follow&#8208;up &#160;(<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>). Of note, participants in the control arm received different interventions across studies; three trials used normal saline as placebo (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>; COV005 included in&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>) and three used MenACWY vaccine (COV001, COV002, COV003 included in&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>) and one trial used adjuvant (<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>) (<xref rid="CD015477-fig-0016" ref-type="fig">Figure 16</xref>).</p><fig id="CD015477-fig-0016" position="float" orientation="portrait"><label>16</label><caption><p>Analysis 2.1.7: non&#8208;replicating viral vector vaccine. Outcome: any adverse event (AE).</p><p>In&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>, the control arm received adjuvant.&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;merged results from four different trials where three used quadrivalent meningococcal conjugate vaccine as placebo and one trial used normal saline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-16.jpg"/></fig></sec></sec><sec id="CD015477-sec-0123"><title>Important outcomes</title><sec id="CD015477-sec-0124"><title>GMTs of a specific antibody against SARS&#8208;COV&#8208;2</title><p><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;reported GMTs of specific antibodies against SARS&#8208;COV&#8208;2. Results are detailed in&#160;<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>.</p></sec><sec id="CD015477-sec-0125"><title>Local reactogenicity events</title><p>The outcome was reported in one trial (<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>). ChAdOx1 probably results in a large increase in the number of local reactogenicity events compared to placebo (RR 6.44, 95% CI 2.98 to 13.92; 1 RCT, 256 participants; absolute effect: 510 more with local reactogenicity events per 1000 (from 186 more to 1000 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0017" ref-type="fig">Figure 17</xref>).</p><fig id="CD015477-fig-0017" position="float" orientation="portrait"><label>17</label><caption><p>Analysis 2.1.8: non&#8208;replicating viral vector vaccine. Outcome: local reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-17.jpg"/></fig></sec><sec id="CD015477-sec-0126"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials.&#160;<xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;reported number of participants with subsequent nervous system diseases,&#160;<xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;reported number of participants with stroke, cavernous sinus thrombosis, venous thrombosis and nervous system disorders,&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;presented results for the number of participants with pulmonary embolism, pericarditis, venous thrombosis, myocardial infarction, anaemia and nervous system diseases, and&#160;<xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>&#160;and&#160;<xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;did not report any specific safety outcome of interest. Outcomes are summarized in detail in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.</p></sec><sec id="CD015477-sec-0127"><title>Vaccine&#8208;enhanced disease</title><p><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;reported no vaccine&#8208;enhanced disease effect.</p></sec></sec></sec><sec id="CD015477-sec-0128"><title>ChAdOx1 &#8211; AstraZeneca+University of Oxford versus SII&#8208;ChAdOx1 &#8211; Serum Institute of India&#160;</title><p>See&#160;<xref rid="CD015477-tbl-0005" ref-type="table">Table 5</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0469" ref-type="app">Appendix 17</xref>.</p><p><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported results on ChAdOx1 compared to SII&#8208;ChAdOx1 (the equivalent of ChAdOx1 manufactured in India at Serum Institute of India).</p><sec id="CD015477-sec-0129"><title>Critical outcomes</title><sec id="CD015477-sec-0130"><title>All&#8208;cause mortality</title><p><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported this outcome at six months' follow&#8208;up. The trial including 400 participants reported zero events for both groups for this outcome (<xref rid="CD015477-fig-0018" ref-type="fig">Figure 18</xref>).</p><fig id="CD015477-fig-0018" position="float" orientation="portrait"><label>18</label><caption><p>Analysis 2.2.1: serum Institute of India/Astra Zeneca+University of Oxford &#8211; SII&#8208;ChAdOx1 versus University of Oxford &#8211; ChAdOx1. Outcome: all&#8208;cause mortality.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-18.jpg"/></fig></sec><sec id="CD015477-sec-0131"><title>Serious adverse events</title><p><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported this outcome at six months' follow&#8208;up. The evidence is uncertain for an effect of SII&#8208;ChAdOx1 on the incidence of SAEs compared to ChAdOx1 due to very serious imprecision (RR 0.50, 95% CI 0.08 to 2.95; 1 RCT, 400 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0019" ref-type="fig">Figure 19</xref>).</p><fig id="CD015477-fig-0019" position="float" orientation="portrait"><label>19</label><caption><p>Analysis 2.2.2: SII&#8208;ChAdOx1 versus ChAdOx1. Outcome: serious adverse events (SAEs).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-19.jpg"/></fig></sec><sec id="CD015477-sec-0132"><title>Systemic reactogenicity events</title><p><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported this outcome. SII&#8208;ChAdOx1 probably results in a slight decrease in the number of systemic reactogenicity events compared to ChAdOx1 (RR 0.73, 95% CI 0.54 to 0.98; 1 RCT, 400 participants; absolute effect: 105 fewer with systemic reactogenicity events per 1000 (from 179 fewer to 8 fewer); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0020" ref-type="fig">Figure 20</xref>).</p><fig id="CD015477-fig-0020" position="float" orientation="portrait"><label>20</label><caption><p>Analysis 2.2.3: SII&#8208;ChAdOx1 versus ChAdOx1. Outcome: systemic reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-20.jpg"/></fig></sec><sec id="CD015477-sec-0133"><title>Any adverse event</title><p><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported this outcome at 1.9 months' follow&#8208;up. The evidence is uncertain for an effect of SII&#8208;ChAdOx1 on the incidence of any adverse event compared to ChAdOx1 due to very serious imprecision (RR 0.83, 95% CI 0.52 to 1.33; 1 RCT, 400 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0021" ref-type="fig">Figure 21</xref>).</p><fig id="CD015477-fig-0021" position="float" orientation="portrait"><label>21</label><caption><p>Analysis 2.2.4: SII&#8208;ChAdOx1 versus ChAdOx1. Outcome: any adverse event (AE).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-21.jpg"/></fig></sec></sec><sec id="CD015477-sec-0134"><title>Important outcomes</title><sec id="CD015477-sec-0135"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported that SII&#8208;ChAdOx1 elicited slightly higher levels of specific antibodies against SARS&#8208;COV&#8208;2 (GMR 1.52, 95% CI 1.03 to 2.26) compared to ChAdOx1 (<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>). Results for neutralizing antibodies against SARS&#8208;COV&#8208;2 were not conclusive because of imprecision (GMR 1.23, 95% CI 0.92 to 1.63).</p></sec><sec id="CD015477-sec-0136"><title>Local reactogenicity events</title><p><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;reported this outcome. The evidence is uncertain for an effect of SII&#8208;ChAdOx1 on the incidence of local reactogenicity events compared to ChAdOx1 (RR 0.76, 95% CI 0.55 to 1.05; 1 RCT, 400 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0022" ref-type="fig">Figure 22</xref>).</p><fig id="CD015477-fig-0022" position="float" orientation="portrait"><label>22</label><caption><p>Analysis 2.2.5: SII&#8208;ChAdOx1 versus ChAdOx1. Outcome: local reactogenicity events.&#160;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-22.jpg"/></fig></sec></sec></sec><sec id="CD015477-sec-0137"><title>Ad26.COV2.S &#8211; Janssen Pharmaceutical Companies versus placebo (normal saline)</title><p>See&#160;<xref rid="CD015477-tbl-0006" ref-type="table">Table 6</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0470" ref-type="app">Appendix 18</xref>.</p><p>We identified and included in the analysis two trials assessing Ad26.COV2.S. The outcomes 'SARS&#8208;CoV&#8208;2 infection after complete vaccination', 'GMT of specific antibodies against SARS&#8208;CoV&#8208;2', and 'cellular immune response' were not reported for this comparison.</p><sec id="CD015477-sec-0138"><title>Critical outcomes</title><sec id="CD015477-sec-0139"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>. Ad26.COV2.S reduces the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to placebo at 1.9 months (median) follow&#8208;up (VE 66.90%, 95% CI 59.10% to 73.40%; 1 RCT, 39,058 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0012" ref-type="fig">Figure 12</xref>).</p></sec><sec id="CD015477-sec-0140"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>. Ad26.COV2.S results in a large reduction of severe or critical COVID&#8208;19 compared to placebo at 1.9 months (median) follow&#8208;up (VE 76.30%, 95% CI 57.90% to 87.50%; 1 RCT, 39,058 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0023" ref-type="fig">Figure 23</xref>).</p><fig id="CD015477-fig-0023" position="float" orientation="portrait"><label>23</label><caption><p>Analysis 2.1.3: non&#8208;replicating viral vector vaccine. Outcome: severe or critical COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-23.jpg"/></fig></sec><sec id="CD015477-sec-0141"><title>All&#8208;cause mortality</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>. Ad26.COV2.S probably results in a reduction in all&#8208;cause mortality compared to placebo at 1.9 months (median) follow&#8208;up (RR 0.25, 95% CI 0.09 to 0.67; 1 RCT, 43,783 participants; absolute effect: 69 fewer per 100,000 (from 83 fewer to 30 fewer); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0013" ref-type="fig">Figure 13</xref>).</p></sec><sec id="CD015477-sec-0142"><title>Serious adverse events</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>. Ad26.COV2.S probably results in little or no difference in the incidence of SAEs at 1.9 months (median) follow&#8208;up (RR 0.92, 95% CI 0.69 to 1.22; 1 RCT, 43,783 participants; absolute effect: 36 fewer per 100,000 (from 139 fewer to 99 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0014" ref-type="fig">Figure 14</xref>).</p></sec><sec id="CD015477-sec-0143"><title>Systemic reactogenicity events</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>). Ad26.COV2.S results in a large increase in systemic reactogenicity events compared to placebo (RR 1.83, 95% CI 1.29 to 2.60; I&#178; = 83%; 2 RCTs, 7222 participants; absolute effect: 28,697 more per 100,000 (from 10,027 more to 55,320 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0015" ref-type="fig">Figure 15</xref>).</p></sec><sec id="CD015477-sec-0144"><title>Any adverse event</title><p>The outcome was reported in two trials (<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>). We decided not to pool the results due to considerable heterogeneity (I&#178; = 96%).&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#160;reported results for 6736 participants at one&#8208;month follow&#8208;up; the risk for any adverse event was 1.09 (95% CI 0.96 to 1.24).&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>&#160;reported results for 486 participants; the risk for adverse events was 2.31 (95% CI 1.80 to 2.97;&#160;<xref rid="CD015477-fig-0016" ref-type="fig">Figure 16</xref>).</p></sec></sec><sec id="CD015477-sec-0145"><title>Important outcomes</title><sec id="CD015477-sec-0146"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>&#160;reported GMTs of neutralizing antibodies against SARS&#8208;COV&#8208;2. Results are detailed in&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>.</p></sec><sec id="CD015477-sec-0147"><title>Local reactogenicity events</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>). Ad26.COV2.S results in a large increase in local reactogenicity events compared to placebo (RR 3.27, 95% CI 1.91 to 5.62; I&#178; = 84%; 2 RCTs, 7222 participants; absolute effect: 433 more with local reactogenicity events per 1000 (from 174 more to 881 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0017" ref-type="fig">Figure 17</xref>).</p></sec><sec id="CD015477-sec-0148"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials:&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#160;reported the number of participants with pulmonary embolism, cavernous sinus thrombosis, pericarditis and venous thrombosis;&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>&#160;did not report any specific safety outcomes of interest. Outcomes are summarized in detail in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.</p></sec><sec id="CD015477-sec-0149"><title>Vaccine&#8208;enhanced disease</title><p><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#160;reported no vaccine&#8208;enhanced disease effect.</p></sec></sec></sec><sec id="CD015477-sec-0150"><title>Gam&#8208;COVID&#8208;Vac &#8211; Gamaleya Research Institute (Sputnik V) versus placebo (adjuvant)</title><p>See&#160;<xref rid="CD015477-tbl-0007" ref-type="table">Table 7</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0471" ref-type="app">Appendix 19</xref>.</p><p>We identified and included one trial in the analysis assessing Gam&#8208;COVID&#8208;Vac (<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>).</p><p>The outcomes 'SARS&#8208;CoV&#8208;2 infection after complete vaccination', 'incidence of any adverse event', 'systemic reactogenicity events' and 'vaccine&#8208;enhanced disease' were not reported for this comparison.</p><p>Some important concerns were raised concerning&#160;<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>: lack of clarity in the definition of the primary outcome; addition of interim analyses; change in outcomes; inadequate reporting with inconsistencies in numbers; and excess of homogeneity of vaccine efficacy across age groups (<xref rid="CD015477-bbs2-0062" ref-type="ref-list">Bucci 2021</xref>). The authors responded to some of these concerns and the manuscript was corrected (<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>). Nevertheless, uncertainty persists related to the prespecification of the interim analysis and excess of homogeneity of vaccine efficacy across age groups. Consequently, we decided to downgrade the certainty of evidence for these reasons.</p><sec id="CD015477-sec-0151"><title>Critical outcomes</title><sec id="CD015477-sec-0152"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>. Gam&#8208;COVID&#8208;Vac probably results in a large reduction in the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to placebo (follow&#8208;up time not reported) (VE 91.10%, 95% CI 83.80% to 95.10%; 1 RCT, 18,695 participants; moderate&#8208;certainty evidence). Of note, vaccine efficacy for this outcome was calculated using RR (<xref rid="CD015477-fig-0012" ref-type="fig">Figure 12</xref>).</p></sec><sec id="CD015477-sec-0153"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>. Gam&#8208;COVID&#8208;Vac probably results in a large reduction in the incidence of severe or critical COVID&#8208;19 compared to placebo (follow&#8208;up time not reported) (VE 100.00%, 95% CI 94.40% to 100.00%; 1 RCT, 19,866 participants; moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0023" ref-type="fig">Figure 23</xref>).</p></sec><sec id="CD015477-sec-0154"><title>All&#8208;cause mortality</title><p><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>&#160;reported this outcome at 1.6 months' follow&#8208;up. The evidence is very uncertain for an effect of Gam&#8208;COVID&#8208;Vac in all&#8208;cause mortality compared to placebo due to serious imprecision (RR 0.99, 95% CI 0.10 to 9.54; 1 RCT, 21,862 participants; very low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0013" ref-type="fig">Figure 13</xref>).</p></sec><sec id="CD015477-sec-0155"><title>Serious adverse events</title><p><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>&#160;reported this outcome. The evidence is uncertain for an effect of Gam&#8208;COVID&#8208;Vac in the incidence of SAEs compared to placebo at 1.6 months' follow&#8208;up (RR 0.65, 95% CI 0.39 to 1.07; 1 RCT, 21,862 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0014" ref-type="fig">Figure 14</xref>).</p></sec></sec><sec id="CD015477-sec-0156"><title>Important outcomes</title><sec id="CD015477-sec-0157"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>&#160;reported GMTs of neutralizing and specific antibodies against SARS&#8208;CoV&#8208;2, and cellular immune response. Results are detailed in&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>,&#160;<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>,&#160;and&#160;<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>,&#160;respectively.</p></sec><sec id="CD015477-sec-0158"><title>Incidence of specific safety outcomes</title><p><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>&#160;reported number of participants with cavernous sinus thrombosis, venous thrombosis, myocardial infarction, lymphadenopathy and nervous system diseases. Details are in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.</p></sec></sec></sec></sec><sec id="CD015477-sec-0159"><title>Inactivated virus vaccines</title><sec id="CD015477-sec-0160"><title>CoronaVac &#8211; Sinovac versus placebo (adjuvant)&#160;</title><p>See&#160;<xref rid="CD015477-tbl-0008" ref-type="table">Table 8</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0473" ref-type="app">Appendix 21</xref>.</p><p>We identified and included in the analysis seven trials assessing CoronaVac &#8211; Sinovac. The outcome 'SARS&#8208;CoV&#8208;2 infection after complete vaccination' was not reported for this comparison.</p><sec id="CD015477-sec-0161"><title>Critical outcomes</title><sec id="CD015477-sec-0162"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in two trials at 1.4 months (median) to 2 months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>). The evidence is uncertain for an effect of CoronaVac on the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to adjuvant due to serious inconsistency and imprecision (VE 69.81%, 95% CI 12.27% to 89.61%; I&#178; = 92%; 2 RCTs, 19,852 participants; low&#8208;certainty evidence). There was considerable heterogeneity between included studies which could be due to participant&#8217;s different level of exposure to the virus across studies (all participants included in&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>&#160;were healthcare workers compared to a third in&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>) (<xref rid="CD015477-fig-0024" ref-type="fig">Figure 24</xref>).</p><fig id="CD015477-fig-0024" position="float" orientation="portrait"><label>24</label><caption><p>Analysis 3.1.2: inactivated virus vaccine. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p><p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-24.jpg"/></fig></sec><sec id="CD015477-sec-0163"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>). We did not conduct a meta&#8208;analysis for this outcome since the typical normality assumption of the meta&#8208;analysis model would be invalid due to the skewness of the data. This can be seen in the forest plots where the CI is not symmetric around the point estimate.&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>, with 0/6559 events in the CoronaVac group versus 1/3470 events in the control group reported a vaccine efficacy of 100.00%, 95% CI 20.40% to 100.00% at 1.4 months (median) follow&#8208;up; and&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>, with 0/4953 events in the CoronaVac group and 6/4870 events in the control group reported a vaccine efficacy of 100.00%, 95% CI 16.90% to 100.00% at two months (median) follow&#8208;up (<xref rid="CD015477-fig-0025" ref-type="fig">Figure 25</xref>).</p><fig id="CD015477-fig-0025" position="float" orientation="portrait"><label>25</label><caption><p>Analysis 3.1.3: inactivated virus vaccine. Outcome: severe or critical COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-25.jpg"/></fig></sec><sec id="CD015477-sec-0164"><title>All&#8208;cause mortality</title><p>This outcome was reported in two trials at 1.4 months (median) to two months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>). The evidence is uncertain for an effect of CoronaVac on all&#8208;cause mortality compared to adjuvant due to very serious imprecision (RR 0.50, 95% CI 0.05 to 5.52; 2 RCTs, 22,610 participants; I&#178; = 32%; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0026" ref-type="fig">Figure 26</xref>).</p><fig id="CD015477-fig-0026" position="float" orientation="portrait"><label>26</label><caption><p>Analysis 3.1.4: inactivated virus vaccine. Outcome: all&#8208;cause mortality.</p><p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refers to two different comparisons from the same report (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-26.jpg"/></fig></sec><sec id="CD015477-sec-0165"><title>Serious adverse events</title><p>Two trials reported this outcome in 482 participants at 1.4 months' follow&#8208;up (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>); there were no events and the trials did not contribute to the effect estimate. Four RCTs contributed to the analysis with follow&#8208;up of two months (median) to four months (<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>). The evidence is uncertain for an effect of CoronaVac on SAEs compared to adjuvant due to very serious imprecision (RR 0.97, 95% CI 0.62 to 1.51; 4 RCTs, 23,139 participants; I&#178; = 0%; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0027" ref-type="fig">Figure 27</xref>).</p><fig id="CD015477-fig-0027" position="float" orientation="portrait"><label>27</label><caption><p>Analysis 3.1.5: inactivated virus vaccine. Outcome: serious adverse events (SAEs).</p><p><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>&#160;included only participants 3 to 17 years of age.&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>&#160;included only participants 60 years of age and older.</p><p><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>&#160;reports data for phase 1 and 2. Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-27.jpg"/></fig></sec><sec id="CD015477-sec-0166"><title>Systemic reactogenicity events</title><p>Six trials reported this outcome (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>). The evidence is uncertain for an effect of CoronaVac on systemic reactogenicity events compared to adjuvant due to serious inconsistency and imprecision (RR 1.19, 95% CI 1.00 to 1.42; 6 RCTs, 23,966 participants; I&#178; = 55%; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0028" ref-type="fig">Figure 28</xref>).</p><fig id="CD015477-fig-0028" position="float" orientation="portrait"><label>28</label><caption><p>Analysis 3.1.6: inactivated virus vaccine. Outcome: systemic reactogenicity events.</p><p>Xia S 2021 included only participants 3 to 17 years of age (<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>).&#160;Wu Z 2021&#160;included only participants 60 years of age and older (<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>).</p><p>Wu Z 2021 reports data for phase 2 (<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-28.jpg"/></fig></sec><sec id="CD015477-sec-0167"><title>Any adverse event</title><p>This outcome was reported in five trials at one month' to three months' (median) follow&#8208;up (<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>). CoronaVac results in a slight difference in the incidence of any adverse event compared to adjuvant (RR 1.09, 95% CI 1.07 to 1.11; 6 RCTs, 23,367 participants; absolute effect: 48 more with any adverse event per 1000 (from 37 more to 58 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0029" ref-type="fig">Figure 29</xref>).</p><fig id="CD015477-fig-0029" position="float" orientation="portrait"><label>29</label><caption><p>Analysis 3.1.7: inactivated virus vaccine. Outcome: any adverse event (AE).</p><p>Han B 2021&#160;and&#160;Xia 2021 included only participants 3 to 17 years of age (<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>).&#160;Wu Z 2021 included only participants 60 years of age and older (<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>).</p><p>Wu Z 2021 reports data for phase 1 and 2 (<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>), Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-29.jpg"/></fig></sec></sec><sec id="CD015477-sec-0168"><title>Important outcomes</title><sec id="CD015477-sec-0169"><title>Immunogenicity outcomes</title><p>Five trials reported GMTs of neutralizing and specific antibodies against SARS&#8208;COV&#8208;2 (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>), and one trial reported results for cellular immune response (<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>). Results are detailed in&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>,&#160;<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>,&#160;and&#160;<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>.</p></sec><sec id="CD015477-sec-0170"><title>Local reactogenicity events</title><p>Six trials reported this outcome (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>) &#160;CoronaVac results in a slight increase in the occurrence of local reactogenicity events compared to adjuvant (RR 1.76, 95% CI 1.69 to 1.82; 6 RCTs, 23,962 participants; I&#178; = 0%; absolute effect: 173 more per 1000 (from 157 more to 187 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0030" ref-type="fig">Figure 30</xref>).</p><fig id="CD015477-fig-0030" position="float" orientation="portrait"><label>30</label><caption><p>Analysis 3.1.8: inactivated virus vaccine. Outcome: local reactogenicity events.</p><p>Xia S 2021 included only participants 3 to 17 years of age (<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>).&#160;Wu Z 2021 included only participants 60 years of age and older (<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>).</p><p>Wu Z 2021 reports data for phase 2 (<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>). Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). Zhang 2020.1 and Zhang 2020.2 refers to two different comparisons from the same report (<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-30.jpg"/></fig></sec><sec id="CD015477-sec-0171"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials:&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>&#160;reported number of participants with myocardial infarction and nervous system diseases;&#160;<xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref>&#160;reported the number of participants with venous thrombosis and nervous system diseases; and five trials reported no specific safety outcome of interest (<xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>;&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>). Outcomes of interest are summarized in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.</p></sec><sec id="CD015477-sec-0172"><title>Vaccine&#8208;enhanced disease</title><p><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>&#160;reported no vaccine&#8208;enhanced disease effect.</p></sec></sec></sec><sec id="CD015477-sec-0173"><title>WIBP&#8208;CorV &#8211; Sinopharm&#8208;Wuhan versus placebo (adjuvant)</title><p>See&#160;<xref rid="CD015477-tbl-0009" ref-type="table">Table 9</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0474" ref-type="app">Appendix 22</xref>.</p><p>We identified and included two trials in the analysis assessing WIBP&#8208;CorV. The outcomes 'severe or critical COVID&#8208;19 after complete vaccination', 'cellular immune response' and 'incidence of specific safety outcomes' were not reported for this comparison.</p><sec id="CD015477-sec-0174"><title>Critical outcomes</title><sec id="CD015477-sec-0175"><title>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>. WIBP&#8208;CorV results in a reduction in the incidence of confirmed SARS&#8208;CoV&#8208;2 infection compared to adjuvant at 2.6 months (median) follow&#8208;up (VE 64.00%, 95% CI 48.80% to 74.70%; 1 RCT, 25,449 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0031" ref-type="fig">Figure 31</xref>).</p><fig id="CD015477-fig-0031" position="float" orientation="portrait"><label>31</label><caption><p>Analysis 3.1.1: inactivated virus vaccine. Outcome: confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination.</p><p>Al Kaabi 2021.1 and Al Kaabi N 2021.2 refer to two different comparisons from the same report (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-31.jpg"/></fig></sec><sec id="CD015477-sec-0176"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>. WIBP&#8208;CorV results in a large reduction in the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to adjuvant at 2.6 months (median) follow&#8208;up (VE 72.80%, 95% CI 58.10% to 82.40%; 1 RCT, 25,480 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0024" ref-type="fig">Figure 24</xref>).</p></sec><sec id="CD015477-sec-0177"><title>All&#8208;cause mortality</title><p>This outcome was assessed in one trial (26,917 participants) at 2.6 months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). There were zero events in both groups, therefore no effect estimate could be calculated for this outcome (<xref rid="CD015477-fig-0026" ref-type="fig">Figure 26</xref>).&#160;</p></sec><sec id="CD015477-sec-0178"><title>Serious adverse events</title><p>Two trials assessed this outcome (<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). The evidence is uncertain for an effect of WIBP&#8208;CorV on SAEs compared to adjuvant at 1.6 months (median) and 2.6 months (median) follow&#8208;up due to serious imprecision (RR 0.83, 95% CI 0.60 to 1.15; I&#178; = 0%; 2 RCTs, 27,029 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0027" ref-type="fig">Figure 27</xref>).</p></sec><sec id="CD015477-sec-0179"><title>Systemic reactogenicity events</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). WIBP&#8208;CorV results in no or little difference in the occurrence of systemic reactogenicity events compared to adjuvant (RR 0.99, 95% CI 0.95 to 1.03; I&#178; = 0%; 2 RCTs, 27,029 participants; absolute effect: 3 fewer with systemic reactogenicity events per 1000 (from 14 fewer to 8 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0028" ref-type="fig">Figure 28</xref>).</p></sec><sec id="CD015477-sec-0180"><title>Any adverse event</title><p>Two trials assessed the outcome (<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). WIBP&#8208;CorV results in little difference in the incidence of any adverse event compared to adjuvant at one&#8208;month follow&#8208;up (RR 0.96, 95% CI 0.93 to 0.98; I&#178; = 0%; 2 RCTs, 27,029 participants; absolute effect: 20 fewer with any adverse event per 1000 (from 35 fewer to 10 fewer); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0029" ref-type="fig">Figure 29</xref>).</p></sec></sec><sec id="CD015477-sec-0181"><title>Important outcomes</title><sec id="CD015477-sec-0182"><title>Immunogenicity outcomes</title><p>Two trials reported GMTs of &#160;neutralizing and specific antibodies against SARS&#8208;COV&#8208;2 (<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). Results are reported in&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>&#160;and&#160;<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>.</p></sec><sec id="CD015477-sec-0183"><title>Local reactogenicity events</title><p>Two trials reported this outcome (<xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>;&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). WIBP&#8208;CorV results in little difference in the occurrence of local reactogenicity events compared to adjuvant (RR 0.88, 95% CI 0.85 to 0.92; I&#178; = 0%; 2 RCTs, 27,029 participants; absolute effect: 35 fewer with local reactogenicity events per 1000 (from 44 fewer to 23 fewer); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0030" ref-type="fig">Figure 30</xref>).</p></sec><sec id="CD015477-sec-0184"><title>Vaccine&#8208;enhanced disease</title><p>One trial reported no vaccine&#8208;enhanced disease effect (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>).</p></sec></sec></sec><sec id="CD015477-sec-0185"><title>BBIBP&#8208;CorV &#8211; Sinopharm&#8208;Beijing versus placebo (adjuvant)</title><p>See&#160;<xref rid="CD015477-tbl-0010" ref-type="table">Table 10</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0475" ref-type="app">Appendix 23</xref>.</p><p>We identified and included in the analysis three trials assessing BBIBP&#8208;CorV. The outcomes 'severe or critical COVID&#8208;19 after complete vaccination', 'cellular immune response' and 'incidence of specific safety outcomes' were not reported for this comparison.</p><sec id="CD015477-sec-0186"><title>Critical outcomes</title><sec id="CD015477-sec-0187"><title>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p>This outcome was reported in one trial (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). BBIBP&#8208;CorV results in a large reduction in SARS&#8208;CoV&#8208;2 infection compared to adjuvant (VE 73.50%, 95% CI 60.60% to 82.20%; 1 RCT, 25,435 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0031" ref-type="fig">Figure 31</xref>).</p></sec><sec id="CD015477-sec-0188"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in one trial (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). BBIBP&#8208;CorV results in a large reduction in the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to placebo (adjuvant) (VE 78.10%, 95% CI 64.80% to 86.30%; 1 RCT, 25,463 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0024" ref-type="fig">Figure 24</xref>).</p></sec><sec id="CD015477-sec-0189"><title>All&#8208;cause mortality</title><p>This outcome was assessed in one trial (26,924 participants) (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). There were zero events in both groups, therefore no effect estimate could be calculated for this outcome (<xref rid="CD015477-fig-0026" ref-type="fig">Figure 26</xref>).</p></sec><sec id="CD015477-sec-0190"><title>Serious adverse events</title><p>One study assessed this outcome in 112 participants (<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>). There were zero events in both groups and the trial did not contribute to the analysis. One trial contributed to the analysis (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>). The evidence is uncertain for an effect of BBIBP&#8208;CorV on SAEs compared to adjuvant at 2.6 months (median) follow&#8208;up (RR 0.76, 95% CI 0.54 to 1.06; 1 RCT, 26,924 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0027" ref-type="fig">Figure 27</xref>).</p></sec><sec id="CD015477-sec-0191"><title>Systemic reactogenicity events</title><p>This outcome was reported in three trials (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>). BBIBP&#8208;CorV probably results in no or little difference in the occurrence of systemic reactogenicity events compared to adjuvant (RR 1.05, 95% CI 0.86 to 1.28; 3 RCTs, 27,540 participants; absolute effect: 14 more per 1000 (from 38 fewer to 77 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0028" ref-type="fig">Figure 28</xref>).</p></sec><sec id="CD015477-sec-0192"><title>Any adverse event</title><p>This outcome was reported in three trials (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>). We decided not to pool the results due to considerable heterogeneity (I&#178; = 90%) probably caused by studies assessing participants in different age groups;&#160;reported data for participants aged three years to 17 years old.&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>&#160;reported results for 504 participants at 2.9 months' follow&#8208;up; the risk of any adverse event in the study was 2.05 (95% CI 1.47 to 2.87).&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>&#160;reported results for 26,941 participants at one&#8208;month follow&#8208;up; the risk for any adverse event was 0.91 (95% CI 0.89 to 0.94).&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>&#160;reported results for 112 participants at one&#8208;month follow&#8208;up; the risk for any adverse event was 0.83 (95% CI 0.36 to 1.94;&#160;<xref rid="CD015477-fig-0029" ref-type="fig">Figure 29</xref>).</p></sec></sec><sec id="CD015477-sec-0193"><title>Important outcomes</title><sec id="CD015477-sec-0194"><title>Immunogenicity outcomes</title><p>Three trials reported GMTs of neutralizing and specific antibodies against SARS&#8208;COV&#8208;2 (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>). Results are reported in&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>&#160;and&#160;<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>.&#160;</p></sec><sec id="CD015477-sec-0195"><title>Local reactogenicity events</title><p>This outcome was reported in three trials (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>;&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>). We decided not to pool the results due to considerable heterogeneity (I&#178; = 90%) probably caused by studies assessing participants in different age groups.&#160;<xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>&#160;reported results for 504 participants at seven days' follow&#8208;up; the risk of local reactogenicity events in the study was 10.00 (95% CI 2.36 to 42.34).&#160;<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>&#160;reported results for 26,924 participants at seven days' follow&#8208;up; the risk for local reactogenicity events was 0.71 (95% CI 0.68 to 0.74).&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>&#160;reported results for 112 participants at seven days' follow&#8208;up; the risk for local reactogenicity events was 3.33 (95% CI 0.45 to 24.89;&#160;<xref rid="CD015477-fig-0030" ref-type="fig">Figure 30</xref>).</p></sec><sec id="CD015477-sec-0196"><title>Vaccine&#8208;enhanced disease</title><p>One trial reported no vaccine&#8208;enhanced disease effect (<xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>).</p></sec></sec></sec><sec id="CD015477-sec-0197"><title>BBV152 &#8211; Bharat Biotech versus placebo (adjuvant)</title><p>See&#160;<xref rid="CD015477-tbl-0011" ref-type="table">Table 11</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0476" ref-type="app">Appendix 24</xref>.</p><p>We identified and included two trials in the analysis assessing BBV152. The outcome 'vaccine&#8208;enhanced disease' was not reported for this comparison.</p><sec id="CD015477-sec-0198"><title>Critical outcomes</title><sec id="CD015477-sec-0199"><title>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p>One trial reported this outcome (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>). BBV152 results in a reduction in the incidence of SARS&#8208;CoV&#8208;2 infections compared to adjuvant at 3.3 months (median) follow&#8208;up (VE 68.80%, 95% CI 46.70% to 82.50%; 1 RCT, 6289 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0031" ref-type="fig">Figure 31</xref>).</p></sec><sec id="CD015477-sec-0200"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in one trial (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>). BBV152 results in a large reduction in the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to adjuvant at 3.3 months (median) follow&#8208;up (VE 77.80%, 95% CI 65.20% to 86.40%; 1 RCT, 16,973 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0024" ref-type="fig">Figure 24</xref>).</p></sec><sec id="CD015477-sec-0201"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in one trial at 3.3 months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>). BBV152 results in a large reduction of severe or critical COVID&#8208;19 after complete vaccination compared to adjuvant due to very serious imprecision (VE 93.40%, 95% CI 57.10% to 99.80%; 1 RCT, 16,976 participants; high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0025" ref-type="fig">Figure 25</xref>).</p></sec><sec id="CD015477-sec-0202"><title>All&#8208;cause mortality</title><p>One trial reported this outcome at 3.3 months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>). The evidence is uncertain for an effect of BBV152 on all&#8208;cause mortality compared to adjuvant due to very serious imprecision (RR 0.50, 95% CI 0.17 to 1.46; 1 RCT, 25,753 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0026" ref-type="fig">Figure 26</xref>).</p></sec><sec id="CD015477-sec-0203"><title>Serious adverse events</title><p>This outcome was reported in two trials (<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>);&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>&#160;contributed to the analysis. BBV152 results in little or no difference in the incidence of SAEs compared to adjuvant at 4.9 months (median) follow&#8208;up (RR 0.65, 95% CI 0.43 to 0.97; 1 RCT, 25,928 participants; absolute effect: 162 fewer per 100,000 (from 264 fewer to 14 fewer); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0027" ref-type="fig">Figure 27</xref>).&#160;</p></sec><sec id="CD015477-sec-0204"><title>Systemic reactogenicity events</title><p>This outcome was reported in two trials (<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>). BBV152 results in little increase in the occurrence of systemic reactogenicity events compared to adjuvant (RR 1.34, 95% CI 1.15 to 1.58; I&#178; = 0%; 2 RCTs, 25,925 participants; absolute effect: 7 more with systemic reactogenicity events per 1000 (from 3 more to 11 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0028" ref-type="fig">Figure 28</xref>).</p></sec><sec id="CD015477-sec-0205"><title>Any adverse event</title><p>This outcome was reported in&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>. BBV152 results in no or little difference in the occurrence of any adverse event compared to adjuvant at 4.9 months (median) follow&#8208;up (RR 1.00, 95% CI 0.94 to 1.07; 1 RCT, 25,753 participants; absolute effect: 0 fewer with any adverse event per 1000 (from 7 fewer to 9 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0029" ref-type="fig">Figure 29</xref>).</p></sec></sec><sec id="CD015477-sec-0206"><title>Important outcomes</title><sec id="CD015477-sec-0207"><title>Immunogenicity outcomes</title><p>Two trials reported GMTs of neutralizing and specific&#160;antibodies against SARS&#8208;COV&#8208;2 (<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>), and&#160;<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>&#160;reported results for cellular immune response. Results are detailed in&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>,&#160;<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>&#160;and&#160;<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>.</p></sec><sec id="CD015477-sec-0208"><title>Local reactogenicity events</title><p>This outcome was reported in two trials (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>). BBV152 results in no or little difference in the occurrence of local reactogenicity events compared to adjuvant (RR 1.08, 95% CI 0.95 to 1.24; I&#178; = 0%; 2 RCTs, 25,750 participants; absolute effect: 2 more with local reactogenicity events per 1000 (from 2 fewer to 7 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0030" ref-type="fig">Figure 30</xref>).</p></sec><sec id="CD015477-sec-0209"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials and are summarized in detail in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>, rather than pooled in a meta&#8208;analysis.</p></sec></sec></sec></sec><sec id="CD015477-sec-0210"><title>Protein subunit vaccines</title><sec id="CD015477-sec-0211"><title>NVX&#8208;CoV2373 &#8211; Novavax versus placebo (normal saline)</title><p>See&#160;<xref rid="CD015477-tbl-0012" ref-type="table">Table 12</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0477" ref-type="app">Appendix 25</xref>.</p><p>We identified and included five trials in the analysis assessing NVX&#8208;CoV2373. The outcomes 'SARS&#8208;CoV&#8208;2 infection after complete vaccination', 'severe or critical COVID&#8208;19 after complete vaccination' and 'cellular immune response' were not reported for this comparison.</p><p>Low&#8208;certainty evidence for the efficacy outcomes might be explained by the inclusion of results from a trial conducted in South Africa during a period of high prevalence of the Beta variant (<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>). Vaccine efficacy against this variant was considerably lower than the efficacy reported in the primary analysis or against the Alpha variant.</p><sec id="CD015477-sec-0212"><title>Critical outcomes</title><sec id="CD015477-sec-0213"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in three trials at two months (median) and three months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>). NVX&#8208;CoV2373 probably results in a large reduction of the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to placebo (VE 82.91%, 95% CI 50.49% to 94.10%; I&#178; = 65%; 3 RCTs, 42,175 participants; moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0032" ref-type="fig">Figure 32</xref>).</p><fig id="CD015477-fig-0032" position="float" orientation="portrait"><label>32</label><caption><p>Analysis 4.1.1: protein subunit vaccine. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-32.jpg"/></fig></sec><sec id="CD015477-sec-0214"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p>This outcome was reported in one trial at two months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>). NVX&#8208;CoV2373 results in a large reduction of severe or critical COVID&#8208;19 after complete vaccination compared to adjuvant due to very serious imprecision (VE 100.00%, 95% CI 86.99% to 100.00%; 1 RCT, 25,452 participants; moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0033" ref-type="fig">Figure 33</xref>).</p><fig id="CD015477-fig-0033" position="float" orientation="portrait"><label>33</label><caption><p>Analysis 4.1.2: protein subunit vaccine. Outcome: severe or critical COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-33.jpg"/></fig></sec><sec id="CD015477-sec-0215"><title>All&#8208;cause mortality</title><p>One trial reported this outcome in 14,039 participants at three months (median) follow&#8208;up (<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>); there were no events and the trial did not contribute to the effect estimate.&#160;<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>&#160;contributed to the analysis with follow&#8208;up of two months (median); the evidence is uncertain for an effect of NVX&#8208;CoV2373 on all&#8208;cause mortality compared to placebo due to very serious imprecision (RR 0.90, 95% CI 0.30 to 2.68; 1 RCT, 29,582 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0034" ref-type="fig">Figure 34</xref>).</p><fig id="CD015477-fig-0034" position="float" orientation="portrait"><label>34</label><caption><p>Analysis 4.1.3: protein subunit vaccine. Outcome: all&#8208;cause mortality.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-34.jpg"/></fig></sec><sec id="CD015477-sec-0216"><title>Serious adverse events</title><p>One trial reported the outcome in 52 participants at 1.15 months' follow&#8208;up (<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>); there were no events and the trial did not contribute to the effect estimate. Four trials contributed to the analysis with follow&#8208;up of 1.15 months, two months (median), and three months (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>). The evidence is uncertain for an effect of NVX&#8208;CoV2373 on SAEs compared to placebo due to very serious imprecision (RR 0.92, 95% CI 0.74 to 1.14, I&#178; = 0%; 4 RCTs, 38,802 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0035" ref-type="fig">Figure 35</xref>).</p><fig id="CD015477-fig-0035" position="float" orientation="portrait"><label>35</label><caption><p>Analysis 4.1.4: protein subunit vaccine. Outcome: serious adverse events (SAEs).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-35.jpg"/></fig></sec><sec id="CD015477-sec-0217"><title>Systemic reactogenicity events</title><p>This outcome was reported in three trials (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>). NVX&#8208;CoV2373 increases slightly the occurrence of systemic reactogenicity events compared to placebo (RR 1.21, 95% CI 1.17 to 1.25, I&#178; = 27%, 3 RCTs, 31,063 participants; absolute effect 76 more per 1000 (from 62 more to 91 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0036" ref-type="fig">Figure 36</xref>).</p><fig id="CD015477-fig-0036" position="float" orientation="portrait"><label>36</label><caption><p>Analysis 4.1.5: protein subunit vaccine. Outcome: systemic reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-36.jpg"/></fig></sec><sec id="CD015477-sec-0218"><title>Any adverse event</title><p>This outcome was reported in five trials (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>). NVX&#8208;CoV2373 probably results in little increase in the incidence of any adverse event compared to placebo at 1.15 months (median) to three months (median) follow&#8208;up (RR 1.15, 95% CI 1.05 to 1.26; I&#178; = 57%; 5 RCTs, 46,231 participants; absolute effect: 26 more with any adverse event per 1000 (from 9 more to 45 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0037" ref-type="fig">Figure 37</xref>).</p><fig id="CD015477-fig-0037" position="float" orientation="portrait"><label>37</label><caption><p>Analysis 4.1.6: protein subunit vaccine. Outcome: any adverse event (AE).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-37.jpg"/></fig></sec></sec><sec id="CD015477-sec-0219"><title>Important outcomes</title><sec id="CD015477-sec-0220"><title>Immunogenetic outcomes</title><p>Two trials reported GMTs of specific antibodies against SARS&#8208;COV&#8208;2 (<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>), and&#160;<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>&#160;reported GMTs of neutralizing antibodies against SARS&#8208;COV&#8208;2. Results are detailed in&#160;<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>&#160;and&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>.</p></sec><sec id="CD015477-sec-0221"><title>Local reactogenicity events</title><p>Three trials reported the outcome (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>). NVX&#8208;CoV2373 results in a large increase in local reactogenicity events compared to placebo (RR 2.78, 95% CI 1.99 to 3.88; I&#178; = 86%; 3 RCTs, 31,063 participants; absolute effect: 340 more with local reactogenicity events per 1000 (from 189 more to 551 more); high&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0038" ref-type="fig">Figure 38</xref>).</p><fig id="CD015477-fig-0038" position="float" orientation="portrait"><label>38</label><caption><p>Analysis 4.1.7 Protein subunit vaccine. Outcome: local reactogenicity events</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-38.jpg"/></fig></sec><sec id="CD015477-sec-0222"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials:&#160;<xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>&#160;reported number of participants with venous thrombosis, lymphadenopathy and nervous system diseases;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#160;reported number of participants with anaemia and nervous system diseases;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>&#160;reported number of participants with myocardial infarction, thrombocytopaenia and nervous system diseases; and&#160;<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>&#160;reported on the number of events for pulmonary embolism, stroke, venous thrombosis, thrombocytopenia, haemorrhage, neutropenia, anaemia, lymphadenopathy and nervous system diseases. Outcomes are summarized in detail in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.</p></sec><sec id="CD015477-sec-0223"><title>Vaccine&#8208;enhanced disease</title><p>One report mentioned this outcome without presenting results (<xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>), and two trials reported no vaccine&#8208;enhanced disease effect (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>).</p></sec></sec></sec><sec id="CD015477-sec-0224"><title>FINLAY&#8208;FR&#8208;2 &#8211; Instituto Finlay de Vacunas versus placebo (adjuvant)</title><p>See&#160;<xref rid="CD015477-tbl-0013" ref-type="table">Table 13</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0478" ref-type="app">Appendix 26</xref>.</p><p>We identified and included in the analysis one trial assessing FINLAY&#8208;FR&#8208;2. The outcomes 'SARS&#8208;CoV&#8208;2 infection after complete vaccination', 'severe or critical COVID&#8208;19 after complete vaccination', 'systemic reactogenicity events', 'incidence of any adverse event', 'incidence of serious adverse events', 'GMT of specific antibodies against SARS&#8208;CoV&#8208;2', 'GMT of neutralizing antibodies against SARS&#8208;CoV&#8208;2', 'cellular immune response', 'incidence of specific safety outcomes' and 'vaccine&#8208;enhanced disease' were not reported for this comparison.</p><sec id="CD015477-sec-0225"><title>Critical outcomes</title><sec id="CD015477-sec-0226"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p>We found one trial reporting this outcome (<xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>). FINLAY&#8208;FR&#8208;2 probably results in a large reduction in the incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination compared to adjuvant (VE 71.00%, 95% CI 58.90% to 79.10%; 1 RCT, 28,674 participants; moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0032" ref-type="fig">Figure 32</xref>).</p></sec><sec id="CD015477-sec-0227"><title>All&#8208;cause mortality</title><p>This outcome was reported in one trial (<xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>). FINLAY&#8208;FR&#8208;2 probably results in a reduction of all&#8208;cause mortality compared to adjuvant due to serious risk of bias and imprecision (RR 0.37, 95% CI 0.17 to 0.80; 1 RCT, 28,674 participants; absolute effect: 106 fewer per 100,000 (from 139 fewer to 34 fewer) moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0034" ref-type="fig">Figure 34</xref>).</p></sec></sec></sec></sec><sec id="CD015477-sec-0228"><title>Primary series heterologous vaccination scheme versus homologous vaccination scheme</title><p>See&#160;<xref rid="CD015477-tbl-0014" ref-type="table">Table 14</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0479" ref-type="app">Appendix 27</xref>.</p><p>Two publications reported results for three different comparisons involving an RNA&#8208;based vaccine (BNT162b2 &#8211; BioNtech/Fosun Pharma/Pfizer), non&#8208;replicating viral vector vaccine (ChAdOx1 &#8211; AstraZeneca/University of Oxford), and inactivated virus vaccine (CoronaVac &#8211; Sinovac). More specifically the following schemes were compared (vaccine first dose/vaccine second dose): BNT162b2/ChAdOx1 versus BNT162b2/BNT162b2 (<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>), and ChAdOx1/BNT162b2 versus ChAdOx1/ChAdOx1 (<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>), and CoronaVac/Ad5 versus CoronaVac/CoronaVac (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>).</p><p>The outcomes 'SARS&#8208;CoV&#8208;2 infection after complete vaccination', 'symptomatic COVID&#8208;19 after complete vaccination', 'severe or critical COVID&#8208;19', 'all&#8208;cause mortality', 'systemic reactogenicity events' and 'vaccine&#8208;enhanced disease' were not reported for these comparisons.</p><sec id="CD015477-sec-0229"><title>Critical outcomes</title><sec id="CD015477-sec-0230"><title>Serious adverse events</title><p>One trial reported this outcome in 101 participants at one&#8208;month follow&#8208;up for the comparison CoronaVac/Ad5 versus CoronaVac homologous (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>), and reported zero events in both groups.&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>&#160;reported the outcome in 234 participants for the comparison BNT162b2/ChAdOx1 versus BNT162b2 homologous and also reported zero events in both groups. The same trial reported the outcome for the comparison ChAdOx1/BNT162b2 versus ChAdOx1 homologous. The evidence is uncertain for an effect of ChAdOx1/BNT162b2 on SAEs compared to ChAdOx1/ChAdOx1 due to serious risk of bias, inconsistency and imprecision (RR 0.34, 95% CI 0.01 to 8.17; 1 RCT, 229 participants; very low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0039" ref-type="fig">Figure 39</xref>).</p><fig id="CD015477-fig-0039" position="float" orientation="portrait"><label>39</label><caption><p>Analysis 5.1.1: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: serious adverse events (SAEs).</p><p>Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-39.jpg"/></fig></sec><sec id="CD015477-sec-0231"><title>Systemic reactogenicity events</title><p>There was one comparison with results for this outcome (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>). The evidence is uncertain for an effect of CoronaVac/Ad5 on the incidence of systemic reactogenicity events compared to CoronaVac/CoronaVac due to very serious imprecision (RR 1.96, 95% CI 0.52 to 7.41; 1 RCT, 101 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0040" ref-type="fig">Figure 40</xref>).</p><fig id="CD015477-fig-0040" position="float" orientation="portrait"><label>40</label><caption><p>Analysis 5.1.2: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: systemic reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-40.jpg"/></fig></sec><sec id="CD015477-sec-0232"><title>Any adverse event</title><p>Two trials reported any adverse event on three different comparisons (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>). CoronaVac/Ad5 versus CoronaVac homologous at 1&#8208;month follow&#8208;up (RR 3.19, 95% CI 1.11 to 9.11), BNT162b2/ChAdOx1 versus BNT162b2 homologous at two months' follow&#8208;up (RR 1.21, 95% CI 0.87 to 1.68) and ChAdOx1/BNT162b2 versus ChAdOx1 homologous at 2 months' follow&#8208;up (RR 1.03, 95% CI 0.75 to 1.43). The evidence is very uncertain about the effect of heterologous schemes on the incidence of any adverse event compared to homologous schemes due to serious risk of bias, inconsistency and imprecision (<xref rid="CD015477-fig-0041" ref-type="fig">Figure 41</xref>).</p><fig id="CD015477-fig-0041" position="float" orientation="portrait"><label>41</label><caption><p>Analysis 5.1.3: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: any adverse event (AE).</p><p><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>&#160;included only participants 50 years of age or older.</p><p>Liu X 2021.1 and Liu X 2021.2 are different comparisons for the same report (<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-41.jpg"/></fig></sec></sec><sec id="CD015477-sec-0233"><title>Important outcomes</title><sec id="CD015477-sec-0234"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>&#160;reported that the heterologous schedule CoronaVac/Ad5 elicited higher levels of specific antibodies against SARS&#8208;COV&#8208;2 (GMR 6.11, 95% CI 3.90 to 9.57) and neutralizing antibodies against SARS&#8208;COV&#8208;2 (GMR 4.25, 95% CI 2.63 to 6.86) compared to the homologous schedule CoronaVac/CoronaVac (<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>&#160;and&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>).</p><p><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>&#160;reported this outcome for two different comparisons. The outcome was measured using IFN&#8208;&#947; ELISpot 28 days after the administration of the second dose.&#160;</p><p>The heterologous schedule ChAdOx1/BNT162b2 elicited a larger immune cellular response compared to the homologous schedule ChAdOx1/ChAdOx1 (GMR of number of spot&#8208;forming cells (SFCs) per million peripheral blood mononuclear cell (PBMC)) 3.9 (95% CI 2.9 to 5.3)).</p><p>The GMR of SFCs per million PBMCs was 1.2 (95% CI 0.87 to 1.7) for the comparison of the heterologous schedule BNT162b2/ChAdOx to the homologous schedule BNT162b2/BNT162b2 (<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>).</p></sec><sec id="CD015477-sec-0235"><title>Local reactogenicity events</title><p>One trial reported this outcome (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>). The heterologous schedule (CoronaVac/Ad5) probably results in a large increase in the number of local reactogenicity events compared to the homologous schedule (CoronaVac/CoronaVac) (RR 11.76, 95% CI 1.59 to 87.14; 1 RCT, 101 participants; absolute effect: 215 more with local reactogenicity events per 1000 (from 12 more to 1000 more); low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0042" ref-type="fig">Figure 42</xref>).</p><fig id="CD015477-fig-0042" position="float" orientation="portrait"><label>42</label><caption><p>Analysis 5.1.4: heterologous vaccination scheme versus homologous vaccination scheme. Outcome: local reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-42.jpg"/></fig></sec><sec id="CD015477-sec-0236"><title>Incidence of specific safety outcomes</title><p>Specific safety outcomes were not consistently reported throughout the included trials. Two trials reported on the number of participants with venous thrombosis (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>). Outcomes are summarized in detail in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.&#160;</p></sec></sec></sec><sec id="CD015477-sec-0237"><title>Boosters</title><sec id="CD015477-sec-0238"><title>Homologous or heterologous booster versus placebo/no booster</title><p>See&#160;<xref rid="CD015477-tbl-0015" ref-type="table">Table 15</xref>&#160;and table of results in&#160;<xref rid="CD015477-sec-0480" ref-type="app">Appendix 28</xref>.</p><p>We identified and included two trials in the analysis (<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>;&#160;<xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>).&#160;<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>&#160;included only kidney transplant recipient participants; in our judgement results from this trial are not generally applicable.</p><sec id="CD015477-sec-0239"><title>mRNA&#8208;1273 booster versus placebo (normal saline)</title><p><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>&#160;compared a booster dose of mRNA&#8208;1273 to placebo after complete vaccination of mRNA&#8208;1273 in kidney transplant recipients. They reported three outcomes of interest.</p><sec id="CD015477-sec-0240"><title>Systemic reactogenicity events</title><p>Follow&#8208;up was seven days, starting after injection of the booster dose. There were 11 systemic reactogenicity events in the intervention arm (60 participants) compared to six in the control arm (59 participants). We assessed the overall risk of bias for the outcome to be low.</p><p>The evidence is uncertain for an effect of mRNA&#8208;1273 booster on the incidence of systemic reactogenicity events compared to placebo due to serious imprecision (RR 1.80, 95% CI 0.71 to 4.56; 1 RCT, 119 participants; low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0043" ref-type="fig">Figure 43</xref>).</p><fig id="CD015477-fig-0043" position="float" orientation="portrait"><label>43</label><caption><p>Analysis 6.1.2: booster versus placebo/no booster. Outcome: systemic reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-43.jpg"/></fig></sec><sec id="CD015477-sec-0241"><title>Immunogenicity outcomes</title><p>One trial reported results for cellular immune response (<xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>). The outcome was measured using intracellular cytokine staining 28 days after the administration of the booster or placebo. The median CD4+ T cells per million was higher in the booster arm than in the placebo arm (432 versus 67 cells per 100 CD4+ T cells; 95% CI for the between&#8208;group difference, 46 to 986;&#160;<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>).&#160;</p></sec><sec id="CD015477-sec-0242"><title>Local reactogenicity events</title><p>The follow&#8208;up period was seven days starting after the injection of the booster dose. There were 46 local reactogenicity events in the intervention arm (N = 60) compared to seven in the control arm (N = 59). We assessed the overall risk of bias for the outcome to be low. A&#8208;1273 booster probably results in a large increase in the number of local reactogenicity events compared to placebo (RR 6.46, 95% CI 3.18 to 13.13; 1 RCT, 119 participants; absolute effect: 648 more local adverse event per 1000 (from 259 more to 1000 more); moderate&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0044" ref-type="fig">Figure 44</xref>).</p><fig id="CD015477-fig-0044" position="float" orientation="portrait"><label>44</label><caption><p>Analysis 6.1.3: booster versus placebo/no booster. Outcome: local reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-44.jpg"/></fig></sec></sec><sec id="CD015477-sec-0243"><title>FINLAY&#8208;FR&#8208;1 booster versus no booster dose</title><sec id="CD015477-sec-0244"><title>All&#8208;cause mortality</title><p><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>&#160;compared a booster dose of FINLAY&#8208;FR&#8208;1 to no booster dose after complete vaccination of FINLAY&#8208;FR&#8208;2 in adults; only all&#8208;cause mortality with a median follow&#8208;up of 1.7 months was reported.</p><p>There were 11 deaths in the intervention arm (of 13,883 participants) compared to nine in the control arm (of 14,371 participants). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information about allocation concealment and the use of per&#8208;protocol analysis.&#160;</p><p>The evidence is very uncertain about the effect of the booster dose of FR&#8208;1 compared to adjuvant due to serious risk of bias and very serious imprecision (RR 1.27, 95% CI 0.52 to 3.05; 1 RCT, 28,254 participants; very low&#8208;certainty evidence;&#160;<xref rid="CD015477-fig-0045" ref-type="fig">Figure 45</xref>).</p><fig id="CD015477-fig-0045" position="float" orientation="portrait"><label>45</label><caption><p>Analysis 6.1.1: booster versus placebo/no booster. Outcome: all&#8208;cause mortality.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-45.jpg"/></fig></sec></sec></sec><sec id="CD015477-sec-0245"><title>Homologous booster versus heterologous booster&#160;</title><p>We identified four trials for this comparison (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>;&#160;<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>;&#160;<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>). Of note, in all trials specific safety outcomes were not consistently reported; these are summarized in&#160;<xref rid="CD015477-sec-0416" ref-type="app">Appendix 9</xref>.</p><sec id="CD015477-sec-0246"><title>BNT162b2 or mRNA&#8208;1273 with homologous booster versus heterologous ChAdOx1 booster</title><p>One trial compared a homologous booster dose of BNT162b2 or mRNA&#8208;1273 to a booster dose of ChAdOx1 in immunocompromized adults under current rituximab therapy (<xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>). They only reported on two outcomes of interest.</p><sec id="CD015477-sec-0247"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>&#160;reported results for cellular immune response. The outcome was measured using IFN&#8208;&#947; ELISpot seven days after the administration of the booster dose. The median interquartile range (IQR) number of SFCs per million PBMCs was 459 (133 to 722) in the heterologous booster arm versus 305 (717 to 416) in the homologous booster arm (<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>).</p></sec><sec id="CD015477-sec-0248"><title>Local reactogenicity events</title><p>Follow&#8208;up was two days starting after the injection of the booster dose. There were fewer local reactogenicity events in the ChAdOx1 heterologous booster arm (8/27) compared to the homologous booster arm (16/28) (RR 0.52, 95% CI 0.27 to 1.01). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information about allocation concealment, missingness of outcome data, unclear blinding which could have influenced the measurement of the outcome, and no information on whether the outcome was analyzed as prespecified (<xref rid="CD015477-fig-0046" ref-type="fig">Figure 46</xref>).</p><fig id="CD015477-fig-0046" position="float" orientation="portrait"><label>46</label><caption><p>Analysis 6.2.4: homologous booster versus heterologous booster. Outcome: local reactogenicity events.</p><p><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>&#160;included only participants under current Rituximab therapy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-46.jpg"/></fig></sec><sec id="CD015477-sec-0249"><title>Incidence of specific safety outcomes</title><p><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref>&#160;reported on the number of participants with thrombocytopaenia and nervous system diseases; details are in&#160;<xref rid="CD015477-sec-0456" ref-type="app">Appendix 12</xref>.</p></sec></sec><sec id="CD015477-sec-0250"><title>Ad26.COV2.S with homologous booster versus heterologous mRNA&#8208;1273 booster</title><p>One trial compared a homologous booster dose of Ad26.COV2.S to a booster dose of mRNA&#8208;1273 in healthcare workers (<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>). They only reported on three outcomes of interest.</p><sec id="CD015477-sec-0251"><title>Systemic reactogenicity events</title><p>Follow&#8208;up was seven days starting after the injection of the booster dose. There were fewer systemic reactogenicity events in the homologous booster arm (62/106) compared to the mRNA&#8208;1273 booster arm (84/111) (RR 0.77, 95% CI 0.64 to 0.94). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per&#8208;protocol analysis and missing outcome data (<xref rid="CD015477-fig-0047" ref-type="fig">Figure 47</xref>).</p><fig id="CD015477-fig-0047" position="float" orientation="portrait"><label>47</label><caption><p>Analysis 6.2.2: homologous booster versus heterologous booster. Outcome: systemic reactogenicity events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-47.jpg"/></fig></sec><sec id="CD015477-sec-0252"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>&#160;reported results for cellular immune response. The proportion of responders was measured using IFN&#8208;y release assay (cut&#8208;off is 0.15 IU/mL) 28 days after the administration of the booster dose. The proportion of responders was lower in the homologous booster arm (32/44; 72.7%) than in the heterologous booster arm (44/48; 91.7%) (RR 0.79, 95% CI 0.64 to 0.96;&#160;<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>).</p></sec><sec id="CD015477-sec-0253"><title>Local reactogenicity events</title><p>Follow&#8208;up was seven days starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (73/106) compared to the mRNA&#8208;1273 booster arm (103/111) (RR 0.74, 95% CI 0.65 to 0.85). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per&#8208;protocol analysis and missing outcome data (<xref rid="CD015477-fig-0046" ref-type="fig">Figure 46</xref>).</p></sec></sec><sec id="CD015477-sec-0254"><title>Ad26.COV2.S with homologous booster versus heterologous BNT162b2 booster</title><p><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>&#160;assessed complete vaccination of Ad26.COV2.S with a homologous booster dose of Ad26.COV2.S versus a heterologous booster dose of BNT162b2 in healthcare workers. They reported on three outcomes of interest.</p><sec id="CD015477-sec-0255"><title>Systemic reactogenicity events</title><p>Follow&#8208;up was seven days starting after the injection of the booster dose. There were 62/106 systemic reactogenicity events in the homologous booster arm compared to 70/111 in the BNT162b2 booster arm (RR 0.93, 95% CI 0.75 to 1.15). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per&#8208;protocol analysis and missing outcome data (<xref rid="CD015477-fig-0047" ref-type="fig">Figure 47</xref>).</p></sec><sec id="CD015477-sec-0256"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>&#160;reported results for cellular immune response. The proportion of responders was measured using IFN&#8208;y release assay (cut&#8208;off is 0.15 IU/mL) 28 days after the administration of the booster dose. The response rate was lower in the homologous booster arm (32/44; 72.7%) than in the heterologous booster arm (43/47; 91.5%) (RR 0.79, 95% CI 0.65 to 0.97;&#160;<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>).</p></sec><sec id="CD015477-sec-0257"><title>Local reactogenicity events</title><p>Follow&#8208;up was seven days starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (73/106) compared to the BNT162b2 booster arm (97/111) (RR 0.79, 95% CI 0.66 to 0.91). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per&#8208;protocol analysis and missing outcome data (<xref rid="CD015477-fig-0046" ref-type="fig">Figure 46</xref>).</p></sec></sec><sec id="CD015477-sec-0258"><title>CoronaVac with homologous booster versus heterologous Ad5 booster</title><p>One trial compared a complete vaccination of CoronaVac with a homologous booster dose of CoronaVac to a heterologous booster dose of Ad5 in healthy adults (<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>). They reported five outcomes of interest.</p><sec id="CD015477-sec-0259"><title>Serious adverse events</title><p>Zero SAEs were reported in both groups (<xref rid="CD015477-fig-0048" ref-type="fig">Figure 48</xref>).</p><fig id="CD015477-fig-0048" position="float" orientation="portrait"><label>48</label><caption><p>Analysis 6.2.1: homologous booster versus heterologous booster. Outcome: serious adverse events.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-48.jpg"/></fig></sec><sec id="CD015477-sec-0260"><title>Systemic reactogenicity events</title><p>Follow&#8208;up was one month starting after the injection of the booster dose. There were fewer systemic reactogenicity events in the homologous booster arm (3/102) compared to the Ad5 booster arm (14/96) (RR 0.20, 95% CI 0.06 to 0.68). We assessed the overall risk of bias for the outcome to have some concerns due to the use of per&#8208;protocol analysis (<xref rid="CD015477-fig-0047" ref-type="fig">Figure 47</xref>).</p></sec><sec id="CD015477-sec-0261"><title>Any adverse event</title><p>Follow&#8208;up was one month starting after the injection of the booster dose. There were fewer adverse events in the homologous booster arm (5/102) compared to the Ad5 booster arm (34/96) (RR 0.14, 95% CI 0.06 to 0.34). We assessed the overall risk of bias for the outcome to have some concerns due to the use of per&#8208;protocol analysis (<xref rid="CD015477-fig-0049" ref-type="fig">Figure 49</xref>).</p><fig id="CD015477-fig-0049" position="float" orientation="portrait"><label>49</label><caption><p>Analysis 6.2.3: homologous booster versus heterologous booster. Outcome: any adverse event.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-49.jpg"/></fig></sec><sec id="CD015477-sec-0262"><title>Immunogenicity outcomes&#160;</title><p><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>&#160;reported that the heterologous booster CoronaVac/Ad5 elicited higher levels of specific antibodies against SARS&#8208;COV&#8208;2 (GMR 8.37, 95% CI 6.52 to 10.75) and neutralizing antibodies against SARS&#8208;COV&#8208;2 (GMR 5.87, 95% CI 4.64 to 7.43) compared to the homologous booster CoronaVac/CoronaVac (<xref rid="CD015477-sec-0463" ref-type="app">Appendix 16</xref>;&#160;<xref rid="CD015477-sec-0449" ref-type="app">Appendix 11</xref>).&#160;</p></sec><sec id="CD015477-sec-0263"><title>Local reactogenicity events</title><p>Follow&#8208;up was one month starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (3/102) compared to the Ad5 booster arm (28/96) (RR 0.10, 95% CI 0.03 to 0.32). We assessed the overall risk of bias for the outcome to have some concerns due to the use of per&#8208;protocol analysis (<xref rid="CD015477-fig-0046" ref-type="fig">Figure 46</xref>).</p></sec></sec><sec id="CD015477-sec-0264"><title>CoronaVac with a homologous booster versus heterologous BNT162b2 booster</title><p>One trial compared complete vaccination of CoronaVac with a homologous booster dose of CoronaVac to a heterologous booster dose of BNT162b2 in adults with low&#8208;immune response against SARS&#8208;CoV&#8208;2 after complete vaccination of CoronaVac (<xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>). They reported two outcomes of interest.</p><sec id="CD015477-sec-0265"><title>Systemic reactogenicity events</title><p>Follow&#8208;up was one month starting after the injection of the booster dose. There were fewer systemic reactogenicity events in the homologous booster arm (24/40) compared to the BNT162b2 booster arm (32/40) (RR 0.75, 95% CI 0.56 to 1.01). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, unclear blinding which could have influenced the measurement of the outcome, and the outcome not being prespecified (<xref rid="CD015477-fig-0047" ref-type="fig">Figure 47</xref>).</p></sec><sec id="CD015477-sec-0266"><title>Local reactogenicity events</title><p>Follow&#8208;up was one month starting after the injection of the booster dose. There were fewer local reactogenicity events in the homologous booster arm (12/40) compared to the BNT162b2 booster arm (34/40) (RR 0.35, 95% CI 0.22 to 0.58). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, unclear blinding which could have influenced the measurement of the outcome, and the outcome not being prespecified (<xref rid="CD015477-fig-0046" ref-type="fig">Figure 46</xref>).</p></sec></sec></sec><sec id="CD015477-sec-0267"><title>Heterologous booster versus heterologous booster&#160;</title><sec id="CD015477-sec-0268"><title>Ad26.COV2.S with mRNA&#8208;1273 booster versus Ad26.COV2.S with BNT162b2 booster</title><p>One trial compared mRNA&#8208;1273 booster to BNT162b2 booster in healthcare workers vaccinated with Ad26.COV2.S (<xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>). They reported on three outcomes of interest.</p><sec id="CD015477-sec-0269"><title>Systemic reactogenicity events</title><p>Follow&#8208;up was seven days starting after the injection of the booster dose. There were more systemic reactogenicity events in the mRNA&#8208;1273 booster arm (84/111) compared to the BNT162b2 booster arm (70/111) (RR 1.20, 95% CI 1.01 to 1.43). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per&#8208;protocol analysis, and missing outcome data (<xref rid="CD015477-fig-0047" ref-type="fig">Figure 47</xref>).</p></sec><sec id="CD015477-sec-0270"><title>Immunogenicity outcomes</title><p><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>&#160;reported results for cellular immune response. The proportion of responders was measured using IFN&#8208;y release assay (cut&#8208;off is 0.15 IU/mL) 28 days after the administration of the booster dose. The number of responders was similar in the mRNA&#8208;1273 booster arm (44/48; 91.7%) compared to the BNT162b2 booster arm (43/47; 91.5%) (RR 1.00, 95% CI 0.88 to 1.13;&#160;<xref rid="CD015477-sec-0472" ref-type="app">Appendix 20</xref>).</p></sec><sec id="CD015477-sec-0271"><title>Local reactogenicity events</title><p>Follow&#8208;up was seven days starting after the injection of the booster dose. There were 103/111 participants with local reactogenicity events in the mRNA&#8208;1273 booster arm compared to 97/111 in the BNT162b2 booster arm (RR 1.06, 95% CI 0.97 to 1.16). We assessed the overall risk of bias for the outcome to have some concerns due to lack of information on allocation concealment, use of per&#8208;protocol analysis, and missing outcome data (<xref rid="CD015477-fig-0046" ref-type="fig">Figure 46</xref>).</p></sec></sec></sec></sec><sec id="CD015477-sec-0272"><title>Effects of the intervention on variants of concern&#160;</title><p>Given that the prevalence of more than one variant in the same population changes and shifts over time, it is to be expected that most of the trials, which collect data over several months, reflect the heterogeneity of COVID&#8208;19 variants in their sample. However, among our included studies, 10 did report vaccine efficacy on confirmed symptomatic COVID&#8208;19 after complete vaccination against four variants of concern: Alpha (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>;&#160;<xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref>;&#160;<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>;&#160;<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>), Beta (<xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>), Gamma (<xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref>;&#160;<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>), and Delta (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>). No study had yet reported data regarding the Omicron variant at the time of the data cut&#8208;off (5 November 2021).&#160;</p><p>We considered the direct evidence when study reports provided evidence on a sequenced sample. When sequencing was not performed, we extrapolated the exposure to variants from the prevalence in the study setting.&#160;</p><sec id="CD015477-sec-0273"><title>Alpha variant (B.1.1.7)</title><p>Vaccine efficacy against the Alpha variant was reported in three trials, assessing three different vaccines. All cases of the Alpha variant were detected with genome sequencing. Of note,&#160;<xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref>&#160;includes only participants of the COV002 trial (<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>).&#160;</p><p>Reported vaccine efficacy on confirmed symptomatic COVID&#8208;19 after complete vaccination was 55.10%, 95% CI 23.50% to 73.60% for CVnCoV (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>); 70.40%, 95% CI 43.60% to 84.50% for ChAdOx1 (<xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref>); and for NVX&#8208;CoV2373 was 86.30%, 95% CI 71.30% to 93.50% (<xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>) and 93.60%, 95% CI 81.70% to 97.80% (<xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>) (<xref rid="CD015477-fig-0050" ref-type="fig">Figure 50</xref>).</p><fig id="CD015477-fig-0050" position="float" orientation="portrait"><label>50</label><caption><p>Analysis 7.1.1: variant&#8208;Alpha. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-50.jpg"/></fig></sec><sec id="CD015477-sec-0274"><title>Beta variant (B.1.351)&#160;</title><p>Vaccine efficacy against the Beta variant was reported in four trials, assessing four different vaccines. Results from three trials are based only on genetically sequenced cases (direct evidence) (<xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>;&#160;<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>). In contrast, results in&#160;<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#160;include all cases identified and the prevalence of the Beta variant among participants (94.5%), obtained by sequencing a sample of RT&#8208;PCR positive cases, was extrapolated to the results (indirect evidence). Of note,&#160;<xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>&#160;includes only participants of the COV005 trial (<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>).</p><p>Reported vaccine efficacy on confirmed symptomatic COVID&#8208;19 after complete vaccination was 100.00%, 95% CI 53.50% to 100.00% for BNT16b2 (<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>); 10.40%, 95% CI 0.00% to 54.80% for ChAdOx1 (<xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>); 52.00%, 95% CI 30.30% to 67.40% for Ad26.COV2.S (<xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>), and 43.00%, 95% CI 0.00% to 70.40% for NVX&#8208;CoV2373 (<xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>) (<xref rid="CD015477-fig-0051" ref-type="fig">Figure 51</xref>).</p><fig id="CD015477-fig-0051" position="float" orientation="portrait"><label>51</label><caption><p>Analysis 7.2.1: variant&#8208;Beta. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-51.jpg"/></fig></sec><sec id="CD015477-sec-0275"><title>Gamma variant (P.1)</title><p>Vaccine efficacy against the Gamma variant was reported in two trials, assessing two different vaccines. All cases of the Gamma variant were detected with genome sequencing. Reported vaccine efficacy on confirmed symptomatic COVID&#8208;19 after complete vaccination was 67.10%, 95% CI 29.80% to 84.60% for CVnCoV (<xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>), and 63.60%, 95% CI 0.00% to 87.00% for ChAdOx1 (<xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref>) (<xref rid="CD015477-fig-0052" ref-type="fig">Figure 52</xref>).</p><fig id="CD015477-fig-0052" position="float" orientation="portrait"><label>52</label><caption><p>Analysis 7.3.1: variant&#8208;Gamma. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-52.jpg"/></fig></sec><sec id="CD015477-sec-0276"><title>Delta (B.1.617.2)</title><p>Vaccine efficacy against the Delta variant was reported in one trial. All cases of the Delta variant were detected with genome sequencing.</p><p>Reported vaccine efficacy on confirmed symptomatic COVID&#8208;19 after complete vaccination was 65.20%, 95% CI 33.10% to 83.00% for BBV152 (<xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>) (<xref rid="CD015477-fig-0053" ref-type="fig">Figure 53</xref>).</p><fig id="CD015477-fig-0053" position="float" orientation="portrait"><label>53</label><caption><p>Analysis 7.4.1: variant&#8208;Delta. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-53.jpg"/></fig></sec></sec><sec id="CD015477-sec-0277"><title>Assessment of vaccine efficacy over time</title><p>Out of the 41 included trials, only two studies reported on the change of vaccine efficacy over time for the outcome 'incidence of confirmed symptomatic COVID&#8208;19 after complete vaccination' for comparisons BNT162b2 versus placebo (BioNtech/Fosun Pharma/Pfizer) and mRNA&#8208;1273 versus placebo (ModernaTX) (<xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>;&#160;<xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>).</p><p>For the comparison BNT162b2 versus placebo, vaccine efficacy seems to decrease slightly over time. However, the effect remains large: VE 96.20%, 95% CI 93.30% to 98.10% after a median follow&#8208;up less than 2 months and VE 83.70%, 95% CI 74.70% to 89.90% after a median follow&#8208;up of 4 months to 6 months (<xref rid="CD015477-fig-0054" ref-type="fig">Figure 54</xref>).</p><fig id="CD015477-fig-0054" position="float" orientation="portrait"><label>54</label><caption><p>Analysis 8.1: follow&#8208;up. RNA&#8208;based vaccine. Outcome: confirmed symptomatic COVID&#8208;19 after complete vaccination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nCD015477-FIG-54.jpg"/></fig><p>When comparing mRNA&#8208;1273 with placebo, vaccine efficacy was consistent over time (VE 91.80%, 95% CI 86.90% to 95.10%; median follow&#8208;up less than two months and VE 92.40%, 84.30% to 96.80%; median follow&#8208;up four months or greater) (<xref rid="CD015477-fig-0054" ref-type="fig">Figure 54</xref>).</p></sec><sec id="CD015477-sec-0278"><title>Exploration of heterogeneity</title><sec id="CD015477-sec-0279"><title>Subgroup analysis</title><p>We had planned to perform subgroup analysis for different age groups and immunocompromized patients; however due to the low number of studies we could not undertake formal subgroup analyses for each comparison.&#160;</p></sec><sec id="CD015477-sec-0280"><title>Sensitivity analysis&#160;</title><p>Overall, all results for all outcomes were consistent in every sensitivity analysis as compared with the primary analysis. Small differences were mostly observed due to the increase of uncertainty in the summary estimate when excluding some trials.</p></sec><sec id="CD015477-sec-0281"><title>RNA&#8208;based vaccines</title><p>Overall, results were consistent in all the analyses (<xref rid="CD015477-tbl-0016" ref-type="table">Table 16</xref>).</p><table-wrap id="CD015477-tbl-0016" position="float" orientation="portrait"><label>1</label><caption><title>Sensitivity analysis: RNA&#8208;based vaccines</title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="3" valign="bottom" colspan="1"><bold>Developer &#8211; comparison</bold></td><td rowspan="3" valign="bottom" colspan="1"><bold>Analyses<sup>a</sup></bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>SARS&#8208;CoV&#8208;2 infection</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Symptomatic COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAEs</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>AEs</bold></td></tr><tr><td colspan="3" align="center" valign="top" rowspan="1"><bold>VE (95% CI)</bold><break/><bold>No. of trials (No. of participants)&#160;</bold></td><td colspan="4" align="center" valign="top" rowspan="1"><bold>RR (95% CI)</bold><break/><bold>No. of trials (No. of participants)&#160;</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1">BNT162b2 <bold>&#8211;</bold> Pfizer/BioNTech+Fosun Pharma versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">97.84% (44.25% to 99.92%)<break/>2 RCTs (44,077)</td><td valign="top" colspan="1" rowspan="1">95.70% (73.90% to 99.90%)<break/>1 RCT (46,077)</td><td valign="top" colspan="1" rowspan="1">1.07 (0.52 to 2.22)<break/>1 RCT (43,846)</td><td valign="top" colspan="1" rowspan="1">1.30 (0.55 to 3.07)<break/>2 RCTs (46,107)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.52 (0.88 to 2.63)<break/>3 RCTs (46,419)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.07 (0.52 to 2.22)<break/>1 RCT (44,165)</td><td valign="top" colspan="1" rowspan="1">1.30 (0.55 to 3.05)<break/>2 RCTs (46,429)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.52 (0.88 to 2.63)<break/>3 RCTs (46,471)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td rowspan="4" valign="top" colspan="1">mRNA&#8208;1273 <bold>&#8211;</bold> ModernaTX&#160; versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">73.27% (35.82% to 88.87%)<break/>2 RCTs (31,632)</td><td valign="top" colspan="1" rowspan="1">93.20% (91.06% to 94.83%)<break/>2 RCTs (31,632)</td><td valign="top" colspan="1" rowspan="1">98.20% (92.80% to 99.60%)<break/>1 RCT (28,451)</td><td valign="top" colspan="1" rowspan="1">1.06 (0.54 to 2.10)<break/>1 RCT (30,346)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.78 to 1.08)<break/>2 RCTs (34,072)</td><td valign="top" colspan="1" rowspan="1">1.28 (1.22 to 1.34)<break/>2 RCTs (34,037)</td><td valign="top" colspan="1" rowspan="1">1.19 (0.79 to 1.80)<break/>2 RCTs (34,072)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.06 (0.54 to 2.10)<break/>1 RCT (30,415)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.78 to 1.09)<break/>2 RCTs (34,147)</td><td valign="top" colspan="1" rowspan="1">1.28 (1.22 to 1.34)<break/>2 RCTs (34,147)</td><td valign="top" colspan="1" rowspan="1">1.20 (0.79 to 1.80)<break/>2 RCTs (34,147)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td rowspan="4" valign="top" colspan="1">CVnCoV <bold>&#8211;</bold> CureVac AG versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">48.20% (31.70% to 60.90%)<break/>1 RCT (25,062)</td><td valign="top" colspan="1" rowspan="1">63.80% (0.00% to 91.70%)<break/>1 RCT (25,062)</td><td valign="top" colspan="1" rowspan="1">1.33 (0.46 to 3.83)<break/>1 RCT (39,529)</td><td valign="top" colspan="1" rowspan="1">1.24 (0.90 to 1.71)<break/>1 RCT (39,529)</td><td valign="top" colspan="1" rowspan="1">1.48 (1.43 to 1.53)<break/>1 RCT (3982)</td><td valign="top" colspan="1" rowspan="1">1.42 (1.38 to 1.47)<break/>1 RCT (3982)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.49 (1.39 to 1.60)<break/>1 RCT (39,529)<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">1.43 (1.34 to 1.53)<break/>1 RCT (39,529)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1"><bold>&#8212;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="9" rowspan="1">AE: adverse event; CI: confidence interval; COVID&#8208;19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS&#8208;CoV&#8208;2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0016" fn-type="fn"><p><sup>a</sup><bold>Sensitivity 1:</bold> participants randomized; <bold>Sensitivity 2:</bold> early&#8208;phase studies excluded; <bold>Sensitivity 3:</bold> only published studies.</p></fn></table-wrap-foot></table-wrap></sec><sec id="CD015477-sec-0282"><title>Non&#8208;replicating viral vector vaccines</title><p>Overall, results were consistent in all the analyses (<xref rid="CD015477-tbl-0017" ref-type="table">Table 17</xref>). An important but not statistically significant reduction in the RR for adverse event was observed, though, when excluding the early&#8208;phase trial.</p><table-wrap id="CD015477-tbl-0017" position="float" orientation="portrait"><label>2</label><caption><title>Sensitivity analysis: non&#8208;replicating viral vector vaccine&#160;</title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="3" valign="bottom" colspan="1"><bold>Developer &#8211; comparison</bold></td><td rowspan="3" valign="bottom" colspan="1">Analyses<bold><sup>a</sup></bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>SARS&#8208;CoV&#8208;2 infection</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Symptomatic COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAEs</bold></td><td valign="bottom" colspan="1" rowspan="1">Systemic <bold>reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>AEs</bold></td></tr><tr><td colspan="3" align="center" valign="top" rowspan="1"><bold>VE (95% CI)</bold><break/><bold>No. of trials (No. of participants)</bold></td><td colspan="4" align="center" valign="top" rowspan="1"><bold>RR (95% CI)</bold><break/><bold>No. of trials (No. of participants)</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1">ChAdOx1 &#8211; AstraZeneca + University of Oxford&#160;versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">59.35% (48.00% to 68.22%)<break/>5 RCTs (43,390)</td><td valign="top" colspan="1" rowspan="1">70.23% (62.10% to 76.62%)<break/>5 RCTs (43,390)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.48 (0.20 to 1.14)<break/>5 RCTs (56,726)</td><td valign="top" colspan="1" rowspan="1">0.88 (0.72 to 1.07)<break/>7 RCTs (58,182)</td><td valign="top" colspan="1" rowspan="1">3.93 (2.11 to 7.29)<break/>&#160;<break/>1 RCT (256)</td><td valign="top" colspan="1" rowspan="1">Not pooled</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.50 (0.20 to 1.21)<break/>5 RCTs (56,873)</td><td valign="top" colspan="1" rowspan="1">0.86 (0.70 to 1.06)<break/>7 RCTs (58,329)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#160;&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.48 (0.20 to 1.14)<break/>5 RCTs (56,623)</td><td valign="top" colspan="1" rowspan="1">0.88 (0.72 to 1.08)<break/>6 RCTs (57,823)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#160;&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#160;&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.50 (0.20 to 1.21)<break/>5 RCTs (56,623)</td><td valign="top" colspan="1" rowspan="1">0.86 (0.70 to 1.05)<break/>6 RCTs (56,879)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#160;&#8212;</td></tr><tr><td rowspan="4" valign="top" colspan="1">Ad26.COV2.S &#8211; Janssen Pharmaceutical Companies&#160; versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">66.90% (59.10% to 73.40%)<break/>1 RCT (39,058)</td><td valign="top" colspan="1" rowspan="1">76.30% (57.90% to 87.50%)<break/>1 RCT (39,058)</td><td valign="top" colspan="1" rowspan="1">0.25 (0.09 to 0.67)<break/>1 RCT (43,783)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.69 to 1.22)<break/>1 RCT (43,783)</td><td valign="top" colspan="1" rowspan="1">1.83 (1.29 to 2.60)<break/>2 RCTs (7222)</td><td valign="top" colspan="1" rowspan="1">1.57 (0.75 to 3.29)<break/>2 RCTs (7222)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.25 (0.09 to 0.67)<break/>1 RCT (44,325)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.69 to 1.22)<break/>1 RCT (44,325)</td><td valign="top" colspan="1" rowspan="1">1.83 (1.27 to 2.63)<break/>2 RCTs (44,813)</td><td valign="top" colspan="1" rowspan="1">1.57 (0.74 to 3.32)<break/>2 RCTs (44,813)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.09 (0.96 to 1.24)<break/>1 RCT (6736)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td rowspan="4" valign="top" colspan="1">Gam&#8208;COVID&#8208;Vac &#8211; Gamaleya Research Institute (Sputnik V) Gam&#8208;COVID&#8208;Vac versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">91.10% (83.80% to 95.10%)<break/>1 RCT (18,695)</td><td valign="top" colspan="1" rowspan="1">100.00% (94.40% to 100.00%)<break/>1 RCT (19,866)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.10 to 9.54)<break/>1 RCT (21,862)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.39 to 1.07)<break/>1 RCT (21,862)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.00 (0.10 to 9.57)<break/>1 RCT (21,977)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.39 to 1.07)<break/>1 RCT (21,977)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="9" rowspan="1">AE: adverse event; CI: confidence interval; COVID&#8208;19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS&#8208;CoV&#8208;2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0017" fn-type="fn"><p><bold><sup>a</sup>Sensitivity 1:</bold> participants randomized; <bold>Sensitivity 2:</bold> early&#8208;phase studies excluded; <bold>Sensitivity 3:</bold> only published studies.</p></fn></table-wrap-foot></table-wrap></sec><sec id="CD015477-sec-0283"><title>Inactivated virus vaccines</title><p>Results were consistent, with the exception of an increase in vaccine efficacy against confirmed symptomatic COVID&#8208;19 after complete vaccination for CoronaVac compared to placebo when excluding results reported as preprints (VE 83.5%, 95% CI 65.4% to 92.1%) (<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>) (<xref rid="CD015477-tbl-0018" ref-type="table">Table 18</xref>). Using the participants randomized instead of those analyzed seemed to increase the heterogeneity, whereas excluding early&#8208;phase trials slightly decreased the heterogeneity and increased the precision of the summary estimate.</p><table-wrap id="CD015477-tbl-0018" position="float" orientation="portrait"><label>3</label><caption><title>Sensitivity analysis: inactivated virus vaccine</title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="3" valign="bottom" colspan="1"><bold>Developer &#8211; comparison&#160;</bold></td><td rowspan="3" valign="bottom" colspan="1">Analyses<bold><sup>a</sup></bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Outcomes</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>SARS&#8208;CoV&#8208;2 infection</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Symptomatic COVID&#8208;19</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Severe COVID&#8208;19</bold></td><td valign="top" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="top" colspan="1" rowspan="1"><bold>SAEs</bold></td><td valign="top" colspan="1" rowspan="1">Systemic <bold>reactogenicity events</bold></td><td valign="top" colspan="1" rowspan="1"><bold>AEs</bold></td></tr><tr><td colspan="3" align="center" valign="top" rowspan="1"><bold>VE (95% CI)</bold><break/><bold>No. of trials (No. of participants)&#160;</bold></td><td colspan="4" align="center" valign="top" rowspan="1"><bold>RR (95% CI)</bold><break/><bold>No. of trials (No. of participants)&#160;</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1">CoronaVac &#8211; Sinovac versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">69.81% (12.27% to 89.61%)<break/>2 RCTs (19,852)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.50 (0.05 to 5.52)<break/>1 RCT (12,396)</td><td valign="top" colspan="1" rowspan="1">0.97 (0.62 to 1.51)<break/>4 RCTs (23,139)</td><td valign="top" colspan="1" rowspan="1">0.95 (0.55 to 1.62)<break/>7 RCTs (23,956)</td><td valign="top" colspan="1" rowspan="1">1.09 (1.07 to 1.11)<break/>6 RCTs (23,367)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.50 (0.05 to 5.52)<break/>1 RCT (12,408)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.64 to 1.51)<break/>4 RCTs (23,157)</td><td valign="top" colspan="1" rowspan="1">1.56 (0.91 to 2.69)<break/>7 RCTs (25,106)<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">1.09 (1.07 to 1.11)<break/>6 RCTs (23,385)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.99 (0.63 to 1.55)<break/>2 RCTs (22,610)</td><td valign="top" colspan="1" rowspan="1">1.21 (0.98 to 1.49)<break/>4 RCTs (23,584)</td><td valign="top" colspan="1" rowspan="1">1.09 (1.07 to 1.11)<break/>2 RCTs (22,610)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">83.50% (65.40% to 92.10%)<break/>1 RCT (10,029)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.73 (0.24 to 2.21)<break/>4 RCTs (10,894)</td><td valign="top" colspan="1" rowspan="1">0.94 (0.49 to 1.81)<break/>6 RCTs (11,617)</td><td valign="top" colspan="1" rowspan="1">1.13 (1.04 to 1.23)<break/>4 RCTs (10,640)</td></tr><tr><td rowspan="4" valign="top" colspan="1">WIBP&#8208;CorV &#8211; Sinopharm&#8208;Wuhan versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">64.00% (48.80% to 74.70%)<break/>1 RCT (25,449)</td><td valign="top" colspan="1" rowspan="1">72.80% (58.10% to 82.40%)<break/>1 RCT (25,480)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.83 (0.60 to 1.15)<break/>2 RCTs (27,029)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.95 to 1.03)<break/>2 RCTs (27,029)</td><td valign="top" colspan="1" rowspan="1">0.96 (0.93 to 0.98)<break/>2 RCTs (27,029)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.83 (0.60 to 1.15)<break/>2 RCTs (27,053)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.95 to 1.03)<break/>2 RCTs (27,053)</td><td valign="top" colspan="1" rowspan="1">0.96 (0.93 to 0.98)<break/>2 RCTs (27,053)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.82 (0.59 to 1.14)<break/>1 RCT (26,917)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.95 to 1.03)<break/>1 RCT (26,917)</td><td valign="top" colspan="1" rowspan="1">0.96 (0.93 to 0.98)<break/>1 RCT (26,917)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#160;&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td rowspan="4" valign="top" colspan="1">BBIBP&#8208;CorV &#8211; Sinopharm&#8208;Beijing&#160;&#8232;&#160;versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">73.50% (60.60% to 82.20%)<break/>1 RCT (25,463)</td><td valign="top" colspan="1" rowspan="1">78.10% (64.80% to 86.30%)<break/>1 RCT (25,463)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.76 (0.54 to 1.06)<break/>1 RCT (26,924)</td><td valign="top" colspan="1" rowspan="1">1.05 (0.86 to 1.28)<break/>3 RCTs (27,540)</td><td valign="top" colspan="1" rowspan="1">Not pooled</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">1.05 (0.86 to 1.28)<break/>3 RCTs (27,557)</td><td valign="top" colspan="1" rowspan="1">Not pooled</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#160;&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">1.02 (0.98 to 1.06)<break/>1 RCT (26,924)</td><td valign="top" colspan="1" rowspan="1">&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td rowspan="4" valign="top" colspan="1">BBV152 &#8211; Bharat Biotech&#8232;&#160;versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">68.80% (46.70% to 82.50%)<break/>1 RCT (6289)</td><td valign="top" colspan="1" rowspan="1">77.80% (65.20% to 86.40%)<break/>1 RCT (16,973)</td><td valign="top" colspan="1" rowspan="1">99.70% (96.79% to 99.79%)<break/>1 RCT (16,976)</td><td valign="top" colspan="1" rowspan="1">0.50 (0.17 to 1.46)<break/>1 RCT (25,753)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.43 to 0.97)<break/>1 RCT (25,753)</td><td valign="top" colspan="1" rowspan="1">1.34 (1.15 to 1.58)<break/>2 RCTs (25,925)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.94 to 1.07)<break/>1 RCT (25,753)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.50 (0.17 to 1.46)<break/>1 RCT (25,778)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.43 to 0.97)<break/>2 RCTs (25,953)</td><td valign="top" colspan="1" rowspan="1">1.35 (1.15 to 1.58)<break/>2 RCTs (25,953)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.94 to 1.07)<break/>1 RCT (25,778)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.65 (0.43 to 0.97)<break/>1 RCT (25,753)</td><td valign="top" colspan="1" rowspan="1">1.34 (1.14 to 1.58)<break/>1 RCT (25,753)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">1.47 (0.63 to 3.47)<break/>1 RCT (172)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="9" rowspan="1">AE: adverse event; CI: confidence interval; COVID&#8208;19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS&#8208;CoV&#8208;2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0018" fn-type="fn"><p><bold><sup>a</sup>Sensitivity 1:</bold> participants randomized; <bold>Sensitivity 2:</bold> early&#8208;phase studies excluded; <bold>Sensitivity 3:</bold> only published studies.</p></fn></table-wrap-foot></table-wrap></sec><sec id="CD015477-sec-0284"><title>Protein subunit vaccines</title><p>Overall, results were consistent in all the analyses (<xref rid="CD015477-tbl-0019" ref-type="table">Table 19</xref>).</p><table-wrap id="CD015477-tbl-0019" position="float" orientation="portrait"><label>4</label><caption><title>Sensitivity analysis: protein subunit vaccine</title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="3" valign="bottom" colspan="1"><bold>Developer&#8208;comparison&#160;</bold></td><td rowspan="3" valign="bottom" colspan="1"><bold>Analyses<sup>a</sup></bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>SARS&#8208;CoV&#8208;2 infection</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Symptomatic COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAEs</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic</bold><break/><bold>reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>AEs</bold></td></tr><tr><td colspan="3" align="center" valign="top" rowspan="1"><bold>VE (95% CI)</bold><break/><bold>No. of trials (No. of participants)&#160;</bold></td><td colspan="4" align="center" valign="top" rowspan="1"><bold>RR (95% CI)</bold><break/><bold>No. of trials (No. of participants)&#160;</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1">NVX&#8208;CoV2373 &#8211; Novavax&#160;&#8232;versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">82.91% (50.49% to 94.10%)<break/>3 RCTs (42,175)</td><td valign="top" colspan="1" rowspan="1">100.00% (86.99% to 100.00%)<break/>1 RCT (25,452)</td><td valign="top" colspan="1" rowspan="1">0.90 (0.30 to 2.68)<break/>1 RCT (29,582)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.74 to 1.14)<break/>&#160;4 RCTs (46,202)</td><td valign="top" colspan="1" rowspan="1">1.21 (1.17 to 1.25)<break/>3 RCTs (31,063)</td><td valign="top" colspan="1" rowspan="1">1.15 (1.05 to 1.26)<break/>5 RCTs (46,231)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">0.92 (0.74 to 1.14)<break/>4 RCTs (50,111)</td><td valign="top" colspan="1" rowspan="1">1.21 (1.17 to 1.26)<break/>3 RCTs (34,870)<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">1.16 (1.05 to 1.27)<break/>5 RCTs (50,111)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.93 (0.75 to 1.15)<break/>3 RCTs (45,689)</td><td valign="top" colspan="1" rowspan="1">1.20 (1.17 to 1.24)<break/>2 RCTs (30,550)</td><td valign="top" colspan="1" rowspan="1">1.14 (1.02 to 1.27)<break/>3 RCTs (45,689)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">77.10% (0.00% to 95.19%)<break/>2 RCTs (16,723)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">0.99 (0.65 to 1.51)<break/>3 RCTs (16,620)</td><td valign="top" colspan="1" rowspan="1">1.24 (1.03 to 1.49)<break/>2 RCTs (1481)</td><td valign="top" colspan="1" rowspan="1">1.18 (1.03 to 1.35)<break/>4 RCTs (16,672)</td></tr><tr><td rowspan="4" valign="top" colspan="1">FINLAY&#8208;FR&#8208;2 &#8211; Instituto Finlay de Vacunas&#8232;&#160;versus placebo</td><td valign="top" colspan="1" rowspan="1"><bold>Main analysis</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">71.00% (58.90% to 79.10%)<break/>1 RCT (28,674)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">0.37 (0.17 to 0.80)<break/>1 RCT (28,674)</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#160;&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 1</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 2</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sensitivity 3&#160;</bold></td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td><td valign="top" colspan="1" rowspan="1">&#8212;</td></tr><tr><td colspan="9" rowspan="1">AE: adverse event; CI: confidence interval; COVID&#8208;19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS&#8208;CoV&#8208;2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy.</td></tr></tbody></table><table-wrap-foot><fn id="CD015477-note-0019" fn-type="fn"><p><bold><sup>a</sup>Sensitivity 1:</bold> participants randomized; <bold>Sensitivity 2:</bold> early&#8208;phase studies excluded; <bold>Sensitivity 3:</bold> only published studies.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec></sec><sec id="CD015477-sec-0285"><title>Discussion</title><sec id="CD015477-sec-0286"><title>Summary of main results</title><p>We identified and included 41 RCTs &#160;evaluating four different vaccine platforms and 12 vaccine candidates published in 65 reports in the analysis. Six RCTs reported results for three RNA&#8208;based vaccines (BNT162b2 from BioNtech/Fosun Pharma/Pfizer; mRNA&#8208;1273 from ModernaTX; CVnCoV by CureVac AG), and 10 RCTs evaluated three non&#8208;replicating viral vector vaccines (ChAdOx1 by AstraZeneca/University of Oxford and SII&#8208;ChAdOx1; Ad26.COV2.S by Janssen Pharmaceutical Companies; Gam&#8208;COVID&#8208;Vac by Gamaleya Research Institute), 13 RCTs evaluated four inactivated virus vaccines (CoronaVac by Sinovac; WIBP&#8208;CorV by Sinopharm&#8208;Wuhan; BBIBP&#8208;CorV by Sinopharm&#8208;Beijing; BBV152 by Bharat Biotech), and 6 RCTs evaluated two protein subunit vaccines (NVX&#8208;CoV2373 by Novavax; FINLAY&#8208;FR&#8208;2 by Instituto Finlay de Vacunas).&#160;</p><p>Our review also retrieved two trials comparing heterologous vaccination schemes with homologous vaccination schemes, two trials comparing booster versus placebo/no booster, and four trials comparing homologous and heterologous booster doses. Only 10 studies reported results on vaccine efficacy of six different vaccine candidates against any specific variant, which limits our ability to make any variant&#8208;specific claims.&#160;</p><sec id="CD015477-sec-0287"><title>Efficacy outcomes for vaccines versus placebo</title><p>There is moderate&#8208; to high&#8208;certainty evidence that several vaccine candidates are effective in preventing SARS&#8208;CoV&#8208;2 infection (i.e. mRNA&#8208;1273, ChAdOx1, WIBP&#8208;CorV, BBIBP&#8208;CorV, BBV152); symptomatic COVID&#8208;19 (i.e. BNT162b2, mRNA&#8208;1273, CVnCoV, ChAdOx1, Ad26.COV2.S, Gam&#8208;COVID&#8208;Vac, WIBP&#8208;CorV, BBIBP&#8208;CorV, BBV152, NVX&#8208;CoV2373, FINLAY&#8208;FR&#8208;2), and severe or critical disease compared to placebo (i.e. BNT162b2, mRNA&#8208;1273, Ad26.COV2.S, Gam&#8208;COVID&#8208;Vac, BBV152, NVX&#8208;CoV2373).&#160;</p><p>There is moderate&#8208;certainty evidence that Ad26.COV2.S and FINLAY&#8208;FR&#8208;2 result in a decrease in all&#8208;cause mortality compared to placebo. Evidence was uncertain and very uncertain for death for all other vaccines because of the low number of events.&#160;</p></sec><sec id="CD015477-sec-0288"><title>Safety outcomes for vaccines versus placebo</title><p>Overall, we identified an increase in local reactogenicity events such as pain, redness, swelling, and systemic reactogenicities such as tiredness, headache, muscle pain, chills, fever, and nausea. There is moderate&#8208; to high&#8208;certainty evidence that most vaccine candidates have an increased risk of systemic reactogenicity events (e.g. fever) compared to placebo (mRNA&#8208;1273, CVnCoV, ChAdOx1, Ad26.COV2.S, WIBP&#8208;CorV, BBIBP&#8208;CorV, BBV152, NVX&#8208;CoV2373). These events were expected.</p><p>We did not find evidence of an increase in SAEs. There is moderate&#8208; to high&#8208;certainty evidence that there is probably little or no difference between mRNA&#8208;1273, ChAdOx1, Ad26.COV2.S and BBV152, and placebo in terms of SAEs. Evidence was uncertain and very uncertain for SAEs for other vaccines because of the low number of events.</p><p>We also extracted some specific adverse events, that is, cardioembolic events (pulmonary embolism, stroke, cavernous sinus thrombosis, pericarditis, venous thrombosis, myocardial infarction); haematological events (thrombocytopaenia, haemorrhage, neutropenia, anaemia, lymphadenopathy); and neurological events. The reporting of these events was very inconsistent and the number of events reported was very low.&#160;</p><p>The outcome 'any adverse event' was reported inconsistently. Some considered only the non&#8208;SAE including local and systemic reactogenicity events. Some also considered SAEs, and frequently it was unclear how these events were classified. Overall, we found moderate&#8208; to high&#8208;certainty evidence that vaccine increases any adverse event for three vaccines (i.e. CVnCoV, NVX&#8208;CoV2373, CoronaVac) and that vaccine results in no increase in any adverse event for two vaccines (i.e. WIBP&#8208;CorV, BBV152). Evidence was uncertain for other vaccines.</p><p>As trials' follow&#8208;up was short and the incidence of SAEs was very low, vaccine safety surveillance systems have been put in place to detect rare adverse events and concerns have been raised related to the occurrence of vaccine&#8208;induced immune thrombocytopaenia and thrombosis (<xref rid="CD015477-bbs2-0114" ref-type="ref-list">Makris 2021</xref>;&#160;<xref rid="CD015477-bbs2-0124" ref-type="ref-list">Ostrowski 2021</xref>;&#160;<xref rid="CD015477-bbs2-0140" ref-type="ref-list">Rizk 2021</xref>;&#160;<xref rid="CD015477-bbs2-0150" ref-type="ref-list">Sharifian&#8208;Dorche 2021</xref>).&#160;</p></sec><sec id="CD015477-sec-0289"><title>Other evidence</title><p>We found little evidence regarding the differences between heterologous and homologous vaccination schemes, and the effect of booster vaccines (homologous or heterologous). Outcomes considered were mainly immunogenicity outcomes.&#160;</p><p>In the two studies (assessing mRNA&#8208;1273 and BNT162b2) for which we have data at different time points, vaccine efficacy at short term was consistent with longer&#8208;term results.&#160;</p></sec><sec id="CD015477-sec-0290"><title>Effects of the interventions on specific subpopulations</title><p>Given the sparsity of data, we were unable to explore heterogeneity in the results by conducting subgroup analyses, and therefore decided to present results separately for specific subpopulations. We identified only four clinical trials including children and adolescents, and assessed BNT162b2, mRNA&#8208;1273, CoronaVac and BBIBP&#8208;CorV (<xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref>;&#160;<xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>;&#160;<xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref>;&#160;<xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>). We found more studies focused on, or reporting subgroup data for elderly participants, with single studies reporting different outcomes in elderly participants. However, data were still sparse and should be interpreted with caution. Finally, only three studies reported data for immunocompromized participants, each assessing a different vaccine candidate (ChAdOx1, NVX&#8208;CoV2373, and mRNA&#8208;1273 booster versus placebo). No studies were conducted on pregnant women, and pregnant women were very rarely included in trials although it has been reported that they are at greater risk of severe COVID&#8208;19 disease (<xref rid="CD015477-bbs2-0136" ref-type="ref-list">Qiao 2020</xref>).</p></sec><sec id="CD015477-sec-0291"><title>Impact of the results on future research</title><p>The high efficacy of several vaccine candidates, their marketing authorization and the rapid roll&#8208;out population&#8208;wide, raise the question of the feasibility and ethics of placebo RCTs assessing a new vaccine candidate.&#160;</p><p>For the ongoing placebo trials, the question is whether participants randomized to the placebo group should be unblinded and offered vaccine. Some argue the need to pursue follow&#8208;up to obtain strong data on long&#8208;term efficacy and safety (<xref rid="CD015477-bbs2-0169" ref-type="ref-list">WHO Ad Hoc Expert Group 2021</xref>); others argue that given the clear evidence of a benefit for important outcomes, it would be unethical not to provide a vaccine to all participants (<xref rid="CD015477-bbs2-0073" ref-type="ref-list">Dal&#8208;R&#233; 2021a</xref>;&#160;<xref rid="CD015477-bbs2-0074" ref-type="ref-list">Dal&#8208;R&#233; 2021b</xref>).&#160;</p><p>Assessing vaccine efficacy and safety in randomized trials is also difficult considering the rapid evolution of the disease and the emergence of new variants that could impact vaccine efficacy. Large population&#8208;based observational data provide useful complementary information, although they need to be interpreted carefully because of the risk of bias.</p><p>Future research questions should focus on the efficacy and safety of vaccines on specific populations, such as pregnant women, immunosuppressed patients and other vulnerable populations, on variants of concerns, and on how we can overcome the waning of vaccine efficacy over time.</p><p>An increasing number of trials consider only immunogenetic outcomes to allow a smaller sample size to generate a more rapid answer. However, there is considerable heterogeneity in assessing these outcomes and a consensus is needed on a core outcome set to enable effective comparison and synthesis of studies. Further, their results must be interpreted with caution.</p></sec></sec><sec id="CD015477-sec-0292"><title>Overall completeness and applicability of evidence</title><p>The evidence identified is incomplete. We identified 344 registered RCTs from registries evaluating the efficacy of COVID&#8208;19, of which 10 were completed but not published (non&#8208;replicating viral vector, replicating viral vector, inactivated virus, protein subunit and DNA&#8208;based platforms). The planned sample size of the completed trials for non&#8208;replicating viral vector vaccines is 27 participants, 90 participants for replicating viral vector vaccines, 19,512 for inactivated virus vaccines, 173 for protein subunit vaccines, and 30 for DNA&#8208;based vaccines, yielding a total planned sample size of 19,832.&#160;</p><p>The applicability of the results should be interpreted with caution. The trials spanned all geographical regions: seven trials were conducted in North America, 14 in Asia, four in South America, eight in Europe, two in Africa, and one in Oceania. Notwithstanding the worldwide geographical representation of trials, it is noteworthy that the representation is skewed. Inactivated vaccine and protein subunit vaccine trials were mostly limited to India, Cuba, and China. Furthermore, trials for mRNA&#8208;1273 were only conducted in the USA.&#160;</p><p>Our review also highlights the lack of evidence from RCTs regarding the efficacy of vaccines against specific variants. This is not surprising, given the relatively short period between the dominance of one variant and the next. Future studies might report more consistently on the specific variant predominating in their sample or report results stratified by variant, which would allow for more specific meta&#8208;analyses in the future. It is likely that data on efficacy by variant will mainly come from large population&#8208;based observational studies. The COVID&#8208;NMA initiative identified observational studies evaluating vaccine efficacy on the Delta variant, and provides some results on the platform (<uri>covid-nma.com</uri>). Given that Omicron has replaced all other variants in most countries, data may not be applicable to the current situation.</p><p>We found high&#8208; or moderate&#8208;certainty evidence for many of the main efficacy results of our review. However, the impact of effect modifiers, such as age or immunocompromized status, could not be explored adequately through subgroup analyses nor by meta&#8208;regression. Specific trials including these specific populations should be conducted. Vaccine efficacy on these subgroups could also be explored through large observational studies using routinely collected data.</p></sec><sec id="CD015477-sec-0293"><title>Certainty of the evidence</title><p>Overall, evidence of the critical outcomes exhibited a certainty of evidence ranging from very low certainty to high certainty. The evidence for outcomes of efficacy against SARS&#8208;CoV&#8208;2 infection, symptomatic COVID&#8208;19, and severe or critical COVID&#8208;19 was most often of moderate or high certainty. In contrast, we frequently downgraded safety outcomes and all&#8208;cause mortality.</p><p>The reason for which we downgraded certainty of evidence most often, throughout the results for all vaccine types, was imprecision, referring to wide CIs in our results. This was often the result of a low number of events, and less often due to inconsistencies between the included studies or risk of bias. This explains why so few of the results related to mortality or severe adverse events, which are more rare events, achieved levels of moderate&#8208; or high&#8208;certainty evidence. We expect higher levels of certainty to be reached as more studies are published, and the body of evidence grows.</p><p>In one trial (<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>), we downgraded the certainty of evidence due to concerns about the trustfulness of the analyses (<xref rid="CD015477-bbs2-0062" ref-type="ref-list">Bucci 2021</xref>). The authors responded to some of these concerns, and the manuscript was corrected (<xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>). Nevertheless, uncertainty persists particularly related to the prespecification of the interim analysis and the excess of homogeneity of vaccine efficacy across age groups.</p></sec><sec id="CD015477-sec-0294"><title>Potential biases in the review process</title><p>We followed the guidance of the&#160;<italic toggle="yes">Cochrane&#160;Handbook for Systematic Reviews of Interventions</italic> in order to minimize several potential biases in the review process (<xref rid="CD015477-bbs2-0101" ref-type="ref-list">Higgins 2021</xref>). First, the search strategy was peer reviewed. We initially performed a thorough search in several electronic databases and then considered only high&#8208;quality sources, particularly the L&#183;OVE platform and the&#160;Cochrane&#160;COVID&#8208;19 Study Register. Second, all data were extracted in duplicate with consensus. Third, to increase our review's informative value, we track all registered trials in a living mapping. Finally, the review is updated continually; each week, we search for new trials and collect data, and bi&#8208;weekly we update the syntheses. All updates of this review are available on the COVID&#8208;NMA platform (<uri>covid-nma.com</uri>).</p><p>Another consideration for this rapidly evolving field is the availability of preprint articles that have not yet undergone peer review. In this review, we also included preprints. However, we are aware of these publications' potentially differing quality and that results could change once the peer&#8208;reviewed journal publications are available (<xref rid="CD015477-bbs2-0123" ref-type="ref-list">Oikonomidi 2020</xref>). To overcome this issue, we developed a preprint tracker to keep us informed of updates, so we can update data collection and data analysis when a preprint is modified or published (<xref rid="CD015477-bbs2-0064" ref-type="ref-list">Cabanac 2021</xref>). We also conducted sensitivity analyses excluding preprints, and found consistent results.</p></sec><sec id="CD015477-sec-0295"><title>Agreements and disagreements with other studies or reviews</title><p>We identified seven systematic reviews reporting on the efficacy of vaccines against COVID&#8208;19 and whose search strategy was run in the second half of 2021 or later. One included only RCTs (<xref rid="CD015477-bbs2-0143" ref-type="ref-list">Rotshild 2021</xref>), three only observational studies (<xref rid="CD015477-bbs2-0097" ref-type="ref-list">Harder 2021</xref>;&#160;<xref rid="CD015477-bbs2-0106" ref-type="ref-list">Kow 2022</xref>;&#160;<xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>), and three a hybrid of RCTs and observational studies (<xref rid="CD015477-bbs2-0098" ref-type="ref-list">Hayawi 2021</xref>;&#160;<xref rid="CD015477-bbs2-0100" ref-type="ref-list">Higdon 2021</xref>;&#160;<xref rid="CD015477-bbs2-0177" ref-type="ref-list">Zeng 2021b</xref>). We identified one systematic review focused on children and adolescents (<xref rid="CD015477-bbs2-0112" ref-type="ref-list">Lv 2021</xref>). Overall, all the trials included in these reviews were identified in our search and our results are consistent.</p><p>There are other living systematic reviews of vaccines for COVID&#8208;19, such as&#160;<xref rid="CD015477-bbs2-0065" ref-type="ref-list">Castagneto Gissey 2021</xref>, which includes only RCTs;&#160;<xref rid="CD015477-bbs2-0097" ref-type="ref-list">Harder 2021</xref>, which includes, but is not limited to RCTs (the second interim results were published in October 2021). Finally, the Living Vaccine Project, a living systematic review with network meta&#8208;analysis that includes only RCTs recently published their results (<xref rid="CD015477-bbs2-0105" ref-type="ref-list">Korang 2022</xref>). All studies included in their review were included in our review (either the same publication or another with more up&#8208;to&#8208;date data). For the most part, their results are consistent with ours. Concurrently, there are over a dozen protocols of systematic reviews assessing the safety or efficacy of vaccines registered in PROSPERO and listed as ongoing.</p></sec></sec><sec id="CD015477-sec-0296"><title>Authors' conclusions</title><p><boxed-text position="float" orientation="portrait"><caption><title>Implications for practice</title></caption><sec id="CD015477-sec-0297"><p>Several COVID&#8208;19 vaccines are highly effective or probably highly effective in preventing SARS&#8208;CoV&#8208;2 infection, symptomatic COVID&#8208;19 and severe or critical COVID&#8208;19.&#160;</p><p>There is moderate&#8208; to high&#8208;certainty evidence that most vaccine candidates increased the risk of systemic reactogenicity events (e.g. fever). Evidence related to any adverse event was mainly uncertain.</p><p>There is moderate&#8208; to high&#8208;certainty evidence that there is probably no difference between mRNA&#8208;1273, CVnCoV, ChAdOx1, Ad26.COV2.S, Gam&#8208;COVID&#8208;Vac, WIBP&#8208;CorV and BBIBP&#8208;CorV and placebo in terms of serious adverse events. Evidence was uncertain and very uncertain for serious adverse events for other vaccines and for all&#8208;cause mortality for most vaccines, mainly because of the low number of events.</p><p>In addition, as most RCTs only followed up participants for 2 months after full vaccination, all reports are related to short&#8208;term impacts of the vaccine.&#160;</p><p>Results cannot easily be generalized to pregnant women and immunocompromized individuals; more evidence is needed to elucidate the degree of additional protection conferred by COVID&#8208;19 vaccines in these populations.</p><p>Finally, the advent of variants of concern has highlighted the need for further research on each of the vaccine&#8217;s capacity to limit infection, disease, and death in regard to specific variants of concern.&#160;</p></sec></boxed-text></p><p><boxed-text position="float" orientation="portrait"><caption><title>Implications for research</title></caption><sec id="CD015477-sec-0298"><p><list id="CD015477-list-0020" list-type="bullet"><list-item><p>Three hundred and forty&#8208;four RCTs are currently registered, of which 10 are completed. The findings from these trials will contribute to the body of evidence on efficacy and safety outcomes. The findings of this review will be updated as soon as new data are available on the COVID&#8208;NMA platform.</p></list-item><list-item><p>Since the efficacy of vaccines is well established at this point, the ethics of RCT designs using a placebo as the comparison group should be questioned, and active comparators should be considered.</p></list-item><list-item><p>With the notable impact of variants of concern on vaccine efficacy, it is crucial that variant type is assessed in clinical trials and reported for future meta&#8208;analyses to assess vaccine efficacy on considerably different variants.</p></list-item><list-item><p>As a non&#8208;negligible global population has been infected by SARS&#8208;CoV&#8208;2, robust evidence&#8208;based vaccination schemes are also required.</p></list-item><list-item><p>Finally, considering the rapidly changing situation (in terms of variants, policies, etc.) and the increasing and important heterogeneity in the population in terms of combinations of vaccines received, history of SARS&#8208;CoV&#8208;2 infection (and by which variant), type of booster vaccine received, and predominant variants at the time of data collection, RCTs might become increasingly difficult to conduct in such a rapidly&#8208;changing context and large population&#8208;based observational studies could provide relevant information.</p></list-item></list></p></sec></boxed-text></p></sec><sec id="CD015477-sec-0481"><title>What's new</title><p><table-wrap id="CD015477-tblf-0160" position="float" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"><bold>Date</bold></th><th colspan="1" rowspan="1"><bold>Event</bold></th><th colspan="1" rowspan="1"><bold>Description</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">13 March 2023</td><td colspan="1" rowspan="1">Amended</td><td colspan="1" rowspan="1">Minor edits made to correct error in the number of events for the outcome 'All&#8208;cause mortality' for the Moderna TX&#8208;mRNA&#8208;1273 vaccine. We previously entered 16 deaths in the intervention arm and 17 deaths in the control arm. The correct data should be 17 deaths in the intervention arm and 16 deaths in the control arm (RR 1.06, 95% CI 0.54 to 2.10). Corresponding edits have been made throughout the review.</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0482"><title>History</title><p>Review first published: Issue 12, 2022</p><p><table-wrap id="CD015477-tblf-0161" position="float" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"><bold>Date</bold></th><th colspan="1" rowspan="1"><bold>Event</bold></th><th colspan="1" rowspan="1"><bold>Description</bold></th></tr></thead><tbody><tr><td valign="bottom" colspan="1" rowspan="1">3 January 2023</td><td valign="bottom" colspan="1" rowspan="1">Amended</td><td valign="bottom" colspan="1" rowspan="1">URL correction in the abstract.</td></tr><tr><td colspan="1" rowspan="1">12 December 2022</td><td colspan="1" rowspan="1">Amended</td><td colspan="1" rowspan="1">'Acknowledgements' updated.</td></tr></tbody></table></table-wrap></p></sec></body><back><ack id="CD015477-sec-0299"><title>Acknowledgements</title><p>We particularly thank Elise Diard for her help on the website and extraction tool development.&#160;</p><p>Solaf Alawadhi<sup>1,2</sup>, Camila &#193;vila<sup>3,</sup>, Camilla Hansen Neistgaard<sup>4</sup>, Fulvia Baldassarre<sup>5</sup>, Rita Banzi<sup>6</sup>, Julien Barnier<sup>7</sup>, Julia Baudry<sup>8</sup>, Guillaume Cabanac<sup>9</sup>, Sarah Charpy<sup>2</sup>, David Chavalarias<sup>10</sup>, Sarah Cohen&#8208;Boulakia<sup>11</sup>, Elise Cogo<sup>12</sup>, Fran&#231;oise Conil<sup>13</sup>, Emmanuel Coquery<sup>13</sup>, Elise Diard<sup>14</sup>, Bastien Doreau<sup>15</sup>, Mishelle Engleton<sup>2</sup>, Laura Esmail<sup>2</sup>, Gilles Feron<sup>16</sup>, Leopold Fezeu<sup>8</sup>, Mathilde Fouet<sup>17</sup>, Joly Ghanawi<sup>18</sup>, Robin Featherstone<sup>19</sup>, Fran&#231;ois Grolleau<sup>1</sup>, Candyce Hamel<sup>12</sup>, Vernon Hedge<sup>20</sup>, Harald Herkner<sup>20</sup>, Mona Hersi<sup>12</sup>, Philipp Kapp<sup>14</sup>, Ameer Hohlfeld<sup>21</sup>, Chantal Julia<sup>8</sup>, Joey Kwong<sup>12</sup>, Ruben Martinez<sup>15</sup>, Pauline Martinot<sup>2</sup>, Dimitris Mavridis<sup>22</sup>, Brice Meyer<sup>15</sup>, Nadia Meziou<sup>1</sup> , Nathan Pace<sup>20</sup>, Matthew Page<sup>23</sup>, Jennifer Petkovic<sup>12</sup>, Elizabeth Pienaar<sup>21</sup>, Fiona Quirke<sup>24</sup>, Pierre Ripoll<sup>13</sup>, Philippe Rivi&#232;re<sup>13</sup>, Jelena Savovic<sup>25</sup>, Yanina Sguassero<sup>12</sup>, Marialena Trivella<sup>20</sup>, Janne Vendt<sup>20</sup>, Romain Vuillemot<sup>13</sup>, Stephanie Weibel<sup>20</sup></p><p><list id="CD015477-list-0021" list-type="order"><list-item><p>Universit&#233; de Paris, France.</p></list-item><list-item><p>Centre of Research in Epidemiology and StatisticS (CRESS UMR1153), Methods team, France.</p></list-item><list-item><p>&#160;Epistemonikos Foundation, Chile.</p></list-item><list-item><p>Open Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.</p></list-item><list-item><p>&#160;McMaster University, Canada.</p></list-item><list-item><p>&#160;Center for Health Regulatory Policies, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy.</p></list-item><list-item><p>&#160;Centre Max Weber, CNRS, France.</p></list-item><list-item><p>&#160;Centre of Research in Epidemiology and StatisticS (CRESS UMR1153), Eren team, France.</p></list-item><list-item><p>Universit&#233; Toulouse 3 &#8211; Paul Sabatier &#8208; Institut de Recherche en Informatique de Toulouse &#8211; IRIT UMR 5505, France.</p></list-item><list-item><p>Institut des Syst&#232;mes Complexes de Paris IDF (ISC&#8208;PIF), CNRS, France.</p></list-item><list-item><p>&#160;Laboratoire de recherche en Informatique (LRI), CNRS, Universit&#233; Paris&#8208;Saclay, France.</p></list-item><list-item><p>Cochrane Response, Cochrane, London, UK.</p></list-item><list-item><p>&#160;Laboratoire d&#8217;InfoRmatique en Image et Syst&#232;mes d&#8217;information (LIRIS), CNRS, Universit&#233; Claude Bernard Lyon 1, France.</p></list-item><list-item><p>Cochrane France.</p></list-item><list-item><p>&#160;Laboratoire d'Informatique, de Mod&#233;lisation et d'Optimisation des Syst&#232;mes (LIMOS), CNRS, Universit&#233; Clermont Auvergne.</p></list-item><list-item><p>Centre for Evidence&#8208;Based Medicine Odense (CEBMO) and Cochrane Denmark, University of Southern Denmark, Denmark.</p></list-item><list-item><p>&#160;Service de Neurochirurgie, H&#244;pital d'Instruction des Arm&#233;es Percy (HIA), France.</p></list-item><list-item><p>The Collaborative Approach to Meta&#8208;Analysis and Review of Animal Data from Experimental Studies (CAMARADES), Centre for Clinical Brain Sciences, University of Edinburgh, Scotland.</p></list-item><list-item><p>&#160;Cochrane Editorial and Methods Department, Cochrane Central.</p></list-item><list-item><p>Cochrane Emergency and Critical Care</p></list-item><list-item><p>Cochrane South Africa.</p></list-item><list-item><p>&#160;Department of Primary Education, University of Ioannina, Greece.</p></list-item><list-item><p>Research Methodology Division, School of Public Health and Preventive Medicine, Monash University, Australia.</p></list-item><list-item><p>Evidence Synthesis Ireland, Cochrane Ireland and HRB&#8208;Trials Methodology Research Network, National University of Ireland, Galway, Ireland</p></list-item><list-item><p>Population Health Sciences, Bristol Medical School, University of Bristol, UK; NIHR CLAHRC West, University Hospitals Bristol and Weston NHS Foundation Trust, UK.</p></list-item></list></p><p>Cochrane Emergency and Critical Care Group supported the authors in the development of this review. The following people conducted the editorial process for this review.</p><p><list id="CD015477-list-0022" list-type="bullet"><list-item><p>Sign&#8208;off Editor (final editorial decision): Harald Herkner, Medical University of Vienna, Austria, Co&#8208;ordinating Editor of the Cochrane Emergency and Critical Care Group.</p></list-item><list-item><p>Managing Editor (selected peer reviewers, collated peer&#8208;reviewer comments, provided editorial guidance to authors, edited the article): Joey Kwong, Cochrane Central Editorial Service.</p></list-item><list-item><p>Editorial Assistant (conducted editorial policy checks and supported editorial team): Leticia Rodrigues, Cochrane Central Editorial Service.</p></list-item><list-item><p>Copy Editor (copy&#8208;editing and production): Clare Dooley, c/o Cochrane Production Service.</p></list-item><list-item><p>Proofreader: Anne Lawson, Central Production Service, Cochrane.</p></list-item><list-item><p>Peer&#8208;reviewers (provided comments and recommended an editorial decision): Ariel Izcovich, Internal Medicine Department, Hospital Alem&#225;n de Buenos Aires, Argentina (clinical/content review); Romina Brignardello&#8208;Petersen, Department of Health Research Methods, Evidence, and Impact, McMaster University (clinical/content review); Ana Katherine Gon&#231;alves, Obstetric and Gynecology Department, Federal University of Rio Grande Do Norte, Brazil (clinical/content review); Stella O'Brien (consumer review); Robert Walton, Cochrane UK (summary versions review); Rachel Richardson, Cochrane Evidence Production and Methods Directorate (methods review); Kerry Dwan, Cochrane Methods Support Unit (statistical review); Robin Featherstone, Cochrane Central Editorial Service (search review). Two additional peer reviewers provided clinical/content peer review but chose not to be publicly acknowledged.</p></list-item></list></p></ack><app-group id="CD015477-sec-0300"><title>Appendices</title><app id="CD015477-sec-0301"><title>Appendix 1. List of definitions used for outcomes 'serious adverse events' and 'severe or critical disease'</title><p><table-wrap id="CD015477-tblf-0001" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Definition: serious adverse events (SAEs)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Definition: severe or critical disease</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>RNA&#8208;based&#160;</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>BNT162b2 &#8211; BioNTech/Fosun Pharma/Pfizer</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref></td><td valign="top" colspan="1" rowspan="1">An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life&#8208;threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other situations. Medical or scientific judgement should be exercised in deciding whether SAE reporting is appropriate in other situations, such as important medical events that may not be immediately life&#8208;threatening or result in death or hospitalisation, but may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the other outcomes listed in the above definition.&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref></td><td valign="top" colspan="1" rowspan="1">An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life&#8208;threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent disability/incapacity; is a congenital anomaly/birth defect.<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Diagnosis of severe COVID&#8208;19 included confirmed COVID&#8208;19 and the presence of any of the following: (1) clinical signs at rest indicative of severe systemic illness (e.g. respiratory rate &#8805; 30 breaths/min, heart rate &#8805; 125 beats/min, SpO<sub>2</sub> &#8804; 93% on room air at sea level, or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg; (2) respiratory failure (i.e. needing high&#8208;flow oxygen, non&#8208;invasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); (3) evidence of shock (i.e. systemic blood pressure &lt; 90 mmHg, diastolic blood pressure &lt; 60 mmHg, or requiring vasopressors); (4) significant acute renal, hepatic, or neurological dysfunction; (5) intensive care unit admission; or (6) death.</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life&#8208;threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent disability/incapacity; is a congenital anomaly/birth defect.<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Confirmed severe COVID&#8208;19 required confirmation of COVID&#8208;19 and the presence of &#8805; 1 of the following: clinical signs at rest indicative of severe systemic illness (respiratory rate &#8805; 30 breaths/min, heart rate &#8805; 125 beats/min, SpO<sub>2</sub> &#8804; 93% on room air at sea level, or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg); respiratory failure (defined as needing high&#8208;flow oxygen, non&#8208;invasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); evidence of shock (systolic blood pressure &lt; 90 mmHg, diastolic blood pressure &lt; 60 mmHg, or requiring vasopressors); significant acute renal, hepatic, or neurological dysfunction; intensive care unit admission; death; or a combination of these.</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>mRNA&#8208;1273 &#8211; ModernaTX</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></td><td valign="top" colspan="1" rowspan="1">An SAE results in any of the following outcomes: death; is life&#8208;threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; is a congenital anomaly or birth defect; is a medically important event.</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">An adverse event (including an adverse reaction) is considered an SAE if, in the view of either the investigator or sponsor, it results in any of the following outcomes: death; is life&#8208;threatening; inpatient hospitalisation or prolongation of existing hospitalisation; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly or birth defect; medically important event.</td><td valign="top" colspan="1" rowspan="1">Confirmed severe COVID&#8208;19 requires any of the following criteria had to be met: clinical signs of severe systemic illness; respiratory rate &#8805; 30 breaths/min; heart rate &#8805; 125 beats/min; SpO<sub>2</sub> &#8804; 93% on room air at sea level or PaO<sub>2</sub>/FIO<sub>2</sub> &lt; 300 mmHg, or respiratory failure or acute respiratory distress syndrome (defined as needing high&#8208;flow oxygen, non&#8208;invasive or mechanical ventilation, or extracorporeal membrane oxygenation); evidence of shock (systolic blood pressure &lt; 90 mmHg, diastolic blood pressure &lt; 60 mmHg or requiring vasopressors) or significant acute renal, hepatic or neurological dysfunction or admission to an intensive care unit or death.</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>CVnCoV &#8211; CureVac AG</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">Severe COVID&#8208;19 was defined by clinical signs at rest that are indicative of severe systemic illness (respiratory rate &#8805; 30 breaths/min, heart rate &#8805; 125 beats/min, altitude&#8208;adjusted SpO<sub>2</sub> &#8804; 93% or PaO<sub>2</sub>/FIO<sub>2</sub> &lt; 300 mmHg), respiratory failure, evidence of shock, significant renal, hepatic, or neurological dysfunction, admission to an intensive care unit, or death.</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>Non&#8208;replicating viral vector</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>ChAdOx1/SII&#8208;ChAdOx1 nCoV&#8208;19 &#8211; AstraZeneca + University of Oxford</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Severity of safety endpoints was assessed according to toxicity grading scales adapted from Food and Drug Administration (FDA) grading guidance<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref></td><td valign="top" colspan="1" rowspan="1">An adverse event that fulfils &#8805; 1 of the following criteria: results in death; is immediately life&#8208;threatening; requires in&#8208;participant hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability or incapacity; is a congenital abnormality or birth defect; is an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above.<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Laboratory&#8208;confirmed COVID&#8208;19 (SARS&#8208;CoV&#8208;2 RT&#8208;PCR&#8208;positive symptomatic illness) plus any of the following: clinical signs at rest indicative of severe systemic illness (respiratory rate &#8805; 30 breaths/min, heart rate &#8805; 125 beats/min, oxygen saturation &#8804; 93% on room air at sea level, or PaO<sub>2</sub>/FIO<sub>2</sub> &lt; 300 mmHg); respiratory failure (defined as needing high&#8208;flow oxygen, non&#8208;invasive ventilation, mechanical ventilation or extracorporeal membrane oxygenation); evidence of shock (systolic blood pressure &lt; 90 mmHg, diastolic blood pressure &lt; 60 mmHg, or requiring vasopressors); significant acute renal, hepatic, or neurological dysfunction; admission to an intensive care unit; death.</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">All adverse events were graded for severity using the Division of AIDS (DAIDS) table for Grading the Severity of Adult and Pediatric Adverse Events (corrected version 2.1, July 2017) from the US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases.</td><td valign="top" colspan="1" rowspan="1">Severe cases as per the WHO clinical progression scale<break/>&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">As defined by WHO ordinal scale</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">Severe COVID&#8208;19 (WHO clinical progression score &#8805; 6)</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>Gam&#8208;COVID&#8208;Vac (Sputnik V) &#8211; Gamaleya Research Institute</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">SAEs were diagnosed on the basis of the event requiring hospital admission.&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Moderate or severe COVID&#8208;19: fever &gt; 38.5 &#176;C; respiratory rate &gt; 22 breaths/min; shortness of breath during physical exertion; pneumonia (confirmed by computed tomography of the lungs); oxygen saturation level &lt; 95%.</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>Ad26.COV2.S &#8211; Janssen Pharmaceutical Companies</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">An SAE based on ICH and EU guidelines on pharmacovigilance for medicinal products for human use is any untoward medical occurrence that at any dose: results in death; is life&#8208;threatening (the participant was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe); requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.&#160;</td><td valign="top" colspan="1" rowspan="1">A SARS&#8208;CoV&#8208;2 positive RT&#8208;PCR or molecular test result.<break/>Respiratory rate &#8805; 30 breaths/min; heart rate &#8805; 125 beats/min; oxygen saturation (SpO<sub>2</sub>) &#8804; 93% on room air at sea level, or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg; respiratory failure; evidence of shock; significant acute renal, hepatic, or neurological dysfunction; admission to the ICU; death<break/>&#160;</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>Inactivated virus</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>BBV152 &#8211; Bharat Biotech</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>CoronaVac &#8211; Sinovac</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref></td><td valign="top" colspan="1" rowspan="1">Any untoward medical occurrence that:&#160;results in death; is life&#8208;threatening (i.e. the subject was, in the opinion of the investigator, at immediate risk&#160;&#8232;of death from the event as it occurred; it does not refer to an event which hypothetically&#160;might have caused death if it were more severe);&#160;requires or prolongs subject&#8217;s hospitalisation; results in persistent or significant disability/incapacity (i.e. the event causes a substantial&#160;disruption of a personal ability to conduct normal life functions); results in a congenital anomaly/birth defect; requires intervention to prevent permanent impairment or damage; is an important and significant medical event that may not be immediately life&#8208;threatening&#160;or resulting in death or hospitalisation but, based upon appropriate medical judgement, may&#160;jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed above.&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 confirmed by RT&#8208;PCR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Any adverse event that results in any of the following outcomes: death; threat to life; there is a risk of death at the time of the event; hospitalisation or extension of hospitalisation; significant or persistent disability; congenital anomaly; any suspicion of transmission of an infectious agent by means of a medication; clinically significant event; any event resulting from the use of drugs that require medical intervention, in order to avoid death, risk to life, significant disability or hospitalisation.</td><td valign="top" colspan="1" rowspan="1">Score &#8805; 6 on WHO 10&#8208;point clinical progression scale (hospitalized with severe COVID&#8208;19 through to death)<break/>&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></td><td valign="top" colspan="1" rowspan="1">An SAE is an adverse event that results in any of the following outcomes, whether or not considered related to the study intervention: death; life&#8208;threatening event (i.e. the volunteer was, in the view of the investigator, at immediate risk of death from the event that occurred);&#160;&#8232;persistent or significant disability or incapacity (i.e. substantial disruption of one&#8217;s ability to carry out normal life functions); hospitalisation or prolongation of existing hospitalisation, regardless of length of stay, even if it is a precautionary measure for continued observation (hospitalisation (including inpatient or outpatient hospitalisation for an elective procedure) for a pre&#8208;existing condition that has not worsened unexpectedly does not constitute an SAE);&#8232;an important medical event (that may not cause death, be life&#8208;threatening, or require hospitalisation) that may, based upon appropriate medical judgement, jeopardise the volunteer, require medical or surgical intervention to prevent 1 of the outcomes listed above, or a combination of these. Examples of such medical events include allergic reaction requiring intensive treatment in an emergency room or clinic, blood dyscrasias, or convulsions that do not result in inpatient hospitalisation.</td><td valign="top" colspan="1" rowspan="1">WHO clinical progression scale &#8805; 6: hospitalized, needing oxygen by non&#8208;invasive or high&#8208;flow ventilation or worse</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Events during the clinical trial that need hospitalisation treatment, prolong hospitalisation time, disability, affect working ability, endanger life or death, cause congenital malformation, etc.</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>WIBP&#8208;CorV &#8211; Sinopharm Wuhan</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">Confirmed COVID&#8208;19 case, meeting any 1 of the following criteria: respiratory distress (respiratory rate &#8805; 30 breaths/min); O<sub>2</sub> saturation &#8804; 93% at rest; PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg (1 mmHg = 0.133 kPa); clinical symptoms progressively worsened, and chest imaging showed &gt; 50% obvious lesion progression within 24&#8211;48 hours.</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>Protein subunit</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>NVX&#8208;CoV2373 &#8211; Novavax</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">Severe refers to &#8805; 1 of the following: tachypnoea &#8805; 30 breaths/min at rest; resting heart rate &#8805; 125 beats/min; SpO<sub>2</sub> &#8804; 93% on room air or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg; high&#8208;flow O<sub>2</sub> therapy or non&#8208;invasive ventilation/non&#8208;invasive positive pressure ventilation (e.g. continuous positive airway pressure or bilevel positive airway pressure; mechanical ventilation or extracorporeal membrane oxygenation; &#8805; 1 major organ system dysfunction or failure to be defined by diagnostic testing/clinical syndrome/interventions, including any of the following &#8211; acute respiratory failure, including acute respiratory distress syndrome, acute renal failure, acute hepatic failure, acute right or left heart failure, septic or cardiogenic shock (with shock defined as systolic blood pressure &lt; 90 mmHg or diastolic blood pressure &lt; 60 mmHg), acute stroke (ischaemic or haemorrhagic), acute thrombotic event; acute myocardial infarction, deep vein thrombosis, pulmonary embolism, requirement for: vasopressors, systemic corticosteroids, or haemodialysis; admission to an intensive care unit; death.</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">An SAE is defined as any event that results in death, is immediately life&#8208;threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Tachypnoea &#8805; 30 breaths/min at rest; resting heart rate &#8805; 125 beats/min; SpO<sub>2</sub> &#8804; 93% on room air or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg; high&#8208;flow O<sub>2</sub> therapy or non&#8208;invasive ventilation/non&#8208;invasive positive pressure ventilation (e.g. continuous positive airway pressure or bilevel positive airway pressure; mechanical ventilation or extracorporeal membrane oxygenation; &#8805; 1 major organ system dysfunction or failure to be defined by diagnostic testing/clinical syndrome/interventions, including any of the following &#8211; acute respiratory failure, including acute respiratory distress syndrome, acute renal failure, acute hepatic failure, acute right or left heart failure, septic or cardiogenic shock (with shock defined as systolic blood pressure &lt; 90 mmHg or diastolic blood pressure &lt; 60 mmHg), acute stroke (ischaemic or haemorrhagic), acute thrombotic event; acute myocardial infarction, deep vein thrombosis, pulmonary embolism, requirement for: vasopressors, systemic corticosteroids, or haemodialysis; admission to an intensive care unit; death.</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">Severe refers to &#8805; 1 of the following: tachypnoea &#8805; 30 breaths/min at rest; resting heart rate &#8805; 125 beats/min; SpO<sub>2</sub> &#8804; 93% on room air or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg; high&#8208;flow O<sub>2</sub> therapy or non&#8208;invasive ventilation/non&#8208;invasive positive pressure ventilation (e.g. continuous positive airway pressure or bilevel positive airway pressure; mechanical ventilation or extracorporeal membrane oxygenation; &#8805; 1 major organ system dysfunction or failure to be defined by diagnostic testing/clinical syndrome/interventions, including any of the following &#8211; acute respiratory failure, including acute respiratory distress syndrome, acute renal failure, acute hepatic failure, acute right or left heart failure, septic or cardiogenic shock (with shock defined as systolic blood pressure &lt; 90 mmHg or diastolic blood pressure &lt; 60 mmHg), acute stroke (ischaemic or haemorrhagic), acute thrombotic event; acute myocardial infarction, deep vein thrombosis, pulmonary embolism, requirement for: vasopressors, systemic corticosteroids, or haemodialysis; admission to an intensive care unit; death.</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>FINLAY&#8208;FR&#8208;2 &#8211; Instituto Finlay de Vacunas</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref></td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">Severe systemic confirmed COVID&#8208;19 disease (serious or critical), defined by 1 of the following criteria: polypnoea; x&#8208;ray infiltration/condensation, pulmonary echography; oxygen saturation &#8804; 90% or assisted mechanical ventilation (serious disease), acute respiratory distress syndrome or evidence of septic shock (critical disease).</td></tr><tr><td colspan="3" valign="top" rowspan="1"><bold>Heterologous vaccination</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">Any untoward medical occurrence that: results in death; is life&#8208;threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability/incapacity; consists of a congenital anomaly or birth defect.</td><td valign="top" colspan="1" rowspan="1">NR</td></tr></tbody></table></table-wrap></p></app><app id="CD015477-sec-0302"><title>Appendix 2. Search strategies</title><sec id="CD015477-sec-0303"><title>&#160;Cochrane COVID&#8208;19 Study Register</title><p><table-wrap id="CD015477-tblf-0002" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Source</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Search strategy &#160;(last search date 5 November 2021)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>PubMed</bold></td><td valign="top" colspan="1" rowspan="1">(2019 nCoV[tiab] OR 2019nCoV[tiab] OR corona virus[tiab] OR corona viruses[tiab] OR coronavirus[tiab] OR coronaviruses[tiab] OR COVID[tiab] OR COVID19[tiab] OR nCov 2019[tiab] OR SARS&#8208;CoV2[tiab] OR SARS CoV&#8208;2[tiab] OR SARSCoV2[tiab] OR SARSCoV&#8208;2[tiab] OR "COVID&#8208;19"[Mesh] OR "COVID&#8208;19 Testing"[Mesh] OR "COVID&#8208;19 Vaccines"[Mesh] OR "Coronavirus"[Mesh:NoExp] OR "Receptors, Coronavirus"[Mesh] OR "SARS&#8208;CoV&#8208;2"[Mesh] OR "Spike Glycoprotein, Coronavirus"[Mesh]) NOT ("animals"[mh] NOT "humans"[mh]) NOT (editorial[pt] OR newspaper article[pt])</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Embase</bold></td><td valign="top" colspan="1" rowspan="1">((('anti&#8208;SARS&#8208;CoV&#8208;2 agent'/exp OR 'coronaviridae'/de OR 'coronavirinae'/de OR 'coronaviridae infection'/de OR 'coronavirus disease 2019'/exp OR 'coronavirus infection'/de OR 'COVID&#8208;19 testing'/exp OR 'sars coronavirus 2 test kit'/exp OR 'sars&#8208;related coronavirus'/de OR 'severe acute respiratory syndrome coronavirus 2'/exp OR '2019 ncov':ti,ab,kw OR 2019ncov:ti,ab,kw OR (((corona* OR corono*) NEAR/1 (virus* OR viral* OR virinae*)):ti,ab,kw) OR coronavir*:ti,ab,kw OR coronovir*:ti,ab,kw OR covid:ti,ab,kw OR covid19:ti,ab,kw OR hcov*:ti,ab,kw OR 'ncov 2019':ti,ab,kw OR 'sars cov2':ti,ab,kw OR 'sars cov 2':ti,ab,kw OR sarscov2:ti,ab,kw OR 'sarscov 2':ti,ab,kw) NOT (('animal experiment'/de OR 'animal'/exp) NOT ('human'/exp OR 'human experiment'/de))) NOT 'editorial'/it) NOT ([medline]/lim OR [pubmed&#8208;not&#8208;medline]/lim) AND [1&#8208;12&#8208;2019]/sd</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>CENTRAL&#160;</bold></td><td valign="top" colspan="1" rowspan="1">1 ("2019 nCoV" OR 2019nCoV OR "corona virus*" OR coronavirus* OR COVID OR COVID19 OR "nCov 2019" OR "SARS&#8208;CoV2" OR "SARS CoV&#8208;2" OR SARSCoV2 OR "SARSCoV&#8208;2"):TI,AB AND CENTRAL:TARGET<break/>2 Coronavirus:MH AND CENTRAL:TARGET<break/>3 Coronavirus:EH AND CENTRAL:TARGET<break/>4 #1 OR #2 OR #3<break/>5 2019 TO 2021:YR AND CENTRAL:TARGET<break/>6 #5 AND #4<break/>7 INSEGMENT<break/>8 #6 NOT #7&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>ClinicalTrials.gov</bold></td><td valign="top" colspan="1" rowspan="1">COVID&#8208;19 OR 2019&#8208;nCoV OR SARS&#8208;CoV&#8208;2 OR coronavirus</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>WHO ICTRP</bold></td><td valign="top" colspan="1" rowspan="1">COVID OR 2019&#8208;nCoV OR SARS&#8208;CoV&#8208;2 OR coronavirus OR corona virus</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>medRxiv</bold></td><td valign="top" colspan="1" rowspan="1">All new medRxiv records are imported each week into the Cochrane Register of Studies. Records captured by this strategy are then evaluated:<break/>("2019 nCoV" OR 2019nCoV OR "corona virus*" OR coronavirus* OR COVID OR COVID19 OR "nCov 2019" OR "SARS&#8208;CoV2" OR "SARS CoV&#8208;2" OR SARSCoV2 OR "SARSCoV&#8208;2"):TI,AB&#160;</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p>&#160;</p></sec><sec id="CD015477-sec-0304"><title>Epistemonikos L&#183;OVE COVID&#8208;19 platform</title><p><table-wrap id="CD015477-tblf-0003" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Search strategy</bold></td></tr><tr><td colspan="1" rowspan="1">coronavir* OR coronovirus* OR betacoronavir* OR "beta&#8208;coronavirus" OR "beta&#8208;coronaviruses" OR "corona virus" OR "virus corona" OR "corono virus" OR "virus corono" OR hcov* OR covid* OR "2019&#8208;ncov" OR cv19* OR "cv&#8208;19" OR "cv 19" OR "n&#8208;cov" OR ncov* OR (wuhan* AND (virus OR viruses OR viral)) OR "2019&#8208;ncov&#8208;related" OR "cv&#8208;19&#8208;related" OR "n&#8208;cov&#8208;related" OR sars* OR sari OR "severe acute respiratory syndrome" OR antisars* OR "anti&#8208;sars&#8208;cov&#8208;2" OR "anti&#8208;sars&#8208;cov2" OR "anti&#8208;sarscov&#8208;2" OR "anti&#8208;sarscov&#8208;2" OR "post&#8208;COVID&#8208;19" OR "Not&#8208;of&#8208;COVID&#8208;19" OR "corona patients" OR "article&#8208;covid&#8208;19" OR "post&#8208;covid&#8208;19" OR "post&#8208;covid" OR "with&#8208;covid&#8208;19" OR "pre&#8208;covid" OR "pre&#8208;covid&#8208;19" OR "with&#8208;covid" OR "anti&#8208;covid&#8208;19" OR "n&#8208;covid" OR "no&#8208;covid"</td></tr></tbody></table></table-wrap></p><p>For the Epistemonikos L*OVE COVID&#8208;19 platform we:</p><p><list id="CD015477-list-0023" list-type="bullet"><list-item><p>select type of question &#8220;Prevention or treatment&#8221;</p></list-item><list-item><p>select intervention &#8220;Public health&#8221;, &#8220;Vaccination&#8221; and &#8220;SARS&#8208;CoV&#8208;2 vaccines&#8221;</p></list-item><list-item><p>select &#8220;Primary studies&#8221;</p></list-item><list-item><p>filter results by &#8220;RCT&#8221;</p></list-item><list-item><p>export the results in a.ris file</p></list-item><list-item><p>upload the results into Rayyan &#174;</p></list-item><list-item><p>export results in an excel file</p></list-item><list-item><p>eliminate duplicates</p></list-item><list-item><p>cross&#8208;check with the latest extraction to eliminate duplicates and obtain only new articles (L*OVE platform does not filter results by day)</p></list-item></list></p><p>For the Cochrane COVID&#8208;19 Study Register we:</p><p><list id="CD015477-list-0024" list-type="bullet"><list-item><p>select new studies &#8220;Last week&#8221;</p></list-item><list-item><p>select update new references &#8220;Last week&#8221;</p></list-item><list-item><p>select results available &#8220;Report results&#8221;</p></list-item><list-item><p>select study characteristics, study type &#8220;Interventional&#8221;</p></list-item><list-item><p>select study characteristics, study aim &#8220;Treatment and management&#8221;</p></list-item><list-item><p>select study characteristics, intervention assignment &#8220;Randomized&#8221;</p></list-item></list></p><p>For the Retraction Watch Website:</p><p><list id="CD015477-list-0025" list-type="bullet"><list-item><p>click in &#171; Retracted coronavirus (COVID&#8208;19) papers &#187;</p></list-item><list-item><p>check the list of news Retracted papers</p></list-item></list></p><p>For the ICTRP:</p><p>The records are automatically extracted in the platform <uri>https://ctr-dwh.limos.fr/</uri></p><p>For the EMA Website we:&#160;</p><p><list id="CD015477-list-0026" list-type="bullet"><list-item><p>select &#171; Vaccines &#187; in Covid&#8208;19 pandemic</p></list-item><list-item><p>select &#171; name of vaccine &#187; in Authorized for use in the European Union</p></list-item><list-item><p>search &#171; Assessment report &#187;</p></list-item><list-item><p>export the results in a PDF file</p></list-item></list></p><p>For the FDA Website we:</p><p><list id="CD015477-list-0027" list-type="bullet"><list-item><p>click in &#171; FDA Covid&#8208;19 Response &#187;</p></list-item><list-item><p>select &#171; name of vaccine &#187; in COVID&#8208;19 Vaccines</p></list-item><list-item><p>search reports of interest&#160;</p></list-item><list-item><p>export the results in a PDF file</p></list-item><list-item><p>in the home page, search in search Search Toolbar &#171; Briefing Document &#187; for each FDA&#8208;approved vaccine</p></list-item></list></p></sec></app><app id="CD015477-sec-0305"><title>Appendix 3. Additional methods for future network meta&#8208;analysis (NMA) updates</title><p>Below are additional methods to consider if a NMA and subgroup analyses are to be conducted in future updates.</p><sec id="CD015477-sec-0306"><title>Unit of analysis issues</title><p>If we perform a NMA, we will properly account for the correlation of effect sizes coming from multiple&#8208;arm trials.&#160;</p><p>If we identify any eligible cluster&#8208;randomized trials, we will extract results that properly account for the cluster design (such as based on a multiple&#8208;level model or on generalized estimating equations). If such an analysis is not reported, we will contact study authors to try to obtain the parameters required to be able to calculate an estimate of the intraclass correlation coefficient for the meta&#8208;analyses to adjust for the design effect. Should these not be obtained, the trial will still be included, although it will be mentioned as a limitation of the analysis.&#160;</p></sec><sec id="CD015477-sec-0307"><title>Assessment of transitivity</title><p>If a certain number of studies are available (e.g. at least 3 studies for 30% of the available direct comparisons), we will opt for conducting a NMA. Prior to this analysis, we will assess whether the assumption that the anchor treatments are transitive to allow valid indirect inference is likely to be plausible. Specifically, we will evaluate the similarity of the distribution of the potential effect modifiers (variants of the virus, baseline risk such as rate of transmission of COVID&#8208;19 at the time the trials were conducted, immune status) across the available comparisons. Throughout the living review, we will be consulting content experts and update, if necessary, the list of potential effect modifiers. We will use boxplots to depict the distributions of these variables across comparisons. In terms of node (i.e. vaccine) definition, we do not expect substantial heterogeneity that could threaten the transitivity assumption.&#160;</p></sec><sec id="CD015477-sec-0308"><title>Assessment of reporting biases</title><p>We will use funnel plots (in the presence of at least 10 studies per meta&#8208;analysis) and statistical tests (such as the Egger&#8217;s test)&#160;(<xref rid="CD015477-bbs2-0078" ref-type="ref-list">Egger 1997</xref>) to assess the potential for small&#8208;study effects. If asymmetry is found, we will explore possible reasons for the apparent association between study size and study effect. If publication bias is suspected, we will apply selection models that make assumptions about the probability of publication based on the study results (<xref rid="CD015477-bbs2-0117" ref-type="ref-list">Mavridis 2014</xref>). If NMA is deemed feasible, we will also draw comparison&#8208;adjusted funnel plots; these are modified funnel plots appropriate for putting together all studies from a NMA, irrespective of the comparison they evaluate(<xref rid="CD015477-bbs2-0067" ref-type="ref-list">Chaimani 2013</xref>). This will be done only for critical outcomes.</p><p>If there are no major concerns about transitivity (see above), we will also perform a random&#8208;effects NMA for each outcome. The analysis will be performed at the vaccine level (not the type of vaccine), hence we will not combine different vaccines. We will assume a common heterogeneity parameter for each network. We will present the results in terms of effect sizes and 95% CIs in league tables and will use colours to represent the certainty of the evidence for every comparison. We will assess the impact of heterogeneity on the results by using prediction intervals. To rank the interventions, in the absence of excessive uncertainty in the relative effects, we will use the surface under the cumulative ranking curve (SUCRA) (<xref rid="CD015477-bbs2-0148" ref-type="ref-list">Salanti 2011</xref>). This will be done for critical outcomes. We will run analyses and produce graphical displays using R (netmeta package)(<xref rid="CD015477-bbs2-0145" ref-type="ref-list">Rucker 2013</xref>) and Stata network (<xref rid="CD015477-bbs2-0163" ref-type="ref-list">White 2008</xref>), and network graphs packages (<xref rid="CD015477-bbs2-0068" ref-type="ref-list">Chaimani 2015</xref>). If important concerns about transitivity are detected, we will only perform pairwise meta&#8208;analyses.</p></sec><sec id="CD015477-sec-0309"><title>Assessment of incoherence</title><p>We will evaluate the assumption coherence, which refers to the agreement between direct and indirect evidence, using local and global tests. Local approaches assess coherence in parts of the network, while global approaches assess coherence in the entire network jointly. Specifically, we will use the side&#8208;splitting method (<xref rid="CD015477-bbs2-0076" ref-type="ref-list">Dias 2010</xref>) and the design&#8208;by&#8208;treatment interaction model (<xref rid="CD015477-bbs2-0101" ref-type="ref-list">Higgins 2021</xref>). We will consider P values &lt; 0.10 as suspicious for incoherence. Tests for incoherence are known to have low power and may not be able to detect incoherence even when present, so we will interpret the results of the tests with caution.</p></sec><sec id="CD015477-sec-0310"><title>Subgroup analysis and investigation of heterogeneity/incoherence</title><p>In the NMA, &#160;we will conduct the same subgroup analysis already prespecified for the for pairwise comparisons.</p></sec><sec id="CD015477-sec-0311"><title>Sensitivity analysis</title><p>We will perform sensitivity analyses by excluding RCTs with an overall high risk of bias, RCTs reported in preprint only, and early&#8208;phase trials. For the NMA, we will also perform a sensitivity analysis assuming that the effects of the vaccines of the same type (e.g. RNA&#8208;based vaccine) are related, although not identical.</p></sec><sec id="CD015477-sec-0312"><title>Summary of findings and assessment of the certainty of the evidence of the review findings</title><p>We will prepare separate summary of findings tables of the NMA for each critical outcome. These tables will report the different comparisons included in the network, relative and absolute effect estimates, and the certainty of the evidence (<xref rid="CD015477-bbs2-0069" ref-type="ref-list">Chaimani 2022</xref>;&#160;<xref rid="CD015477-bbs2-0174" ref-type="ref-list">Yepes&#8208;Nu&#241;ez 2019</xref>). We will calculate absolute effects using the baseline risks in the control groups of the included studies. Two review authors will independently rate the evidence's overall certainty for each outcome using the CINeMA tool and all decisions to downgrade or update the certainty of evidence will be made explicit.&#160;</p><p>To evaluate the certainty of the evidence in the NMA for the critical outcomes, we will use the CINeMA tool that considers the following domains: within&#8208;study&#8208;bias, across&#8208;studies bias, indirectness, imprecision, heterogeneity and incoherence (<xref rid="CD015477-bbs2-0122" ref-type="ref-list">Nikolakopoulou 2020</xref>). For within&#8208;study bias and indirectness, CINeMA calculates the contribution of each study in the estimation and combines these contributions with the study&#8208;specific evaluations (low, moderate, high) to rate the relative effect for each comparison in the network. The domains of imprecision, heterogeneity and incoherence use a prespecified important size of effect to specify the margin of equivalence between two interventions. This will be defined by consulting the content experts.</p></sec></app><app id="CD015477-sec-0313"><title>Appendix 4. Characteristics of unpublished registered studies</title><p><table-wrap id="CD015477-tblf-0004" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: RNA&#8208;based vaccine (73 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated&#160;</bold><break/><bold>sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000034112</td><td valign="top" colspan="1" rowspan="1">24 June 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ARCoV</td><td valign="top" colspan="1" rowspan="1">168</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100041855&#160;</td><td valign="top" colspan="1" rowspan="1">8 January 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ARCoV</td><td valign="top" colspan="1" rowspan="1">420</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04847102">NCT04847102</ext-link></td><td valign="top" colspan="1" rowspan="1">15 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Cross&#8208;over</td><td valign="top" colspan="1" rowspan="1">ARCoV</td><td valign="top" colspan="1" rowspan="1">28,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04668339">NCT04668339</ext-link></td><td valign="top" colspan="1" rowspan="1">16 December</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ARCT&#8208;021</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000040044</td><td valign="top" colspan="1" rowspan="1">19 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">960</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04588480">NCT04588480</ext-link></td><td valign="top" colspan="1" rowspan="1">19 October 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">160</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04649021">NCT04649021</ext-link></td><td valign="top" colspan="1" rowspan="1">2 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">950</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04816669">NCT04816669</ext-link></td><td valign="top" colspan="1" rowspan="1">25 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">610</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04955626">NCT04955626</ext-link></td><td valign="top" colspan="1" rowspan="1">9 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">10,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04961229">NCT04961229</ext-link></td><td valign="top" colspan="1" rowspan="1">14 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">450</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04969250">NCT04969250</ext-link></td><td valign="top" colspan="1" rowspan="1">20 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Factorial</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">640</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05057169">NCT05057169</ext-link></td><td valign="top" colspan="1" rowspan="1">27 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05029245">NCT05029245</ext-link></td><td valign="top" colspan="1" rowspan="1">31 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">1000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05081271">NCT05081271</ext-link></td><td valign="top" colspan="1" rowspan="1">18 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05077254">NCT05077254</ext-link></td><td valign="top" colspan="1" rowspan="1">14 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210923012</td><td valign="top" colspan="1" rowspan="1">23 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2 + CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">80</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ACTRN12621001465842</td><td valign="top" colspan="1" rowspan="1">26 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2 + inulin</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1">ACTRN12621001412820</td><td valign="top" colspan="1" rowspan="1">20 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2 + sirolimus</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04566276">NCT04566276</ext-link></td><td valign="top" colspan="1" rowspan="1">28 September 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">ChulaCov19 mRNA vaccine</td><td valign="top" colspan="1" rowspan="1">96</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04674189">NCT04674189</ext-link></td><td valign="top" colspan="1" rowspan="1">19 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CVnCoV</td><td valign="top" colspan="1" rowspan="1">2520</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04848467">NCT04848467</ext-link></td><td valign="top" colspan="1" rowspan="1">19 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CVnCoV + influenza vaccine</td><td valign="top" colspan="1" rowspan="1">1000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04821674">NCT04821674</ext-link></td><td valign="top" colspan="1" rowspan="1">29 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">DS&#8208;5670a</td><td valign="top" colspan="1" rowspan="1">152</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04844268">NCT04844268</ext-link></td><td valign="top" colspan="1" rowspan="1">14 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">HDT 301 vaccine</td><td valign="top" colspan="1" rowspan="1">78</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100049349</td><td valign="top" colspan="1" rowspan="1">31 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">LVRNA009</td><td valign="top" colspan="1" rowspan="1">144</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100049104</td><td valign="top" colspan="1" rowspan="1">21 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA vaccine&#160;</td><td valign="top" colspan="1" rowspan="1">2000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100049521</td><td valign="top" colspan="1" rowspan="1">2 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA vaccine&#160;</td><td valign="top" colspan="1" rowspan="1">320</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04677660">NCT04677660</ext-link></td><td valign="top" colspan="1" rowspan="1">21 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">200</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04805125">NCT04805125</ext-link></td><td valign="top" colspan="1" rowspan="1">18 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">380</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACTR202105817814362</td><td valign="top" colspan="1" rowspan="1">20 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Cross&#8208;over</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">14,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05000216">NCT05000216</ext-link></td><td valign="top" colspan="1" rowspan="1">11 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04978038">NCT04978038</ext-link></td><td valign="top" colspan="1" rowspan="1">27 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">414</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04785144">NCT04785144</ext-link></td><td valign="top" colspan="1" rowspan="1">5 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273.351</td><td valign="top" colspan="1" rowspan="1">210</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05069636">NCT05069636</ext-link></td><td valign="top" colspan="1" rowspan="1">6 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 + osteopathic manipulative medicine</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04765436">NCT04765436</ext-link></td><td valign="top" colspan="1" rowspan="1">21 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">PTX&#8208;COVID19&#8208;B</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2021&#8208;005043&#8208;71&#8208;NL</td><td valign="top" colspan="1" rowspan="1">9 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000039212</td><td valign="top" colspan="1" rowspan="1">22 October 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ARCoV</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ISRCTN15779782</td><td valign="top" colspan="1" rowspan="1">8 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">ARCT&#8208;021</td><td valign="top" colspan="1" rowspan="1">100,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05012943">NCT05012943</ext-link></td><td valign="top" colspan="1" rowspan="1">19 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ARCT&#8208;154</td><td valign="top" colspan="1" rowspan="1">21,000</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05037097">NCT05037097</ext-link></td><td valign="top" colspan="1" rowspan="1">8 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ARCT&#8208;165</td><td valign="top" colspan="1" rowspan="1">72</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ACTRN12621000661875</td><td valign="top" colspan="1" rowspan="1">1 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04713553">NCT04713553</ext-link></td><td valign="top" colspan="1" rowspan="1">19 January 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">1530</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04754594">NCT04754594</ext-link></td><td valign="top" colspan="1" rowspan="1">15 February 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">4000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04907331">NCT04907331</ext-link></td><td valign="top" colspan="1" rowspan="1">28 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">3000</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04949490">NCT04949490</ext-link></td><td valign="top" colspan="1" rowspan="1">2 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">549</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2021&#8208;003331&#8208;28&#8208;ES</td><td valign="top" colspan="1" rowspan="1">21 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">776</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2020&#8208;005442&#8208;42&#8208;PL</td><td valign="top" colspan="1" rowspan="1">11 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">4644</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05022329">NCT05022329</ext-link></td><td valign="top" colspan="1" rowspan="1">26 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05047640">NCT05047640</ext-link></td><td valign="top" colspan="1" rowspan="1">17 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">200</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ISRCTN12348322</td><td valign="top" colspan="1" rowspan="1">16 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210917004</td><td valign="top" colspan="1" rowspan="1">17 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04977479">NCT04977479</ext-link></td><td valign="top" colspan="1" rowspan="1">27 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Cross&#8208;over</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2021&#8208;004526&#8208;29&#8208;DE</td><td valign="top" colspan="1" rowspan="1">6 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">BNT162b2</td><td valign="top" colspan="1" rowspan="1">85</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2021&#8208;001993&#8208;52&#8208;BE</td><td valign="top" colspan="1" rowspan="1">5 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;</td><td valign="top" colspan="1" rowspan="1">840</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04887948">NCT04887948</ext-link></td><td valign="top" colspan="1" rowspan="1">14 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2 + pneumococcal vaccine</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05060991">NCT05060991</ext-link></td><td valign="top" colspan="1" rowspan="1">29 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BNT162b2 + reduction in antimetabolite immunosuppression</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100045984</td><td valign="top" colspan="1" rowspan="1">1 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COVID&#8208;19 mRNA vaccine (nucleoside&#8208;modified)</td><td valign="top" colspan="1" rowspan="1">240</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05028361">NCT05028361</ext-link></td><td valign="top" colspan="1" rowspan="1">31 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COVID&#8208;19 mRNA vaccine (nucleoside&#8208;modified) + influenza vaccine</td><td valign="top" colspan="1" rowspan="1">450</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04863131">NCT04863131</ext-link></td><td valign="top" colspan="1" rowspan="1">28 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">EXG&#8208;5003</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/04/032688</td><td valign="top" colspan="1" rowspan="1">28 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">HGCO19</td><td valign="top" colspan="1" rowspan="1">620</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ISRCTN17072692</td><td valign="top" colspan="1" rowspan="1">4 June 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">LNP&#8208;nCoVsaRNA</td><td valign="top" colspan="1" rowspan="1">320</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ISRCTN27841311</td><td valign="top" colspan="1" rowspan="1">26 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">1050</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04761822">NCT04761822</ext-link></td><td valign="top" colspan="1" rowspan="1">21 February 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">3400</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04796896">NCT04796896</ext-link></td><td valign="top" colspan="1" rowspan="1">15 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">7050</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04811664">NCT04811664</ext-link></td><td valign="top" colspan="1" rowspan="1">23 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Cross&#8208;over</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">37,500</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04894435">NCT04894435</ext-link></td><td valign="top" colspan="1" rowspan="1">20 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">1300</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2021&#8208;004558&#8208;44&#8208;NL</td><td valign="top" colspan="1" rowspan="1">13 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">460</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04900467">NCT04900467</ext-link></td><td valign="top" colspan="1" rowspan="1">25 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04852978">NCT04852978</ext-link></td><td valign="top" colspan="1" rowspan="1">21 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 + casirivimab + imdevimab</td><td valign="top" colspan="1" rowspan="1">180</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04969276">NCT04969276</ext-link></td><td valign="top" colspan="1" rowspan="1">20 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 + quadrivalent influenza vaccine</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04813796">NCT04813796</ext-link></td><td valign="top" colspan="1" rowspan="1">24 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1283</td><td valign="top" colspan="1" rowspan="1">125</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04798027">NCT04798027</ext-link></td><td valign="top" colspan="1" rowspan="1">15 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">MRT5500</td><td valign="top" colspan="1" rowspan="1">333</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05079633">NCT05079633</ext-link></td><td valign="top" colspan="1" rowspan="1">15 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">MVC&#8208;COV1901 + mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">220</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">JPRN&#8208;jRCT2071210067</td><td valign="top" colspan="1" rowspan="1">28 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">VLPCOV&#8208;01</td><td valign="top" colspan="1" rowspan="1">45</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0005" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: non&#8208;replicating viral vector (73 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04690387">NCT04690387</ext-link></td><td valign="top" colspan="1" rowspan="1">30 December 2020</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">AV&#8208;COVID&#8208;19</td><td valign="top" colspan="1" rowspan="1">27</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000031781</td><td valign="top" colspan="1" rowspan="1">10 April 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant novel coronavirus (2019&#8208;ncov) vaccine (adenovirus vector)</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/02/031295</td><td valign="top" colspan="1" rowspan="1">15 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBV154</td><td valign="top" colspan="1" rowspan="1">175</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/05/033665</td><td valign="top" colspan="1" rowspan="1">18 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COVID&#8208;Vac Combined Vector Vaccine</td><td valign="top" colspan="1" rowspan="1">228</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04398147">NCT04398147</ext-link></td><td valign="top" colspan="1" rowspan="1">21 May 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">696</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04509947">NCT04509947</ext-link></td><td valign="top" colspan="1" rowspan="1">12 August 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">250</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04540419">NCT04540419</ext-link></td><td valign="top" colspan="1" rowspan="1">7 September 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04564716">NCT04564716</ext-link></td><td valign="top" colspan="1" rowspan="1">25 September 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04614948">NCT04614948</ext-link></td><td valign="top" colspan="1" rowspan="1">4 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">30,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04640233">NCT04640233</ext-link></td><td valign="top" colspan="1" rowspan="1">23 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac</td><td valign="top" colspan="1" rowspan="1">1600</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04642339">NCT04642339</ext-link></td><td valign="top" colspan="1" rowspan="1">24 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac</td><td valign="top" colspan="1" rowspan="1">2000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04656613">NCT04656613</ext-link></td><td valign="top" colspan="1" rowspan="1">7 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac</td><td valign="top" colspan="1" rowspan="1">1000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04679909">NCT04679909</ext-link></td><td valign="top" colspan="1" rowspan="1">22 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">AdCOVID</td><td valign="top" colspan="1" rowspan="1">180</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04751682">NCT04751682</ext-link></td><td valign="top" colspan="1" rowspan="1">12 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBV154</td><td valign="top" colspan="1" rowspan="1">175</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04760730">NCT04760730</ext-link></td><td valign="top" colspan="1" rowspan="1">18 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19 + rAd26&#8208;S</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04791423">NCT04791423</ext-link></td><td valign="top" colspan="1" rowspan="1">10 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">GRAd&#8208;COV2</td><td valign="top" colspan="1" rowspan="1">10,300</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04840992">NCT04840992</ext-link></td><td valign="top" colspan="1" rowspan="1">12 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">840</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04843722">NCT04843722</ext-link></td><td valign="top" colspan="1" rowspan="1">13 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">hAd5&#8208;S&#8208;Fusion/N&#8208;ETSD vaccine</td><td valign="top" colspan="1" rowspan="1">540</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04845191">NCT04845191</ext-link></td><td valign="top" colspan="1" rowspan="1">14 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">hAd5&#8208;S&#8208;Fusion/N&#8208;ETSD vaccine</td><td valign="top" colspan="1" rowspan="1">540</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04894305">NCT04894305</ext-link></td><td valign="top" colspan="1" rowspan="1">20 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">380</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04895449">NCT04895449</ext-link></td><td valign="top" colspan="1" rowspan="1">20 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">MVA&#8208;SARS&#8208;2&#8208;S</td><td valign="top" colspan="1" rowspan="1">240</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04977024">NCT04977024</ext-link></td><td valign="top" colspan="1" rowspan="1">26 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COH04S1</td><td valign="top" colspan="1" rowspan="1">240</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACTR202104601572565</td><td valign="top" colspan="1" rowspan="1">12 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Sputnik light vaccine</td><td valign="top" colspan="1" rowspan="1">2200</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05011526">NCT05011526</ext-link></td><td valign="top" colspan="1" rowspan="1">18 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">1020</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05027672">NCT05027672</ext-link></td><td valign="top" colspan="1" rowspan="1">30 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac</td><td valign="top" colspan="1" rowspan="1">348</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05030974">NCT05030974</ext-link></td><td valign="top" colspan="1" rowspan="1">1 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S vaccine</td><td valign="top" colspan="1" rowspan="1">460</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04998240">NCT04998240</ext-link></td><td valign="top" colspan="1" rowspan="1">10 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV + ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210717002</td><td valign="top" colspan="1" rowspan="1">17 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19 + CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">165</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210903006</td><td valign="top" colspan="1" rowspan="1">3 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19 + CoronaVac</td><td valign="top" colspan="1" rowspan="1">80</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210904004</td><td valign="top" colspan="1" rowspan="1">4 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19 + inactivated COVID&#8208;19 vaccine</td><td valign="top" colspan="1" rowspan="1">40</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05091307">NCT05091307</ext-link></td><td valign="top" colspan="1" rowspan="1">25 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S + influenza vaccine</td><td valign="top" colspan="1" rowspan="1">1680</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04833101">NCT04833101</ext-link></td><td valign="top" colspan="1" rowspan="1">6 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV + ZF2001</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05048940">NCT05048940</ext-link></td><td valign="top" colspan="1" rowspan="1">17 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">386</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05049226">NCT05049226</ext-link></td><td valign="top" colspan="1" rowspan="1">20 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19&#160;</td><td valign="top" colspan="1" rowspan="1">1320</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100049530</td><td valign="top" colspan="1" rowspan="1">2 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdTS&#8208;S</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210907003</td><td valign="top" colspan="1" rowspan="1">7 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19&#160;</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20211004005</td><td valign="top" colspan="1" rowspan="1">4 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19&#160;</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04730895">NCT04730895</ext-link></td><td valign="top" colspan="1" rowspan="1">29 January 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05094609">NCT05094609</ext-link></td><td valign="top" colspan="1" rowspan="1">26 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;triCoV/Mac</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05007496">NCT05007496</ext-link></td><td valign="top" colspan="1" rowspan="1">16 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">AV&#8208;COVID&#8208;19</td><td valign="top" colspan="1" rowspan="1">145</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2020&#8208;005226&#8208;28&#8208;IT</td><td valign="top" colspan="1" rowspan="1">23 November 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">40,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100044249</td><td valign="top" colspan="1" rowspan="1">12 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">40,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2020&#8208;002584&#8208;63&#8208;DE</td><td valign="top" colspan="1" rowspan="1">12 August 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">225</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2020&#8208;005801&#8208;14&#8208;PL</td><td valign="top" colspan="1" rowspan="1">30 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">570</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2021&#8208;002693&#8208;10&#8208;AT</td><td valign="top" colspan="1" rowspan="1">19 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">150</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ISRCTN73765130</td><td valign="top" colspan="1" rowspan="1">13 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">2886</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526990">NCT04526990</ext-link></td><td valign="top" colspan="1" rowspan="1">26 August 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">40,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04536051">NCT04536051</ext-link></td><td valign="top" colspan="1" rowspan="1">2 September 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">10,300</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04639466">NCT04639466</ext-link></td><td valign="top" colspan="1" rowspan="1">20 November 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COH04S1</td><td valign="top" colspan="1" rowspan="1">129</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04666012">NCT04666012</ext-link></td><td valign="top" colspan="1" rowspan="1">14 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">AdCLD&#8208;CoV19</td><td valign="top" colspan="1" rowspan="1">150</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04684446">NCT04684446</ext-link></td><td valign="top" colspan="1" rowspan="1">24 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19 + rAd26&#8208;S</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04741061">NCT04741061</ext-link></td><td valign="top" colspan="1" rowspan="1">5 February 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Sputnik light vaccine</td><td valign="top" colspan="1" rowspan="1">6000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04776317">NCT04776317</ext-link></td><td valign="top" colspan="1" rowspan="1">1 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdV68&#8208;S&#8208;TCE</td><td valign="top" colspan="1" rowspan="1">140</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04816019">NCT04816019</ext-link></td><td valign="top" colspan="1" rowspan="1">25 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">54</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04830800">NCT04830800</ext-link></td><td valign="top" colspan="1" rowspan="1">5 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COVIVAC</td><td valign="top" colspan="1" rowspan="1">420</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04916886">NCT04916886</ext-link></td><td valign="top" colspan="1" rowspan="1">8 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">2016</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04952727">NCT04952727</ext-link></td><td valign="top" colspan="1" rowspan="1">7 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04954092">NCT04954092</ext-link></td><td valign="top" colspan="1" rowspan="1">8 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac M</td><td valign="top" colspan="1" rowspan="1">350</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04962906">NCT04962906</ext-link></td><td valign="top" colspan="1" rowspan="1">15 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac + ChAdOx1 nCov&#8208;19</td><td valign="top" colspan="1" rowspan="1">150</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04973449">NCT04973449</ext-link></td><td valign="top" colspan="1" rowspan="1">22 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCov&#8208;19</td><td valign="top" colspan="1" rowspan="1">2475</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACTR202006922165132</td><td valign="top" colspan="1" rowspan="1">22 June 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19</td><td valign="top" colspan="1" rowspan="1">2000</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04983537">NCT04983537</ext-link></td><td valign="top" colspan="1" rowspan="1">30 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04988048">NCT04988048</ext-link></td><td valign="top" colspan="1" rowspan="1">3 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac + ChAdOx1 nCov&#8208;19</td><td valign="top" colspan="1" rowspan="1">1760</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05007951">NCT05007951</ext-link></td><td valign="top" colspan="1" rowspan="1">17 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCov&#8208;19</td><td valign="top" colspan="1" rowspan="1">3990</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05005156">NCT05005156</ext-link></td><td valign="top" colspan="1" rowspan="1">13 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV</td><td valign="top" colspan="1" rowspan="1">876</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2019&#8208;003102&#8208;26&#8208;IT</td><td valign="top" colspan="1" rowspan="1">7 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCov&#8208;19</td><td valign="top" colspan="1" rowspan="1">33</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05054621">NCT05054621</ext-link></td><td valign="top" colspan="1" rowspan="1">23 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19 + MVC&#8208;COV1901</td><td valign="top" colspan="1" rowspan="1">110</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2021&#8208;001978&#8208;37&#8208;ES</td><td valign="top" colspan="1" rowspan="1">6 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCoV&#8208;19 + BNT162b2</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05037188">NCT05037188</ext-link></td><td valign="top" colspan="1" rowspan="1">8 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">BCD&#8208;250</td><td valign="top" colspan="1" rowspan="1">160</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05067933">NCT05067933</ext-link></td><td valign="top" colspan="1" rowspan="1">5 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">VXA&#8208;CoV2&#8208;1.1&#8208;S</td><td valign="top" colspan="1" rowspan="1">896</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210722003</td><td valign="top" colspan="1" rowspan="1">22 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 nCov&#8208;19</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04685603">NCT04685603</ext-link></td><td valign="top" colspan="1" rowspan="1">25 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">AV&#8208;COVID&#8208;19</td><td valign="top" colspan="1" rowspan="1">27</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04535453">NCT04535453</ext-link></td><td valign="top" colspan="1" rowspan="1">2 September 2020</td><td valign="top" colspan="1" rowspan="1">Cancelled</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">1210</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0006" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: replicating viral vector (10 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04497298">NCT04497298</ext-link></td><td valign="bottom" colspan="1" rowspan="1">4 August 2020</td><td valign="bottom" colspan="1" rowspan="1">Completed</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">TMV&#8208;083/V&#8208;591</td><td valign="bottom" colspan="1" rowspan="1">90</td><td valign="bottom" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">ChiCTR2000037782</td><td valign="bottom" colspan="1" rowspan="1">1 September 2020</td><td valign="bottom" colspan="1" rowspan="1">Not recruiting</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">DelNS1&#8208;2019&#8208;nCoV&#8208;RBD&#8208;OPT1</td><td valign="bottom" colspan="1" rowspan="1">60</td><td valign="bottom" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">ChiCTR2100048316</td><td valign="bottom" colspan="1" rowspan="1">5 July 2021</td><td valign="bottom" colspan="1" rowspan="1">Not recruiting</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">DelNS1&#8208;2019&#8208;nCoV&#8208;RBD&#8208;OPT1</td><td valign="bottom" colspan="1" rowspan="1">400</td><td valign="bottom" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04990466">NCT04990466</ext-link></td><td valign="bottom" colspan="1" rowspan="1">4 August 2021</td><td valign="bottom" colspan="1" rowspan="1">Not recruiting</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">rVSV&#8208;SARS&#8208;CoV&#8208;2&#8208;S vaccine</td><td valign="bottom" colspan="1" rowspan="1">550</td><td valign="bottom" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">ChiCTR2100051391</td><td valign="bottom" colspan="1" rowspan="1">22 September 2021</td><td valign="bottom" colspan="1" rowspan="1">Not recruiting</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">DelNS1&#8208;2019&#8208;nCoV&#8208;RBD&#8208;OPT1</td><td valign="bottom" colspan="1" rowspan="1">40,000</td><td valign="bottom" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">ChiCTR2000039715</td><td valign="bottom" colspan="1" rowspan="1">6 November 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">DelNS1&#8208;2019&#8208;nCoV&#8208;RBD&#8208;OPT1</td><td valign="bottom" colspan="1" rowspan="1">720</td><td valign="bottom" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04608305">NCT04608305</ext-link></td><td valign="top" colspan="1" rowspan="1">29 October 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="bottom" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">rVSV&#8208;SARS&#8208;CoV&#8208;2&#8208;S vaccine</td><td valign="top" colspan="1" rowspan="1">1040</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04993209">NCT04993209</ext-link></td><td valign="bottom" colspan="1" rowspan="1">6 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="bottom" colspan="1" rowspan="1">Adaptive</td><td valign="bottom" colspan="1" rowspan="1">NDV&#8208;HXP&#8208;S</td><td valign="bottom" colspan="1" rowspan="1">5394</td><td valign="bottom" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04498247">NCT04498247</ext-link></td><td valign="bottom" colspan="1" rowspan="1">4 August 2020</td><td valign="bottom" colspan="1" rowspan="1">Terminated</td><td valign="bottom" colspan="1" rowspan="1">Sequential assignment</td><td valign="bottom" colspan="1" rowspan="1">V591&#8208;001</td><td valign="bottom" colspan="1" rowspan="1">263</td><td valign="bottom" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04569786">NCT04569786</ext-link></td><td valign="bottom" colspan="1" rowspan="1">30 September 2020</td><td valign="bottom" colspan="1" rowspan="1">Terminated</td><td valign="bottom" colspan="1" rowspan="1">Sequential assignment</td><td valign="bottom" colspan="1" rowspan="1">V590&#8208;001</td><td valign="bottom" colspan="1" rowspan="1">232</td><td valign="bottom" colspan="1" rowspan="1">Phase 1</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0007" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: inactivated virus vaccine (61 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000034780</td><td valign="top" colspan="1" rowspan="1">8 July 2020</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">15,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100041704</td><td valign="top" colspan="1" rowspan="1">1 January 2021</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04691908">NCT04691908</ext-link></td><td valign="top" colspan="1" rowspan="1">31 December 2020</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">QazCovid&#8208;in</td><td valign="top" colspan="1" rowspan="1">3000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04790851">NCT04790851</ext-link></td><td valign="top" colspan="1" rowspan="1">10 March 2021</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell) + IIV4 + Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell) + pneumococcal vaccine</td><td valign="top" colspan="1" rowspan="1">1152</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100046174</td><td valign="top" colspan="1" rowspan="1">8 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">1152</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000040146</td><td valign="top" colspan="1" rowspan="1">22 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">INO&#8208;4800 + CoronaVac</td><td valign="top" colspan="1" rowspan="1">640</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100046227</td><td valign="top" colspan="1" rowspan="1">11 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">1404</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">JPRN&#8208;jRCT2071200106</td><td valign="top" colspan="1" rowspan="1">3 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">KD&#8208;414</td><td valign="top" colspan="1" rowspan="1">210</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04560881">NCT04560881</ext-link></td><td valign="top" colspan="1" rowspan="1">23 September 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">3000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04612972">NCT04612972</ext-link></td><td valign="top" colspan="1" rowspan="1">3 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">12,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04747821">NCT04747821</ext-link></td><td valign="top" colspan="1" rowspan="1">10 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">27,711</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04852705">NCT04852705</ext-link></td><td valign="top" colspan="1" rowspan="1">21 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">28,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04884685">NCT04884685</ext-link></td><td valign="top" colspan="1" rowspan="1">13 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04894227">NCT04894227</ext-link></td><td valign="top" colspan="1" rowspan="1">20 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">1080</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04917523">NCT04917523</ext-link></td><td valign="top" colspan="1" rowspan="1">8 June 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">1800</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04953325">NCT04953325</ext-link></td><td valign="top" colspan="1" rowspan="1">7 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">270</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04956224">NCT04956224</ext-link></td><td valign="top" colspan="1" rowspan="1">9 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">VLA2001</td><td valign="top" colspan="1" rowspan="1">750</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">PER&#8208;051&#8208;20</td><td valign="top" colspan="1" rowspan="1">18 August 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">12,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04984408">NCT04984408</ext-link></td><td valign="top" colspan="1" rowspan="1">30 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">8825</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04992182">NCT04992182</ext-link></td><td valign="top" colspan="1" rowspan="1">5 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">534</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05003466">NCT05003466</ext-link></td><td valign="top" colspan="1" rowspan="1">12 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)</td><td valign="top" colspan="1" rowspan="1">480</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05003479">NCT05003479</ext-link></td><td valign="top" colspan="1" rowspan="1">12 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)</td><td valign="top" colspan="1" rowspan="1">84</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20210206050259N3</td><td valign="top" colspan="1" rowspan="1">29 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine FAKHRAVAC (MIVAC)</td><td valign="top" colspan="1" rowspan="1">41,128</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05035238">NCT05035238</ext-link></td><td valign="top" colspan="1" rowspan="1">3 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Turkovac</td><td valign="top" colspan="1" rowspan="1">200</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/08/035648</td><td valign="top" colspan="1" rowspan="1">13 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Covaxin</td><td valign="top" colspan="1" rowspan="1">1100</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05046548">NCT05046548</ext-link></td><td valign="top" colspan="1" rowspan="1">16 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Kovivac</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05079217">NCT05079217</ext-link></td><td valign="top" colspan="1" rowspan="1">15 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">1200</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04993365">NCT04993365</ext-link></td><td valign="top" colspan="1" rowspan="1">6 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac + influenza vaccine + pneumococcal vaccine</td><td valign="top" colspan="1" rowspan="1">440</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05079152">NCT05079152</ext-link></td><td valign="top" colspan="1" rowspan="1">15 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV + influenza vaccine + pneumococcal vaccine</td><td valign="top" colspan="1" rowspan="1">1404</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20201202049567N1</td><td valign="top" colspan="1" rowspan="1">15 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">56</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20201202049567N2</td><td valign="top" colspan="1" rowspan="1">13 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Antigen protein</td><td valign="top" colspan="1" rowspan="1">32</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20201202049567N3</td><td valign="top" colspan="1" rowspan="1">13 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Antigen protein</td><td valign="top" colspan="1" rowspan="1">20,000</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20210206050259N1</td><td valign="top" colspan="1" rowspan="1">8 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Factorial</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine FAKHRAVAC (MIVAC)</td><td valign="top" colspan="1" rowspan="1">135</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20210206050259N2</td><td valign="top" colspan="1" rowspan="1">8 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine FAKHRAVAC (MIVAC)</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000039000</td><td valign="top" colspan="1" rowspan="1">13 October 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100043907</td><td valign="top" colspan="1" rowspan="1">5 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">16</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100045109</td><td valign="top" colspan="1" rowspan="1">7 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated COVID&#8208;19 vaccine</td><td valign="top" colspan="1" rowspan="1">472</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100047917</td><td valign="top" colspan="1" rowspan="1">27 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">20</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2020/07/026300</td><td valign="top" colspan="1" rowspan="1">26 August 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Covaxin</td><td valign="top" colspan="1" rowspan="1">1125</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2020/09/027674</td><td valign="top" colspan="1" rowspan="1">8 September 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">Covaxin</td><td valign="top" colspan="1" rowspan="1">124</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470609">NCT04470609</ext-link></td><td valign="top" colspan="1" rowspan="1">14 July 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">471</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04617483">NCT04617483</ext-link></td><td valign="top" colspan="1" rowspan="1">5 November 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine (inactivated)</td><td valign="top" colspan="1" rowspan="1">1040</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04659239">NCT04659239</ext-link></td><td valign="top" colspan="1" rowspan="1">9 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">34,020</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04691947">NCT04691947</ext-link></td><td valign="top" colspan="1" rowspan="1">31 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ERUCOV&#8208;VAC</td><td valign="top" colspan="1" rowspan="1">44</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04824391">NCT04824391</ext-link></td><td valign="top" colspan="1" rowspan="1">1 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ERUCOV&#8208;VAC</td><td valign="top" colspan="1" rowspan="1">250</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04838080">NCT04838080</ext-link></td><td valign="top" colspan="1" rowspan="1">8 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated COVID&#8208;19 vaccine</td><td valign="top" colspan="1" rowspan="1">38</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04863638">NCT04863638</ext-link></td><td valign="top" colspan="1" rowspan="1">28 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">4400</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04864561">NCT04864561</ext-link></td><td valign="top" colspan="1" rowspan="1">29 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">VLA2001</td><td valign="top" colspan="1" rowspan="1">4000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04866069">NCT04866069</ext-link></td><td valign="top" colspan="1" rowspan="1">29 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04942405">NCT04942405</ext-link></td><td valign="top" colspan="1" rowspan="1">28 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">40,800</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04962308">NCT04962308</ext-link></td><td valign="top" colspan="1" rowspan="1">14 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">1400</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/04/032942</td><td valign="top" colspan="1" rowspan="1">19 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Covaxin</td><td valign="top" colspan="1" rowspan="1">190</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04979949">NCT04979949</ext-link></td><td valign="top" colspan="1" rowspan="1">28 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">111</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04992260">NCT04992260</ext-link></td><td valign="top" colspan="1" rowspan="1">5 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">7000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05033847">NCT05033847</ext-link></td><td valign="top" colspan="1" rowspan="1">3 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">1800</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/08/035993</td><td valign="top" colspan="1" rowspan="1">27 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Covaxin</td><td valign="top" colspan="1" rowspan="1">608</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05043259">NCT05043259</ext-link></td><td valign="top" colspan="1" rowspan="1">14 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">420</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100050589</td><td valign="top" colspan="1" rowspan="1">31 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">TCTR20210731003</td><td valign="top" colspan="1" rowspan="1">31 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">960</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100051645</td><td valign="top" colspan="1" rowspan="1">29 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Inactivated SARS&#8208;CoV&#8208;2 vaccine (vero cell)&#160;</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05095298">NCT05095298</ext-link></td><td valign="top" colspan="1" rowspan="1">27 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine (inactivated)</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0008" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: protein subunit (91 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04453852">NCT04453852</ext-link></td><td valign="top" colspan="1" rowspan="1">1 July 2020</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COVAX&#8208;19&#160;</td><td valign="top" colspan="1" rowspan="1">40</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20201214049709N1</td><td valign="top" colspan="1" rowspan="1">21 January 2021</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">RAZI&#8208;COV PARS</td><td valign="top" colspan="1" rowspan="1">133</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000345</td><td valign="top" colspan="1" rowspan="1">26 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">&#160;Parallel</td><td valign="top" colspan="1" rowspan="1">CIGB&#8208;669 (RBD/AgnHB)</td><td valign="top" colspan="1" rowspan="1">88</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000381</td><td valign="top" colspan="1" rowspan="1">1 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">&#160;Parallel</td><td valign="top" colspan="1" rowspan="1">CIGB&#8208;66 (RBD/aluminium hydroxide)</td><td valign="top" colspan="1" rowspan="1">592</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000382</td><td valign="top" colspan="1" rowspan="1">9 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">&#160;Parallel</td><td valign="top" colspan="1" rowspan="1">CIGB&#8208;669 (RBD/HBcAg)</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05084989">NCT05084989</ext-link></td><td valign="top" colspan="1" rowspan="1">20 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Cross&#8208;over</td><td valign="top" colspan="1" rowspan="1">Recov &#8211; recombinant 2&#8208;component COVID&#8208;19 vaccine (cho cell)</td><td valign="top" colspan="1" rowspan="1">20,301</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000346</td><td valign="top" colspan="1" rowspan="1">26 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Factorial</td><td valign="top" colspan="1" rowspan="1">CIGB&#8208;66 (RBD/aluminium hydroxide)</td><td valign="top" colspan="1" rowspan="1">132</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACTR202107562417077</td><td valign="top" colspan="1" rowspan="1">23 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Factorial</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 fusion protein vaccine (v&#8208;01)&#160;</td><td valign="top" colspan="1" rowspan="1">22,500</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACTR202108616900606</td><td valign="top" colspan="1" rowspan="1">6 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Factorial</td><td valign="top" colspan="1" rowspan="1">CpG 1018/alum adjuvant + scb&#8208;2019&#160;</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ACTRN12620001308987</td><td valign="top" colspan="1" rowspan="1">4 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">RBD + alum adjuvant</td><td valign="top" colspan="1" rowspan="1">255</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ACTRN12621000882820</td><td valign="top" colspan="1" rowspan="1">8 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">IVX&#8208;411</td><td valign="top" colspan="1" rowspan="1">84</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000035691</td><td valign="top" colspan="1" rowspan="1">16 August 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000037518</td><td valign="top" colspan="1" rowspan="1">28 August 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">168</td><td valign="top" colspan="1" rowspan="1">Phase 1&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000040153</td><td valign="top" colspan="1" rowspan="1">22 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">29,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100048439</td><td valign="top" colspan="1" rowspan="1">7 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO cell)</td><td valign="top" colspan="1" rowspan="1">75</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2020/11/029032</td><td valign="top" colspan="1" rowspan="1">10 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">BECOV2</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/02/031554</td><td valign="top" colspan="1" rowspan="1">25 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 rS/Matrix M1&#8208;adjuvant</td><td valign="top" colspan="1" rowspan="1">1600</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">JPRN&#8208;jRCT2051200092</td><td valign="top" colspan="1" rowspan="1">9 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">S&#8208;268019</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04473690">NCT04473690</ext-link></td><td valign="top" colspan="1" rowspan="1">16 July 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">KBP&#8208;COVID&#8208;19</td><td valign="top" colspan="1" rowspan="1">180</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04672395">NCT04672395</ext-link></td><td valign="top" colspan="1" rowspan="1">17 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SCB&#8208;2019 + CpG 1018/Alum&#8208;adjuvant</td><td valign="top" colspan="1" rowspan="1">22,000</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04683224">NCT04683224</ext-link></td><td valign="top" colspan="1" rowspan="1">24 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">UB&#8208;612</td><td valign="top" colspan="1" rowspan="1">7320</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04712110">NCT04712110</ext-link></td><td valign="top" colspan="1" rowspan="1">15 January 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">TAK&#8208;019</td><td valign="top" colspan="1" rowspan="1">200</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04742738">NCT04742738</ext-link></td><td valign="top" colspan="1" rowspan="1">8 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">GBP510 + aluminium hydroxide adjuvant</td><td valign="top" colspan="1" rowspan="1">260</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04750343">NCT04750343</ext-link></td><td valign="top" colspan="1" rowspan="1">11 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">GBP510 + AS03 adjuvant</td><td valign="top" colspan="1" rowspan="1">320</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04760743">NCT04760743</ext-link></td><td valign="top" colspan="1" rowspan="1">18 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">NBP2001</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04780035">NCT04780035</ext-link></td><td valign="top" colspan="1" rowspan="1">3 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">EpiVacCorona</td><td valign="top" colspan="1" rowspan="1">3000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04784767">NCT04784767</ext-link></td><td valign="top" colspan="1" rowspan="1">5 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SpFN_1B&#8208;06&#8208;PL + ALFQ (QS21 adjuvant)</td><td valign="top" colspan="1" rowspan="1">72</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">NCT04887207</td><td valign="top" colspan="1" rowspan="1">14 May 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">40,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04930003">NCT04930003</ext-link></td><td valign="top" colspan="1" rowspan="1">18 June 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">QazCoVac&#8208;P</td><td valign="top" colspan="1" rowspan="1">244</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04944368">NCT04944368</ext-link></td><td valign="top" colspan="1" rowspan="1">29 June 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 recombinant spike protein + Advax&#8208;SM adjuvant</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04950751">NCT04950751</ext-link></td><td valign="top" colspan="1" rowspan="1">6 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SCB&#8208;2020S</td><td valign="top" colspan="1" rowspan="1">150</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04951388">NCT04951388</ext-link></td><td valign="top" colspan="1" rowspan="1">6 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COV1901</td><td valign="top" colspan="1" rowspan="1">385</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04954131">NCT04954131</ext-link></td><td valign="top" colspan="1" rowspan="1">8 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SCB&#8208;2019</td><td valign="top" colspan="1" rowspan="1">800</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACTR202011523101903</td><td valign="top" colspan="1" rowspan="1">2 November 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 recombinant protein vaccine + AS03 adjuvant</td><td valign="top" colspan="1" rowspan="1">34,520</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACTR202103845381761</td><td valign="top" colspan="1" rowspan="1">3 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">40,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000347</td><td valign="top" colspan="1" rowspan="1">17 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2 anti&#8208;SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">910</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000359</td><td valign="top" colspan="1" rowspan="1">18 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CIGB&#8208;66 (RBD/aluminium hydroxide)</td><td valign="top" colspan="1" rowspan="1">48,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000366</td><td valign="top" colspan="1" rowspan="1">9 April 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;1A anti&#8208;SARS&#8208;CoV&#8208;2 Vaccine</td><td valign="top" colspan="1" rowspan="1">450</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05007509">NCT05007509</ext-link></td><td valign="top" colspan="1" rowspan="1">16 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Hipra</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05005559">NCT05005559</ext-link></td><td valign="top" colspan="1" rowspan="1">13 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 recombinant spike p + Advax&#8208;cpg adjuvant</td><td valign="top" colspan="1" rowspan="1">16,876</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05012787">NCT05012787</ext-link></td><td valign="top" colspan="1" rowspan="1">19 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SCB&#8208;2019 + CpG 1018 adjuvant</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05013983">NCT05013983</ext-link></td><td valign="top" colspan="1" rowspan="1">20 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05016934">NCT05016934</ext-link></td><td valign="top" colspan="1" rowspan="1">23 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Versamune&#8208;CoV&#8208;2FC</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">JPRN&#8208;jRCT2051210057</td><td valign="top" colspan="1" rowspan="1">29 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">240</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05029856">NCT05029856</ext-link></td><td valign="top" colspan="1" rowspan="1">1 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Monovalent B.1.351 vaccine + Matrix&#8208;M1 Adjuvant</td><td valign="top" colspan="1" rowspan="1">240</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/08/036074</td><td valign="top" colspan="1" rowspan="1">31 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Corbevax</td><td valign="top" colspan="1" rowspan="1">2140</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05043285">NCT05043285</ext-link></td><td valign="top" colspan="1" rowspan="1">14 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SCTV01C</td><td valign="top" colspan="1" rowspan="1">8420</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05043311">NCT05043311</ext-link></td><td valign="top" colspan="1" rowspan="1">14 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SCTV01C</td><td valign="top" colspan="1" rowspan="1">12,420</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05067894">NCT05067894</ext-link></td><td valign="top" colspan="1" rowspan="1">5 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 recombinant protein vaccine</td><td valign="top" colspan="1" rowspan="1">780</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">JPRN&#8208;jRCT2031210269</td><td valign="top" colspan="1" rowspan="1">23 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">S&#8208;268019</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000385</td><td valign="top" colspan="1" rowspan="1">23 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Finlay&#8208;fr&#8208;1a anti&#8208;SARS&#8208;CoV&#8208;2 vaccine + FINLAY&#8208;Fr&#8208;1 anti&#8208;SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">1166</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05096832">NCT05096832</ext-link></td><td valign="top" colspan="1" rowspan="1">27 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 fusion protein vaccine (v&#8208;01)</td><td valign="top" colspan="1" rowspan="1">10,722</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04961541">NCT04961541</ext-link></td><td valign="top" colspan="1" rowspan="1">14 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ICC vaccine</td><td valign="top" colspan="1" rowspan="1">720</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05087368">NCT05087368</ext-link></td><td valign="top" colspan="1" rowspan="1">21 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Alum adjuvant + SCB&#8208;2019</td><td valign="top" colspan="1" rowspan="1">520</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04522089">NCT04522089</ext-link></td><td valign="top" colspan="1" rowspan="1">21 August 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">AdimrSC&#8208;2f</td><td valign="top" colspan="1" rowspan="1">70</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04550351">NCT04550351</ext-link></td><td valign="top" colspan="1" rowspan="1">16 September 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO cell)</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000360</td><td valign="top" colspan="1" rowspan="1">19 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Single&#8208;group assignment</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2 anti&#8208;SARS&#8208;CoV&#8208;2 vaccine + FINLAY&#8208;FR&#8208;1A anti&#8208;SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">150,000</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1">RPCEC00000363</td><td valign="top" colspan="1" rowspan="1">27 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Single group assignment</td><td valign="top" colspan="1" rowspan="1">CIGB&#8208;66 (RBD/aluminium hydroxide)</td><td valign="top" colspan="1" rowspan="1">124,000</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20150303021315N23</td><td valign="top" colspan="1" rowspan="1">24 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 spike (S) protein subunit vaccine + Advax&#8208;CpG adjuvant</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20201214049709N2</td><td valign="top" colspan="1" rowspan="1">13 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">RAZI&#8208;COV PARS</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20150303021315N24</td><td valign="top" colspan="1" rowspan="1">3 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 recombinant spike protein + Advax&#8208;SM adjuvant</td><td valign="top" colspan="1" rowspan="1">16,876</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20210303050558N1</td><td valign="top" colspan="1" rowspan="1">24 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2 anti&#8208;SARS&#8208;CoV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">24,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ACTRN12621000738820</td><td valign="top" colspan="1" rowspan="1">11 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">IVX&#8208;411</td><td valign="top" colspan="1" rowspan="1">84</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000039994</td><td valign="top" colspan="1" rowspan="1">17 November 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">960</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100042374</td><td valign="top" colspan="1" rowspan="1">21 January 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">4800</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">EUCTR2020&#8208;004272&#8208;17&#8208;DE</td><td valign="top" colspan="1" rowspan="1">6 January 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SCB&#8208;2019</td><td valign="top" colspan="1" rowspan="1">800</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20210620051639N1</td><td valign="top" colspan="1" rowspan="1">25 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Noora</td><td valign="top" colspan="1" rowspan="1">70</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04636333">NCT04636333</ext-link></td><td valign="top" colspan="1" rowspan="1">19 November 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">216</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04646590">NCT04646590</ext-link></td><td valign="top" colspan="1" rowspan="1">30 November 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">29,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04773067">NCT04773067</ext-link></td><td valign="top" colspan="1" rowspan="1">26 February 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">UB&#8208;612</td><td valign="top" colspan="1" rowspan="1">3850</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04783311">NCT04783311</ext-link></td><td valign="top" colspan="1" rowspan="1">5 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">EuCorVac&#8208;19</td><td valign="top" colspan="1" rowspan="1">280</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04813562">NCT04813562</ext-link></td><td valign="top" colspan="1" rowspan="1">24 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">480</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04818801">NCT04818801</ext-link></td><td valign="top" colspan="1" rowspan="1">26 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ReCOV &#8211; recombinant 2&#8208;component COVID&#8208;19 vaccine (CHO cell)</td><td valign="top" colspan="1" rowspan="1">160</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04822025">NCT04822025</ext-link></td><td valign="top" colspan="1" rowspan="1">30 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">MVC&#8208;COV1901</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04869592">NCT04869592</ext-link></td><td valign="top" colspan="1" rowspan="1">3 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">3580</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04885361">NCT04885361</ext-link></td><td valign="top" colspan="1" rowspan="1">13 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">CoVepiT (OSE13E)</td><td valign="top" colspan="1" rowspan="1">48</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04904471">NCT04904471</ext-link></td><td valign="top" colspan="1" rowspan="1">27 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">40,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04904549">NCT04904549</ext-link></td><td valign="top" colspan="1" rowspan="1">27 May 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 adjuvanted recombinant protein vaccine (monovalent)</td><td valign="top" colspan="1" rowspan="1">37,430</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04922788">NCT04922788</ext-link></td><td valign="top" colspan="1" rowspan="1">11 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Nanocovax</td><td valign="top" colspan="1" rowspan="1">13,000</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04982068">NCT04982068</ext-link></td><td valign="top" colspan="1" rowspan="1">29 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">202&#8208;CoV</td><td valign="top" colspan="1" rowspan="1">144</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04990544">NCT04990544</ext-link></td><td valign="top" colspan="1" rowspan="1">4 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">202&#8208;CoV</td><td valign="top" colspan="1" rowspan="1">1056</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20201214049709N3</td><td valign="top" colspan="1" rowspan="1">29 August 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">RAZI&#8208;COV PARS</td><td valign="top" colspan="1" rowspan="1">41,128</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05069129">NCT05069129</ext-link></td><td valign="top" colspan="1" rowspan="1">6 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">1848</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05091411">NCT05091411</ext-link></td><td valign="top" colspan="1" rowspan="1">25 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">1680</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05096845">NCT05096845</ext-link></td><td valign="top" colspan="1" rowspan="1">27 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 fusion protein vaccine (v&#8208;01)</td><td valign="top" colspan="1" rowspan="1">22,500</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05097053">NCT05097053</ext-link></td><td valign="top" colspan="1" rowspan="1">27 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Mvc&#8208;cov1901</td><td valign="top" colspan="1" rowspan="1">200</td><td valign="top" colspan="1" rowspan="1">Phase 4</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100050849</td><td valign="top" colspan="1" rowspan="1">5 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO Cell)</td><td valign="top" colspan="1" rowspan="1">14,600</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04702178">NCT04702178</ext-link></td><td valign="top" colspan="1" rowspan="1">8 January 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">COVAC&#8208;2</td><td valign="top" colspan="1" rowspan="1">108</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04961359">NCT04961359</ext-link></td><td valign="top" colspan="1" rowspan="1">14 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (CHO cell)</td><td valign="top" colspan="1" rowspan="1">75</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04718467">NCT04718467</ext-link></td><td valign="top" colspan="1" rowspan="1">22 January 2021</td><td valign="top" colspan="1" rowspan="1">Cancelled</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Recombinant SARS&#8208;CoV&#8208;2 vaccine (Sf9 Cell)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04806529">NCT04806529</ext-link></td><td valign="top" colspan="1" rowspan="1">19 March 2021</td><td valign="top" colspan="1" rowspan="1">Cancelled</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Adjuvanted SARS&#8208;CoV&#8208;2 subunit vaccine (aCoV2)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0009" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: live attenuated virus (2 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04619628">NCT04619628</ext-link></td><td valign="bottom" colspan="1" rowspan="1">6 November 2020</td><td valign="bottom" colspan="1" rowspan="1">Not recruiting</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">COVI&#8208;VAC</td><td valign="bottom" colspan="1" rowspan="1">48</td><td valign="bottom" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04809389">NCT04809389</ext-link></td><td valign="bottom" colspan="1" rowspan="1">22 March 2021</td><td valign="bottom" colspan="1" rowspan="1">Not recruiting</td><td valign="bottom" colspan="1" rowspan="1">Parallel</td><td valign="bottom" colspan="1" rowspan="1">DelNS1&#8208;nCoV&#8208;RBD LAIV</td><td valign="bottom" colspan="1" rowspan="1">115</td><td valign="bottom" colspan="1" rowspan="1">Phase 1</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0010" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: DNA&#8208;based vaccine (18 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2000038152</td><td valign="top" colspan="1" rowspan="1">11 September 2020</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">INO&#8208;4800 + electroporation</td><td valign="top" colspan="1" rowspan="1">45</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527081">NCT04527081</ext-link></td><td valign="top" colspan="1" rowspan="1">26 August 2020</td><td valign="top" colspan="1" rowspan="1">Completed</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">AG0302&#8208;COVID19</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2020/07/026352</td><td valign="top" colspan="1" rowspan="1">4 July 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Adaptive</td><td valign="top" colspan="1" rowspan="1">nCov vaccine</td><td valign="top" colspan="1" rowspan="1">1048</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/03/032051</td><td valign="top" colspan="1" rowspan="1">16 March 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ZyCov&#8208;D</td><td valign="top" colspan="1" rowspan="1">150</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04655625">NCT04655625</ext-link></td><td valign="top" colspan="1" rowspan="1">7 July 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">AG0302&#8208;COVID19</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04742842">NCT04742842</ext-link></td><td valign="top" colspan="1" rowspan="1">8 February 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">COVIGEN</td><td valign="top" colspan="1" rowspan="1">150</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04993586">NCT04993586</ext-link></td><td valign="top" colspan="1" rowspan="1">6 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">AG0302&#8208;COVID19</td><td valign="top" colspan="1" rowspan="1">80</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">JPRN&#8208;jRCT2051210052</td><td valign="top" colspan="1" rowspan="1">16 July 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">AG0302&#8208;COVID19</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05067946">NCT05067946</ext-link></td><td valign="top" colspan="1" rowspan="1">5 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Gx&#8208;19n</td><td valign="top" colspan="1" rowspan="1">14,000</td><td valign="top" colspan="1" rowspan="1">Phase 2/Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05085639">NCT05085639</ext-link></td><td valign="top" colspan="1" rowspan="1">20 October 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">GLS&#8208;5130</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05102643">NCT05102643</ext-link></td><td valign="top" colspan="1" rowspan="1">1 November 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 DNA vaccine + electroporation</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1">CTRI/2021/01/030416</td><td valign="top" colspan="1" rowspan="1">12 January 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">ZyCov&#8208;D</td><td valign="top" colspan="1" rowspan="1">28,216</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445389">NCT04445389</ext-link></td><td valign="top" colspan="1" rowspan="1">24 June 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">GX&#8208;19</td><td valign="top" colspan="1" rowspan="1">210</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04447781">NCT04447781</ext-link></td><td valign="top" colspan="1" rowspan="1">25 June 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">INO&#8208;4800 + electroporation</td><td valign="top" colspan="1" rowspan="1">160</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04591184">NCT04591184</ext-link></td><td valign="top" colspan="1" rowspan="1">19 October 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Covigenix VAX&#8208;001</td><td valign="top" colspan="1" rowspan="1">72</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04673149">NCT04673149</ext-link></td><td valign="top" colspan="1" rowspan="1">17 December 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">GLS&#8208;5310</td><td valign="top" colspan="1" rowspan="1">345</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05047445">NCT05047445</ext-link></td><td valign="top" colspan="1" rowspan="1">17 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Covidity</td><td valign="top" colspan="1" rowspan="1">40</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04715997">NCT04715997</ext-link></td><td valign="top" colspan="1" rowspan="1">20 January 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">GX&#8208;19N</td><td valign="top" colspan="1" rowspan="1">170</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0011" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: virus&#8208;like particle (12 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">NCT04662697</td><td valign="top" colspan="1" rowspan="1">10 December 2020</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Coronavirus&#8208;like particle COVID&#8208;19 + adjuvant</td><td valign="top" colspan="1" rowspan="1">918</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05040789">NCT05040789</ext-link></td><td valign="top" colspan="1" rowspan="1">10 September 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 VLP vaccine</td><td valign="top" colspan="1" rowspan="1">900</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">JPRN&#8208;jRCT2051210093</td><td valign="top" colspan="1" rowspan="1">28 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Adjuvant + coronavirus&#8208;like particle COVID&#8208;19&#160;</td><td valign="top" colspan="1" rowspan="1">145</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05065619">NCT05065619</ext-link></td><td valign="top" colspan="1" rowspan="1">4 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">Coronavirus&#8208;like particle COVID&#8208;19</td><td valign="top" colspan="1" rowspan="1">145</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">ACTRN12620000817943</td><td valign="top" colspan="1" rowspan="1">14 August 2020</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">RBD SARS&#8208;CoV&#8208;2 HBsAg VLP vaccine</td><td valign="top" colspan="1" rowspan="1">280</td><td valign="top" colspan="1" rowspan="1">Phase 1/Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1">IRCT20210620051639N2</td><td valign="top" colspan="1" rowspan="1">11 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">RBD SARS&#8208;CoV&#8208;2 HBsAg VLP vaccine</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Phase 2&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04935528">NCT04935528</ext-link></td><td valign="top" colspan="1" rowspan="1">23 June 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Single&#8208;group assignment</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;COV&#8208;2 vaccine</td><td valign="top" colspan="1" rowspan="1">430</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04844346">NCT04844346</ext-link></td><td valign="top" colspan="1" rowspan="1">14 April 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine + plant stanol esters</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04818281">NCT04818281</ext-link></td><td valign="top" colspan="1" rowspan="1">26 March 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 VLP vaccine</td><td valign="top" colspan="1" rowspan="1">36</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04962893">NCT04962893</ext-link></td><td valign="top" colspan="1" rowspan="1">15 July 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 VLP vaccine&#8208;Wuhan</td><td valign="top" colspan="1" rowspan="1">330</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04773665">NCT04773665</ext-link></td><td valign="top" colspan="1" rowspan="1">26 February 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Sequential assignment</td><td valign="top" colspan="1" rowspan="1">VBI&#8208;2902a</td><td valign="top" colspan="1" rowspan="1">780</td><td valign="top" colspan="1" rowspan="1">Phase 1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04854876">NCT04854876</ext-link></td><td valign="top" colspan="1" rowspan="1">22 April 2021</td><td valign="top" colspan="1" rowspan="1">Cancelled</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 vaccine + 5&#8208;ALA/SFC</td><td valign="top" colspan="1" rowspan="1">200</td><td valign="top" colspan="1" rowspan="1">Not reported</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0012" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="7" valign="bottom" rowspan="1"><bold>Characteristics of unpublished registered studies: any COVID&#8208;19 vaccine (3 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Registration number</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Registration date</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Status</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Design</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Interventions</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Estimated sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100049467</td><td valign="top" colspan="1" rowspan="1">2 August 2021</td><td valign="top" colspan="1" rowspan="1">Not recruiting</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COVID&#8208;19 vaccine&#160;</td><td valign="top" colspan="1" rowspan="1">1314</td><td valign="top" colspan="1" rowspan="1">Phase 3</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChiCTR2100051297</td><td valign="top" colspan="1" rowspan="1">18 September 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Single&#8208;group assignment</td><td valign="top" colspan="1" rowspan="1">COVID&#8208;19 vaccine</td><td valign="top" colspan="1" rowspan="1">1500</td><td valign="top" colspan="1" rowspan="1">Phase 0</td></tr><tr><td valign="top" colspan="1" rowspan="1">ISRCTN15279830</td><td valign="top" colspan="1" rowspan="1">14 October 2021</td><td valign="top" colspan="1" rowspan="1">Ongoing</td><td valign="top" colspan="1" rowspan="1">Parallel</td><td valign="top" colspan="1" rowspan="1">COVID&#8208;19 vaccine</td><td valign="top" colspan="1" rowspan="1">800</td><td valign="top" colspan="1" rowspan="1">Phase 2</td></tr></tbody></table></table-wrap></p><p>&#160;</p></app><app id="CD015477-sec-0314"><title>Appendix 5. Baseline characteristics of early&#8208;phase studies not included in the analysis</title><p><table-wrap id="CD015477-tblf-0013" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Type of vaccine</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Reference ID</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Register</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Vaccine</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Comparator</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Participants/centre/location</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><bold>RNA&#8208;based vaccine</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0141" ref-type="ref-list">Roozen 2021</xref></td><td valign="top" colspan="1" rowspan="1">NL9275</td><td valign="top" colspan="1" rowspan="1">1&#8208;2</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 20 &#956;g ID</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 20 &#956;g IM</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/the Netherlands</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0111" ref-type="ref-list">Low 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04480957">NCT04480957</ext-link></td><td valign="top" colspan="1" rowspan="1">1&#8208;2</td><td valign="top" colspan="1" rowspan="1">ARCT&#8208;021&#160;<break/>(1 &#956;g; 5 &#956;g; 7.5 &#956;g; 10 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">106</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/Singapore</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0108" ref-type="ref-list">Li 2021b</xref></td><td valign="top" colspan="1" rowspan="1">ChiCTR2000034825<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04523571">NCT04523571</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">BNT162b1 10 &#956;g</td><td valign="top" colspan="1" rowspan="1">BNT162b1 30 &#956;g</td><td valign="top" colspan="1" rowspan="1">144</td><td valign="top" colspan="1" rowspan="1">Healthy young adults/single centre/China&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0120" ref-type="ref-list">Mulligan 2020</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td><td valign="top" colspan="1" rowspan="1">1&#8208;2</td><td valign="top" colspan="1" rowspan="1">BNT162b1 (10 &#956;g; 30 &#956;g; 100 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">45</td><td valign="top" colspan="1" rowspan="1">Healthy adults/2 centres/USA</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Non&#8208;replicating viral vector</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0137" ref-type="ref-list">Ramasamy 2020</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>; ISRCTN, 15281137</td><td valign="top" colspan="1" rowspan="1">2/3</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 (2.2 &#215; 10<sup>10</sup> vp; 1 or 2 doses)</td><td valign="top" colspan="1" rowspan="1">MenACWY</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">Healthy adults/2 centres/UK</td></tr><tr><td rowspan="10" valign="top" colspan="1"><bold>Inactivated virus</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0171" ref-type="ref-list">Wu 2021c</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04552366">NCT04552366</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV 0.2 mL neb 2D</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;nCoV (0.1 mL neb 2D; 0.5 mL IM + 0.2 mL neb; 0.5 mL IM; 1.0 mL IM)</td><td valign="top" colspan="1" rowspan="1">130</td><td valign="top" colspan="1" rowspan="1">Adults/single centre/China<break/>&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0179" ref-type="ref-list">Zhu 2020</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04341389">NCT04341389</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;vectored (1 &#215; 10<sup>11</sup> vp; 5 &#215; 10<sup>10</sup> vp)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">508</td><td valign="top" colspan="1" rowspan="1">Healthy young adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0181" ref-type="ref-list">Zhu 2022</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04566770">NCT04566770</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">Ad5&#8208;vectored (3 &#215; 10<sup>10</sup> vp)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Healthy children and adolescents/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0071" ref-type="ref-list">Che 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04412538">NCT04412538</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">KMS&#8208;1 (100 EU; 150 EU) D0/14; D0/28<break/>KMS&#8208;1</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">750</td><td valign="top" colspan="1" rowspan="1">Healthy adults/2 centres/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0107" ref-type="ref-list">Lazarus 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04671017">NCT04671017</ext-link>, ISRCTN 82411169</td><td valign="top" colspan="1" rowspan="1">1&#8208;2</td><td valign="top" colspan="1" rowspan="1">VL A2001 3 AU<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">VL A2001 35 AU; 7 AU</td><td valign="top" colspan="1" rowspan="1">153</td><td valign="top" colspan="1" rowspan="1">Healthy adults/4 centres/UK</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0129" ref-type="ref-list">Pan 2021a</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04758273">NCT04758273</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">KCONVAC 5 &#956;g</td><td valign="top" colspan="1" rowspan="1">KCONVAC 10 &#956;g</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0129" ref-type="ref-list">Pan 2021a</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04756323">NCT04756323</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">KCONVAC (5 &#956;g; 10 &#956;g)<break/>(D0/14; D0/28)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">500</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0132" ref-type="ref-list">Pitisuttithum 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04764422">NCT04764422</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NDV&#8208;HXP&#8208;S (1 &#956;g; 1 &#956;g + CpG1018; 3 &#956;g; 3 &#956;g + CpG1018; 10 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">210</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/Thailand</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0135" ref-type="ref-list">Pu 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04412538">NCT04412538</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">KMS&#8208;1 100 EU D0/14; D0/28</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">192</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0175" ref-type="ref-list">Zakarya 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530357">NCT04530357</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">QazCovid&#8208;in</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">44</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/Kazakhstan</td></tr><tr><td rowspan="14" valign="top" colspan="1"><bold>Protein subunit</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0070" ref-type="ref-list">Chappell 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04495933">NCT04495933</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">SARS&#8208;CoV&#8208;2 Sclamp&#160;<break/>(5 &#956;g; 15 &#956;g; 45 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/Australia</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0094" ref-type="ref-list">Goepfert 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537208">NCT04537208</ext-link></td><td valign="top" colspan="1" rowspan="1">1&#8208;2</td><td valign="top" colspan="1" rowspan="1">CoV2 preS dTM LD + AFO3<break/>CoV2 preS dTM LD + ASO3<break/>CoV2 preS dTM HD + AFO3<break/>CoV2 preS dTM HD + ASO3<break/>CoV2 preS dTM HD</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">271</td><td valign="top" colspan="1" rowspan="1">Healthy adults/10 centres/USA</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0047" ref-type="ref-list">Hsieh 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04695652">NCT04695652</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">MVC&#8208;COV1901</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">3854</td><td valign="top" colspan="1" rowspan="1">Healthy adults/11 centres/Taiwan</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0178" ref-type="ref-list">Zhang 2021b</xref></td><td valign="top" colspan="1" rowspan="1">ChiCTR2100045108</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">V&#8208;01 (10 &#956;g; 25 &#956;g; 50 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">180</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0118" ref-type="ref-list">Meng 2021b</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530656">NCT04530656</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">Sf9 cells vaccine (low dose in 2 doses; high dose in 2 or 3 doses)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">168</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0118" ref-type="ref-list">Meng 2021b</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04640402">NCT04640402</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">Sf9 cells vaccine (low dose or high dose in 2 or 3 doses)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">960</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0121" ref-type="ref-list">Nguyen 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04683484">NCT04683484</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">Nanocovax&#160;<break/>(25 &#956;g; 50 &#956;g; 75 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">560</td><td valign="top" colspan="1" rowspan="1">Healthy adults/2 centres/Vietnam</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0121" ref-type="ref-list">Nguyen 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04683484">NCT04683484</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">Nanocovax&#160;<break/>(25 &#956;g; 50 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Nanocovax 75 &#956;g</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Healthy adults/2 centres/Vietnam</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0138" ref-type="ref-list">Richmond 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405908">NCT04405908</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">SCB&#8208;2019&#160;<break/>(3 &#956;g; 3 &#956;g + AS03; 3 &#956;g + CpG/Alum; 9 &#956;g; 9 &#956;g + AS03 9 &#956;g + CpG/Alum; 30 &#956;g; 30 &#956;g + AS03; 30 &#956;g + CpG/Alu)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">151</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/Australia</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0146" ref-type="ref-list">Ryzhikov 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527575">NCT04527575</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">EpiVacCorona</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">86</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/Russia</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0152" ref-type="ref-list">Shu 2021</xref></td><td valign="top" colspan="1" rowspan="1">ChiCTR2100045107</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">V&#8208;01 (10 &#956;g; 25 &#956;g; 50 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">880</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0153" ref-type="ref-list">Sridhar 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04762680">NCT04762680</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">CoV2 preS dTM (15 &#181;g; 10 &#181;g)</td><td valign="top" colspan="1" rowspan="1">CoV2 preS dTM 5 &#181;g</td><td valign="top" colspan="1" rowspan="1">722</td><td valign="top" colspan="1" rowspan="1">Adults with and without prior SARS&#8208;CoV&#8208;2 infection and risk factors for severe disease/20 centres/USA and Honduras</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0173" ref-type="ref-list">Yang 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04466085">NCT04466085</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">ZF2001 (25 &#956;g 2 doses; 50 &#956;g 2 doses; 25 &#956;g 3 doses; 50 &#956;g 3 doses)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">900</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0173" ref-type="ref-list">Yang 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445194">NCT04445194</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">ZF2001 (25 &#956;g 3 doses; 50 &#956;g 3 dose)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>DNA&#8208;based vaccine</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0115" ref-type="ref-list">Mammen 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04642638">NCT04642638</ext-link></td><td valign="top" colspan="1" rowspan="1">&#160;</td><td valign="top" colspan="1" rowspan="1">INO&#8208;4800 (1 mg; 2 mg) D0/28<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">201</td><td valign="top" colspan="1" rowspan="1">Healthy adults/19 centres/USA</td></tr><tr><td rowspan="2" valign="top" colspan="1"><bold>Virus&#8208;like particle (VLP)</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0093" ref-type="ref-list">Gobeil 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04636697">NCT04636697</ext-link></td><td valign="top" colspan="1" rowspan="1">&#160;</td><td valign="top" colspan="1" rowspan="1">CoVLP 3.75 &#956;g + AS03</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">753</td><td valign="top" colspan="1" rowspan="1">Healthy adults/multiple centres/Canada and USA&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0162" ref-type="ref-list">Ward 2021b</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04450004">NCT04450004</ext-link></td><td valign="top" colspan="1" rowspan="1">&#160;</td><td valign="top" colspan="1" rowspan="1">CoVLP (3.75 &#956;g with CpG1018, AS03 or without adjuvant; 7.5 &#956;g with CpG1018, AS03 or without adjuvant; 15 &#956;g with CpG1018, AS03 or without adjuvant)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">180</td><td valign="top" colspan="1" rowspan="1">Canada</td></tr></tbody></table></table-wrap></p><p>&#160;</p></app><app id="CD015477-sec-0315"><title>Appendix 6. Baseline characteristics of studies with no outcomes of interest or not extractable</title><p><table-wrap id="CD015477-tblf-0014" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="8" valign="top" rowspan="1"><bold>Reports of trials not included in the analysis (5 studies)</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Type of vaccine</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Reference</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Register</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Phase</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Vaccine</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Comparator</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Sample size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Population/centre/location</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>RNA&#8208;based vaccine</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0072" ref-type="ref-list">Chu 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405076">NCT04405076</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 (50 &#956;g; 100 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Healthy adults/8 centres/USA</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Inactivated virus</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0088" ref-type="ref-list">Feng 2021</xref></td><td valign="top" colspan="1" rowspan="1">ChiCTR2100041705; ChiCTR2100041706</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV D0/14; D0/21</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV D0/28</td><td valign="top" colspan="1" rowspan="1">809</td><td valign="top" colspan="1" rowspan="1">Healthy adults /single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Protein subunit</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0131" ref-type="ref-list">P&#233;rez&#8208;Rodr&#237;guez 2021</xref></td><td valign="top" colspan="1" rowspan="1">RPCEC00000338&#8208;En</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;1A (25 &#956;g; 50 &#956;g)</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;1</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/Cuba</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Heterologous scheme</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0059" ref-type="ref-list">Borobia 2021</xref></td><td valign="top" colspan="1" rowspan="1">NCT04860739; EudraCT2021&#8208;001978</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">BNT162b2 after 1 dose ChAdOx1&#8208;S &#8211; 1 IM dose 30 &#956;g/0.3 mL BNT162b2 8&#8208;12 weeks after 1 dose ChAdOx1&#8208;S</td><td valign="top" colspan="1" rowspan="1">No second vaccine dose</td><td valign="top" colspan="1" rowspan="1">676</td><td valign="top" colspan="1" rowspan="1">Adults/multicentre/Spain</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Non&#8208;replicating viral vector/inactivated virus</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0055" ref-type="ref-list">Angkasekwinai 2022</xref></td><td valign="top" colspan="1" rowspan="1">TCTR20210720002</td><td valign="top" colspan="1" rowspan="1">&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac 3 &#956;g&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 (5 &#215; 10<sup>10</sup> vp)</td><td valign="top" colspan="1" rowspan="1">360</td><td valign="top" colspan="1" rowspan="1">Healthcare workers/single centre/Thailand</td></tr><tr><td colspan="8" valign="top" rowspan="1"><bold>Reports of trials already included in the analysis (7 studies)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>RNA&#8208;based vaccine</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0128" ref-type="ref-list">Pajon 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link></td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">791</td><td valign="top" colspan="1" rowspan="1">Healthy adults/99 centres/USA</td></tr><tr><td rowspan="2" valign="top" colspan="1"><bold>Non&#8208;replicating viral vector</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0160" ref-type="ref-list">Voysey 2021b</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>; ISRCTN89951424; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link></td><td valign="top" colspan="1" rowspan="1">1/2/3</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 (5 &#215; 10<sup>10</sup> vp or 2.2 &#215; 10<sup>10</sup> vp)</td><td valign="top" colspan="1" rowspan="1">Placebo/MenACWY&#160;</td><td valign="top" colspan="1" rowspan="1">17, 177</td><td valign="top" colspan="1" rowspan="1">Adults/multicentre/Brazil, South Africa and UK</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0154" ref-type="ref-list">Stephenson 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436276">NCT04436276</ext-link></td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">10</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/USA</td></tr><tr><td rowspan="4" valign="top" colspan="1"><bold>Inactivated virus</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0130" ref-type="ref-list">Pan 2021b</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">CoronaVac (3 doses, 4 different schedules, 3 &#956;g and 6 &#956;g)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">600</td><td valign="top" colspan="1" rowspan="1">Healthy adults/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0080" ref-type="ref-list">Ella 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">6 &#956;g BBV152 + Algel&#8208;IMDG</td><td valign="top" colspan="1" rowspan="1">3 &#956;g BBV152 + Algel&#8208;IMDG</td><td valign="top" colspan="1" rowspan="1">380</td><td valign="top" colspan="1" rowspan="1">Healthy adults/9 centres/India</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0109" ref-type="ref-list">Li 2021c</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link></td><td valign="top" colspan="1" rowspan="1">1/2</td><td valign="top" colspan="1" rowspan="1">CoronaVac (3 doses)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">350</td><td valign="top" colspan="1" rowspan="1">Healthy adults aged &#8805; 60 years/single centre/China</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0079" ref-type="ref-list">Ella 2020b</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link></td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">6 &#956;g BBV152 + Algel&#8208;IMDG</td><td valign="top" colspan="1" rowspan="1">3 &#956;g BBV152 + Algel&#8208;IMDG</td><td valign="top" colspan="1" rowspan="1">380</td><td valign="top" colspan="1" rowspan="1">Healthy adults/9 centres/India</td></tr></tbody></table></table-wrap></p></app><app id="CD015477-sec-0316"><title>Appendix 7. List of previous publications later updated</title><p><table-wrap id="CD015477-tblf-0015" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Reference/study ID</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Registry</bold></td></tr><tr><td rowspan="6" valign="top" colspan="1"><bold>RNA&#8208;based vaccine</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0084" ref-type="ref-list">FDA 2020b</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0057" ref-type="ref-list">Baden 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0161" ref-type="ref-list">Walsh 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0156" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0085" ref-type="ref-list">FDA 2020c</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0133" ref-type="ref-list">Polack 2020</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td></tr><tr><td rowspan="4" valign="top" colspan="1"><bold>Non&#8208;replicating viral vector</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0113" ref-type="ref-list">Madhi 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0089" ref-type="ref-list">Folegatti 2020</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0086" ref-type="ref-list">FDA 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505722">NCT04505722</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0147" ref-type="ref-list">Sadoff 2020c</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436276">NCT04436276</ext-link></td></tr><tr><td rowspan="3" valign="top" colspan="1"><bold>Inactivated virus</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0063" ref-type="ref-list">Bueno 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04651790">NCT04651790</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0172" ref-type="ref-list">Xia 2020</xref></td><td valign="top" colspan="1" rowspan="1">ChiCTR2000031809</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0090" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link></td></tr><tr><td rowspan="2" valign="top" colspan="1"><bold>Protein subunit</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0151" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04533399">NCT04533399</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0099" ref-type="ref-list">Heath 2021&#160;</xref></td><td valign="top" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04583995">NCT04583995</ext-link></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Heterologous schedule</bold></td><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0110" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">ISRCTN69254139</td></tr></tbody></table></table-wrap></p></app><app id="CD015477-sec-0317"><title>Appendix 8. Risk of bias assessments</title><sec id="CD015477-sec-0318"><title>RNA&#8208;based vaccines</title><sec id="CD015477-sec-0319"><title>BNT162b2 &#8211; BioNTech/Fosun Pharma/Pfizer versus placebo</title><sec id="CD015477-sec-0320"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0016" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "observer&#8208;blinded" (report) &#8220;Masking: Triple (Participant, Care Provider, Investigator)&#8221; (registry)&#8232;Comment: blinded study (participants, personnel, investigators). Per&#8208;protocol analysis as planned in the trial protocol) was performed on the outcomes: 'confirmed symptomatic COVID'. As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;Risk assessed as some concerns for this outcome.&#160;</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "observer blinded"&#8232;Comment: blinded study (participants and personnel/carers)&#8232;Per&#8208;protocol analysis was performed on the outcome: 'confirmed symptomatic COVID'.&#8232;Reasons for exclusion: positive at baseline (689 versus 716) not received 2 vaccinations as randomized (326 versus 430)&#8232;Reasons for exclusion in the 12&#8211;15&#8208;year group not reported&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0321"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0017" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0322"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0018" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0323"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0019" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0324"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0020" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;&#160;</p></sec></sec><sec id="CD015477-sec-0325"><title>mRNA&#8208;1273 &#8211; ModernaTX versus placebo&#160;</title><sec id="CD015477-sec-0326"><title>SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p><table-wrap id="CD015477-tblf-0021" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The investigators and trial staff, participants, site monitors, and sponsor personnel (or its designees) were unaware of the trial vaccine administered until unblinding of the trial data as specified in the protocol; however, pharmacists and vaccine administrators who were involved in injection preparation and administration and who had no other role in trial conduct were aware of these assignments."&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Data for this outcome were analyzed using modified intention&#8208;to&#8208;treat or per protocol analysis. As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately. There was probably no substantial impact of failure to analyse participants according to their randomized assignment.&#8232;Reasons for exclusion: mITT &#8211; did not receive at least one dose, had serological or virological evidence of previous SARS&#8208;CoV&#8208;2 infection before the first injection, received wrong injection; per protocol &#8211; did not receive planned injections of mRNA&#8208;1273 or placebo, did not comply with the timing of the second injection, had immunological or virological evidence of previous COVID&#8208;19 at baseline, and major protocol deviations.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The investigator, study staff, study participants, site monitors, and Sponsor personnel (or its designees) will be blinded to the IP administered until study end." (protocol) "Masking: quadruple (participant, care provider, investigator, outcomes assessor." (registry)&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;Reasons for exclusions were balanced between treatment groups (922 (6.1%) versus 1042 (6.9%)), with the majority of those excluded due to positive or unknown baseline SARS&#8208;CoV&#8208;2 status (434 versus 421). Other reasons: did not receive any injection (29 versus 40), received an incorrect injection (6 versus 7), discontinued without receiving second dose (334 versus 425), received dose 2 outside planned time frame (102 versus 119), other major protocol deviation (17 versus 30).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately. There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.</p></sec><sec id="CD015477-sec-0327"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0022" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The investigators and trial staff, participants, site monitors, and sponsor personnel (or its designees) were unaware of the trial vaccine administered until unblinding of the trial data as specified in the protocol; however, pharmacists and vaccine administrators who were involved in injection preparation and administration and who had no other role in trial conduct were aware of these assignments."&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Data for this outcome were analyzed using modified intention&#8208;to&#8208;treat or per protocol analysis. As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately. There was probably no substantial impact of failure to analyse participants according to their randomized assignment.&#8232;Reasons for exclusion: mITT &#8211; did not receive at least one dose, had serological or virological evidence of previous SARS&#8208;CoV&#8208;2 infection before the first injection, received wrong injection; per protocol &#8211; did not receive planned injections of mRNA&#8208;1273 or placebo, did not comply with the timing of the second injection, had immunological or virological evidence of previous COVID&#8208;19 at baseline, and major protocol deviations.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#160;&#8232;Quote: "The investigator, study staff, study participants, site monitors, and Sponsor personnel (or its designees) will be blinded to the IP administered until study end." (protocol) "Masking: quadruple (participant, care provider, investigator, outcomes assessor." (registry)&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;Reasons for exclusions were balanced between treatment groups (922 (6.1%) versus 1042 (6.9%)), with the majority of those excluded due to positive or unknown baseline SARS&#8208;CoV&#8208;2 status (434 versus 421). Other reasons: did not receive any injection (29 versus 40), received an incorrect injection (6 versus 7), discontinued without receiving second dose (334 versus 425), received dose 2 outside planned time frame (102 versus 119), other major protocol deviation (17 versus 30).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately. There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0328"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0023" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "The investigator, study staff, study participants, site monitors, and Sponsor personnel (or its designees) will be blinded to the IP administered until study end." (protocol) "Masking: quadruple (participant, care provider, investigator, outcomes assessor." (registry)&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;Reasons for exclusions were balanced between treatment groups (922 (6.1%) versus 1042 (6.9%)), with the majority of those excluded due to positive or unknown baseline SARS&#8208;CoV&#8208;2 status (434 versus 421). Other reasons: did not receive any injection (29 versus 40), received an incorrect injection (6 versus 7), discontinued without receiving second dose (334 versus 425), received dose 2 outside planned time frame (102 versus 119), other major protocol deviation (17 versus 30).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately. There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0329"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0024" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0330"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0025" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0331"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0026" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0332"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0027" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;&#160;</p></sec></sec><sec id="CD015477-sec-0333"><title>CVnCoV &#8211; CureVac AG versus placebo</title><sec id="CD015477-sec-0334"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0028" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Low</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "Due to the difference in appearance and presentation between the CVnCoV vaccine candidate and placebo, site personnel involved in preparing and administering the vaccine were not involved in the further conduct of the trial, and investigators, site personnel, and others directly involved in the conduct of the trial were blinded to participant treatment for the duration of the trial."&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the outcome: confirmed symptomatic COVID&#8208;19.&#8232;Analyses were carried out on participants who received both doses of CVnCoV or placebo according to their treatment allocation, who had not developed virologically confirmed COVID&#8208;19 before day 43 (15 days after the second dose), and who were SARS&#8208;CoV&#8208;2 na&#239;ve at baseline and day 43.&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to these being standard reasons from exclusion from per&#8208;protocol analyses. Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0335"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0029" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "Due to the difference in appearance and presentation between the CVnCoV vaccine candidate and placebo, site personnel involved in preparing and administering the vaccine were not involved in the further conduct of the trial, and investigators, site personnel, and others directly involved in the conduct of the trial were blinded to participant treatment for the duration of the trial."&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the outcome: severe confirmed COVID&#8208;19.&#8232;Analyses were carried out on participants who received both doses of CVnCoV or placebo according to their treatment allocation, who had not developed virologically confirmed COVID&#8208;19 before day 43 (15 days after the second dose), and who were SARS&#8208;CoV&#8208;2 na&#239;ve at baseline and day 43.&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to these being standard reasons from exclusion from per&#8208;protocol analyses. Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0336"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0030" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0337"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0031" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0338"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0032" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0339"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0033" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec></sec></sec><sec id="CD015477-sec-0340"><title>Non&#8208;replicating viral vector&#160;</title><sec id="CD015477-sec-0341"><title>ChAdOx1/SII&#8208;ChAdOx1 nCoV&#8208;19 &#8211; AstraZeneca + University of Oxford &#160;versus placebo/MenACWY</title><sec id="CD015477-sec-0342"><title>SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p><table-wrap id="CD015477-tblf-0034" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "double&#8208;blind"&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed for the outcome: confirmed COVID&#8208;19.&#160;&#8232;Reasons for exclusion: did not receive first dose: 52 (0.2%) versus 20 (0.2%), had a positive, missing, or indeterminate serostatus at baseline: 1046 (4.8%) versus 516 (4.8%); were followed for &lt; 15 days after second dose: 2206 (10.2%) versus 920 (8.5%); had confirmed SARS&#8208;CoV&#8208;2 RT&#8208;PCR&#8211;positive COVID&#8208;19 infection &lt; 15 days after second dose: 73 (0.3%) versus 69 (0.6%).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to similar levels of and reasons for exclusion in either arm.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "three single&#8208;blind randomized controlled trials in the UK (COV001/COV002), Brazil (COV003), and one double&#8208;blind study in South Africa (COV005)"&#8232;Comment: blinded studies (patients in 3 trials, patients and physicians in 1 trial).&#8232;No participant cross&#8208;over.&#8232;Per&#8208;protocol analysis (as planned in the trial protocol) was performed on the outcomes: confirmed COVID&#8208;19.&#160;&#8232;Reasons for exclusions: in non&#8208;randomized open&#8208;label group; in HIV cohorts; not enrolled in an efficacy cohort; not in SD/SD or LD/SD vaccine group; baseline seropositivity results unavailable; baseline seropositivity results positive; Vaccine administration errors; Less than 15 days of follow&#8208;up accrued post second dose; PCR+ test &lt; 14 days post&#8208;second dose&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance in the number of exclusions.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0343"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0035" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quotes: "double&#8208;blind"&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed for the outcome: confirmed COVID&#8208;19.&#8232;Reasons for exclusion: did not receive first dose: 52 (0.2%) versus 20 (0.2%), had a positive, missing, or indeterminate serostatus at baseline: 1046 (4.8%) versus 516 (4.8%); were followed for &lt; 15 days after second dose: 2206 (10.2%) versus 920 (8.5%); had confirmed SARS&#8208;CoV&#8208;2 RT&#8208;PCR&#8211;positive COVID&#8208;19 infection &lt; 15 days after second dose: 73 (0.3%) versus 69 (0.6%).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to similar levels of and reasons for exclusion in either arm.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "three single&#8208;blind randomized controlled trials in the UK (COV001/COV002), Brazil (COV003), and one double&#8208;blind study in South Africa (COV005)"&#8232;Comment: blinded studies (patients in 3 trials, patients and physicians in 1 trial).&#8232;No participant cross&#8208;over.&#8232;Per&#8208;protocol analysis (as planned in the trial protocol) was performed on the outcomes: confirmed COVID&#8208;19.&#8232;Reasons for exclusions: in non&#8208;randomized open&#8208;label group; in HIV cohorts; not enrolled in an efficacy cohort; not in SD/SD or LD/SD vaccine group; baseline seropositivity results unavailable; baseline seropositivity results positive; Vaccine administration errors; Less than 15 days of follow&#8208;up accrued post second dose; PCR+ test &lt; 14 days post&#8208;second dose&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance in the number of exclusions.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0344"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0036" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref><bold>, RoB 5. Selection of the reported results:&#160;</bold>&#8232;Comment: the trial registry was available (registered prospectively on 15 August 2020).&#8232;No information on whether the result was selected from multiple outcome measurements or analyses of the data.&#8232;Trial probably not analyzed as prespecified.&#8232;Risk assessed as some concerns for this outcome. Outcome not prespecified.</p></sec><sec id="CD015477-sec-0345"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0037" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0346"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0038" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0347"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0039" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0348"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0040" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec></sec><sec id="CD015477-sec-0349"><title>Ad26.COV2.S &#8211; Janssen Pharmaceutical Companies versus placebo</title><sec id="CD015477-sec-0350"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0041" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Quadruple (participant, care provider, investigator, outcomes assessor)."&#8232;Comment: blinded study (participants and personnel/carers)&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;Reasons for exclusion: positive SARS&#8208;CoV&#8208;2 status at time of vaccination based on serology or PCR (or both); major protocol deviation evaluated to possibly impact efficacy (inclusion/exclusion criteria; received wrong treatment or incorrect dose; received a disallowed concomitant medication; other).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0351"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0042" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Quadruple (participant, care provider, investigator, outcomes assessor)."&#8232;Comment: blinded study (participants and personnel/carers)&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;Reasons for exclusion: positive SARS&#8208;CoV&#8208;2 status at time of vaccination based on serology or PCR (or both); major protocol deviation evaluated to possibly impact efficacy (in/exclusion criteria; received wrong treatment or incorrect dose; received a disallowed concomitant medication; other)&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0352"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0043" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0353"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0044" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Quadruple (participant, care provider, investigator, outcomes assessor)."&#8232;Comment: blinded study (participants and personnel/carers)&#8232;Adverse events (solicited and unsolicited) were monitored in a safety subset of volunteers in centres (as planned in the trial protocol).&#8232;Reasons: centres selected based on rapid start&#8208;up capacity and projected incidence rates for COVID&#8208;19 that would allow for rapid efficacy signal detection&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to:</p><p><list id="CD015477-list-0028" list-type="bullet"><list-item><p>the safety subset was prespecified and the researchers are transparent about any differences between the safety subset and the overall population;</p></list-item><list-item><p>furthermore, it was used as a way to gather detailed data on solicited local/systemic adverse events for the 7 days after each injection. All participants were trained in assessing and reporting events by study staff. All data was transferred automatically to the centres using e&#8208;diaries. As a result, the participants were all at a subset of centres that had sufficient research capacity, which we considered a reasonable logistical decision. Risk assessed to have some concerns for this outcome.&#160;</p></list-item></list></p></sec><sec id="CD015477-sec-0354"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0045" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Quadruple (participant, care provider, investigator, outcomes assessor)."&#8232;Comment: blinded study (participants and personnel/carers)&#8232;Adverse events (solicited and unsolicited) were monitored in a safety subset of volunteers in centres (as planned in the trial protocol).&#8232;Reasons: centres selected based on rapid start&#8208;up capacity and projected incidence rates for COVID&#8208;19 that would allow for rapid efficacy signal detection&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to:</p><p><list id="CD015477-list-0029" list-type="bullet"><list-item><p>the safety subset was prespecified and the researchers are transparent about any differences between the safety subset and the overall population;</p></list-item><list-item><p>furthermore, it was used as a way to gather detailed data on solicited local/systemic adverse events for the 7 days after each injection. All participants were trained in assessing and reporting events by study staff. All data was transferred automatically to the centres using e&#8208;diaries. As a result, the participants were all at a subset of centres that had sufficient research capacity, which we considered a reasonable logistical decision. Risk assessed to have some concerns for this outcome.&#160;</p></list-item></list></p></sec><sec id="CD015477-sec-0355"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0046" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low&#160;</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec></sec><sec id="CD015477-sec-0356"><title>Gam&#8208;COVID&#8208;Vac (Sputnik V) &#8211; Gamaleya Research Institute versus placebo</title><sec id="CD015477-sec-0357"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0047" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "Investigators, participants, and all study staff were masked to group assignment."&#8232;Comment: blinded study (participants, personnel/carers).&#8232;Patients were excluded from analysis due to protocol violations such as vaccine administration error, not meeting eligibility criteria, receipt of other vaccines, error in date of second dose, skipped visits.&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0358"><title>Severe or critical COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0048" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Investigators, participants, and all study staff were masked to group assignment."&#8232;Comment: blinded study (participants, personnel/carers).&#8232;Patients were excluded from analysis due to protocol violations such as vaccine administration error, not meeting eligibility criteria, receipt of other vaccines, error in date of second dose, skipped visits.&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.</p></sec><sec id="CD015477-sec-0359"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0049" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Investigators, participants, and all study staff were masked to group assignment."&#8232;Comment: blinded study (participants, personnel/carers).&#8232;Patients were excluded from analysis due to protocol violations such as vaccine administration error, not meeting eligibility criteria, receipt of other vaccines, error in date of second dose, skipped visits.&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.</p></sec><sec id="CD015477-sec-0360"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0050" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Investigators, participants, and all study staff were masked to group assignment."&#8232;Comment: blinded study (participants, personnel/carers).&#8232;Patients were excluded from analysis due to protocol violations such as vaccine administration error, not meeting eligibility criteria, receipt of other vaccines, error in date of second dose, skipped visits.&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment due to the small number.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec></sec></sec><sec id="CD015477-sec-0361"><title>Inactivated virus</title><sec id="CD015477-sec-0362"><title>CoronaVac &#8211; Sinovac versus adjuvant</title><sec id="CD015477-sec-0363"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0051" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Participants and all other study staff as well as monitors, lab technicians, and data management team remained unaware of the product allocation."&#160;&#8232;Comment: blinded study (participants, personnel, investigators).&#160;&#8232;Per&#8208;protocol analysis (as planned in the trial protocol was performed on the outcome: confirmed symptomatic COVID&#8208;19.&#160;&#8232;65 (1.0%) versus 74 (1.2%) participants were excluded due to protocol violations, reasons for exclusions: not eligible (0 versus 1), received 3rd dose or incorrect injection (11 versus 8), out of window for per&#8208;protocol analysis (54 versus 65).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance of the exclusions between arms.&#160;&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Participants and practitioners were masked to the group allocation. The masking was removed in the event of a medical emergency requiring acute intervention, upon the responsible investigator's approval and the data and safety monitoring board's knowledge." "the placebo and study vaccine looked exactly the same, they were administered by staff masked to group allocation."&#160;&#8232;Comment: blinded study (participants, staff, investigators).&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#160;&#8232;69 (1%) versus 86 (2.4%) participants were excluded from the efficacy analysis post&#8208;randomization because of protocol violations: positive for SARS&#8208;CoV&#8208;2 (60 (0.9%) versus 35 (1%)), unmasked before the second dose (due to emergency use authorization and commencement of community vaccination) (4 (0.06%) versus 45 (1.3%)), received incorrect injection (1 (0.02%) versus 4 (0.1%)), had protocol violations (2 (0.03%) versus 0), pregnant (2 (0.03%) versus 1 (0.03%)), withdrawn by study investigator (0 versus 1 (0.03%)).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), this method was considered inappropriate to estimate the effect of assignment to intervention. Although reasons for exclusions were not balanced between treatment groups, there was probably no substantial impact of failure to analyse participants according to their randomized groups since the imbalance was due to unmasking and subsequent vaccination after emergency use authorization.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0364"><title>Severe or critical COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0052" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Participants and all other study staff as well as monitors, lab technicians, and data management team remained unaware of the product allocation"&#8232;Comment: blinded study (participants, personnel, investigators).&#8232;Per&#8208;protocol analysis (as planned in the trial protocol was performed on the outcome: confirmed symptomatic COVID&#8208;19.&#8232;65 (1.0%) versus 74 (1.2%) participants were excluded due to protocol violations, reasons for exclusions: not eligible (0 versus 1), received 3rd dose or incorrect injection (11 versus 8), out of window for per&#8208;protocol analysis (54 versus 65).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance of the exclusions between arms.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "Participants and practitioners were masked to the group allocation. The masking was removed in the event of a medical emergency requiring acute intervention, upon the responsible investigator's approval and the data and safety monitoring board's knowledge." "the placebo and study vaccine looked exactly the same, they were administered by staff masked to group allocation."&#8232;Comment: blinded study (participants, staff, investigators).&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;69 (1%) versus 86 (2.4%) participants were excluded from the efficacy analysis post&#8208;randomization because of protocol violations: positive for SARS&#8208;CoV&#8208;2 (60 (0.9%) versus 35 (1%)), unmasked before the second dose (due to emergency use authorization and commencement of community vaccination) (4 (0.06%) versus 45 (1.3%)), received incorrect injection (1 (0.02%) versus 4 (0.1%)), had protocol violations (2 (0.03%) versus 0), pregnant (2 (0.03%) versus 1 (0.03%)), withdrawn by study investigator (0 versus 1 (0.03%)).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), this method was considered inappropriate to estimate the effect of assignment to intervention. Although reasons for exclusions were not balanced between treatment groups, there was probably no substantial impact of failure to analyse participants according to their randomized groups since the imbalance was due to unmasking and subsequent vaccination after emergency use authorization.&#8232;Risk assessed to have some concerns for this outcome.</p></sec><sec id="CD015477-sec-0365"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0053" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0366"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0054" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><sup>a</sup></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><sup>a</sup></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>c</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>d</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>e</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>f</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><sup>a</sup><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref>&#160;reported two different comparisons/sets of participants.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "no specific randomization was used when allocating participants to the vaccinations schedule cohorts." "The randomization codes for each vaccination schedule cohort were generated individually, using block randomization with a block size of six in phase 1 and a block size of five in phase 2, using SAS software (version 9.4). The randomization code was assigned to each participant in sequence in the order of enrolment, and then the participants received the investigational products labelled with the same code."&#8232;Comment: no specific randomization between schedule cohorts. The allocation sequence between vaccine groups and placebo was generated adequately. Unclear allocation concealment.&#8232;Risk assessed as some concerns</p><p><bold><sup>c</sup></bold><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "no specific randomization was used when allocating participants to the vaccinations schedule cohorts." "In phase 1, participants in blocks 1 and 2 in each schedule cohort were randomly assigned (2:1) to either CoronaVac or placebo." "The randomization codes for each vaccination schedule cohort were generated individually, using block randomization with a block size of six in phase 1 and a block size of five in phase 2, using SAS software (version 9.4). The randomization code was assigned to each participant in sequence in the order of enrolment, and then the participants received the investigational products labelled with the same code."&#8232;Comment: no specific randomization between schedule cohorts or between low&#8208;dose and high&#8208;dose arms. The allocation sequence between vaccine groups and placebo was generated adequately. Unclear allocation concealment. Imbalances in baseline characteristics appear to be compatible with chance.&#8232;Risk assessed as some concerns.</p><p><bold><sup>d</sup></bold><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Volunteers were randomly assigned to immunization with CoronaVac or injection with placebo in a 1:1 ratio. A subgroup of volunteers was assigned to the immunogenicity arm and randomly received CoronaVac or placebo (3:1 ratio). Randomization was done using a sealed enveloped system integrated into the electronic Case Report Forms (eCRF) in the OpenClinica platform."&#8232;Comment: authors report 1:1 allocation ratio for intervention/control group. However, in the flow chart and result tables there are 290 participants in the vaccine group and 164 in the control group.&#8232;Comment: allocation sequence concealed. Allocation sequence unclear. Baseline characteristics not reported by arm. Risk assessed as some concerns.</p><p><bold><sup>e</sup></bold><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Double&#8208;blind."&#8232;Comment: blinded study (participants and outcome assessors)&#8232;Safety outcomes were monitored in a safety subset (first 540 participants randomized).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants all participants according to their randomized assignment&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>f</sup></bold><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref><bold>, RoB 5. Selection of the reported results:&#160;</bold>&#8232;Comment: the prospective registry was available (12 May 2020). The outcome: systemic adverse events was not prespecified.&#8232;No information on whether the result was selected from multiple outcome measurements or analyses of the data. Trial not analyzed as prespecified. Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0367"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0055" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "no specific randomization was used when allocating participants to the vaccinations schedule cohorts." "The randomization codes for each vaccination schedule cohort were generated individually, using block randomization with a block size of six in phase 1 and a block size of five in phase 2, using SAS software (version 9.4). The randomization code was assigned to each participant in sequence in the order of enrolment, and then the participants received the investigational products labelled with the same code."&#8232;Comment: no specific randomization between schedule cohorts. The allocation sequence between vaccine groups and placebo was generated adequately. Unclear allocation concealment.&#8232;Risk assessed as some concerns</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "no specific randomization was used when allocating participants to the vaccinations schedule cohorts." "In phase 1, participants in blocks 1 and 2 in each schedule cohort were randomly assigned (2:1) to either CoronaVac or placebo." "The randomization codes for each vaccination schedule cohort were generated individually, using block randomization with a block size of six in phase 1 and a block size of five in phase 2, using SAS software (version 9.4). The randomization code was assigned to each participant in sequence in the order of enrolment, and then the participants received the investigational products labelled with the same code."&#8232;Comment: no specific randomization between schedule cohorts or between low&#8208;dose and high&#8208;dose arms. The allocation sequence between vaccine groups and placebo was generated adequately. Unclear allocation concealment. Imbalances in baseline characteristics appear to be compatible with chance. Risk assessed as some concerns.&#160;</p></sec><sec id="CD015477-sec-0368"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0056" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Volunteers were randomly assigned to immunization with CoronaVac or injection with placebo in a 1:1 ratio. A subgroup of volunteers was assigned to the immunogenicity arm and randomly received CoronaVac or placebo (3:1 ratio). Randomization was done using a sealed enveloped system integrated into the electronic Case Report Forms (eCRF) in the OpenClinica platform."&#8232;Comment: authors report 1:1 allocation ratio for intervention/control group. However, in the flow chart and result tables there are 290 participants in the vaccine group and 164 in the control group.&#8232;Comment: allocation sequence concealed. Allocation sequence unclear. Baseline characteristics not reported by arm.&#8232;Risk assessed as some concerns.</p><p>&#160;</p></sec></sec><sec id="CD015477-sec-0369"><title>WIBP&#8208;CorV &#8211; Sinopharm &#8211; Wuhan versus adjuvant&#160;</title><sec id="CD015477-sec-0370"><title>SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p><table-wrap id="CD015477-tblf-0057" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The concealed random grouping allocation and blind codes were kept in signed and sealed envelopes and were blinded to the investigators, participants, and statisticians." "The vaccines and controls were approved by the National Institutes for Food and Drug Control of China, and were supplied in coded, identical&#8208;appearing, single&#8208;dose vials." (report) "Masking: quadruple (participant, care provider, investigator, outcomes assessor)." (registry)&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#160;&#8232;Reasons for exclusions were balanced between treatment groups: due to positive or unknown baseline SARS&#8208;CoV&#8208;2 RT&#8208;PCR status (118 versus 134 versus 98), did not receive any injection (11 versus 5 versus 13), did not receive second dose (393 versus 379 versus 387).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0371"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0058" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The concealed random grouping allocation and blind codes were kept in signed and sealed envelopes and were blinded to the investigators, participants, and statisticians." "The vaccines and controls were approved by the National Institutes for Food and Drug Control of China, and were supplied in coded, identical&#8208;appearing, single&#8208;dose vials." (report) "Masking: quadruple (participant, care provider, investigator, outcomes assessor)." (registry)&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#160;&#8232;Reasons for exclusions were balanced between treatment groups: due to positive or unknown baseline SARS&#8208;CoV&#8208;2 RT&#8208;PCR status (118 versus 134 versus 98), did not receive any injection (11 versus 5 versus 13), did not receive second dose (393 versus 379 versus 387).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0372"><title>Severe or critical COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0059" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The concealed random grouping allocation and blind codes were kept in signed and sealed envelopes and were blinded to the investigators, participants, and statisticians." "The vaccines and controls were approved by the National Institutes for Food and Drug Control of China, and were supplied in coded, identical&#8208;appearing, single&#8208;dose vials." (report) "Masking: quadruple (participant, care provider, investigator, outcomes assessor)." (registry)&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#160;&#8232;Reasons for exclusions were balanced between treatment groups: due to positive or unknown baseline SARS&#8208;CoV&#8208;2 RT&#8208;PCR status (118 versus 134 versus 98), did not receive any injection (11 versus 5 versus 13), did not receive second dose (393 versus 379 versus 387).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0373"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0060" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0374"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0061" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Sequential computer&#8208;generated randomization numbers were assigned to participants, and stratified block randomization by age and doses was adopted (block size 8)."&#8232;Comment: allocation sequence random. Unclear allocation concealment.&#160;&#8232;Imbalances in baseline characteristics appear to be compatible with chance.&#160;&#8232;Risk assessed as some concerns&#160;</p></sec><sec id="CD015477-sec-0375"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0062" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Sequential computer&#8208;generated randomization numbers were assigned to participants, and stratified block randomization by age and doses was adopted (block size 8)."&#8232;Comment: allocation sequence random. Unclear allocation concealment.&#160;&#8232;Imbalances in baseline characteristics appear to be compatible with chance.&#160;&#8232;Risk assessed as some concerns.</p></sec><sec id="CD015477-sec-0376"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0063" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Sequential computer&#8208;generated randomization numbers were assigned to participants, and stratified block randomization by age and doses was adopted (block size 8)."&#8232;Comment: allocation sequence random. Unclear allocation concealment.&#160;&#8232;Imbalances in baseline characteristics appear to be compatible with chance.&#160;&#8232;Risk assessed as some concerns&#160;</p><p>&#160;</p></sec></sec><sec id="CD015477-sec-0377"><title>BBIBP&#8208;CorV &#8211; Sinopharm&#8208;Beijing versus adjuvant&#160;</title><sec id="CD015477-sec-0378"><title>SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p><table-wrap id="CD015477-tblf-0064" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The concealed random grouping allocation and blind codes were kept in signed and sealed envelopes and were blinded to the investigators, participants, and statisticians." "The vaccines and controls were approved by the National Institutes for Food and Drug Control of China, and were supplied in coded, identical&#8208;appearing, single&#8208;dose vials." (report) "Masking: quadruple (participant, care provider, investigator, outcomes assessor)." (registry)&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;Reasons for exclusions were balanced between treatment groups: due to positive or unknown baseline SARS&#8208;CoV&#8208;2 RT&#8208;PCR status (118 versus 134 versus 98), did not receive any injection (11 versus 5 versus 13), did not receive second dose (393 versus 379 versus 387).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0379"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination</title><p><table-wrap id="CD015477-tblf-0065" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "The concealed random grouping allocation and blind codes were kept in signed and sealed envelopes and were blinded to the investigators, participants, and statisticians." "The vaccines and controls were approved by the National Institutes for Food and Drug Control of China, and were supplied in coded, identical&#8208;appearing, single&#8208;dose vials." (report) "Masking: quadruple (participant, care provider, investigator, outcomes assessor)." (registry)&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#8232;Reasons for exclusions were balanced between treatment groups: due to positive or unknown baseline SARS&#8208;CoV&#8208;2 RT&#8208;PCR status (118 versus 134 versus 98), did not receive any injection (11 versus 5 versus 13), did not receive second dose (393 versus 379 versus 387).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was no substantial impact of failure to analyse participants according to their randomized assignment.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0380"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0066" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0381"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0067" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0382"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0068" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0383"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0069" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="CD015477-sec-0384"><title>BBV152 &#8211; Bharat Biotech versus adjuvant</title><sec id="CD015477-sec-0385"><title>SARS&#8208;CoV&#8208;2 infection after complete vaccination</title><p><table-wrap id="CD015477-tblf-0070" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Participants, investigators, study coordinators, study&#8208;related personnel, and the sponsor were masked to the treatment group allocation, and masked study nurses at each site were responsible for vaccine preparation and administration."&#160;&#8232;Comment: blinded study (participants, personnel, investigators).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcome: Confirmed COVID (as planned in the trial protocol).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;Reasons for exclusions were balanced: did not received dose 1 (20 versus 25), did not received dose 2 (658 versus 676), positive for anti&#8208;SARS&#8208;CoV&#8208;2 IgG (3932 versus 3886), positive for SARS&#8208;CoV&#8208;2 by PCR (108 versus 105).&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0386"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0071" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Participants, investigators, study coordinators, study&#8208;related personnel, and the sponsor were masked to the treatment group allocation, and masked study nurses at each site were responsible for vaccine preparation and administration."&#160;&#8232;Comment: blinded study (participants, personnel, investigators).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes: Confirmed symptomatic COVID (as planned in the trial protocol).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;Reasons for exclusions were balanced: did not received dose 1 (20 versus 25), did not received dose 2 (658 versus 676), positive for anti&#8208;SARS&#8208;CoV&#8208;2 IgG (3932 versus 3886), positive for SARS&#8208;CoV&#8208;2 by PCR (108 versus 105).&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0387"><title>Severe or critical COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0072" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Participants, investigators, study coordinators, study&#8208;related personnel, and the sponsor were masked to the treatment group allocation, and masked study nurses at each site were responsible for vaccine preparation and administration."&#160;&#8232;Comment: blinded study (participants, personnel, investigators).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes: Confirmed severe COVID (as planned in the trial protocol).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;Reasons for exclusions were balanced: did not received dose 1 (20 versus 25), did not received dose 2 (658 versus 676), positive for anti&#8208;SARS&#8208;CoV&#8208;2 IgG (3932 versus 3886), positive for SARS&#8208;CoV&#8208;2 by PCR (108 versus 105).&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0388"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0073" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0389"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0074" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Quote: "The appearance, color, and viscosity were identical across all treatment and control formulations. Participants, investigators, study coordinators, study&#8208;related personnel, and the sponsor were blinded to the treatment group allocation (excluding an unblinded CRO, who was tasked with the dispatch and labeling of vaccine vials and the generation of the master randomization code). Blinding was maintained using the randomization code."&#160;&#8232;Comment: blinded study (patients, personnel, and investigators).&#160;&#8232;No participant cross&#8208;over.&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#160;&#8232;Reasons for exclusion: protocol deviation (1), positive for SARS&#8208;CoV&#8208;2 (1)&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the small number of exclusions&#160;&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref><bold>, RoB 5. Selection of the reported results:&#160;</bold>&#8232;Comment: the prospective registry was available (July 15, 2020). Outcome not prespecified&#160;&#8232;No information on whether the results were selected from multiple outcome measurements or analyses of the data. Trial not analyzed as prespecified.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0390"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0075" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0391"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0076" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "The appearance, color, and viscosity were identical across all treatment and control formulations. Participants, investigators, study coordinators, study&#8208;related personnel, and the sponsor were blinded to the treatment group allocation (excluding an unblinded CRO, who was tasked with the dispatch and labeling of vaccine vials and the generation of the master randomization code). Blinding was maintained using the randomization code."&#160;&#8232;Comment: blinded study (patients, personnel, and investigators).&#160;&#8232;No participant cross&#8208;over.&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#160;&#8232;Reasons for exclusion: protocol deviation (1), positive for SARS&#8208;CoV&#8208;2 (1)&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the small number of exclusions&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec></sec></sec><sec id="CD015477-sec-0392"><title>Protein subunit</title><sec id="CD015477-sec-0393"><title>NVX&#8208;CoV2373 &#8211; Novavax versus placebo&#160;</title><sec id="CD015477-sec-0394"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0077" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>c</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Masking: quadruple (participant, care provider, investigator, outcomes assessor)." "Only unblinded site personnel managed study vaccine logistics/preparation and had no other role in trial conduct." "The trial is ongoing, and investigators and Novavax clinical team remain blinded to participant&#8208;level treatment assignments."&#8232;Comment: blinded study (participants and personnel/carers)&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes.&#160;&#8232;Reasons for exclusion: were anti&#8208;NP or PCR positive at baseline (vaccine 6.2%, placebo 6.8%), did not receive two Nv&#8208;CXoV2373 doses or were dosed out of window (vaccine 3.2%, placebo 4.6%), had major protocol deviation, were unblinded, or had a censoring event (vaccine 3.3%, placebo 6.9%).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to relatively equal attrition in both arms.&#160;&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "This was an observer&#8208;blinded study. Only unblinded site personnel managed study vaccine logistics and preparation and they were not involved in study&#8208;related assessments or had participant contact for data collection following vaccine administration" (report) "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor" (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04583995">NCT04583995</ext-link> registry) "Double blind" (EudraCT 2020&#8208;004123&#8208;16 registry)&#160;&#8232;Comment: blinded study (participants, personnel, investigators).&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#160;&#8232;Reasons for exclusions were balanced between treatment groups (549 (7.2%) versus 551 (7.3%)), with the majority of those excluded due to seropositivity before 7 days after dose 2 (399 versus 402). Other reasons: received only one dose (102 versus 107); had major protocol deviation, missed dose, or censoring event (48 versus 42).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>c</sup></bold><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "To maintain the blind, placebo vaccination via the intramuscular route was included, and unblinded site personnel managed vaccine logistics, preparation, and administration (if necessary) to maintain the blind from the remainder of the site personnel and participants."&#160;&#8232;Comment: not fully blinded study (participants and some personnel were blinded).&#160;&#8232;Two participants crossed over from placebo to vaccine group.&#160;&#8232;This deviation was considered negligible among 2684 participants analyzed for efficacy outcomes.&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes evaluated in this cohort (as planned in the trial protocol).&#160;&#8232;Reasons for exclusion: seropositivity at baseline (849 versus 873), SARS&#8208;CoV&#8208;2 positivity before day 28 (97 versus 78), did not receive both doses (24 versus 31), had important protocol deviations (4 versus 7), lost to follow&#8208;up (6 versus 9), was withdrawn by physicians (1 versus 0), became pregnant (2 versus 3), withdrew with no reason reported (10 versus 15), had adverse event, not related to vaccine (1 versus 0).&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0395"><title>Severe or critical COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0078" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "masking: quadruple (participant, care provider, investigator, outcomes assessor)." "Only unblinded site personnel managed study vaccine logistics/preparation and had no other role in trial conduct." "The trial is ongoing, and investigators and Novavax clinical team remain blinded to participant&#8208;level treatment assignments."&#8232;Comment: blinded study (participants and personnel/carers)&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes.&#160;&#8232;Reasons for exclusion: Were Anti&#8208;NP or PCR positive at baseline (vaccine 6.2%, placebo 6.8%), did not receive two Nv&#8208;CXoV2373 doses or were dosed out of window (vaccine 3.2%, placebo 4.6%), had major protocol deviation, were unblinded, or had a censoring event (vaccine 3.3%, placebo 6.9%).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to relatively equal attrition in both arms.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0396"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0079" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "Masking: quadruple (participant, care provider, investigator, outcomes assessor)." "Only unblinded site personnel managed study vaccine logistics/preparation and had no other role in trial conduct." "The trial is ongoing, and investigators and Novavax clinical team remain blinded to participant&#8208;level treatment assignments."&#8232;Comment: blinded study (participants and personnel/carers)&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes.&#8232;Reasons for exclusion: were anti&#8208;NP or PCR positive at baseline (vaccine 6.2%, placebo 6.8%), did not receive two Nv&#8208;CXoV2373 doses or were dosed out of window (vaccine 3.2%, placebo 4.6%), had major protocol deviation, were unblinded, or had a censoring event (vaccine 3.3%, placebo 6.9%).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to relatively equal attrition in both arms.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "This was an observer&#8208;blinded study. Only unblinded site personnel managed study vaccine logistics and preparation and they were not involved in study&#8208;related assessments or had participant contact for data collection following vaccine administration." (report) "Masking: quadruple (participant, care provider, investigator, outcomes assessor." (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04583995">NCT04583995</ext-link> registry) "Double blind" (EudraCT 2020&#8208;004123&#8208;16 registry)&#160;&#8232;Comment: blinded study (participants, personnel, investigators).&#160;&#8232;Per&#8208;protocol analysis was performed on the efficacy outcomes (as planned in the trial protocol).&#160;&#8232;Reasons for exclusions were balanced between treatment groups (549 (7.2%) versus 551 (7.3%)), with the majority of those excluded due to seropositivity before 7 days after dose 2 (399 versus 402). Other reasons: received only 1 dose (102 versus 107); had major protocol deviation, missed dose, or censoring event (48 versus 42).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;&#160;</p></sec><sec id="CD015477-sec-0397"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0080" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "participants were randomly assigned in a blinded manner to one of five vaccine groups &#8230; according to pre&#8208;generated randomization schedules with two&#8208;factor, two&#8208;level stratification employed."&#160;&#8232;Comment: allocation sequence probably random&#160;&#8232;No information on allocation concealment&#8232;Imbalances in baseline characteristics appear to be compatible with chance.&#8232;Risk assessed to have some concerns</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref><bold>, RoB 3. Missing outcome data:&#160;</bold>&#8232;Comment: data from interim analysis&#160;&#8232;4406 participants randomized; 968 participants analyzed for safety.&#160;&#8232;Data available for 22% of population for safety.&#160;&#8232;For safety, only participants who were enrolled in the first stage were analyzed for the interim analysis. A large proportion (participants enrolled in the second stage of the trial) was missing, but it is unlikely that missingness depended on the true value of the outcome.&#160;&#8232;Risk assessed to have some concerns for this outcome&#160;</p></sec><sec id="CD015477-sec-0398"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0081" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>c</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>d</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "As a safety measure, 6 participants were initially randomly assigned in a 1:1 ratio to the 5&#8208;&#956;g and 25&#8208;&#956;g rSARS&#8208;CoV&#8208;2 plus Matrix&#8208;M1 groups (groups C and D), vaccinated in an open&#8208;label manner, and observed for reactogenicity for 48 hours. Thereafter, the remaining 125 participants were randomly assigned, in a 1:1:1:1:1 ratio and in a blinded manner to one of five vaccine groups according to pregenerated randomization schedules, without stratification."&#8232;Comment: allocation sequence probably random&#160;&#8232;No information on allocation concealment&#160;&#8232;Risk assessed to have some concerns</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref><bold>, RoB 1. Randomization:</bold>&#8232;Quote: "participants were randomly assigned in a blinded manner to one of five vaccine groups &#8230; according to pre&#8208;generated randomization schedules with two&#8208;factor, two&#8208;level stratification employed."&#160;&#8232;Comment: allocation sequence probably random&#160;&#8232;No information on allocation concealment&#160;&#8232;Imbalances in baseline characteristics appear to be compatible with chance.&#8232;Risk assessed to have some concerns</p><p><bold><sup>c</sup></bold><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref><bold>, RoB 5. Selection of the reported results:&#160;</bold>&#8232;Comment: the prospective trial registry was available (30 April).&#160;&#8232;Different time point in the registry (prespecified at 28 days and reported at 35 days after first dose)&#160;&#8232;No information on whether the result was selected from multiple outcome measurements or analyses of the data.&#160;&#8232;Trial not analyzed as prespecified.&#160;&#8232;Risk assessed to have some concerns for this outcome</p><p><bold><sup>d</sup></bold><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref><bold>, RoB 3. Missing outcome data:</bold>&#8232;Comment: data from interim analysis&#160;&#8232;4406 participants randomized; 968 participants analyzed for safety.&#160;&#8232;For safety, only participants who were enrolled in the first stage were analyzed for the interim analysis. A large proportion (participants enrolled in the second stage of the trial) was missing, but it is unlikely that missingness depended on the true value of the outcome.&#160;&#8232;Risk assessed to have some concerns for this outcome. Data available for 22% of population for safety.&#160;&#160;</p></sec><sec id="CD015477-sec-0399"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0082" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>c</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>d</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>e</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "As a safety measure, 6 participants were initially randomly assigned in a 1:1 ratio to the 5&#8208;&#956;g and 25&#8208;&#956;g rSARS&#8208;CoV&#8208;2 plus Matrix&#8208;M1 groups (groups C and D), vaccinated in an open&#8208;label manner, and observed for reactogenicity for 48 hours. Thereafter, the remaining 125 participants were randomly assigned, in a 1:1:1:1:1 ratio and in a blinded manner to one of five vaccine groups according to pregenerated randomization schedules, without stratification".&#160;&#8232;Comment: allocation sequence probably random&#160;&#8232;No information on allocation concealment&#160;&#8232;Risk assessed to have some concerns</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "participants were randomly assigned in a blinded manner to one of five vaccine groups &#8230; according to pre&#8208;generated randomization schedules with two&#8208;factor, two&#8208;level stratification employed."&#160;&#8232;Comment: allocation sequence probably random&#160;&#8232;No information on allocation concealment&#160;&#8232;Imbalances in baseline characteristics appear to be compatible with chance.&#8232;Risk assessed to have some concerns</p><p><bold><sup>c</sup></bold><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref><bold>, RoB 5. Selection of the reported results:&#160;</bold>&#8232;Comment: the prospective trial registry was available (April 30th).&#160;&#8232;No information on whether the result was selected from multiple outcome measurements or analyses of the data.&#160;&#8232;Trial not analyzed as prespecified.&#160;&#8232;Risk assessed to have some concerns for this outcome. Outcome not prespecified&#160;</p><p><bold><sup>d</sup></bold><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "To maintain the blind, placebo vaccination via the intramuscular route was included, and unblinded site personnel managed vaccine logistics, preparation, and administration (if necessary) so as to maintain the blind from the remainder of the site personnel and participants."&#160;&#8232;Comment: not fully blinded study (participants and some personnel were blinded).&#160;&#8232;Two participants crossed over from placebo to vaccine group.&#160;&#8232;This deviation was considered negligible among 968 participants analyzed for safety outcomes.&#160;&#8232;The two participants randomized to the placebo group that crossed over were analyzed "as&#8208;treated" in the intervention group. Nevertheless, due to the small proportion crossing over, we considered the safety analyses to be probably appropriate to estimate the effect of assignment to intervention.&#160;&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>e</sup></bold><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref><bold>, RoB 3. Missing outcome data:&#160;</bold>&#8232;Comment: data from interim analysis. 4406 participants randomized; 968 participants analyzed for safety.&#160;&#8232;For safety, only participants who were enrolled in the first stage were analyzed for the interim analysis. A large proportion (participants enrolled in the second stage of the trial) was missing, but it is unlikely that missingness depended on the true value of the outcome.&#160;&#8232;Risk assessed to have some concerns for this outcome. Data available for 22% of population for safety.&#160;&#160;</p></sec></sec><sec id="CD015477-sec-0400"><title>FINLAY&#8208;FR&#8208;2 &#8211; Instituto Finlay de Vacunas versus placebo</title><sec id="CD015477-sec-0401"><title>Confirmed symptomatic COVID&#8208;19 after complete vaccination&#160;</title><p><table-wrap id="CD015477-tblf-0083" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Randomization into study arms (A and B) and placebo was done on day 0 at a 1:1:1 ratio using a site stratified random and previously defined risk strata (19&#8211;64 years without risk comorbidities, 19&#8211;64 years with risk comorbidities and &#8805;65 years)."&#160;&#8232;Comment: allocation sequence random. No information on allocation concealment.&#160;</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#160;&#8232;Reasons for exclusion: did not receive or discontinued the intervention.&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance between groups. Imbalances in baseline characteristics appear to be compatible with chance.&#160;</p></sec><sec id="CD015477-sec-0402"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0084" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Randomization into study arms (A and B) and placebo was done on day 0 at a 1:1:1 ratio using a site stratified random and previously defined risk strata (19&#8211;64 years without risk comorbidities, 19&#8211;64 years with risk comorbidities and &#8805;65 years)."&#160;&#8232;Comment: allocation sequence random. No information on allocation concealment.&#160;&#8232;Imbalances in baseline characteristics appear to be compatible with chance.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#160;&#8232;Reasons for exclusion: did not receive or discontinued the intervention.&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance between groups.&#160;</p></sec></sec></sec><sec id="CD015477-sec-0403"><title>Heterologous vaccine&#160;</title><sec id="CD015477-sec-0404"><title>Comparison: heterologous vaccination scheme versus homologous vaccination scheme</title><sec id="CD015477-sec-0405"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0085" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote "We masked participants, investigators, laboratory staff, and outcome assessors to the allocation of treatment groups &#8230; Designated unblinded personnel were responsible for the preparation and administration of the vaccination and were forbidden to reveal the identity of the study vaccines to the participants or other investigators"&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#160;&#8232;One participant randomized to the Convidecia boost group (additional arm in the study extracted separately) crossed over to the CoronaVac/Convidecia group because the participant had in fact only received one primary dose.&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the single participant that crossed over.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0406"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0086" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>c</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote "We masked participants, investigators, laboratory staff, and outcome assessors to the allocation of treatment groups &#8230; Designated unblinded personnel were responsible for the preparation and administration of the vaccination and were forbidden to reveal the identity of the study vaccines to the participants or other investigators"&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#160;&#8232;One participant randomized to the Convidecia boost group (additional arm in the study extracted separately) crossed over to the CoronaVac/Convidecia group because the participant had in fact only received one primary dose.&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the single participant that crossed over.&#160;&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref><bold>, RoB 4. Measurement of the outcome:&#160;</bold>&#8232;Comment: method of measuring the outcome probably appropriate.&#160;&#8232;Measurement or ascertainment of outcome probably does not differ between groups.&#160;&#8232;Quote: "Laboratory staff will also be blinded to the vaccine schedule received." (protocol) "The clinical team assessing the safety endpoints were not blinded" (report)&#160;&#8232;Comment: outcome assessment was unblinded for safety outcomes;&#160;&#8232;Adverse events may contain both clinically and laboratory&#8208;detected events, which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. Risk assessed to have some concerns for this outcome.</p><p><bold><sup>c</sup></bold><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref><bold>, RoB 4. Measurement of the outcome:&#160;</bold>&#8232;Comment: method of measuring the outcome probably appropriate.&#160;&#8232;Measurement or ascertainment of outcome probably does not differ between groups.&#160;&#8232;Quote: "Laboratory staff will also be blinded to the vaccine schedule received." (protocol) "The clinical team assessing the safety endpoints were not blinded" (report)&#160;&#8232;Comment: outcome assessment was unblinded for safety outcomes;&#160;&#8232;Adverse events may contain both clinically and laboratory&#8208;detected events, which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0407"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0087" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>c</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote "We masked participants, investigators, laboratory staff, and outcome assessors to the allocation of treatment groups &#8230; Designated unblinded personnel were responsible for the preparation and administration of the vaccination and were forbidden to reveal the identity of the study vaccines to the participants or other investigators"&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#160;&#8232;One participant randomized to the Convidecia boost group (additional arm in the study extracted separately) crossed over to the CoronaVac/Convidecia group because the participant had in fact only received one primary dose.&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the single participant that crossed over.&#160;&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref><bold>, RoB 4. Measurement of the outcome:&#160;</bold>&#8232;Comment: method of measuring the outcome probably appropriate.&#8232;Measurement or ascertainment of outcome probably does not differ between groups.&#8232;Quote: "Laboratory staff will also be blinded to the vaccine schedule received." (protocol) "The clinical team assessing the safety endpoints were not blinded" (report)&#8232;Serious adverse events may contain both clinically and laboratory&#8208;detected events, which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic.&#8232;Risk assessed to have some concerns for this outcome. Outcome assessment was unblinded for safety outcomes</p><p><bold><sup>c</sup></bold><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref><bold>, RoB 4. Measurement of the outcome:&#160;</bold>&#8232;Comment: method of measuring the outcome probably appropriate.&#8232;Measurement or ascertainment of outcome probably does not differ between groups.&#8232;Quote: "Laboratory staff will also be blinded to the vaccine schedule received." (protocol) "The clinical team assessing the safety endpoints were not blinded" (report)&#8232;Comment: outcome assessment was unblinded for safety outcomes;&#8232;Serious adverse events may contain both clinically and laboratory&#8208;detected events, which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec></sec></sec><sec id="CD015477-sec-0408"><title>Boosters</title><sec id="CD015477-sec-0409"><title>Comparison: booster versus placebo/no booster</title><sec id="CD015477-sec-0410"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0088" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>c</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>d</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>e</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>f</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>g</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>h</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>i</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>j</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>k</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>l</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>m</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote "We masked participants, investigators, laboratory staff, and outcome assessors to the allocation of treatment groups &#8230; Designated unblinded personnel were responsible for the preparation and administration of the vaccination and were forbidden to reveal the identity of the study vaccines to the participants or other investigators"&#160;&#8232;Comment: blinded study (participants and personnel/carers). Per&#8208;protocol analysis was performed. Reasons for exclusion: three participants randomized to the Convidecia boost group crossed over to other groups. Two participants were wrongly administrated with a homogeneous boost dose of CoronaVac and were re&#8208;classified into the CoronaVac boost group. One participant had in fact only received one primary dose and was re&#8208;classified into the CoronaVac/Convidecia 2 dose group (additional arm in the study extracted separately). As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately. There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the small number of participants who crossed over. Risk assessed to have some concerns for this outcome.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "participants were randomized to receive either BNT162b2 (n = 40) or CoronaVac (n = 40) as the third dose."&#160;&#8232;Comment: allocation sequence probably random. No information on allocation concealment.</p><p><bold><sup>c</sup></bold><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref><bold>, RoB 4. Measurement of the outcome:&#160;</bold>&#8232;Comment: method of measuring the outcome probably appropriate. Measurement or ascertainment of outcome probably does not differ between groups. Unclear blinding (outcome assessor).&#160;&#8232;The authors reported on adverse events that may contain both clinically and laboratory&#8208;detected events, which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic.</p><p><bold><sup>d</sup></bold><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref><bold>, RoB 5. Selection of the reported results:&#160;</bold>&#8232;Comment: the protocol, statistical analysis plan, registry were available (revision dated August 17, 2021). Outcome not prespecified. No information on whether the result was selected from multiple outcome measurements or analyses of the data. Trial not analyzed as prespecified.</p><p><bold><sup>e</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Participants were assigned to study groups in a 1:1:1:1 fashion; randomization was stratified by study site after obtaining written informed consent."&#160;&#8232;Comment: allocation sequence probably random. No information on allocation concealment. Imbalances in baseline characteristics appear to be compatible with chance. Risk assessed as some concerns</p><p><bold><sup>f</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "single&#8208;(participant)&#8208;blinded Participants were unblinded for the booster vaccination by e&#8208;mail eight days after injection, after completing the reactogenicity questionnaires."&#8232;Comment: blinded study (participants). Deviations from intended intervention arising because of the study context: No participant cross&#8208;over. Per&#8208;protocol analysis was performed on the outcomes. Reasons for exclusion: baseline positive (2.6%, 1.7%, 0.9%, 1.7%), positive between baseline and follow&#8208;up (1.8%, 0.9%, 0.0%, 0.0%). As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately. There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance between groups. Risk assessed to have some concerns for this outcome.</p><p><bold><sup>g</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 3. Missing outcome data:&#160;</bold>&#8232;Comment: 461 participants randomized; 433 participants analyzed for reactogenicity. No evidence that the result is not biased. Reasons (reactogenicity): baseline positive (2.6%, 1.7%, 0.9%, 1.7%), positive between baseline and follow&#8208;up (1.8%, 0.9%, 0.0%, 0.0%), failed bleed at baseline or follow&#8208;up (1.8%, 0.9%, 0.9%, 0.0%) or withdrew from the study (3.5%, 5.2%, 1.7%, 1.7%).&#8232;Not likely that missingness depended on the true value of the outcome because there is no major imbalance between groups.&#8232;Risk assessed to have some concerns for this outcome. Data not available for all or nearly all participants randomized. Missingness could depend on the true value of the outcome.</p><p><bold><sup>h</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Participants were assigned to study groups in a 1:1:1:1 fashion; randomization was stratified by study site after obtaining written informed consent."&#8232;Comment: allocation sequence probably random. No information on allocation concealment.&#8232;Imbalances in baseline characteristics appear to be compatible with chance.&#8232;Risk assessed as some concerns</p><p><bold><sup>i</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "single&#8208;(participant)&#8208;blinded Participants were unblinded for the booster vaccination by e&#8208;mail eight days after injection, after completing the reactogenicity questionnaires."&#8232;Comment: blinded study (participants). Deviations from intended intervention arising because of the study context: no participant cross&#8208;over.&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#8232;Reasons for exclusion: baseline positive (2.6%, 1.7%, 0.9%, 1.7%), positive between baseline and follow&#8208;up (1.8%, 0.9%, 0.0%, 0.0%).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance between groups.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>j</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 3. Missing outcome data:&#160;</bold>&#8232;Comment: 461 participants randomized; 433 participants analyzed for reactogenicity.&#8232;Data not available for all or nearly all participants randomized.&#8232;No evidence that the result is not biased. Reasons (reactogenicity): baseline positive (2.6%, 1.7%, 0.9%, 1.7%), positive between baseline and follow&#8208;up (1.8%, 0.9%, 0.0%, 0.0%), failed bleed at baseline or follow&#8208;up (1.8%, 0.9%, 0.9%, 0.0%) or withdrew from the study (3.5%, 5.2%, 1.7%, 1.7%).&#8232;Missingness could depend on the true value of the outcome.&#8232;Not likely that missingness depended on the true value of the outcome because there is no major imbalance between groups.&#8232;Risk assessed to have some concerns for this outcome.</p><p><bold><sup>k</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Participants were assigned to study groups in a 1:1:1:1 fashion; randomization was stratified by study site after obtaining written informed consent."&#8232;Comment: allocation sequence probably random. No information on allocation concealment. Imbalances in baseline characteristics appear to be compatible with chance. Risk assessed as some concerns</p><p><bold><sup>l</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote: "single&#8208;(participant)&#8208;blinded. Participants were unblinded for the booster vaccination by e&#8208;mail eight days after injection, after completing the reactogenicity questionnaires."&#8232;Comment: blinded study (participants) Deviations from intended intervention arising because of the study context: no participant cross&#8208;over. Per&#8208;protocol analysis was performed on the outcomes. Reasons for exclusion: baseline positive (2.6%, 1.7%, 0.9%, 1.7%), positive between baseline and follow&#8208;up (1.8%, 0.9%, 0.0%, 0.0%).&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance between groups. Risk assessed to have some concerns for this outcome.</p><p><bold><sup>m</sup></bold><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref><bold>, RoB 3. Missing outcome data:&#160;</bold>&#8232;Comment: 461 participants randomized; 433 participants analyzed for reactogenicity. Data not available for all or nearly all participants randomized. No evidence that the result is not biased.&#8232;Reasons (reactogenicity): baseline positive (2.6%, 1.7%, 0.9%, 1.7%), positive between baseline and follow&#8208;up (1.8%, 0.9%, 0.0%, 0.0%), failed bleed at baseline or follow&#8208;up (1.8%, 0.9%, 0.9%, 0.0%) or withdrew from the study (3.5%, 5.2%, 1.7%, 1.7%).&#8232;Missingness could depend on the true value of the outcome. Not likely that missingness depended on the true value of the outcome because there is no major imbalance between groups.&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0411"><title>Any adverse event</title><p><table-wrap id="CD015477-tblf-0089" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote "We masked participants, investigators, laboratory staff, and outcome assessors to the allocation of treatment groups &#8230; Designated unblinded personnel were responsible for the preparation and administration of the vaccination and were forbidden to reveal the identity of the study vaccines to the participants or other investigators"&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed.&#160;&#8232;Reasons for exclusion: three participants randomized to the Convidecia boost group crossed over to other groups. Two participants were wrongly administrated with a homogeneous boost dose of CoronaVac and were reclassified into the CoronaVac boost group. One participant had in fact only received one primary dose and was re&#8208;classified into the CoronaVac/Convidecia 2 dose group (additional arm in the study extracted separately).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the small number of participants who crossed over.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec><sec id="CD015477-sec-0412"><title>Serious adverse events</title><p><table-wrap id="CD015477-tblf-0090" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><bold>, RoB 2. Deviations from intervention:&#160;</bold>&#8232;Quote "We masked participants, investigators, laboratory staff, and outcome assessors to the allocation of treatment groups &#8230; Designated unblinded personnel were responsible for the preparation and administration of the vaccination and were forbidden to reveal the identity of the study vaccines to the participants or other investigators"&#160;&#8232;Comment: blinded study (participants and personnel/carers).&#160;&#8232;Per&#8208;protocol analysis was performed.&#160;&#8232;Reasons for exclusion: three participants randomized to the Convidecia boost group crossed over to other groups. Two participants were wrongly administrated with a homogeneous boost dose of CoronaVac and were reclassified into the CoronaVac boost group. One participant had in fact only received one primary dose and was re&#8208;classified into the CoronaVac/Convidecia 2 dose group (additional arm in the study extracted separately).&#160;&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#160;&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to the small number of participants who crossed over.&#160;&#8232;Risk assessed to have some concerns for this outcome.&#160;</p></sec></sec><sec id="CD015477-sec-0413"><title>Comparison: booster versus booster</title><sec id="CD015477-sec-0414"><title>All&#8208;cause mortality</title><p><table-wrap id="CD015477-tblf-0091" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Toledo&#8208;Romani 2021</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>a</sup></bold></td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns<sup>b</sup></bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1"><bold>Some concerns</bold></td></tr></tbody></table></table-wrap></p><p><bold><sup>a</sup></bold><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref><bold>, RoB 1. Randomization:&#160;</bold>&#8232;Quote: "Randomization into study arms (A and B) and placebo was done on day 0 at a 1:1:1 ratio using a site stratified random and previously defined risk strata (19&#8211;64 years without risk comorbidities, 19&#8211;64 years with risk comorbidities and &#8805;65 years)."&#8232;Comment: allocation sequence random. No information on allocation concealment.&#8232;Imbalances in baseline characteristics appear to be compatible with chance.</p><p><bold><sup>b</sup></bold><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref><bold>, RoB 2. Deviations from intervention:</bold>&#8232;Comment: blinded study (participants and personnel/carers).&#8232;Per&#8208;protocol analysis was performed on the outcomes.&#8232;Reasons for exclusion: did not receive or discontinued the intervention.&#8232;As we are assessing the effect of assignment to intervention (intention&#8208;to&#8208;treat effect), we considered that the data were analyzed inappropriately.&#8232;There was probably no substantial impact of failure to analyse participants according to their randomized assignment due to balance between groups.&#160;</p></sec><sec id="CD015477-sec-0415"><title>Systemic reactogenicity events</title><p><table-wrap id="CD015477-tblf-0092" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>1. Randomization</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>2. Deviations from intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>3. Missing outcome data&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>4. Measurement of the outcome</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>5. Selection of the reported results</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Overall risk of bias</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref><sup>a</sup></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">Low</td></tr></tbody></table></table-wrap></p><p><sup>a</sup>Trial in immunocompromized participants.&#160;</p></sec></sec></sec></app><app id="CD015477-sec-0416"><title>Appendix 9. Matrix indicating availability of trial results for the critical and important outcomes of the review</title><p><bold>Key to tables:</bold>&#160;&#8232;&#10003; A study result is available for inclusion in the synthesis.&#8232;X No study result is available for inclusion, (probably) because the P value, magnitude or direction of the results generated were considered unfavourable by the study investigators.&#8232;* No study result is available for inclusion, (probably) because the outcome was not assessed, or for a reason unrelated to the P value, magnitude or direction of the results.&#8232;? No study result is available for inclusion, and it is unclear if the outcome was assessed in the study.</p><p><bold>Abbreviations:</bold> AE: adverse event; GMR: geometric mean ratio; n: number of participants; SAE: serious adverse event.</p><sec id="CD015477-sec-0417"><title>RNA&#8208;based vaccines</title><sec id="CD015477-sec-0418"><title>BNT162b2 &#8211; BioNTech/Fosun Pharma/Pfizer versus placebo</title><p><table-wrap id="CD015477-tblf-0093" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BNT162b2 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.68</td><td valign="top" colspan="1" rowspan="1">24</td><td valign="top" colspan="1" rowspan="1">18</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>)</td><td valign="top" colspan="1" rowspan="1">4.7</td><td valign="top" colspan="1" rowspan="1">1134</td><td valign="top" colspan="1" rowspan="1">1130</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">22,085</td><td valign="top" colspan="1" rowspan="1">22,080</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0094" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1">BNT162b2 <bold>(n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.68</td><td valign="top" colspan="1" rowspan="1">24</td><td valign="top" colspan="1" rowspan="1">18</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>)</td><td valign="top" colspan="1" rowspan="1">4.7</td><td valign="top" colspan="1" rowspan="1">1134</td><td valign="top" colspan="1" rowspan="1">1130</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">22,085</td><td valign="top" colspan="1" rowspan="1">22,080</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0419"><title>mRNA&#8208;1273 &#8211; ModernaTX versus placebo&#160;</title><p><table-wrap id="CD015477-tblf-0095" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>mRNA&#8208;1273 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04649151">NCT04649151</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2.8</td><td valign="top" colspan="1" rowspan="1">2489</td><td valign="top" colspan="1" rowspan="1">1243</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>)</td><td valign="top" colspan="1" rowspan="1">5.3</td><td valign="top" colspan="1" rowspan="1">15,209</td><td valign="top" colspan="1" rowspan="1">15,206</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>Results reported in Pajon 2021 are already reported in El Sahly 2021; consequently, Pajon 2021 is not included in the forest plots.&#160;</p><p><table-wrap id="CD015477-tblf-0096" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>mRNA&#8208;1273 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref><break/>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04649151">NCT04649151</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2.8</td><td valign="top" colspan="1" rowspan="1">2489</td><td valign="top" colspan="1" rowspan="1">1243</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>)</td><td valign="top" colspan="1" rowspan="1">5.3</td><td valign="top" colspan="1" rowspan="1">15,209</td><td valign="top" colspan="1" rowspan="1">15,206</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0420"><title>CVnCoV &#8211; CureVac AG versus placebo&#160;</title><p><table-wrap id="CD015477-tblf-0097" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CVnCoV (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="top" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04652102">NCT04652102</ext-link>; EudraCT 2020&#8208;003998&#8208;22)</td><td valign="top" colspan="1" rowspan="1">6.23</td><td valign="top" colspan="1" rowspan="1">19,783</td><td valign="top" colspan="1" rowspan="1">19,746</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0098" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CVnCoV (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04652102">NCT04652102</ext-link>; EudraCT 2020&#8208;003998&#8208;22)</td><td valign="top" colspan="1" rowspan="1">6.23</td><td valign="top" colspan="1" rowspan="1">19,783</td><td valign="top" colspan="1" rowspan="1">19,746</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="CD015477-sec-0421"><title>Non&#8208;replicating viral vector</title><sec id="CD015477-sec-0422"><title>ChAdOx1/SII&#8208;ChAdOx1 &#8211; AstraZeneca/University of Oxford versus placebo/MenACWY</title><p><table-wrap id="CD015477-tblf-0099" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>ChAdOx1 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04568031">NCT04568031</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.9</td><td valign="top" colspan="1" rowspan="1">192</td><td valign="top" colspan="1" rowspan="1">64</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link>)</td><td valign="top" colspan="1" rowspan="1">6.27</td><td valign="top" colspan="1" rowspan="1">21,635</td><td valign="top" colspan="1" rowspan="1">10,816</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref><sup>a</sup> (ISRCTN89951424)</td><td valign="top" colspan="1" rowspan="1">8.27</td><td valign="top" colspan="1" rowspan="1">5207</td><td valign="top" colspan="1" rowspan="1">5209</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>)</td><td valign="top" colspan="1" rowspan="1">4.93</td><td valign="top" colspan="1" rowspan="1">5600</td><td valign="top" colspan="1" rowspan="1">5211</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref>&#160;<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>; PACTR202006922165132)</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">52</td><td valign="top" colspan="1" rowspan="1">52</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>; PACTR202006922165132)</td><td valign="top" colspan="1" rowspan="1">6.73</td><td valign="top" colspan="1" rowspan="1">1013</td><td valign="top" colspan="1" rowspan="1">1013</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;(CTRI/2020/08/027170)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">900</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>; ISRCTN89951424; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>)</td><td valign="top" colspan="1" rowspan="1">3.94</td><td valign="top" colspan="1" rowspan="1">12,408</td><td valign="top" colspan="1" rowspan="1">12,014</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref><sup>b</sup> (ISRCTN89951424; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>)</td><td valign="top" colspan="1" rowspan="1">3.94</td><td valign="top" colspan="1" rowspan="1">12,048</td><td valign="top" colspan="1" rowspan="1">12,014</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr></tbody></table></table-wrap></p><p><sup>a</sup>Results reported in&#160;<xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref>&#160;are included in&#160;<xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>. Only results for "Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination" against Gamma variant were extracted and analyzed.&#8232;<sup>b</sup>Results reported in Voysey 2021b are already reported in Voysey 2021a, consequently Voysey 2021b is not included in the forest plots.&#160;</p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0100" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>ChAdOx1 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04568031">NCT04568031</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.9</td><td valign="top" colspan="1" rowspan="1">192</td><td valign="top" colspan="1" rowspan="1">64</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link>)</td><td valign="top" colspan="1" rowspan="1">6.27</td><td valign="top" colspan="1" rowspan="1">21,635</td><td valign="top" colspan="1" rowspan="1">10,816</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref>&#160;(ISRCTN89951424)</td><td valign="top" colspan="1" rowspan="1">8.27</td><td valign="top" colspan="1" rowspan="1">5207</td><td valign="top" colspan="1" rowspan="1">5209</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>)</td><td valign="top" colspan="1" rowspan="1">4.93</td><td valign="top" colspan="1" rowspan="1">5600</td><td valign="top" colspan="1" rowspan="1">5211</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>; PACTR202006922165132)</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">52</td><td valign="top" colspan="1" rowspan="1">52</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref>&#160;<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>; PACTR202006922165132)</td><td valign="top" colspan="1" rowspan="1">6.73</td><td valign="top" colspan="1" rowspan="1">1013</td><td valign="top" colspan="1" rowspan="1">1013</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;(CTRI/2020/08/027170)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">900</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>; ISRCTN89951424; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>)</td><td valign="top" colspan="1" rowspan="1">3.94</td><td valign="top" colspan="1" rowspan="1">12,408</td><td valign="top" colspan="1" rowspan="1">12,014</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref>&#160;(ISRCTN89951424; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>)</td><td valign="top" colspan="1" rowspan="1">3.94</td><td valign="top" colspan="1" rowspan="1">12,048</td><td valign="top" colspan="1" rowspan="1">12,014</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0423"><title>ChAdOx1 &#8211; AstraZeneca/University of Oxford versus SII&#8208;ChAdOx1&#160;</title><p><table-wrap id="CD015477-tblf-0101" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>ChAdOx1 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>SII&#8208;ChAdOx (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>AE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;(CTRI/2020/08/027170)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">*&#160;</td><td valign="top" colspan="1" rowspan="1">*&#160;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0102" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>ChAdOx1 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>SII&#8208;ChAdOx (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref>&#160;(CTRI/2020/08/027170)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">300</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0424"><title>Ad26.COV2.S &#8211; Janssen Pharmaceutical Companies versus placebo&#160;</title><p><table-wrap id="CD015477-tblf-0103" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26.COV2.S (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436276">NCT04436276</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2.33</td><td valign="top" colspan="1" rowspan="1">324</td><td valign="top" colspan="1" rowspan="1">164</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505722">NCT04505722</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.84 (median)</td><td valign="top" colspan="1" rowspan="1">22,174</td><td valign="top" colspan="1" rowspan="1">22,151</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr></tbody></table></table-wrap></p><p>Stephenson 2021 reported on a subset of participants included in&#160;<xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref>. We could not retrieve data from Stephenson 2021 and it was not included in the analysis.</p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0104" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26.COV2.S (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436276">NCT04436276</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2.33</td><td valign="top" colspan="1" rowspan="1">324</td><td valign="top" colspan="1" rowspan="1">164</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505722">NCT04505722</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.84 (median)</td><td valign="top" colspan="1" rowspan="1">22,174</td><td valign="top" colspan="1" rowspan="1">22,151</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0425"><title>Gam&#8208;COVID&#8208;Vac (Sputnik V) &#8211; Gamaleya Research Institute versus placebo</title><p><table-wrap id="CD015477-tblf-0105" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="4" valign="top" rowspan="1"><bold>&#160;</bold></td><td colspan="7" align="center" valign="top" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Study ID</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Study follow&#8208;up (months)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Gam&#8208;COVID&#8208;Vac (n)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Placebo (n)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2.56</td><td valign="top" colspan="1" rowspan="1">16,501</td><td valign="top" colspan="1" rowspan="1">5476</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0106" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Gam&#8208;COVID&#8208;Vac (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2.56</td><td valign="top" colspan="1" rowspan="1">16,501</td><td valign="top" colspan="1" rowspan="1">5476</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">*</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec></sec><sec id="CD015477-sec-0426"><title>Inactivated virus vaccine</title><sec id="CD015477-sec-0427"><title>CoronaVac &#8211; Sinovac versus adjuvant&#160;</title><p><table-wrap id="CD015477-tblf-0107" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>) Phase 2</td><td valign="top" colspan="1" rowspan="1">1.41</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>) Phase 1</td><td valign="top" colspan="1" rowspan="1">1.41</td><td valign="top" colspan="1" rowspan="1">24</td><td valign="top" colspan="1" rowspan="1">24</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>a (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04651790">NCT04651790</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.4</td><td valign="top" colspan="1" rowspan="1">270</td><td valign="top" colspan="1" rowspan="1">164</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04551547">NCT04551547</ext-link>)</td><td valign="top" colspan="1" rowspan="1">4.1</td><td valign="top" colspan="1" rowspan="1">219</td><td valign="top" colspan="1" rowspan="1">114</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04456595">NCT04456595</ext-link>)</td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">6201</td><td valign="top" colspan="1" rowspan="1">6207</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04582344">NCT04582344</ext-link>)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">6650</td><td valign="top" colspan="1" rowspan="1">3568</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.84</td><td valign="top" colspan="1" rowspan="1">124</td><td valign="top" colspan="1" rowspan="1">74</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><sup>a</sup><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link>)</td><td valign="top" colspan="1" rowspan="1">10.46</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0129" ref-type="ref-list">Pan 2021a</xref><sup>b</sup><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>)</td><td valign="top" colspan="1" rowspan="1">&#160;</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p><sup>a</sup>Results reported in&#160;<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>&#160;are already reported in&#160;<xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref>; consequently,&#160;<xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>&#160;is not included in the forest plots.&#8232;<sup>b</sup>We could not retrieve data from Pan 2021c; not included in the forest plots.</p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0108" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.41</td><td valign="top" colspan="1" rowspan="1">120</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.41</td><td valign="top" colspan="1" rowspan="1">24</td><td valign="top" colspan="1" rowspan="1">24</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>a&#160;<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04651790">NCT04651790</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.4</td><td valign="top" colspan="1" rowspan="1">270</td><td valign="top" colspan="1" rowspan="1">164</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04551547">NCT04551547</ext-link>)</td><td valign="top" colspan="1" rowspan="1">4.1</td><td valign="top" colspan="1" rowspan="1">219</td><td valign="top" colspan="1" rowspan="1">114</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04456595">NCT04456595</ext-link>)</td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">6201</td><td valign="top" colspan="1" rowspan="1">6207</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04582344">NCT04582344</ext-link>)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">6650</td><td valign="top" colspan="1" rowspan="1">3568</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.84</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">74</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link>)</td><td valign="top" colspan="1" rowspan="1">10.46</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">50</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0129" ref-type="ref-list">Pan 2021a</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>)</td><td valign="top" colspan="1" rowspan="1">&#160;</td><td valign="top" colspan="1" rowspan="1">60</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0428"><title>WIBP&#8208;CorV &#8211; Sinopharm&#8208;Wuhan versus adjuvant</title><p><table-wrap id="CD015477-tblf-0109" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>WIV04 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510207">NCT04510207</ext-link>; ChiCTR2000034780)</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">13,470</td><td valign="top" colspan="1" rowspan="1">13,471</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>&#160;(ChiCTR2000031809)</td><td valign="top" colspan="1" rowspan="1">4.77</td><td valign="top" colspan="1" rowspan="1">168</td><td valign="top" colspan="1" rowspan="1">168</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0110" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>WIV04 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>&#8232;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510207">NCT04510207</ext-link>; ChiCTR2000034780)</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">13,470</td><td valign="top" colspan="1" rowspan="1">13,471</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref>&#160;(ChiCTR2000031809)</td><td valign="top" colspan="1" rowspan="1">4.77</td><td valign="top" colspan="1" rowspan="1">168</td><td valign="top" colspan="1" rowspan="1">168</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0429"><title>BBIBP&#8208;CorV &#8211; Sinopharm&#8208; Beijing versus adjuvant</title><p><table-wrap id="CD015477-tblf-0111" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BBIBP&#8208;CorV (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Adjuvant (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>&#160;(ChiCTR2000032459)</td><td valign="top" colspan="1" rowspan="1">0.92</td><td valign="top" colspan="1" rowspan="1">84</td><td valign="top" colspan="1" rowspan="1">28</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510207">NCT04510207</ext-link>; ChiCTR2000034780)</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">13,470</td><td valign="top" colspan="1" rowspan="1">13,471</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>&#160;(ChiCTR2000032459)</td><td valign="top" colspan="1" rowspan="1">2.9</td><td valign="top" colspan="1" rowspan="1">252</td><td valign="top" colspan="1" rowspan="1">252</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0112" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BBIBP&#8208;CorV (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Adjuvant (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref>&#160;(ChiCTR2000032459)</td><td valign="top" colspan="1" rowspan="1">0.92</td><td valign="top" colspan="1" rowspan="1">84</td><td valign="top" colspan="1" rowspan="1">28</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510207">NCT04510207</ext-link>; ChiCTR2000034780)</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">13,470</td><td valign="top" colspan="1" rowspan="1">13,471</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref>&#160;(ChiCTR2000032459)</td><td valign="top" colspan="1" rowspan="1">2.9</td><td valign="top" colspan="1" rowspan="1">252</td><td valign="top" colspan="1" rowspan="1">252</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0430"><title>BBV152 &#8211; Bharat Biotech versus adjuvant</title><p><table-wrap id="CD015477-tblf-0113" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BBV152 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link>)</td><td valign="top" colspan="1" rowspan="1">6.38</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">75</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04641481">NCT04641481</ext-link>)</td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">12,889</td><td valign="top" colspan="1" rowspan="1">12,889</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0080" ref-type="ref-list">Ella 2021a</xref><sup>a</sup><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link>)</td><td valign="top" colspan="1" rowspan="1">3.87</td><td valign="top" colspan="1" rowspan="1">190</td><td valign="top" colspan="1" rowspan="1">190</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p><sup>a</sup>We could not retrieve data from Ella 2021c and the trial is not included in the analysis.</p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0114" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BBV152 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref><break/>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link>)&#160;</td><td valign="top" colspan="1" rowspan="1">6.38</td><td valign="top" colspan="1" rowspan="1">100</td><td valign="top" colspan="1" rowspan="1">75</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04641481">NCT04641481</ext-link>)</td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">12,889</td><td valign="top" colspan="1" rowspan="1">12,889</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0080" ref-type="ref-list">Ella 2021a</xref><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link>)</td><td valign="top" colspan="1" rowspan="1">3.87</td><td valign="top" colspan="1" rowspan="1">190</td><td valign="top" colspan="1" rowspan="1">190</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="CD015477-sec-0431"><title>Protein subunit</title><sec id="CD015477-sec-0432"><title>NVX&#8208;CoV2373 &#8211; Novavax versus placebo</title><p><table-wrap id="CD015477-tblf-0115" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>NVX&#8208;CoV2373 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.15</td><td valign="top" colspan="1" rowspan="1">29</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04611802">NCT04611802</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">19,965</td><td valign="top" colspan="1" rowspan="1">9984</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.15</td><td valign="top" colspan="1" rowspan="1">258</td><td valign="top" colspan="1" rowspan="1">257</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04583995">NCT04583995</ext-link>; EudraCT 2020&#8208;004123&#8208;16)</td><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">7593</td><td valign="top" colspan="1" rowspan="1">7594</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04533399">NCT04533399</ext-link>; PACTR202009726132275)</td><td valign="top" colspan="1" rowspan="1">1.15</td><td valign="top" colspan="1" rowspan="1">2206</td><td valign="top" colspan="1" rowspan="1">2200</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0116" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>NVX&#8208;CoV2373 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.15</td><td valign="top" colspan="1" rowspan="1">29</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04611802">NCT04611802</ext-link>)</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">19,965</td><td valign="top" colspan="1" rowspan="1">9984</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link>)</td><td valign="top" colspan="1" rowspan="1">1.15</td><td valign="top" colspan="1" rowspan="1">258</td><td valign="top" colspan="1" rowspan="1">257</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1"><bold>*</bold></td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04583995">NCT04583995</ext-link>; EudraCT 2020&#8208;004123&#8208;16)</td><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">7593</td><td valign="top" colspan="1" rowspan="1">7594</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04533399">NCT04533399</ext-link>; PACTR202009726132275)</td><td valign="top" colspan="1" rowspan="1">1.15</td><td valign="top" colspan="1" rowspan="1">2206</td><td valign="top" colspan="1" rowspan="1">2200</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0433"><title>FINLAY&#8208;FR&#8208;2 &#8211; FINLAY versus placebo</title><p><table-wrap id="CD015477-tblf-0117" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>FINLAY&#8208;FR&#8208;2 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>&#160;(RPCEC00000354)</td><td valign="top" colspan="1" rowspan="1">5.2</td><td valign="top" colspan="1" rowspan="1">14,679</td><td valign="top" colspan="1" rowspan="1">14,675</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">*</td></tr></tbody></table></table-wrap></p><p>&#160;</p><p><table-wrap id="CD015477-tblf-0118" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>FINLAY&#8208;FR&#8208;2 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT of specific antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMT of neutralizing antibody against 2019 novel coronavirus</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>&#160;(RPCEC00000354)</td><td valign="top" colspan="1" rowspan="1">5.2</td><td valign="top" colspan="1" rowspan="1">14,679</td><td valign="top" colspan="1" rowspan="1">14,675</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">*</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="CD015477-sec-0434"><title>Heterologous vaccine&#160;</title><sec id="CD015477-sec-0435"><title>Comparison: CoronaVac/Ad5&#8208;vectored versus homologous CoronaVac</title><p><table-wrap id="CD015477-tblf-0119" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac/</bold>&#8232;<bold>Ad5&#8208;vectored (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04892459">NCT04892459</ext-link>)</td><td rowspan="4" valign="top" colspan="1">1</td><td rowspan="4" valign="top" colspan="1">50</td><td rowspan="4" valign="top" colspan="1">50</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="7" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1">&#10003;</td><td colspan="2" valign="top" rowspan="1">&#10003;</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0436"><title>Comparison: ChAdOx1&#8208;S/BNT162b2 versus ChAdOx1&#8208;S</title><p><table-wrap id="CD015477-tblf-0120" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>ChAdOx1&#8208;S/BNT162b2 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>ChAdOx1&#8208;S (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref><break/>(ISRCTN69254139; EudraCT 2020&#8208;005085&#8208;33)</td><td rowspan="4" valign="top" colspan="1">2</td><td rowspan="4" valign="top" colspan="1">115</td><td rowspan="4" valign="top" colspan="1">115</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td colspan="7" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1"><bold>*</bold></td><td colspan="2" valign="top" rowspan="1"><bold>*</bold></td><td colspan="3" valign="top" rowspan="1">X</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0437"><title>Comparison: BNT162b2/ChAdOx1&#8208;S versus BNT162b2</title><p><table-wrap id="CD015477-tblf-0121" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BNT162b2/</bold><break/><bold>ChAdOx1&#8208;S (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BNT162b2 (n)</bold></td><td colspan="8" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref>&#8232;(ISRCTN69254139; EudraCT 2020&#8208;005085&#8208;33)</td><td rowspan="4" valign="top" colspan="1">2</td><td rowspan="4" valign="top" colspan="1">114</td><td rowspan="4" valign="top" colspan="1">119</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td><td valign="top" colspan="1" rowspan="1">&#10003;&#160;</td></tr><tr><td colspan="8" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1">&#10003;</td><td colspan="3" valign="top" rowspan="1">&#10003;</td><td colspan="3" valign="top" rowspan="1"><bold>*</bold></td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec></sec><sec id="CD015477-sec-0438"><title>Boosters</title><sec id="CD015477-sec-0439"><title>Comparison: BNT162b2 versus placebo</title><p><table-wrap id="CD015477-tblf-0122" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BNT162b2 (n)</bold><break/><bold>&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="8" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04885907">NCT04885907</ext-link>)<sup>a</sup></td><td rowspan="4" valign="top" colspan="1">1</td><td rowspan="4" valign="top" colspan="1">60</td><td rowspan="4" valign="top" colspan="1">60</td><td valign="top" colspan="1" rowspan="1">X</td><td colspan="2" valign="top" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td colspan="8" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p><sup>a</sup>Trial in immunocompromized participants.</p></sec><sec id="CD015477-sec-0440"><title>Comparison: FINLAY&#8208;FR&#8208;2 (25 &#956;g) + FR&#8208;1 (50 &#956;g) versus no booster</title><p><table-wrap id="CD015477-tblf-0123" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>FINLAY&#8208;FR&#8208;2 (25 &#956;g) + FR&#8208;1 (50 &#956;g) (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Placebo (n)</bold></td><td colspan="8" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref>&#160;(RPCEC00000354)</td><td rowspan="4" valign="top" colspan="1">5.2</td><td rowspan="4" valign="top" colspan="1">14,679</td><td rowspan="4" valign="top" colspan="1">14,675</td><td valign="top" colspan="1" rowspan="1">X</td><td colspan="2" valign="top" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td colspan="8" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1"><bold>*</bold></td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec></sec><sec id="CD015477-sec-0441"><title>Booster versus booster</title><sec id="CD015477-sec-0442"><title>Comparison: BNT162b2 or mRNA&#8208;1273/boost ChAdOx1 versus BNT162b2 or mRNA&#8208;1273/boost BNT162b2 or mRNA&#8208;1273</title><p><table-wrap id="CD015477-tblf-0124" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BNT162b2 or mRNA&#8208;1273/ Boost ChAdOx1 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>BNT162b2 or mRNA&#8208;1273/ Boost BNT162b2 or mRNA&#8208;1273 (n)</bold></td><td colspan="7" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref><sup>a</sup> (EudraCT 2021&#8208;002348&#8208;57)</td><td rowspan="4" valign="top" colspan="1">1</td><td rowspan="4" valign="top" colspan="1">30</td><td rowspan="4" valign="top" colspan="1">30</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td colspan="7" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p><sup>a</sup>Trial in immunocompromized participants.</p></sec><sec id="CD015477-sec-0443"><title>Comparison: CoronaVac/boost Ad5&#8208;vectored versus CoronaVac/boost</title><p><table-wrap id="CD015477-tblf-0125" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac/boost Ad5&#8208;vectored (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac/boost (n)</bold></td><td colspan="10" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04892459">NCT04892459</ext-link>)</td><td rowspan="4" valign="top" colspan="1">1</td><td rowspan="4" valign="top" colspan="1">100</td><td rowspan="4" valign="top" colspan="1">100</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="10" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="4" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1">&#10003;</td><td colspan="5" valign="top" rowspan="1">&#10003;</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0444"><title>Comparison: CoronaVac/boost BNT162b2 versus CoronaVac/boost</title><p><table-wrap id="CD015477-tblf-0126" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac/boost BNT162b2 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>CoronaVac/boost (n)</bold></td><td colspan="8" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04611243">NCT04611243</ext-link>)</td><td rowspan="4" valign="top" colspan="1">5.8</td><td rowspan="4" valign="top" colspan="1">40</td><td rowspan="4" valign="top" colspan="1">40</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td colspan="8" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0445"><title>Comparison: Ad26/Boost mRNA&#8208;1273 versus Ad26/boost</title><p><table-wrap id="CD015477-tblf-0127" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26/Boost mRNA&#8208;1273 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26/boost (n)</bold></td><td colspan="9" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04927936">NCT04927936</ext-link>)</td><td rowspan="4" valign="top" colspan="1">1</td><td rowspan="4" valign="top" colspan="1">106</td><td rowspan="4" valign="top" colspan="1">111</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td colspan="9" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="4" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="2" valign="top" rowspan="1">*</td><td colspan="4" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0446"><title>Comparison: Ad26/Boost BNT162b2 versus Ad26/boost</title><p><table-wrap id="CD015477-tblf-0128" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26/Boost BNT162b2 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26</bold><break/><bold>/boost (n)</bold></td><td colspan="8" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04927936">NCT04927936</ext-link>)</td><td rowspan="4" valign="top" colspan="1">1</td><td rowspan="4" valign="top" colspan="1">106</td><td rowspan="4" valign="top" colspan="1">111</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td colspan="8" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p>&#160;</p></sec><sec id="CD015477-sec-0447"><title>Comparison: Ad26/Boost BNT162b2 versus Ad26/Boost mRNA&#8208;1273</title><p><table-wrap id="CD015477-tblf-0129" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study ID</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Study follow&#8208;up (months</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26/Boost mRNA&#8208;1273 (n)</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Ad26/boost</bold><break/><bold>BNT162b2 (n)</bold></td><td colspan="8" align="center" valign="bottom" rowspan="1"><bold>Critical outcomes</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>Confirmed symptomatic COVID&#8208;19 after complete vaccination</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Severe or critical COVID&#8208;19</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>All&#8208;cause mortality</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Systemic reactogenicity events</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Any AE</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>SAE</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref>&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04927936">NCT04927936</ext-link>)</td><td rowspan="4" valign="top" colspan="1">1</td><td rowspan="4" valign="top" colspan="1">111</td><td rowspan="4" valign="top" colspan="1">111</td><td valign="top" colspan="1" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">&#10003;</td><td valign="top" colspan="1" rowspan="1">*</td><td valign="top" colspan="1" rowspan="1">*</td></tr><tr><td colspan="8" align="center" valign="top" rowspan="1"><bold>Important outcomes</bold></td></tr><tr><td colspan="2" valign="bottom" rowspan="1"><bold>GMT of specific antibody against SARS&#8208;COV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>GMT of neutralizing antibody against SARSCOV&#8208;2</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Local reactogenicity events</bold></td></tr><tr><td colspan="3" valign="top" rowspan="1">*</td><td colspan="2" valign="top" rowspan="1">*</td><td colspan="3" valign="top" rowspan="1">&#10003;</td></tr></tbody></table></table-wrap></p><p><bold>Key:</bold>&#160;&#8232;&#10003; A study result is available for inclusion in the synthesis.&#8232;X No study result is available for inclusion, (probably) because the P value, magnitude or direction of the results generated were considered unfavourable by the study investigators.&#8232;* No study result is available for inclusion, (probably) because the outcome was not assessed, or for a reason unrelated to the P value, magnitude or direction of the results.&#8232;? No study result is available for inclusion, and it is unclear if the outcome was assessed in the study.</p><p><bold>Abbreviations:</bold> AE: adverse event; GMR: geometric mean ratio; n: number of participants; SAE: serious adverse event.</p></sec></sec></app><app id="CD015477-sec-0448"><title>Appendix 10. BNT162b2 &#8211; BioNtech/Fosun Pharma/Pfizer versus placebo</title><p><table-wrap id="CD015477-tblf-0130" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">44,077</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">97.84% (44.25% to 99.92%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">46,077</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">95.70% (73.90% to 99.90%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">43,847</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.07 (0.52 to 2.22)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">46,107</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.30 (0.55 to 3.07)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">46,149</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.52 (0.88 to 2.63)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td colspan="6" rowspan="1">CI: confidence interval; N/A: not applicable.</td></tr></tbody></table></table-wrap></p></app><app id="CD015477-sec-0449"><title>Appendix 11. Neutralizing antibody geometric mean titre</title><sec id="CD015477-sec-0450"><title>RNA&#8208;based vaccines</title><p><table-wrap id="CD015477-tblf-0131" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="top" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1">COVID&#8208;19 <bold>vaccine versus placebo</bold></td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref></td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;</td><td valign="top" colspan="1" rowspan="1">1283.00<break/>(1139.60 to 1444.50)</td><td rowspan="2" valign="top" colspan="1">84.96 (58.90 to 122.55)</td><td rowspan="2" valign="top" colspan="1">Not specified</td><td rowspan="2" valign="top" colspan="1">1 month after 2nd dose</td><td rowspan="2" valign="top" colspan="1">SARS&#8208;CoV&#8208;2 50% neutralizing assay<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">12&#8211;15 years<break/>&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">15.10 (10.70 to 21.40)</td></tr><tr><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;</td><td valign="top" colspan="1" rowspan="1">730.80 (646.70 to 825.80)</td><td rowspan="2" valign="top" colspan="1">68.29 (56.55 to 82.48)</td><td rowspan="2" valign="top" colspan="1">Not specified</td><td rowspan="2" valign="top" colspan="1">1 month after 2nd dose</td><td rowspan="2" valign="top" colspan="1">SARS&#8208;CoV&#8208;2 50% neutralizing assay<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">16&#8211;25 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">10.70<break/>(9.30 to 12.40)</td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;</td><td rowspan="2" valign="top" colspan="1">163 (no CIs)</td><td rowspan="2" valign="top" colspan="1">16.30</td><td rowspan="2" valign="top" colspan="1">Not specified</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose (time point not specified for placebo)</td><td rowspan="2" valign="top" colspan="1">SARS&#8208;CoV&#8208;2 serum 50% neutralizing assay</td><td rowspan="2" valign="top" colspan="1">18&#8211;55 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td></tr><tr><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;</td><td rowspan="2" valign="top" colspan="1">206 (no CIs)</td><td rowspan="2" valign="top" colspan="1">20.60</td><td rowspan="2" valign="top" colspan="1">Not specified</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose (time point not specified for placebo)</td><td rowspan="2" valign="top" colspan="1">SARS&#8208;CoV&#8208;2 serum 50% neutralizing assay</td><td rowspan="2" valign="top" colspan="1">65&#8211;85 years<break/>&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean ratio; GMT: geometric mean titre.</p></sec><sec id="CD015477-sec-0451"><title>Non&#8208;replicant viral vector vaccines&#160;</title><p><table-wrap id="CD015477-tblf-0132" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>&#160;Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1">COVID&#8208;19 <bold>vaccine versus placebo</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">224 (158 to 318)</td><td rowspan="2" valign="top" colspan="1">3.86 (2.72 to 5.47)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">29 days after vaccination</td><td rowspan="2" valign="top" colspan="1">Wild&#8208;type virus microneutralization assay using the Victoria/1/2020 SARSCoV&#8208;2 strain</td><td rowspan="2" valign="top" colspan="1">18 and 55 years&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">58 (58 to 58)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S</td><td valign="top" colspan="1" rowspan="1">212<break/>&#160;(137 to 284)</td><td rowspan="2" valign="top" colspan="1">3.65 (2.53 to 5.26)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">15 days after vaccination</td><td rowspan="2" valign="top" colspan="1">Wild&#8208;type virus microneutralization assay using the Victoria/1/2020 SARS&#8208;CoV&#8208;2 strain</td><td rowspan="2" valign="top" colspan="1">&#8805; 65 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">&#160;58 (58 to 58)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac rAd26&#8208;S</td><td valign="top" colspan="1" rowspan="1">44.50&#160;<break/>(31.80 to 62.20)</td><td rowspan="2" valign="top" colspan="1">28.46 (17.71 to 45.75)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">21 days after second dose</td><td rowspan="2" valign="top" colspan="1">Microneutralization assay using SARS&#8208;CoV&#8208;2 (hCoV&#8208;19/Russia/Moscow_PMVL&#8208;1/2020) in a 96&#8208;well plate and a 50% tissue culture infective dose (TCID50) of 100</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">1.60<break/>(1.12 to 2.19)</td></tr><tr><td colspan="8" valign="top" rowspan="1">COVID&#8208;19 <bold>vaccine versus</bold> COVID&#8208;19 <bold>vaccine&#160;</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">SII&#8208;ChAdOx1</td><td valign="top" colspan="1" rowspan="1">69.90&#160;<break/>(60.80 to 80.40)</td><td rowspan="2" valign="top" colspan="1">1.23 (0.92 to 1.63)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after dose 2<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">Pseudo virus&#8208;based microneutralization assay<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years<break/>&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">56.80 (44.40 to 72.50)</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean ratio; GMT: geometric mean titre.</p></sec><sec id="CD015477-sec-0452"><title>Inactivated virus vaccines</title><p><table-wrap id="CD015477-tblf-0133" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Units of analysis</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Timepoint</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1">COVID&#8208;19 <bold>vaccine versus adjuvant/placebo</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">10.10<break/>(7.28 to 14.01)</td><td rowspan="2" valign="top" colspan="1">1.84 (1.32 to 2.55)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">2 weeks after 2nd dose</td><td rowspan="2" valign="top" colspan="1">A SINOVAC standardized microtitre methodology, conventional virus neutralization</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">5.48<break/>(1.84 to 16.29)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">&#160;5.60 (3.60 to 8.70)</td><td rowspan="2" valign="top" colspan="1">2.80 (1.80 to 4.25)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">2 weeks after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Microcytopathogenic effect assay</td><td rowspan="2" valign="top" colspan="1">Phase 1: 18&#8211;59 years, healthy</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">&#160;2 (2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">27.60 (22.70 to 33.50)</td><td rowspan="2" valign="top" colspan="1">11.90 (10.23 to 13.83)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">2 weeks after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Microcytopathogenic effect assay</td><td rowspan="2" valign="top" colspan="1">Phase 2: 18&#8211;59 years, healthy</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">&#160;2 (2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">142.20 (124.70 to 162.10)</td><td rowspan="2" valign="top" colspan="1">67.71 (59.25 to 77.37)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Microcytopathogenic effect assay&#160;</td><td rowspan="2" valign="top" colspan="1">Phase 2: 3&#8211;17 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.10 (2 to 2.1)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">42.20<break/>(35.20 to 50.60)</td><td rowspan="2" valign="top" colspan="1">20.09 (16.73 to 24.13)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Microcytopathogenic effect assay</td><td rowspan="2" valign="top" colspan="1">Phase 2: &#8805; 60 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">2.10 (2 to 2.10)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">15.76 (14.57 to 17.04)</td><td rowspan="2" valign="top" colspan="1">7.80 (7.20 to 8.45)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Not clear</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.02 (1.98 to 2.05)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">94.50 (89.70 to 99.50)</td><td rowspan="2" valign="top" colspan="1">35 (32.83 to 37.30)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.70 (2.60 to 2.80)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">156 (149.60 to 162.70)</td><td rowspan="2" valign="top" colspan="1">57.77 (54.63 to 61.10)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nddose</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.70 (2.60 to 2.80)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">134&#160;<break/>(104 to 174)</td><td rowspan="2" valign="top" colspan="1">26.80 (20.71 to 34.66)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after whole course vaccination</td><td rowspan="2" valign="top" colspan="1">Plaque reduction neutralization test (PRNT)&#160;<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">5<break/>(5 to 5)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">218.90&#160;<break/>(165.60 to 289.50)</td><td rowspan="2" valign="top" colspan="1">109.45 (82.77 to 144.73)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 1st inoculation</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">Phase 2:<break/>&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2<break/>(2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV&#160;</td><td valign="top" colspan="1" rowspan="1">180.20<break/>(163.60 to 198.40)</td><td rowspan="2" valign="top" colspan="1">90.10 (81.81 to 99.22)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd inoculation&#160;</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">3&#8211;5 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">2<break/>(2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV&#160;</td><td valign="top" colspan="1" rowspan="1">168.60 (151.90 to 187)</td><td rowspan="2" valign="top" colspan="1">84.30 (75.97 to 93.53)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd inoculation</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">6&#8211;12 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">2<break/>(2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">155.7 (137.7 to 176.5)</td><td rowspan="2" valign="top" colspan="1">77.87 (68.71 to 88.24)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd inoculation</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">13&#8211;17 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">2<break/>(2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">BBV152</td><td valign="top" colspan="1" rowspan="1">125.60<break/>(111.20 to 141.80)</td><td rowspan="2" valign="top" colspan="1">9.16 (2.28 to 36 to 78)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd vaccination</td><td rowspan="2" valign="top" colspan="1">MNT50 assay<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">13.70<break/>(10.70 to 170.40)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">BBV152</td><td valign="top" colspan="1" rowspan="1">66.40&#160;<break/>(53.40 to 82.40)</td><td rowspan="2" valign="top" colspan="1">9.22 (7.25 to 11.80)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">Day 28</td><td rowspan="2" valign="top" colspan="1">MNT50 assay<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">18&#8211;55 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">7.20&#160;<break/>(6.40 to 8.10)</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean ratio; GMT: geometric mean titre.</p></sec><sec id="CD015477-sec-0453"><title>Protein subunit vaccines</title><p><table-wrap id="CD015477-tblf-0134" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="3" valign="bottom" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td colspan="2" valign="top" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="9" valign="top" rowspan="1">COVID&#8208;19 <bold>vaccine versus placebo</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref></td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td colspan="2" valign="top" rowspan="1">3906.30<break/>(2555.90 to 5970)</td><td rowspan="2" valign="top" colspan="1">195.315 (127.79 to 298.50)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">Day 35 (14 days after 2nddose)</td><td rowspan="2" valign="top" colspan="1">Wild&#8208;type SARS&#8208;CoV&#8208;2 microneutralization<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td colspan="2" valign="top" rowspan="1">20&#160;<break/>(20 to 20)</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean ratio; GMT: geometric mean titre.</p></sec><sec id="CD015477-sec-0454"><title>Primary series heterologous vaccination scheme versus homologous vaccination scheme</title><p><table-wrap id="CD015477-tblf-0135" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Result</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1"><bold>Heterologous schedule versus homologous schedule</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac/Ad5&#160;</td><td valign="top" colspan="1" rowspan="1">54.40<break/>(37.90 to 78)&#160;</td><td rowspan="2" valign="top" colspan="1">4.25 (2.63 to 6.86)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Cytopathic effect&#8208;based microneutralization assay with a wild&#8208;type SARS&#8208;CoV&#8208;2 virus strain&#160;</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">12.80&#160;<break/>(9.30 to 17.50)&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean ratio; GMT: geometric mean titre.</p></sec><sec id="CD015477-sec-0455"><title>Boosters</title><p><table-wrap id="CD015477-tblf-0136" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Estimate effect</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1"><bold>Heterologous boost versus homologous boost</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac/Ad5 boost</td><td valign="top" colspan="1" rowspan="1">197.40&#160;<break/>(167.70 to 232.40)</td><td rowspan="2" valign="top" colspan="1">5.87 (4.64 to 7.43)</td><td rowspan="2" valign="top" colspan="1">BAU/mL</td><td rowspan="2" valign="top" colspan="1">14 days after boost</td><td rowspan="2" valign="top" colspan="1">ELISA RBD&#8208;binding IgG</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">CoronaVac/CoronaVac boost</td><td valign="top" colspan="1" rowspan="1">33.60&#160;<break/>(28.30 to 39.80)</td></tr></tbody></table></table-wrap></p><p>BAU: binding antibody units; CI: confidence interval; ELISA: enzyme&#8208;linked immunosorbent assay; GMR: geometric mean ratio; GMT: geometric mean titre; IgG: immunoglobulin G; RBD: receptor&#8208;binding domain.</p></sec></app><app id="CD015477-sec-0456"><title>Appendix 12. Specific adverse events</title><sec id="CD015477-sec-0457"><title>Cardioembolic events</title><p><table-wrap id="CD015477-tblf-0137" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Type of vaccine</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>&#160;Study ID</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Arms&#160;</bold><break/><bold>(number analyzed)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>&#160;Intervention</bold><break/><bold>&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Pulmonary embolism&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Stroke</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Cavernous sinus thrombosis</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Pericarditis</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Venous thrombosis</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Myocardial infarction</bold></td></tr><tr><td rowspan="14" valign="top" colspan="1"><bold>RNA&#8208;based vaccine</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,926)</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(21,921)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(1131)</td><td valign="top" colspan="1" rowspan="1">BNT162b2<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1129)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(24)</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(18)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(15,166)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">6<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">47;&#160;<break/>8 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">7</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(15,151)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">7<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">43;&#160;<break/>6 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">9</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(2482)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1238)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(2002)</td><td valign="top" colspan="1" rowspan="1">CVnCoV</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1980)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#8232;(60)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 booster&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(59)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273/placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="16" valign="top" colspan="1"><bold>Non&#8208;replicating viral vector</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(52)&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(52)</td><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,587)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1&#160;</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(10,792)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(12,021)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(11,724)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">0 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">&#160;<break/>2</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(192)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(64)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(300)</td><td valign="top" colspan="1" rowspan="1">SII&#8208;ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(100)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref><break/>&#160;<break/>&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(323)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(163)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,895)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S&#160;</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">6 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(21,888)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">2 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(16,427)</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">2</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(5435)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">1</td></tr><tr><td rowspan="29" valign="top" colspan="1"><bold>Inactivated virus</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(99)</td><td valign="top" colspan="1" rowspan="1">BBV152&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(73)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(12,879)</td><td valign="top" colspan="1" rowspan="1">BBV152</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(12,874)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(24)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(24)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(270)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(164)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(217)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(114)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#8232;(6202)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(6194)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#160;<break/>(124)&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(74)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="3" valign="top" colspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(13,464)</td><td valign="top" colspan="1" rowspan="1">WIV04&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(13,471)</td><td valign="top" colspan="1" rowspan="1">HBO2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(13,453)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention (6646)<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(3568)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention&#160;&#8232;(405)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0 vascular disorders</td><td valign="top" colspan="1" rowspan="1">NR<break/>&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(135)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1 vascular disorder</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref><break/>Phase 1 and 2</td><td valign="bottom" colspan="1" rowspan="1">Intervention (84)</td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention (252)</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(252)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(84)</td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="13" valign="top" colspan="1"><bold>Protein subunit</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(258)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2 vascular disorders</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(255)</td><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2 vascular disorders</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(29)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(23)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(484)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(484)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(7569)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1 myocarditis</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(7570)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0 myocarditis</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(19,965)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(9984)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2&#160;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="3" valign="top" colspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(14,675)</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(14,679)</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2/booster FR&#8208;1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(14,677)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="6" valign="top" colspan="1"><bold>Homologous versus</bold><break/><bold>heterologous scheme&#160;</bold><break/>&#160;</td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(51)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/Ad5</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(50)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(115)</td><td valign="top" colspan="1" rowspan="1">ChAd/BNT</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1 deep venous thrombosis</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(114)</td><td valign="top" colspan="1" rowspan="1">ChAd/ChAd</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(119)</td><td valign="top" colspan="1" rowspan="1">BNT162b2/ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(115)</td><td valign="top" colspan="1" rowspan="1">BNT162b2/BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="10" valign="top" colspan="1"><bold>Homologous or heterologous booster</bold><break/><bold>versus</bold><break/><bold>heterologous booster</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#160;<break/>(27)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 booster</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">BNT162b2 or mRNA&#8208;1273 booster</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></td><td valign="top" colspan="1" rowspan="1">Control<break/>(105)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S/no booster</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(106)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(112)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(111)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(30)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(30)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(96)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster Ad5</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(102)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr></tbody></table></table-wrap></p><p>NR: not reported; RNA: ribonucleic acid.</p></sec><sec id="CD015477-sec-0458"><title>Haematological events&#160;</title><p><table-wrap id="CD015477-tblf-0138" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Type of vaccine</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>&#160;Study ID</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Arms&#160;</bold><break/><bold>(number analyzed)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>&#160;Intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Thrombocytopaenia&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Haemorrhage</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Neutropenia</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Anaemia</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Lymphadenopathy</bold></td></tr><tr><td rowspan="14" valign="top" colspan="1"><bold>RNA&#8208;based vaccine</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,926)</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(21,921)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(1131)</td><td valign="top" colspan="1" rowspan="1">BNT162b2<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">10</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1129)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref>a</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(24)</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(18)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(15,166)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(15,151)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(2482)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">108</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1238)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">5</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(2002)</td><td valign="top" colspan="1" rowspan="1">CVnCoV</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1980)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#8232;(60)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 booster&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(59)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273/placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="16" valign="top" colspan="1"><bold>Non&#8208;replicating viral vector</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(52)&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(52)</td><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,587)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1&#160;</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(10,792)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(12,021)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(11,724)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(192)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(64)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(300)</td><td valign="top" colspan="1" rowspan="1">SII&#8208;ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(100)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(323)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(163)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,895)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(21,888)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(16,427)</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">6</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(5435)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td></tr><tr><td rowspan="29" valign="top" colspan="1"><bold>Inactivated virus</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(99)</td><td valign="top" colspan="1" rowspan="1">BBV152&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(73)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(12,879)</td><td valign="top" colspan="1" rowspan="1">BBV152</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1 death due to cerebellar haemorrhage; 1 death due to haemorrhagic stroke</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(12,874)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(24)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(24)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref>a</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(270)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(164)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(217)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(114)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#8232;(6202)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(6194)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#160;<break/>(124)&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(74)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="3" valign="top" colspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(13,464)</td><td valign="top" colspan="1" rowspan="1">WIV04&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(13,471)</td><td valign="top" colspan="1" rowspan="1">HBO2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(13,453)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention&#160;<break/>(6646)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(3568)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention&#160;<break/>(405)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(135)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention (84)</td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">NR&#160;</td><td valign="top" colspan="1" rowspan="1">NR&#160;</td><td valign="top" colspan="1" rowspan="1">NR&#160;</td><td valign="top" colspan="1" rowspan="1">NR&#160;</td><td valign="top" colspan="1" rowspan="1">NR&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention (252)</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(252)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">&#160;NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(84)</td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#160;&#8232;(28)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="13" valign="top" colspan="1">&#160;<break/>&#160;<break/>&#160;<break/>&#160;<break/>&#160;<break/>&#160;<break/>&#160;<break/>&#160;<break/>&#160;<break/><bold>Protein subunit</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(258)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">3</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(255)</td><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(29)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(23)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(484)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(484)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(7569)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">72 blood and lymphatic system disorders</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(7570)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">61 blood and lymphatic system disorders</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(19,965)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">1&#160;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">53</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(9984)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">13</td></tr><tr><td rowspan="3" valign="top" colspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(14,675)</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(14,679)</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2/boost FR&#8208;1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(14,677)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="6" valign="top" colspan="1"><bold>Homologous versus</bold><break/><bold>heterologous scheme&#160;</bold><break/>&#160;</td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(51)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/Ad5</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(50)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention<break/>(115)&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1/BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control&#160;<break/>(114)&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1/ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Intervention<break/>(119)&#160;</td><td valign="top" colspan="1" rowspan="1">BNT162b2/ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control&#160;<break/>(115)&#160;</td><td valign="top" colspan="1" rowspan="1">BNT162b2/BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="10" valign="top" colspan="1"><bold>Homologous or heterologous booster</bold><break/><bold>versus</bold><break/><bold>heterologous booster</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#160;<break/>(27)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 booster</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">BNT162b2 or mRNA&#8208;1273 booster</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></td><td valign="top" colspan="1" rowspan="1">Control<break/>(105)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S/no boost</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(106)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(112)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(111)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(30)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(30)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(96)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster Ad5</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(102)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr></tbody></table></table-wrap></p><p>NR: not reported; RNA: ribonucleic acid.</p></sec><sec id="CD015477-sec-0459"><title>Neurological events</title><p><table-wrap id="CD015477-tblf-0139" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Type of vaccine</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>&#160;Study ID</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Arms&#160;</bold><break/><bold>(number analyzed)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>&#160;Intervention</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Nervous system diseases</bold></td></tr><tr><td rowspan="14" valign="top" colspan="1"><bold>RNA&#8208;based vaccine</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,926)</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(21,921)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(1131)</td><td valign="top" colspan="1" rowspan="1">BNT162b2<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1129)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(24)</td><td valign="top" colspan="1" rowspan="1">BNT162b2&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(18)</td><td valign="top" colspan="1" rowspan="1">Placebo<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(15,166)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">2 embolic stroke; 0 ischaemic stroke</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(15,151)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">0 embolic stroke; 1 ischaemic stroke</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(2482)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1238)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(2002)</td><td valign="top" colspan="1" rowspan="1">CVnCoV</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(1980)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention&#8232;(60)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273 boost&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(59)</td><td valign="top" colspan="1" rowspan="1">mRNA&#8208;1273/placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="16" valign="top" colspan="1"><bold>Non&#8208;replicating viral vector</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(52)&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">16</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(52)</td><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">10</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,587)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1&#160;</td><td valign="top" colspan="1" rowspan="1">34 paresthesia</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(10,792)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">16 paresthesia</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(12,021)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">1 ischaemic stroke</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(11,724)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">0 ischaemic stroke</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(192)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(64)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(300)</td><td valign="top" colspan="1" rowspan="1">SII&#8208;ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(100)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(323)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(163)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref><break/>&#160;<break/>&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(21,895)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(21,888)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(16,427)</td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac&#160;</td><td valign="top" colspan="1" rowspan="1">0 haemorrhagic stroke; 1 paraesthesia</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(5435)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">1 haemorrhagic stroke; 1 paraesthesia</td></tr><tr><td rowspan="29" valign="top" colspan="1"><bold>Inactivated virus</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(99)</td><td valign="top" colspan="1" rowspan="1">&#160;BBV152&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(73)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref>&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(12,879)</td><td valign="top" colspan="1" rowspan="1">BBV152</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(12,874)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(24)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(24)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(270)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(164)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(217)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(114)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#8232;(6202)</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(6194)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#160;<break/>(124)&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(74)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="3" valign="top" colspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(13,464)</td><td valign="top" colspan="1" rowspan="1">WIV04 Al Kaabi</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(13,471)</td><td valign="top" colspan="1" rowspan="1">HBO2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(13,453)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1">&#160;<xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">Intervention&#160;&#8232;(6646)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control (3568)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">1 acute cerebellar infarction</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention (405)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">51</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(135)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">20</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention (84)</td><td valign="top" colspan="1" rowspan="1">&#160;WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">NR&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention (252)</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control<break/>(252)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(84)</td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="13" valign="top" colspan="1"><bold>Protein subunit</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(258)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373&#160;</td><td valign="top" colspan="1" rowspan="1">5</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(255)</td><td valign="top" colspan="1" rowspan="1">Placebo&#160;</td><td valign="top" colspan="1" rowspan="1">4</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(29)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(23)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(484)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(484)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">1</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(7569)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">32</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(7570)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">31</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(19,965)</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td valign="top" colspan="1" rowspan="1">2 stroke</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(9984)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">0 stroke</td></tr><tr><td rowspan="3" valign="top" colspan="1"><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(14,675)</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(14,679)</td><td valign="top" colspan="1" rowspan="1">FINLAY&#8208;FR&#8208;2/boostwe FR&#8208;1</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(14,677)</td><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="6" valign="top" colspan="1"><bold>Homologous versus heterologous scheme&#160;</bold><break/>&#160;</td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(51)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/Ad5</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(50)</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="4" valign="top" colspan="1">&#160;<break/>&#160;<break/><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention<break/>(115)&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1/BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control&#160;<break/>(114)&#160;</td><td valign="top" colspan="1" rowspan="1">ChAdOx1/<break/>ChAdOx1NR</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Intervention<break/>(119)&#160;</td><td valign="top" colspan="1" rowspan="1">BNT162b2/ChAdOx1</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Control&#160;<break/>(115)&#160;</td><td valign="top" colspan="1" rowspan="1">BNT162b2/BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="10" valign="top" colspan="1"><bold>Homologous or heterologous booster versus</bold><break/><bold>heterologous booster</bold></td><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention&#160;<break/>(27)</td><td valign="top" colspan="1" rowspan="1">ChAdOx1 booster</td><td valign="top" colspan="1" rowspan="1">0 neurological complications</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(28)</td><td valign="top" colspan="1" rowspan="1">BNT162b2 or mRNA&#8208;1273 booster</td><td valign="top" colspan="1" rowspan="1">0 neurological complications</td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></td><td valign="top" colspan="1" rowspan="1">Control<break/>(105)</td><td valign="top" colspan="1" rowspan="1">Ad26.COV2.S/no booster</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(106)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(112)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster mRNA&#8208;1273</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention<break/>(111)</td><td valign="top" colspan="1" rowspan="1">Ad26/booster BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(30)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control<break/>(30)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster BNT162b2</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention<break/>(96)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/boost Ad5</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control&#8232;(102)</td><td valign="top" colspan="1" rowspan="1">CoronaVac/booster&#160;</td><td valign="top" colspan="1" rowspan="1">NR</td></tr><tr><td colspan="5" rowspan="1">NR: not reported; RNA: ribonucleic acid.</td></tr></tbody></table></table-wrap></p></sec></app><app id="CD015477-sec-0460"><title>Appendix 13. mRNA&#8208;1273 &#8211; ModernaTX versus placebo</title><p><table-wrap id="CD015477-tblf-0140" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">31,632</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">73.27% (35.82% to 88.87%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">31,632</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">93.20% (91.06% to 94.83%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">28,451</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">98.20% (92.80% to 99.60%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">30,346</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.06 (0.54 to 2.10)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">34,072</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.78 to 1.08)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">34,037</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.28 (1.22 to 1.34)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">34,072</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">Outcome not pooled due to considerable heterogeneity&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">34,037</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">3.30 (2.02 to 5.40)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td colspan="6" rowspan="1">CI: confidence interval; N/A: not applicable.</td></tr></tbody></table></table-wrap></p></app><app id="CD015477-sec-0461"><title>Appendix 14. CVnCoV &#8211; CureVac AG versus placebo</title><p><table-wrap id="CD015477-tblf-0141" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,062</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">48.20% (31.70% to 60.90%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,062</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">63.80% (0.00% to 91.70%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">39,529</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.33 (0.46 to 3.83)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">39,529</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.24 (0.90 to 1.71)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">3982</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.48 (1.43 to 1.53)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">3982</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.42 (1.38 to 1.47)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">3982</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">3.51 (3.24 to 3.81)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td colspan="6" rowspan="1">CI: confidence interval; N/A: not applicable</td></tr></tbody></table></table-wrap></p></app><app id="CD015477-sec-0462"><title>Appendix 15. ChAdOx1/SII&#8208;ChAdOx1 &#8211; AstraZeneca + University of Oxford/Serum Institute of India versus placebo</title><p><table-wrap id="CD015477-tblf-0142" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">43,390</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">59.35% (48.00% to 68.22%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">43,390</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">70.23% (62.10% to 76.62%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">56,727&#8232;&#160;</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.48 (0.20 to 1.14)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">7</td><td valign="top" colspan="1" rowspan="1">58,182</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.88 (0.72 to 1.07)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">256</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">3.93 (2.11 to 7.29)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">7</td><td valign="top" colspan="1" rowspan="1">57,580</td><td valign="top" colspan="1" rowspan="1">&#160;</td><td valign="top" colspan="1" rowspan="1">Not pooled</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">256</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">6.44 (2.98 to 13.92)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0463"><title>Appendix 16. Specific antibody geometric mean titre</title><sec id="CD015477-sec-0464"><title>Non&#8208;replicant viral vector vaccines&#160;</title><p><table-wrap id="CD015477-tblf-0143" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td colspan="2" valign="top" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="9" valign="top" rowspan="1"><bold>COVID&#8208;19 vaccine versus placebo/other no COVID&#8208;19 vaccine</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">&#160;ChAdOx1 at&#160;<break/>&lt; 6 weeks interval</td><td colspan="2" valign="top" rowspan="1">219.66<break/>(197.53 to 244.27)<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">296.83&#160;<break/>(245.86 to 358.37)&#160;</td><td rowspan="2" valign="top" colspan="1">ELISA units&#160;</td><td rowspan="2" valign="top" colspan="1">28 days after second dose</td><td rowspan="2" valign="top" colspan="1">Multiplexed immunoassay/RBD&#8208;binding IgG</td><td rowspan="2" valign="top" colspan="1">18&#8211;55 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">MenACWY vaccine/placebo</td><td colspan="2" valign="top" rowspan="1">74 (63 to 86)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></td><td valign="top" colspan="1" rowspan="1">&#160;ChAdOx1 at&#160;<break/>&lt; 6 weeks interval</td><td colspan="2" valign="top" rowspan="1">188.59&#160;<break/>(169.00 to 210.46)</td><td rowspan="2" valign="top" colspan="1">471.47<break/>&#160;(395.69 to 561.77)<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">ELISA units&#160;</td><td rowspan="2" valign="top" colspan="1">28 days after second dose</td><td rowspan="2" valign="top" colspan="1">Multiplexed immunoassay/RBD&#8208;binding IgG</td><td rowspan="2" valign="top" colspan="1">&#8805; 56 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">MenACWY vaccine/placebo</td><td colspan="2" valign="top" rowspan="1">40<break/>(35 to 46)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Gam&#8208;COVID&#8208;Vac rAd26&#8208;S</td><td colspan="2" valign="top" rowspan="1">8996<break/>(7610 to 10 635)</td><td rowspan="2" valign="top" colspan="1">294.46 (188.27 to 460.56)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">21 days after second dose&#160;<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">ELISA<break/>RBD&#8208;binding IgG</td><td rowspan="2" valign="top" colspan="1">&#8805; 18</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td colspan="2" valign="top" rowspan="1">30.55 (20.18 to 46.26)</td></tr><tr><td colspan="9" valign="top" rowspan="1"><bold>COVID&#8208;19 vaccine versus COVID&#8208;19 vaccine</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></td><td valign="top" colspan="1" rowspan="1">SII&#8208;ChAdOx1</td><td colspan="2" valign="top" rowspan="1">&#160;9636.70&#160;<break/>(7983.70 to 11,631.90)</td><td rowspan="2" valign="top" colspan="1">1.52 (1.03 to 2.26)</td><td rowspan="2" valign="top" colspan="1">Arbitrary units<break/>(AU)/mL<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">28 days after dose 1</td><td rowspan="2" valign="top" colspan="1">ELISpot assay<break/>RBD&#8208;binding IgG<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">&#8805; 18</td></tr><tr><td valign="top" colspan="1" rowspan="1">ChAdOx1</td><td colspan="2" valign="top" rowspan="1">6311.20&#160;<break/>(4470.10 to 8910.60)</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; ELISA: enzyme&#8208;linked immunosorbent assay; GMR: geometric mean rate; GMT: geometric mean titre; IgG: immunoglobulin G; RBD: receptor&#8208;binding domain.</p></sec><sec id="CD015477-sec-0465"><title>Inactivated virus vaccines</title><p><table-wrap id="CD015477-tblf-0144" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Units of analysis</bold><break/><bold>&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="top" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1">COVID&#8208;19 <bold>vaccine versus adjuvant/placebo</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">10.10<break/>(7.28 to 14.01)</td><td rowspan="2" valign="top" colspan="1">1.84 (1.32 to 2.55)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">2 weeks after 2nd dose</td><td rowspan="2" valign="top" colspan="1">A SINOVAC standardized microtitre methodology, conventional virus neutralization</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">5.48<break/>(1.84 to 16.29)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">5.60 (3.60 to 8.70)</td><td rowspan="2" valign="top" colspan="1">2.80 (1.80 to 4.25)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">2 weeks after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Micro&#8208;cytopathogenic effect assay</td><td rowspan="2" valign="top" colspan="1">Phase 1: healthy and aged 18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">&#160;2 (2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">27.60 (22.70 to 33.5)</td><td rowspan="2" valign="top" colspan="1">11.90 (10.23 to 13.83)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">2 weeks after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Micro&#8208;cytopathogenic effect assay</td><td rowspan="2" valign="top" colspan="1">Phase 2: healthy and aged 18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2 (2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">142.20 (124.70 to 162.10)</td><td rowspan="2" valign="top" colspan="1">67.71 (59.25 to 77.37)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Micro&#8208;cytopathogenic effect assay&#160;</td><td rowspan="2" valign="top" colspan="1">Phase 2: 3&#8211;17 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.10 (2 to 2.10)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">42.20<break/>(35.20 to 50.60)</td><td rowspan="2" valign="top" colspan="1">20.09 (16.73 to 24.13)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Micro&#8208;cytopathogenic effect assay</td><td rowspan="2" valign="top" colspan="1">Phase 2: aged &#8805; 60 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">2.10 (2 to 2.10)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></td><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">15.76 (14.57 to 17.04)</td><td rowspan="2" valign="top" colspan="1">7.80 (7.20 to 8.45)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Not clear</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.02 (1.98 to 2.05)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">94.50 (89.70 to 99.50)</td><td rowspan="2" valign="top" colspan="1">35 (32.83 to 37.30)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.70 (2.60 to 2.80)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">156 (149.60 to 162.70)</td><td rowspan="2" valign="top" colspan="1">57.77 (54.63 to 61.10)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">&#8805; 80 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2.70 (2.60 to 2.80)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></td><td valign="top" colspan="1" rowspan="1">WIBP&#8208;CorV&#160;<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">134&#160;<break/>(104 to 174)</td><td rowspan="2" valign="top" colspan="1">26.80 (20.71 to 34.66)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after whole course vaccination</td><td rowspan="2" valign="top" colspan="1">Plaque reduction neutralization test (PRNT)&#160;<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">5<break/>(5 to 5)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref></td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV<break/>&#160;</td><td valign="top" colspan="1" rowspan="1">218.90&#160;<break/>(165.60 to 289.50)</td><td rowspan="2" valign="top" colspan="1">109.45 (82.77 to 144.73)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after lst inoculation</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">Phase 2<break/>&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td valign="top" colspan="1" rowspan="1">2&#160;<break/>(2 to 2)</td></tr><tr><td rowspan="6" valign="top" colspan="1"><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV&#160;</td><td valign="top" colspan="1" rowspan="1">180.20<break/>(163.60 to 198.40)</td><td rowspan="2" valign="top" colspan="1">90.10 (81.81 to 99.22)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd inoculation&#160;</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">3&#8211;5 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">20<break/>(20 to 20)</td></tr><tr><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV&#160;</td><td valign="top" colspan="1" rowspan="1">168.60<break/>(151.90 to 187)</td><td rowspan="2" valign="top" colspan="1">84.30 (75.97 to 93.53)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd inoculation</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">6&#8211;12 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">2<break/>(2 to 2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">BBIBP&#8208;CorV</td><td valign="top" colspan="1" rowspan="1">155.70<break/>(137.70 to 176.50)</td><td rowspan="2" valign="top" colspan="1">77.87 (68.71 to 88.24)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd inoculation</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">13&#8211;17 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">2<break/>(2 to 2)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></td><td valign="top" colspan="1" rowspan="1">BBV152</td><td valign="top" colspan="1" rowspan="1">125.60<break/>(111.20 to 141.80)</td><td rowspan="2" valign="top" colspan="1">9.16 (2.28 to 36.78)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">28 days after 2nd vaccination</td><td rowspan="2" valign="top" colspan="1">MNT50 assay<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">13.70&#160;<break/>(10.70 to 170.40)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">BBV152</td><td valign="top" colspan="1" rowspan="1">66.40&#160;<break/>(53.40 to 82.40)</td><td rowspan="2" valign="top" colspan="1">9.22 (7.25 to 11.80)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">Day 28</td><td rowspan="2" valign="top" colspan="1">MNT50 assay<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">18&#8211;55 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Adjuvant</td><td valign="top" colspan="1" rowspan="1">7.20&#160;<break/>(6.40 to 8.10)</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean rate; GMT: geometric mean titre.</p></sec><sec id="CD015477-sec-0466"><title>Protein subunit vaccines</title><p><table-wrap id="CD015477-tblf-0145" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="3" align="center" valign="bottom" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td colspan="2" valign="bottom" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="9" valign="top" rowspan="1"><bold>COVID&#8208;19 vaccine versus placebo</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td colspan="2" valign="top" rowspan="1">1984.20 (1405.80 to 2800.70)</td><td rowspan="2" valign="top" colspan="1">18.08 (12.18 to 26.85)</td><td rowspan="2" valign="top" colspan="1">EU/mL</td><td rowspan="2" valign="top" colspan="1">Day 21 after 1st dose</td><td rowspan="2" valign="top" colspan="1">ELISA<break/>RBD&#8208;binding IgG</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td colspan="2" valign="top" rowspan="1">109.70 (90.40 to 133.20)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">NVX&#8208;CoV2373</td><td colspan="2" valign="top" rowspan="1">44,420.90 (37,929.10 to 52,023.80)</td><td rowspan="2" valign="top" colspan="1">352.26 (290 to 427.89)</td><td rowspan="2" valign="top" colspan="1">EU/mL</td><td rowspan="2" valign="top" colspan="1">Day 35 (14 days after the 2nd dose)<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">ELISA</td><td rowspan="2" valign="top" colspan="1">18&#8211;84 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Placebo</td><td colspan="2" valign="top" rowspan="1">126.10 (114 to 139.40)</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; ELISA: enzyme&#8208;linked immunosorbent assay; GMR: geometric mean rate; GMT: geometric mean titre; IgG: immunoglobulin G; RBD: receptor&#8208;binding domain.</p></sec><sec id="CD015477-sec-0467"><title>Primary series heterologous vaccination scheme versus homologous vaccination scheme</title><p><table-wrap id="CD015477-tblf-0146" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="bottom" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="bottom" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Unit of analysis</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="bottom" colspan="1"><bold>Population</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1"><bold>Heterologous schedule versus homologous schedule</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac/Ad5&#160;</td><td valign="top" colspan="1" rowspan="1">941.80 (663.90 to 1336.10)&#160;</td><td rowspan="2" valign="top" colspan="1">6.11 (3.90 to 9.57)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after 2nd dose</td><td rowspan="2" valign="top" colspan="1">ELISA</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">CoronaVac</td><td valign="top" colspan="1" rowspan="1">154.10 (116.30 to 204.30)&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean rate; GMT: geometric mean titre.</p></sec><sec id="CD015477-sec-0468"><title>Boosters</title><p><table-wrap id="CD015477-tblf-0147" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="2" valign="top" colspan="1"><bold>Study&#160;</bold></td><td rowspan="2" valign="top" colspan="1"><bold>Intervention name</bold></td><td colspan="2" align="center" valign="top" rowspan="1"><bold>Results</bold></td><td rowspan="2" valign="top" colspan="1"><bold>Unit of analysis</bold></td><td rowspan="2" valign="top" colspan="1"><bold>Time point</bold></td><td rowspan="2" valign="top" colspan="1"><bold>Type of assay&#160;</bold></td><td rowspan="2" valign="top" colspan="1"><bold>Population</bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><bold>GMT (95% CI)</bold></td><td valign="bottom" colspan="1" rowspan="1"><bold>GMR (95% CI)</bold></td></tr><tr><td colspan="8" valign="top" rowspan="1"><bold>Heterologous booster versus homologous booster</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref><break/>&#160;</td><td valign="top" colspan="1" rowspan="1">CoronaVac/Ad5 booster</td><td valign="top" colspan="1" rowspan="1">3090.10 (2636.10 to 3622.30)</td><td rowspan="2" valign="top" colspan="1">8.37 (6.52 to 10.75)</td><td rowspan="2" valign="top" colspan="1">Not reported</td><td rowspan="2" valign="top" colspan="1">14 days after boost</td><td rowspan="2" valign="top" colspan="1">ELISA</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">CoronaVac/CoronaVac boost</td><td valign="top" colspan="1" rowspan="1">369 (304.20 to 447.50)</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; GMR: geometric mean rate; GMT: geometric mean titre.</p></sec></app><app id="CD015477-sec-0469"><title>Appendix 17. ChAdOx1 &#8211; AstraZeneca + University of Oxford versus SII&#8208;ChAdOx1 &#8211; Serum Institute of India</title><p><table-wrap id="CD015477-tblf-0148" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.50 (0.08 to 2.95)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.73 (0.54 to 0.98)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.83 (0.52 to 1.33)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">400</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.76 (0.55 to 1.05)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0470"><title>Appendix 18. Ad26.COV2.S &#8211; Janssen Pharmaceutical Companies versus placebo</title><p><table-wrap id="CD015477-tblf-0149" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">39,058</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">66.90% (59.10% to 73.40%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">39,058</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">76.30% (57.90% to 87.50%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">43,783</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.25 (0.09 to 0.67)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">43,783</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.69 to 1.22)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">7222</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.83 (1.29 to 2.60)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">7222</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.57 (0.75 to 3.29)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">7222</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">3.27 (1.91 to 5.62)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0471"><title>Appendix 19. Gam&#8208;COVID&#8208;Vac (Sputnik V) &#8211; Gamaleya Research Institute &#160;versus placebo</title><p><table-wrap id="CD015477-tblf-0150" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">18,695</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">91.10% (83.80% to 95.10%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">19,866</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">100.00% (94.40% to 100.00%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">21,862</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.10 to 9.54)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">21,862</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.39 to 1.07)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0472"><title>Appendix 20. Cellular immune response</title><p><table-wrap id="CD015477-tblf-0151" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Study&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Intervention name</bold></td><td colspan="2" valign="top" rowspan="1"><bold>Estimate effect</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Unit of analysis&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Time point</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Type of assay</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Population&#160;</bold></td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></td><td valign="top" colspan="1" rowspan="1">Intervention: BBV152&#160;</td><td valign="top" colspan="1" rowspan="1">Median (IQR)</td><td valign="top" colspan="1" rowspan="1">55N (22 to 173.80)</td><td rowspan="2" valign="top" colspan="1">Number of &#160;SFCs per million PBMCs</td><td rowspan="2" valign="top" colspan="1">28&#8208;D1</td><td rowspan="2" valign="top" colspan="1">IFN&#8208;&#947; ELISpot</td><td rowspan="2" valign="top" colspan="1">18&#8211;55 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: placebo</td><td valign="top" colspan="1" rowspan="1">Median (IQR)</td><td valign="top" colspan="1" rowspan="1">3 (1 to 23)</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention: Gam&#8208;COVID&#8208;Vac&#160;</td><td valign="top" colspan="1" rowspan="1">Median (IQR)</td><td valign="top" colspan="1" rowspan="1">32.77 (13.94 to 50.76)</td><td rowspan="2" valign="top" colspan="1">IFN&#8208;&#947; concentration pg/mL</td><td rowspan="2" valign="top" colspan="1">28&#8208;D1</td><td rowspan="2" valign="top" colspan="1">IFN&#8208;&#947; measured by ELISA</td><td rowspan="2" valign="top" colspan="1">&#8805; 18 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: placebo</td><td valign="top" colspan="1" rowspan="1">Median (IQR)</td><td valign="top" colspan="1" rowspan="1">&#160;0.41 (0.11 to 0.85)</td></tr><tr><td rowspan="4" valign="top" colspan="1"><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention: ChAdOx1/ BNT162b2</td><td rowspan="4" valign="top" colspan="1">&#160;<break/>Geometric mean ratio (95% CI)</td><td rowspan="2" valign="top" colspan="1">&#160;<break/>3.90 (95% CI 2.90 to 5.30)</td><td rowspan="4" valign="top" colspan="1">Number of spot&#8208;forming cells (SFCs) per million PBMCs</td><td rowspan="4" valign="top" colspan="1">28&#8208;D2</td><td rowspan="4" valign="top" colspan="1">IFN&#8208;&#947; ELISpot</td><td rowspan="4" valign="top" colspan="1">&#8805; 50 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: ChAdOx1/ChAdOx1</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention: BNT162b2/ChAdOx1</td><td rowspan="2" valign="top" colspan="1">1.20 (95% CI 0.87 to 1.70)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: BNT162b2/ BNT162b2</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention: mRNA&#8208;1273/mRNA&#8208;1273 boost&#160;</td><td valign="top" colspan="1" rowspan="1">Median</td><td rowspan="2" valign="top" colspan="1">432 versus 67; 95% CI for the between&#8208;group difference, 46 to 986</td><td rowspan="2" valign="top" colspan="1">T&#8208;cell counts &#8211; cells per million CD4+ T cells</td><td rowspan="2" valign="top" colspan="1">28&#8208;D3</td><td rowspan="2" valign="top" colspan="1">Intracellular cytokine staining</td><td rowspan="2" valign="top" colspan="1">Transplant recipients only&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: mRNA&#8208;1273/placebo boost</td><td valign="top" colspan="1" rowspan="1">Median</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention: BNT162b2 or mRNA&#8208;1273/ChAdOx1 boost</td><td valign="top" colspan="1" rowspan="1">Median (IQR)</td><td valign="top" colspan="1" rowspan="1">459 (133 to 722)</td><td rowspan="2" valign="top" colspan="1">Number of SFCs per million PBMCs</td><td rowspan="2" valign="top" colspan="1">7&#8208;D3</td><td rowspan="2" valign="top" colspan="1">IFN&#8208;&#947; ELISpot</td><td rowspan="2" valign="top" colspan="1">People currently receiving rituximab</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: BNT162b2 or mRNA&#8208;1273/BNT162b2 or mRNA&#8208;1273 boost</td><td valign="top" colspan="1" rowspan="1">Median (IQR)</td><td valign="top" colspan="1" rowspan="1">305 (171 to 416)&#160;</td></tr><tr><td rowspan="2" valign="top" colspan="1"><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref><bold>&#160;</bold></td><td valign="top" colspan="1" rowspan="1">Intervention: CoronaVac&#160;</td><td valign="top" colspan="1" rowspan="1">Median (Min, Max)&#160;</td><td valign="top" colspan="1" rowspan="1">5.50 (0 to 35.70)</td><td rowspan="2" valign="top" colspan="1">Number of SFCs per million PBMCs</td><td rowspan="2" valign="top" colspan="1">14&#8208;D2</td><td rowspan="2" valign="top" colspan="1">IFN&#8208;&#947; ELISpot&#160;</td><td rowspan="2" valign="top" colspan="1">18&#8211;59 years</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: placebo</td><td valign="top" colspan="1" rowspan="1">Median (Min, Max)&#160;</td><td valign="top" colspan="1" rowspan="1">0 (0 to 11.70)</td></tr><tr><td rowspan="6" valign="top" colspan="1"><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></td><td valign="top" colspan="1" rowspan="1">Intervention: Ad26.COV2.S/mRNA&#8208;1273 boost</td><td rowspan="2" valign="top" colspan="1">Percentage of responders</td><td rowspan="2" valign="top" colspan="1">44/48 (91.66%) versus 32/44 (72.72%) (RR 0.79, 95% CI 0.64 to 0.96, P = 0.01726)&#160;</td><td rowspan="6" valign="top" colspan="1">Number of responders (responder cut&#8208;off is 0.15 IU/mL)&#160;</td><td rowspan="6" valign="top" colspan="1">28&#8208;D2</td><td rowspan="6" valign="top" colspan="1">IFN&#8208;y release assay</td><td rowspan="6" valign="top" colspan="1">18&#8211;65 years&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: Ad26.COV2.S/Ad26.COV2.S boost</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention: Ad26.COV2.S/BNT162b2 boost</td><td rowspan="2" valign="top" colspan="1">Percentage of responders<break/>&#160;</td><td rowspan="2" valign="top" colspan="1">43/47 (91.48%) versus 32/44 (72.72%) (RR 0.79, 95% CI 0.65 to 0.97, P = 0.01946)&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: Ad26.COV2.S/Ad26.COV2.S boost</td></tr><tr><td valign="top" colspan="1" rowspan="1">Intervention: Ad26.COV2.S/BNT162b2 boost</td><td rowspan="2" valign="top" colspan="1">Percentage of responders</td><td rowspan="2" valign="top" colspan="1">43/47 (91.48%) versus 44/48 (91.66%) (RR 1.00, 95% CI 0.88 to 1.13, P = 0.9753)&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Control: Ad26.COV2.S/mRNA&#8208;1273 boost</td></tr></tbody></table></table-wrap></p><p>IFN: interferon; IQR: interquartile range; min: minimum; max: maximum; PBMC: peripheral blood mononuclear cell; RR: risk ratio; SFC: spot&#8208;forming cell</p></app><app id="CD015477-sec-0473"><title>Appendix 21. CoronaVac &#8211; Sinovac versus placebo</title><p><table-wrap id="CD015477-tblf-0152" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">19,852</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">69.81% (12.27% to 89.61%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">19,852</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">12,396</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.50 (0.05 to 5.52)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">23,139</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.97 (0.62 to 1.51)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">23,956</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.95 (0.55 to 1.62)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">23,367</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.09 (1.07 to 1.11)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">23,962</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.76 (1.69 to 1.82)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0474"><title>Appendix 22. WIBP&#8208;CorV &#8211; Sinopharm&#8208;Wuhan versus placebo</title><p><table-wrap id="CD015477-tblf-0153" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,449</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">64.00% (48.80% to 74.70%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,480</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">72.80% (58.10% to 82.40%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">27,029</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.83 (0.60 to 1.15)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">27,029</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.99 (0.95 to 1.03)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">27,029</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.96 (0.93 to 0.98)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">27,029</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.88 (0.85 to 0.92)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0475"><title>Appendix 23. BBIBP&#8208;CorV &#8211; Sinopharm&#8208;Beijing versus placebo</title><p><table-wrap id="CD015477-tblf-0154" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,435</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">73.50% (60.60% to 82.20%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,463</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">78.10% (64.80% to 86.30%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">26,924</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.76 (0.54 to 1.06)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">27,540</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.05 (0.86 to 1.28)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">27,540</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">Not pooled due to high heterogeneity</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">27,540</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">Not pooled due to high heterogeneity</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0476"><title>Appendix 24. BBV152 &#8211; Bharat Biotech versus placebo</title><p><table-wrap id="CD015477-tblf-0155" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">6289</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">68.80% (46.70% to 82.50%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">16,973</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">77.80% (65.20% to 86.40%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">16,976</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">93.40% (57.10% to 99.80%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,753</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.50 (0.17 to 1.46)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,753</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.43 to 0.97)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">25,925</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.34 (1.15 to 1.58)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,753</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.00 (0.94 to 1.07)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">25,750</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.08 (0.95 to 1.24)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0477"><title>Appendix 25. NVX&#8208;CoV2373 &#8211; Novavax versus placebo</title><p><table-wrap id="CD015477-tblf-0156" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">42,175</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">82.91% (50.49% to 94.10%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">25,452</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">100.00% (86.99% to 100.00%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">29,582</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.90 (0.30 to 2.68)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events&#160;</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">46,202</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.92 (0.74 to 1.14)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">31,063</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.21 (1.17 to 1.25)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">46,231</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.15 (1.05 to 1.26)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">31,063</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">2.78 (1.99 to 3.88)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0478"><title>Appendix 26. FINLAY&#8208;FR&#8208;2 &#8211; Instituto Finlay de Vacunas versus placebo</title><p><table-wrap id="CD015477-tblf-0157" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">28,674</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">71.00% (58.90% to 79.10%)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">28,674</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.37 (0.17 to 0.80)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0479"><title>Appendix 27. Heterologous vaccination scheme versus homologous vaccination scheme</title><p><table-wrap id="CD015477-tblf-0158" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events&#160;</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">229</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">0.34 (0.01 to 8.17)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">101</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.96 (0.52 to 7.41)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)<break/>Not pooled</td><td valign="top" colspan="1" rowspan="1">1.03 (0.75 to 1.43)<break/>1.21 (0.87 to 1.68)<break/>3.19 (1.11 to 9.11)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">101</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">11.76 (1.59 to 87.14)</td><td valign="top" colspan="1" rowspan="1">N/A&#160;</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app><app id="CD015477-sec-0480"><title>Appendix 28. Booster versus placebo/no booster</title><p><table-wrap id="CD015477-tblf-0159" position="anchor" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Outcome&#160;</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of studies</bold></td><td valign="top" colspan="1" rowspan="1"><bold>No. of participants</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Statistical method</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Effect size</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Vaccine efficacy (95% CI)</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed SARS&#8208;CoV&#8208;2 infection after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr><tr><td valign="top" colspan="1" rowspan="1">Confirmed symptomatic COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr><tr><td valign="top" colspan="1" rowspan="1">Severe or critical COVID&#8208;19 after complete vaccination</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr><tr><td valign="top" colspan="1" rowspan="1">All&#8208;cause mortality&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">28,254</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.27 (0.52 to 3.05)</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr><tr><td valign="top" colspan="1" rowspan="1">Serious adverse events</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr><tr><td valign="top" colspan="1" rowspan="1">Systemic reactogenicity events</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">119</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">1.80 (0.71 to 4.56)</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr><tr><td valign="top" colspan="1" rowspan="1">Any adverse event</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr><tr><td valign="top" colspan="1" rowspan="1">Local reactogenicity events&#160;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">119</td><td valign="top" colspan="1" rowspan="1">Risk Ratio (M&#8208;H, Random, 95% CI)</td><td valign="top" colspan="1" rowspan="1">6.46 (3.18 to 13.13)</td><td valign="top" colspan="1" rowspan="1">N/A</td></tr></tbody></table></table-wrap></p><p>CI: confidence interval; N/A: not applicable.</p></app></app-group><notes id="CD015477-sec-0489" notes-type="study-characteristics"><title>Characteristics of studies</title><sec id="CD015477-sec-0490"><title>Characteristics of included studies [ordered by study ID]</title><p><table-wrap id="CD015477-tblf-0162" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0001" ref-type="ref-list">Ali 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0163" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0002" ref-type="ref-list">Al Kaabi 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0164" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0003" ref-type="ref-list">Asano 2022</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0165" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0004" ref-type="ref-list">Bonelli 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0166" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0005" ref-type="ref-list">Bueno 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0167" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0006" ref-type="ref-list">Clemens 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0168" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0007" ref-type="ref-list">Dunkle 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0169" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0008" ref-type="ref-list">Ella 2021a</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0170" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0009" ref-type="ref-list">Ella 2021b</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0171" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0010" ref-type="ref-list">El Sahly 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0172" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0011" ref-type="ref-list">Emary 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0173" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0012" ref-type="ref-list">Fadlyana 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0174" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0013" ref-type="ref-list">Falsey 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0175" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0014" ref-type="ref-list">Formica 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0176" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0015" ref-type="ref-list">Frenck 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0177" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0016" ref-type="ref-list">Guo 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0178" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0017" ref-type="ref-list">Hall 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0179" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0018" ref-type="ref-list">Han 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0180" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0019" ref-type="ref-list">Heath 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0181" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0020" ref-type="ref-list">Keech 2020</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0182" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0021" ref-type="ref-list">Kremsner 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0183" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0022" ref-type="ref-list">Kulkarni 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0184" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0023" ref-type="ref-list">Li 2021a</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0185" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0024" ref-type="ref-list">Liu 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0186" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0025" ref-type="ref-list">Logunov 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0187" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0026" ref-type="ref-list">Madhi 2021a</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0188" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0027" ref-type="ref-list">Madhi 2021b</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0189" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0028" ref-type="ref-list">Mok 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0190" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0029" ref-type="ref-list">Palacios 2020</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0191" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0030" ref-type="ref-list">Sablerolles 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0192" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0031" ref-type="ref-list">Sadoff 2021a</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0193" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0032" ref-type="ref-list">Sadoff 2021b</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0194" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0033" ref-type="ref-list">Shinde 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0195" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0034" ref-type="ref-list">Tanriover 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0196" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0035" ref-type="ref-list">Thomas 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0197" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0036" ref-type="ref-list">Toledo&#8208;Romani 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0198" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0037" ref-type="ref-list">Voysey 2021a</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0199" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0038" ref-type="ref-list">Walsh 2020</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0200" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0039" ref-type="ref-list">Wu 2021a</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0201" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0040" ref-type="ref-list">Xia 2020</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0202" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0041" ref-type="ref-list">Xia 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap><table-wrap id="CD015477-tblf-0203" position="float" orientation="portrait"><caption><title><xref rid="CD015477-bbs2-0042" ref-type="ref-list">Zhang 2021</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td colspan="3" valign="bottom" rowspan="1"><bold><italic toggle="yes">Study characteristics</italic></bold></td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Methods</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Participants</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Interventions</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td valign="bottom" colspan="1" rowspan="1">Outcomes</td><td colspan="2" valign="bottom" rowspan="1">&#160;</td></tr><tr><td colspan="1" rowspan="1">Notes</td><td colspan="2" rowspan="1">&#160;</td></tr></tbody></table></table-wrap></p></sec><sec id="CD015477-sec-0491"><title>Characteristics of excluded studies [ordered by study ID]</title><p><table-wrap id="CD015477-tblf-0204" position="float" orientation="portrait"><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1">Study</th><th colspan="1" rowspan="1">Reason for exclusion</th></tr></thead><tbody><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0043" ref-type="ref-list">Baden 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Exploratory analysis</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0044" ref-type="ref-list">Barrett 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Secondary analysis</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0045" ref-type="ref-list">Ewer 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Secondary analysis</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0046" ref-type="ref-list">Flaxman 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Not randomized</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0047" ref-type="ref-list">Hsieh 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Not randomized</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0048" ref-type="ref-list">Irfan 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Commentary</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0049" ref-type="ref-list">Lazarus 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention not relevant to review</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0050" ref-type="ref-list">Patamatamkul 2021</xref></td><td valign="bottom" colspan="1" rowspan="1">Not randomized</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0051" ref-type="ref-list">Ward 2021a</xref></td><td valign="bottom" colspan="1" rowspan="1">Intervention not relevant to review</td></tr><tr><td valign="bottom" colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0052" ref-type="ref-list">Wu 2021b</xref></td><td valign="bottom" colspan="1" rowspan="1">Not randomized</td></tr><tr><td colspan="1" rowspan="1"><xref rid="CD015477-bbs2-0053" ref-type="ref-list">Zdanowski 2021</xref></td><td colspan="1" rowspan="1">Not randomized</td></tr></tbody></table></table-wrap></p></sec></notes><notes id="CD015477-sec-0488" notes-type="protocol-review-differences"><title>Differences between protocol and review</title><p>The protocol was developed early during the pandemic and is evolving.&#160;</p><p>We are no longer considering the following less relevant outcomes.</p><p><list id="CD015477-list-0032" list-type="bullet"><list-item><p>Incidence of confirmed symptomatic COVID&#8208;19 <underline>after first dose</underline> (confirmed with positive test for SARS&#8208;CoV&#8208;2 infection by RT&#8208;PCR or NAAT or any other validated test)&#160;</p></list-item><list-item><p>Incidence of participants with confirmed SARS&#8208;CoV&#8208;2 infection <underline>after first dose</underline> (confirmed by RT&#8208;PCR or NAAT or any other validated test (symptomatic or asymptomatic))&#160;</p></list-item><list-item><p>Incidence of withdrawals due to adverse events</p></list-item></list></p><p>We clarified some outcomes. For the outcome 'specific adverse events' we collected data for 'nervous system diseases' (instead of stroke, headache, delirium, and paraesthesia) since we found this was reported more often. We did not collect data on 'bruising.'</p><p>As research and data on COVID&#8208;19 vaccines evolved, we noticed that authors started using the term 'reactogenicity' to define the immediate, short&#8208;in&#8208;duration, and usually expected effects of the vaccine, and to differentiate them from any other medium&#8208;term, long&#8208;term, or unexpected adverse event (related or unrelated to the vaccine). Therefore, we adopted the term to describe local and systemic effects of the vaccine in the immediate days after the injection.&#160;</p><p>Post&#8208;hoc analysis due to concern related to the waning of efficacy over time (<xref rid="CD015477-bbs2-0087" ref-type="ref-list">Feikin 2022</xref>), we added a post&#8208;hoc analysis of vaccine efficacy according to the delay since vaccination.</p><p>We initially planned to conduct an NMA; however, the network of vaccines appeared very sparse, included mainly comparisons of vaccines against placebo, and only one or two studies informed most of the available comparisons (<xref rid="CD015477-fig-0001" ref-type="fig">Figure 1</xref>). A network of such structure does not allow proper evaluation of the synthesis assumptions. Additionally, the NMA estimates from this network would not be substantially more precise (and could even be less precise for some comparisons) than the direct ones. We decided not to perform a NMA and will revisit its feasibility throughout the living systematic review process.&#160;</p><p>We obtained clinical study reports (CSRs) after the corresponding publication was available and data were already extracted. When CSRs were available, we cross&#8208;checked whether these provided data on the critical outcomes already extracted or critical outcome not available in the publication. In all cases, we did not obtain new data. The follow&#8208;up of outcome assessment in the CSR was frequently lower than the one reported in the publication. We have not contacted study authors yet for missing results or to request additional information.</p></notes><notes id="CD015477-sec-0483" notes-type="author-contribution"><title>Contributions of authors</title><p>Conception and design of the review: CG, LG, AC, MM, PA, JDL, LA DD, JJM, GR, AH, GG, DT, PR, IB&#160;</p><p>Co&#8208;ordination of the review: AC, LG, IB&#160;</p><p>Search and selection of studies for inclusion in the review: GF, CR, HB, RA&#160;</p><p>Collection of data for the review: BB, HB, KP, NH, EG, GV, CG, HB, MD, LG, SM</p><p>Assessment of the risk of bias in the included studies: BB, HB, KP, NH, EG, GV, CG, HB, MD, LG, IB&#160;</p><p>Analysis of data: AC, TE&#160;</p><p>Assessment of the certainty in the body of evidence: KP, HB, NH, GV&#160;</p><p>Interpretation of data: CG, LG, TE, AJ, SM, HB, BB, KP, GV, NH, HB, RA, SM, MM, DD, PM, JDL, LA, TK, GF, MD, CR, DT, JJM, GG, GR, AH, PR, AC, IB</p><p>Writing of and commenting on the review: CG, LG, AJ, AC, TE, BB, KP, NH, GF, CR, PK, HB, JDL, DD, JJM, GR, AH, GG, DT, PR, IB</p></notes><notes id="CD015477-sec-0485" notes-type="funding"><title>Sources of support</title><sec id="CD015477-sec-0486"><title>Internal sources</title><p><list id="CD015477-list-0030" list-type="bullet"><list-item><p>Cochrane France, France</p></list-item><list-item><p>Center of Research in Epidemiology and Statistics (CRESS), France</p></list-item><list-item><p>Centre d&#8217;Epid&#233;miologie Clinique (GHU Cochin, H&#244;tel Dieu), France</p></list-item><list-item><p>Universit&#233; de Paris, France</p></list-item><list-item><p>National Institute of Health and Medical Research (Inserm), France</p></list-item><list-item><p>Assistance Publique H&#244;pitaux de Paris (APHP), France</p></list-item><list-item><p>Centre National de la Recherche Scientifique (CNRS), France</p></list-item></list></p></sec><sec id="CD015477-sec-0487"><title>External sources</title><p><list id="CD015477-list-0031" list-type="bullet"><list-item><p>French Ministry of Health, France</p></list-item><list-item><p>French Ministry of Higher Education, Research and Innovation, France</p></list-item><list-item><p>Agence Nationale de la Recherche (ANR), France</p></list-item><list-item><p>World Health Organization (WHO), Switzerland</p></list-item><list-item><p>European Union&#8217;s Horizon 2020 Research and Innovation programme under the grant agreement N&#176;101037867, Other</p><p>The research funding leading to these results was conducted as part of the VACCELERATE consortium. For further information please refer to <uri>https://www.vaccelerate.eu/</uri>.</p></list-item></list></p></sec></notes><notes id="CD015477-sec-0484" notes-type="COI-statement"><title>Declarations of interest</title><p>Carolina Gra&#241;a: none known.</p><p>Lina Ghosn: none known.</p><p>Theodoros Evrenoglou: none known.</p><p>Alexander Jarde: none known.</p><p>Silvia Minozzi: no relevant interests; Joint Co&#8208;ordinating Editor and Method editor of the Drugs and Alcohol Group.</p><p>Hanna Bergman: Cochrane Response &#8211; consultant; WHO &#8211; grant/contract (Cochrane Response was commissioned by the WHO to perform review tasks that contribute to this publication).&#160;</p><p>Brian Buckley: none known.&#160;</p><p>Katrin Probyn: Cochrane Response &#8211; consultant; WHO &#8211; consultant (Cochrane Response was commissioned to perform review tasks that contribute to this publication).&#160;</p><p>Gemma Villanueva: Cochrane Response &#8211; employment (Cochrane Response has been commissioned by WHO to perform parts of this systematic review).&#160;</p><p>Nicholas Henschke: Cochrane Response &#8211; consultant; WHO &#8211; consultant (Cochrane Response was commissioned by the WHO to perform review tasks that contributed to this publication).&#160;</p><p>Hillary Bonnet: none known.</p><p>Rouba Assi: none known.</p><p>Sonia Menon: P95 &#8211; consultant.</p><p>Melanie Marti: no relevant interests; Medical Officer at WHO.</p><p>Declan Devane: Health Research Board (HRB) &#8211; grant/contract; registered nurse and registered midwife but no longer in clinical practice; Editor, Cochrane Pregnancy and Childbirth Group.</p><p>Patrick Mallon: AstraZeneca &#8211; Advisory Board; spoken of vaccine effectiveness to media (print, online, and live); works as a consultant in a hospital that provides vaccinations; employed by St Vincent's University Hospital.</p><p>Jean&#8208;Daniel Lelievre: no relevant interests; published numerous interviews in the national press on the subject of COVID vaccination; Head of the Department of Infectious Diseases and Clinical Immunology CHU Henri Mondor APHP, Cr&#233;teil; WHO (IVRI&#8208;AC): expert Vaccelarate (European project on COVID19 Vaccine): head of WP; involved with COVICOMPARE P et M Studies (APHP, INSERM) (public fundings).&#160;</p><p>Lisa Askie: no relevant interests; Co&#8208;convenor, Cochrane Prospective Meta&#8208;analysis Methods Group.</p><p>Tamara Kredo: no relevant interests; Medical Officer in an Infectious Diseases Clinic at Tygerberg Hospital, Stellenbosch University.</p><p>Gabriel Ferrand: none known.</p><p>Mauricia Davidson: none known.</p><p>Carolina Riveros: no relevant interests; works as an epidemiologist.</p><p>David Tovey: no relevant interests; Emeritus Editor in Chief, Feedback Editors for 2 Cochrane review groups.</p><p>Joerg J Meerpohl: no relevant interests; member of the German Standing Vaccination Committee (STIKO).</p><p>Giacomo Grasselli: Pfizer &#8211; speaking engagement.</p><p>Gabriel Rada: none known.</p><p>Asbj&#248;rn Hr&#243;bjartsson: no relevant interests; Cochrane Methodology Review Group Editor.</p><p>Philippe Ravaud: no relevant interests; involved with Mariette CORIMUNO&#8208;19 Collaborative 2021, the Ministry of Health, Programme Hospitalier de Recherche Clinique, Foundation for Medical Research, and AP&#8208;HP Foundation.</p><p>Anna Chaimani: none known.</p><p>Isabelle Boutron: no relevant interests; member of Cochrane Editorial Board.</p></notes><ref-list><title>References</title><ref-list id="CD015477-bbs1-0001"><title>References to studies included in this review</title><ref-list id="CD015477-bbs2-0001"><title>Ali 2021 {published data only}</title><ref id="CD015477-bib-0001"><mixed-citation id="cit1" publication-type="journal"><name name-style="western"><surname>Ali</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Berman</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Faughnan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Coronado-Voges</surname><given-names>M</given-names></name>, et al. <article-title>Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>385</volume>(<issue>24</issue>):<fpage>2241</fpage>-<lpage>51</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2109522</pub-id><pub-id pub-id-type="pmcid">PMC8385554</pub-id><pub-id pub-id-type="pmid">34379915</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0002"><title>Al Kaabi 2021 {published data only}</title><ref id="CD015477-bib-0002"><mixed-citation id="cit2" publication-type="journal"><name name-style="western"><surname>Al Kaabi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Al Qahtani</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Abdulrazzaq</surname><given-names>N</given-names></name>, et al. <article-title>Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial</article-title>. <source>JAMA</source><year>2021</year>;<volume>326</volume>(<issue>1</issue>):<fpage>35</fpage>-<lpage>45</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.8565</pub-id><pub-id pub-id-type="pmcid">PMC8156175</pub-id><pub-id pub-id-type="pmid">34037666</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0003"><title>Asano 2022 {published data only}</title><ref id="CD015477-bib-0003"><mixed-citation id="cit3" publication-type="journal"><name name-style="western"><surname>Asano</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Okada</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hirata</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ishikawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>E</given-names></name>, et al. <article-title>Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial</article-title>. <source>International Journal of Infectious Diseases</source><year>2022</year>;<volume>114</volume>:<fpage>165</fpage>-<lpage>74</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2021.10.030</pub-id><pub-id pub-id-type="pmcid">PMC8531242</pub-id><pub-id pub-id-type="pmid">34688944</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0004"><title>Bonelli 2021 {published data only}</title><ref id="CD015477-bib-0004"><mixed-citation id="cit4" publication-type="other"><name name-style="western"><surname>Bonelli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mrak</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tobudic</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sieghart</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Koblischke</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mandl</surname><given-names>P</given-names></name>, et al. <article-title>Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.05.21263125</pub-id>]<pub-id pub-id-type="pmid">35027397</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0005"><title>Bueno 2021 {published data only}</title><ref id="CD015477-bib-0005"><mixed-citation id="cit5" publication-type="other"><name name-style="western"><surname>Bueno</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Abarca</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>G&#225;lvez</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Soto</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Duarte</surname><given-names>LF</given-names></name>, et al. <article-title>Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.03.31.21254494</pub-id>]</mixed-citation></ref><ref id="CD015477-bib-0006"><mixed-citation id="cit6" publication-type="other"><name name-style="western"><surname>Bueno</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Abarca</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>G&#225;lvez</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Soto</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Duarte</surname><given-names>LF</given-names></name>, et al. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile</article-title>. <source>Clinical Infectious Diseases</source> 2021 Sep 19 [Epub ahead of print]. [DOI: <pub-id pub-id-type="doi">10.1093/cid/ciab823</pub-id>]<pub-id pub-id-type="pmcid">PMC9402626</pub-id><pub-id pub-id-type="pmid">34537835</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0006"><title>Clemens 2021 {published data only}</title><ref id="CD015477-bib-0007"><mixed-citation id="cit7" publication-type="journal"><name name-style="western"><surname>Clemens</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Emary</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name>, <name name-style="western"><surname>Ratcliff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bibi</surname><given-names>S</given-names></name>, et al. <article-title>Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil</article-title>. <source>Nature Communications</source><year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>5861</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-25982-w</pub-id><pub-id pub-id-type="pmcid">PMC8494913</pub-id><pub-id pub-id-type="pmid">34615860</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0007"><title>Dunkle 2021 {published data only}</title><ref id="CD015477-bib-0008"><mixed-citation id="cit8" publication-type="other"><name name-style="western"><surname>Dunkle</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Kotloff</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Gay</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>&#193;&#241;ez</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Adelglass</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Barrat Hern&#225;ndez</surname><given-names>AQ</given-names></name>, et al. <article-title>Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.10.05.21264567</pub-id>]<pub-id pub-id-type="pmcid">PMC8693692</pub-id><pub-id pub-id-type="pmid">34910859</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0008"><title>Ella 2021a {published data only}</title><ref id="CD015477-bib-0009"><mixed-citation id="cit9" publication-type="other"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name>, et al. <article-title>A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152</article-title>. <source>medRxiv 2020 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2020.12.11.20210419</pub-id>]<pub-id pub-id-type="pmcid">PMC7825810</pub-id><pub-id pub-id-type="pmid">33485468</pub-id></mixed-citation></ref><ref id="CD015477-bib-0010"><mixed-citation id="cit10" publication-type="journal"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name>, et al. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>5</issue>):<fpage>637</fpage>-<lpage>46</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30942-7</pub-id><pub-id pub-id-type="pmcid">PMC7825810</pub-id><pub-id pub-id-type="pmid">33485468</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0009"><title>Ella 2021b {published data only}</title><ref id="CD015477-bib-0011"><mixed-citation id="cit11" publication-type="other"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Blackwelder</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Potdar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Yadav</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name>, et al. <article-title>Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.06.30.21259439</pub-id>]<pub-id pub-id-type="pmcid">PMC8584828</pub-id><pub-id pub-id-type="pmid">34774196</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0010"><title>El Sahly 2021 {published data only}</title><ref id="CD015477-bib-0012"><mixed-citation id="cit12" publication-type="journal"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Essink</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kotloff</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Frey</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Novak</surname><given-names>R</given-names></name>, et al. <article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>384</volume>(<issue>5</issue>):<fpage>403</fpage>-<lpage>16</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id><pub-id pub-id-type="pmid">33378609</pub-id></mixed-citation></ref><ref id="CD015477-bib-0013"><mixed-citation id="cit13" publication-type="journal"><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Essink</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Doblecki-Lewis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name>, et al. <article-title>Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>385</volume>(<issue>19</issue>):<fpage>1774</fpage>-<lpage>85</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2113017</pub-id><pub-id pub-id-type="pmcid">PMC8482810</pub-id><pub-id pub-id-type="pmid">34551225</pub-id></mixed-citation></ref><ref id="CD015477-bib-0014"><mixed-citation id="cit14" publication-type="other">Food and Drug Administration. <article-title>Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine</article-title>. <source>www.fda.gov/media/144434/download</source> (accessed prior to 1 November 2022). </mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0011"><title>Emary 2021 {published data only}</title><ref id="CD015477-bib-0015"><mixed-citation id="cit15" publication-type="journal"><name name-style="western"><surname>Emary</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Golubchik</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Ariani</surname><given-names>CV</given-names></name>, <name name-style="western"><surname>Angus</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bibi</surname><given-names>S</given-names></name>, et al. <article-title>Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>(<issue>10282</issue>):<fpage>1351</fpage>-<lpage>62</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00628-0</pub-id><pub-id pub-id-type="pmcid">PMC8009612</pub-id><pub-id pub-id-type="pmid">33798499</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0012"><title>Fadlyana 2021 {published data only}</title><ref id="CD015477-bib-0016"><mixed-citation id="cit16" publication-type="journal"><name name-style="western"><surname>Fadlyana</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rusmil</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tarigan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rahmadi</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Prodjosoewojo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sofiatin</surname><given-names>Y</given-names></name>, et al. <article-title>A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18&#8211;59&#160;years: an interim analysis in Indonesia</article-title>. <source>Vaccine</source><year>2021</year>;<volume>39</volume>(<issue>44</issue>):<fpage>6520</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.09.052</pub-id><pub-id pub-id-type="pmcid">PMC8461222</pub-id><pub-id pub-id-type="pmid">34620531</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0013"><title>Falsey 2021 {published data only}</title><ref id="CD015477-bib-0017"><mixed-citation id="cit17" publication-type="journal"><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Sobieszczyk</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Hirsch</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Sproule</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Corey</surname><given-names>L</given-names></name>, et al. <article-title>Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>385</volume>(<issue>25</issue>):<fpage>2348</fpage>-<lpage>60</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2105290</pub-id><pub-id pub-id-type="pmcid">PMC8522798</pub-id><pub-id pub-id-type="pmid">34587382</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0014"><title>Formica 2021 {published data only}</title><ref id="CD015477-bib-0018"><mixed-citation id="cit18" publication-type="journal"><name name-style="western"><surname>Formica</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mallory</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Plested</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>I</given-names></name>, et al. <article-title>Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial</article-title>. <source>PLOS Medicine</source><year>2021</year>;<volume>18</volume>(<issue>10</issue>):<fpage>e1003769</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1003769</pub-id><pub-id pub-id-type="pmcid">PMC8486115</pub-id><pub-id pub-id-type="pmid">34597298</pub-id></mixed-citation></ref><ref id="CD015477-bib-0019"><mixed-citation id="cit19" publication-type="other"><name name-style="western"><surname>Formica</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mallory</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Plested</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>I</given-names></name>, et al. <article-title>Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.02.26.21252482</pub-id>]<pub-id pub-id-type="pmcid">PMC8486115</pub-id><pub-id pub-id-type="pmid">34597298</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0015"><title>Frenck 2021 {published data only}</title><ref id="CD015477-bib-0020"><mixed-citation id="cit20" publication-type="journal">Frenck RW Jr, <name name-style="western"><surname>Klein</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name>, et al. <article-title>Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>385</volume>(<issue>3</issue>):<fpage>239</fpage>-<lpage>50</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2107456</pub-id><pub-id pub-id-type="pmcid">PMC8174030</pub-id><pub-id pub-id-type="pmid">34043894</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0016"><title>Guo 2021 {published data only}</title><ref id="CD015477-bib-0021"><mixed-citation id="cit21" publication-type="journal"><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>YB</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, et al. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial</article-title>. <source>eClinicalMedicine</source><year>2021</year>;<volume>38</volume>:<fpage>101010</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101010</pub-id><pub-id pub-id-type="pmcid">PMC8260504</pub-id><pub-id pub-id-type="pmid">34250456</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0017"><title>Hall 2021 {published data only}</title><ref id="CD015477-bib-0022"><mixed-citation id="cit22" publication-type="journal"><name name-style="western"><surname>Hall</surname><given-names>VG</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>VH</given-names></name>, <name name-style="western"><surname>Ku</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ierullo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Majchrzak-Kita</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chaparro</surname><given-names>C</given-names></name>, et al. <article-title>Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>385</volume>(<issue>13</issue>):<fpage>1244</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2111462</pub-id><pub-id pub-id-type="pmcid">PMC8385563</pub-id><pub-id pub-id-type="pmid">34379917</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0018"><title>Han 2021 {published data only}</title><ref id="CD015477-bib-0023"><mixed-citation id="cit23" publication-type="journal"><name name-style="western"><surname>Han</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name>, et al. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1645</fpage>-<lpage>53</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00319-4</pub-id><pub-id pub-id-type="pmcid">PMC8238449</pub-id><pub-id pub-id-type="pmid">34197764</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0019"><title>Heath 2021 {published data only}</title><ref id="CD015477-bib-0024"><mixed-citation id="cit24" publication-type="journal"><name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Galiza</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Boffito</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Browne</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Burns</surname><given-names>F</given-names></name>, et al. <article-title>Safety and efficacy of NVX-CoV2373 Covid-19 vaccine</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>385</volume>(<issue>13</issue>):<fpage>1172</fpage>-<lpage>83</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2107659</pub-id><pub-id pub-id-type="pmcid">PMC8262625</pub-id><pub-id pub-id-type="pmid">34192426</pub-id></mixed-citation></ref><ref id="CD015477-bib-0025"><mixed-citation id="cit25" publication-type="other"><name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Galiza</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Boffito</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Browne</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Burns</surname><given-names>F</given-names></name>, et al&#160;. <article-title>Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant</article-title>. <source>medRxiv 2021 [Preprint]</source>. </mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0020"><title>Keech 2020 {published data only}</title><ref id="CD015477-bib-0026"><mixed-citation id="cit26" publication-type="journal"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Robertson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Neal</surname><given-names>S</given-names></name>, et al. <article-title>Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title>. <source>New England Journal of Medicine&#160;</source><year>2020</year>;<volume>383</volume>:<fpage>2320</fpage>-<lpage>32</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id><pub-id pub-id-type="pmid">32877576</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0021"><title>Kremsner 2021 {published data only}</title><ref id="CD015477-bib-0027"><mixed-citation id="cit27" publication-type="other"><name name-style="western"><surname>Kremsner</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Ahuad Guerrero</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Arana-Arri</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Aroca Martinez</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Bonten</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chandler</surname><given-names>R</given-names></name>, et al. <article-title>Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America</article-title>. <source>SSRN 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.2139/ssrn.3911826</pub-id>]<pub-id pub-id-type="pmcid">PMC8610426</pub-id><pub-id pub-id-type="pmid">34826381</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0022"><title>Kulkarni 2021 {published data only}</title><ref id="CD015477-bib-0028"><mixed-citation id="cit28" publication-type="journal"><name name-style="western"><surname>Kulkarni</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Padmapriyadarsini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bavdekar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kulkarni</surname><given-names>P</given-names></name>, et al. <article-title>A phase 2/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India</article-title>. <source>eClinicalMedicine</source><year>2021</year>;<volume>42</volume>:<fpage>101218</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101218</pub-id><pub-id pub-id-type="pmcid">PMC8629682</pub-id><pub-id pub-id-type="pmid">34870133</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0023"><title>Li 2021a {published data only}</title><ref id="CD015477-bib-0029"><mixed-citation id="cit29" publication-type="other"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, et al. <article-title>Heterologous prime-boost immunization with CoronaVac and Convidecia</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.03.21263062</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0024"><title>Liu 2021 {published data only}</title><ref id="CD015477-bib-0030"><mixed-citation id="cit30" publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Greenland</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>NJ</given-names></name>, et al. <article-title>Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>398</volume>(<issue>10303</issue>):<fpage>856</fpage>-<lpage>69</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01694-9</pub-id><pub-id pub-id-type="pmcid">PMC8346248</pub-id><pub-id pub-id-type="pmid">34370971</pub-id></mixed-citation></ref><ref id="CD015477-bib-0031"><mixed-citation id="cit31" publication-type="other"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Greenland</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>NJ</given-names></name>, et al. <article-title>Safety and immunogenicity report from the Com-COV Study &#8211; a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine</article-title>. <source>SSRN 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.2139/ssrn.3874014</pub-id>]<pub-id pub-id-type="pmcid">PMC8346248</pub-id><pub-id pub-id-type="pmid">34370971</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0025"><title>Logunov 2021 {published data only}</title><ref id="CD015477-bib-0032"><mixed-citation id="cit32" publication-type="journal"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name>, <name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Tukhvatulin</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></name>, <name name-style="western"><surname>Dzharullaeva</surname><given-names>AS</given-names></name>, et al. <article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>(<issue>10275</issue>):<fpage>671</fpage>-<lpage>81</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id><pub-id pub-id-type="pmid">33545094</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0026"><title>Madhi 2021a {published data only}</title><ref id="CD015477-bib-0033"><mixed-citation id="cit33" publication-type="journal"><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Koen</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Izu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cutland</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Baillie</surname><given-names>V</given-names></name>, et al. <article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B/2A trial</article-title>. <source>Lancet HIV</source><year>2021</year>;<volume>8</volume>(<issue>9</issue>):<fpage>e568</fpage>-<lpage>80</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-3018(21)00157-0</pub-id><pub-id pub-id-type="pmcid">PMC8372504</pub-id><pub-id pub-id-type="pmid">34416193</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0027"><title>Madhi 2021b {published data only}</title><ref id="CD015477-bib-0034"><mixed-citation id="cit34" publication-type="journal"><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Baillie</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Cutland</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Koen</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name>, et al. <article-title>Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>384</volume>(<issue>20</issue>):<fpage>1885</fpage>-<lpage>98</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102214</pub-id><pub-id pub-id-type="pmcid">PMC7993410</pub-id><pub-id pub-id-type="pmid">33725432</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0028"><title>Mok 2021 {published data only}</title><ref id="CD015477-bib-0035"><mixed-citation id="cit35" publication-type="other"><name name-style="western"><surname>Mok</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yiu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>TO</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>KC</given-names></name>, et al. <article-title>A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.11.02.21265843</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0029"><title>Palacios 2020 {published data only}</title><ref id="CD015477-bib-0036"><mixed-citation id="cit36" publication-type="journal"><name name-style="western"><surname>Palacios</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pati&#241;o</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Oliveira Piorelli</surname><given-names>R</given-names><prefix>de</prefix></name>, <name name-style="western"><surname>Conde</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Batista</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name>, et al. <article-title>Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac &#8211; PROFISCOV: a structured summary of a study protocol for a randomized controlled trial</article-title>. <source>Trials</source><year>2020</year>;<volume>21</volume>(<issue>1</issue>):<fpage>853</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13063-020-04775-4</pub-id><pub-id pub-id-type="pmcid">PMC7558252</pub-id><pub-id pub-id-type="pmid">33059771</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0030"><title>Sablerolles 2021 {published data only}</title><ref id="CD015477-bib-0037"><mixed-citation id="cit37" publication-type="other"><name name-style="western"><surname>Sablerolles</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Rietdijk</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Goorhuis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Postma</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Visser</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Geers</surname><given-names>D</given-names></name>, et al. <article-title>Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.10.18.21264979</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0031"><title>Sadoff 2021a {published data only}</title><ref id="CD015477-bib-0038"><mixed-citation id="cit38" publication-type="other">Food and Drug Administration. <article-title>Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19</article-title>. <source>www.fda.gov/media/146217/download</source> (accessed prior to 1 November 2022). </mixed-citation></ref><ref id="CD015477-bib-0039"><mixed-citation id="cit39" publication-type="journal"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Heerwegh</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Truyers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Groot</surname><given-names>AM</given-names><prefix>de</prefix></name>, et al. <article-title>Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>384</volume>(<issue>19</issue>):<fpage>1824</fpage>-<lpage>35</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034201</pub-id><pub-id pub-id-type="pmcid">PMC7821985</pub-id><pub-id pub-id-type="pmid">33440088</pub-id></mixed-citation></ref><ref id="CD015477-bib-0040"><mixed-citation id="cit40" publication-type="other"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Heerwegh</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Truyers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Groot</surname><given-names>AM</given-names><prefix>de</prefix></name>, et al. <article-title>Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial</article-title>. <source>medRxiv 2020 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2020.09.23.20199604</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0032"><title>Sadoff 2021b {published data only}</title><ref id="CD015477-bib-0041"><mixed-citation id="cit41" publication-type="journal"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Vandebosch</surname><given-names>A</given-names></name>, <name name-style="western"><surname>C&#225;rdenas</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Grinsztejn</surname><given-names>B</given-names></name>, et al. <article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>384</volume>(<issue>23</issue>):<fpage>2187</fpage>-<lpage>201</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id><pub-id pub-id-type="pmid">33882225</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0033"><title>Shinde 2021 {published data only}</title><ref id="CD015477-bib-0042"><mixed-citation id="cit42" publication-type="journal"><name name-style="western"><surname>Shinde</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bhikha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hoosain</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Archary</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bhorat</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name>, et al. <article-title>Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>384</volume>(<issue>20</issue>):<fpage>1899</fpage>-<lpage>909</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2103055</pub-id><pub-id pub-id-type="pmcid">PMC8091623</pub-id><pub-id pub-id-type="pmid">33951374</pub-id></mixed-citation></ref><ref id="CD015477-bib-0043"><mixed-citation id="cit43" publication-type="other"><name name-style="western"><surname>Shinde</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bhikha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hoosain</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Archary</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bhorat</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name>, et al. <article-title>Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.02.25.21252477</pub-id>]<pub-id pub-id-type="pmcid">PMC8091623</pub-id><pub-id pub-id-type="pmid">33951374</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0034"><title>Tanriover 2021 {published data only}</title><ref id="CD015477-bib-0044"><mixed-citation id="cit44" publication-type="journal"><name name-style="western"><surname>Tanriover</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Do&#287;anay</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Akova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>G&#252;ner</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Azap</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Akhan</surname><given-names>S</given-names></name>, et al. <article-title>Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey</article-title>. <source>Lancet</source><year>2021</year>;<volume>398</volume>(<issue>10296</issue>):<fpage>213</fpage>-<lpage>22</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01429-X</pub-id><pub-id pub-id-type="pmcid">PMC8266301</pub-id><pub-id pub-id-type="pmid">34246358</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0035"><title>Thomas 2021 {published data only}</title><ref id="CD015477-bib-0045"><mixed-citation id="cit45" publication-type="other">Food and Drug Administration. <article-title>Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine</article-title>. <source>www.fda.gov/media/144245/download</source> (accessed prior to 1 November 2022). </mixed-citation></ref><ref id="CD015477-bib-0046"><mixed-citation id="cit46" publication-type="journal"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name>, et al. <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title>. <source>New England Journal of Medicine</source><year>2020</year>;<volume>383</volume>(<issue>27</issue>):<fpage>2603</fpage>-<lpage>15</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></mixed-citation></ref><ref id="CD015477-bib-0047"><mixed-citation id="cit47" publication-type="journal"><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name>, Moreira ED Jr, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name>, et al. <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>385</volume>(<issue>19</issue>):<fpage>1761</fpage>-<lpage>773</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2110345</pub-id><pub-id pub-id-type="pmcid">PMC8461570</pub-id><pub-id pub-id-type="pmid">34525277</pub-id></mixed-citation></ref><ref id="CD015477-bib-0048"><mixed-citation id="cit48" publication-type="other"><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name>, Moreira ED Jr, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name>, et al. <article-title>Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.07.28.21261159</pub-id>]<pub-id pub-id-type="pmcid">PMC8461570</pub-id><pub-id pub-id-type="pmid">34525277</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0036"><title>Toledo&#8208;Romani 2021 {published data only}</title><ref id="CD015477-bib-0049"><mixed-citation id="cit49" publication-type="other"><name name-style="western"><surname>Toledo-Romani</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Garcia-Carmenate</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Silva-Valenzuela</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Baldoquin-Rodriguez</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Mart&#237;nez-P&#233;rez</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rodr&#237;guez-Gonz&#225;lez</surname><given-names>M</given-names></name>, et al. <article-title>Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.10.31.21265703</pub-id>]<pub-id pub-id-type="pmcid">PMC9803910</pub-id><pub-id pub-id-type="pmid">36618081</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0037"><title>Voysey 2021a {published data only}</title><ref id="CD015477-bib-0050"><mixed-citation id="cit50" publication-type="journal"><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Angus</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name>, et al. <article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial</article-title>. <source>Lancet</source><year>2020</year>;<volume>396</volume>(<issue>10249</issue>):<fpage>467</fpage>-<lpage>78</lpage>. [PMID: <pub-id pub-id-type="pmid">32702298</pub-id>]<pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></mixed-citation></ref><ref id="CD015477-bib-0051"><mixed-citation id="cit51" publication-type="journal"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Clemens</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name>, <name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, et al. <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>(<issue>10269</issue>):<fpage>99</fpage>-<lpage>111</lpage>. [PMID: <pub-id pub-id-type="pmid">33306989</pub-id>]<pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0038"><title>Walsh 2020 {published data only}</title><ref id="CD015477-bib-0052"><mixed-citation id="cit52" publication-type="other"><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Frenck</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, et al. <article-title>RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study</article-title>. <source>medRxiv 2020 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2020.08.17.20176651</pub-id>]</mixed-citation></ref><ref id="CD015477-bib-0053"><mixed-citation id="cit53" publication-type="journal"><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name>, Frenck RW Jr, <name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, et al. <article-title>Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates</article-title>. <source>New England Journal of Medicine</source><year>2020</year>;<volume>383</volume>(<issue>25</issue>):<fpage>2439</fpage>-<lpage>50</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id><pub-id pub-id-type="pmid">33053279</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0039"><title>Wu 2021a {published data only}</title><ref id="CD015477-bib-0054"><mixed-citation id="cit54" publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name>, et al. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>6</issue>):<fpage>803</fpage>-<lpage>12</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30987-7</pub-id><pub-id pub-id-type="pmcid">PMC7906628</pub-id><pub-id pub-id-type="pmid">33548194</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0040"><title>Xia 2020 {published data only}</title><ref id="CD015477-bib-0055"><mixed-citation id="cit55" publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name>, et al. <article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title>. <source>JAMA</source><year>2020</year>;<volume>324</volume>(<issue>10</issue>):<fpage>951</fpage>-<lpage>60</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.15543</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id><pub-id pub-id-type="pmid">32789505</pub-id></mixed-citation></ref><ref id="CD015477-bib-0056"><mixed-citation id="cit56" publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name>, et al. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial</article-title>. <source>Lancet Infectious Diseases</source><year>2020</year>;<volume>21</volume>(<issue>1</issue>):<fpage>39</fpage>-<lpage>51</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id><pub-id pub-id-type="pmid">33069281</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0041"><title>Xia 2021 {published data only}</title><ref id="CD015477-bib-0057"><mixed-citation id="cit57" publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name>, et al. <article-title>Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1/2 trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>22</volume>(<issue>2</issue>):<fpage>196</fpage>-<lpage>208</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00462-X</pub-id><pub-id pub-id-type="pmcid">PMC8443232</pub-id><pub-id pub-id-type="pmid">34536349</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0042"><title>Zhang 2021 {published data only}</title><ref id="CD015477-bib-0058"><mixed-citation id="cit58" publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>K</given-names></name>, et al. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#8211;59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>2</issue>):<fpage>181</fpage>-<lpage>92</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id><pub-id pub-id-type="pmid">33217362</pub-id></mixed-citation></ref></ref-list></ref-list><ref-list id="CD015477-bbs1-0002"><title>References to studies excluded from this review</title><ref-list id="CD015477-bbs2-0043"><title>Baden 2021 {published data only}</title><ref id="CD015477-bib-0059"><mixed-citation id="cit59" publication-type="other"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Essink</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Follmann</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Neuzil</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>August</surname><given-names>A</given-names></name>, et al. <article-title>Covid-19 in the phase 3 trial of mRNA-1273 during the Delta-variant surge</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.17.21263624</pub-id>]<pub-id pub-id-type="pmcid">PMC8609569</pub-id><pub-id pub-id-type="pmid">34731553</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0044"><title>Barrett 2021 {published data only}</title><ref id="CD015477-bib-0060"><mixed-citation id="cit60" publication-type="journal"><name name-style="western"><surname>Barrett</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dold</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Gilbride</surname><given-names>C</given-names></name>, et al. <article-title>Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses</article-title>. <source>Nature Medicine</source><year>2021</year>;<volume>27</volume>(<issue>2</issue>):<fpage>279</fpage>-<lpage>88</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01179-4</pub-id><pub-id pub-id-type="pmid">33335322</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0045"><title>Ewer 2021 {published data only}</title><ref id="CD015477-bib-0061"><mixed-citation id="cit61" publication-type="journal"><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sharpe</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Makinson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Morter</surname><given-names>R</given-names></name>, et al. <article-title>T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial</article-title>. <source>Nature Medicine</source><year>2021</year>;<volume>27</volume>(<issue>2</issue>):<fpage>270</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01194-5</pub-id><pub-id pub-id-type="pmid">33335323</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0046"><title>Flaxman 2021 {published data only}</title><ref id="CD015477-bib-0062"><mixed-citation id="cit62" publication-type="journal"><name name-style="western"><surname>Flaxman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Marchevsky</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Jenkin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Aboagye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Angus</surname><given-names>B</given-names></name>, et al. <article-title>Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomized controlled trials (COV001 and COV002)</article-title>. <source>Lancet</source><year>2021</year>;<volume>398</volume>(<issue>10304</issue>):<fpage>981</fpage>-<lpage>90</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01699-8</pub-id><pub-id pub-id-type="pmcid">PMC8409975</pub-id><pub-id pub-id-type="pmid">34480858</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0047"><title>Hsieh 2021 {published data only}</title><ref id="CD015477-bib-0063"><mixed-citation id="cit63" publication-type="journal"><name name-style="western"><surname>Hsieh</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Lian</surname><given-names>WC</given-names></name>, et al. <article-title>Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC-COV1901) adjuvanted with CpG 1018 and aluminum hydroxide in healthy adults: a phase 1, dose-escalation study</article-title>. <source>eClinicalMedicine</source><year>2021</year>;<volume>38</volume>:<fpage>100989</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.100989</pub-id><pub-id pub-id-type="pmcid">PMC8233066</pub-id><pub-id pub-id-type="pmid">34222848</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0048"><title>Irfan 2021 {published data only}</title><ref id="CD015477-bib-0064"><mixed-citation id="cit64" publication-type="journal"><name name-style="western"><surname>Irfan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chagla</surname><given-names>Z</given-names></name>. <article-title>In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)</article-title>. <source>Annals of Internal Medicine</source><year>2021</year>;<volume>174</volume>(<issue>5</issue>):<fpage>JC50</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/ACPJ202105180-050</pub-id><pub-id pub-id-type="pmid">33939483</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0049"><title>Lazarus 2021 {published data only}</title><ref id="CD015477-bib-0065"><mixed-citation id="cit65" publication-type="other"><name name-style="western"><surname>Lazarus</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Baos</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cappel-Porter</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Carson-Stevens</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Clout</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Culliford</surname><given-names>L</given-names></name>, et al. <article-title>The safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults: a phase IV, multicentre randomized controlled trial with blinding (ComFluCOV)</article-title>. <source>SSRN 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.2139/ssrn.3931758</pub-id>]<pub-id pub-id-type="pmcid">PMC8585490</pub-id><pub-id pub-id-type="pmid">34774197</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0050"><title>Patamatamkul 2021 {published data only}</title><ref id="CD015477-bib-0066"><mixed-citation id="cit66" publication-type="other"><name name-style="western"><surname>Patamatamkul</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Thammawat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Buranrat</surname><given-names>B</given-names></name>. <article-title>Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.25.21264099</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0051"><title>Ward 2021a {published data only}</title><ref id="CD015477-bib-0067"><mixed-citation id="cit67" publication-type="journal"><name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>S&#233;guin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Couillard</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tr&#233;panier</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Landry</surname><given-names>N</given-names></name>. <article-title>Phase III: randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49&#160;years of age</article-title>. <source>Vaccine</source><year>2021</year>;<volume>39</volume>(<issue>10</issue>):<fpage>1528</fpage>-<lpage>33</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.01.004</pub-id><pub-id pub-id-type="pmid">33581920</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0052"><title>Wu 2021b {published data only}</title><ref id="CD015477-bib-0068"><mixed-citation id="cit68" publication-type="other"><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>LZ</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nunna</surname><given-names>N</given-names></name>, et al. <article-title>Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster</article-title>. <source>medRxiv 2021 [Preprint]</source>. [DOI: <pub-id pub-id-type="doi">10.1101/2021.05.05.21256716</pub-id>]<pub-id pub-id-type="pmcid">PMC8604720</pub-id><pub-id pub-id-type="pmid">34526698</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0053"><title>Zdanowski 2021 {published data only}</title><ref id="CD015477-bib-0069"><mixed-citation id="cit69" publication-type="journal"><name name-style="western"><surname>Zdanowski</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wa&#347;niewski</surname><given-names>T</given-names></name>. <article-title>Evaluation of SARS-CoV-2 spike protein antibody titers in cord blood after COVID-19 vaccination during pregnancy in Polish healthcare workers: preliminary results</article-title>. <source>Vaccines</source><year>2021</year>;<volume>9</volume>(<issue>6</issue>):<fpage>675</fpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9060675</pub-id><pub-id pub-id-type="pmcid">PMC8234119</pub-id><pub-id pub-id-type="pmid">34205434</pub-id></mixed-citation></ref></ref-list></ref-list><ref-list id="CD015477-bbs1-0003"><title>Additional references</title><ref-list id="CD015477-bbs2-0054"><title>Abbasi 2020</title><ref id="CD015477-bib-0070"><mixed-citation id="cit70" publication-type="journal"><name name-style="western"><surname>Abbasi</surname><given-names>J</given-names></name>. <article-title>COVID-19 and mRNA vaccines &#8211; first large test for a new approach</article-title>. <source>JAMA</source><year>2020</year>;<volume>324</volume>(<issue>12</issue>):<fpage>1125</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.16866</pub-id><pub-id pub-id-type="pmid">32880613</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0055"><title>Angkasekwinai 2022</title><ref id="CD015477-bib-0071"><mixed-citation id="cit71" publication-type="journal"><name name-style="western"><surname>Angkasekwinai</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sewatanon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Niyomnaitham</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Phumiamorn</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sukapirom</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sapsutthipas</surname><given-names>S</given-names></name>, et al. <article-title>Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers</article-title>. <source>Vaccine X</source><year>2022</year>;<volume>10</volume>:<fpage>100153</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvacx.2022.100153</pub-id><pub-id pub-id-type="pmcid">PMC8896862</pub-id><pub-id pub-id-type="pmid">35282410</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0056"><title>Attaway 2021</title><ref id="CD015477-bib-0072"><mixed-citation id="cit72" publication-type="journal"><name name-style="western"><surname>Attaway</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Scheraga</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Bhimraj</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Biehl</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hatipo&#287;lu</surname><given-names>U</given-names></name>. <article-title>Severe Covid-19 pneumonia: pathogenesis and clinical management</article-title>. <source>BMJ</source><year>2021</year>;<volume>372</volume>:<fpage>n436</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n436</pub-id><pub-id pub-id-type="pmid">33692022</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0057"><title>Baden 2021</title><ref id="CD015477-bib-0073"><mixed-citation id="cit73" publication-type="journal"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Essink</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kotloff</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Frey</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Novak</surname><given-names>R</given-names></name>, et al. <article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>384</volume>(<issue>5</issue>):<fpage>403</fpage>-<lpage>16</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id><pub-id pub-id-type="pmid">33378609</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0058"><title>Balduzzi 2019</title><ref id="CD015477-bib-0074"><mixed-citation id="cit74" publication-type="journal"><name name-style="western"><surname>Balduzzi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>R&#252;cker</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schwarzer</surname><given-names>G</given-names></name>. <article-title>How to perform a meta-analysis with R: a practical tutorial</article-title>. <source>Evidence-Based Mental Health</source><year>2019</year>;<volume>22</volume>:<fpage>153</fpage>-<lpage>60</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ebmental-2019-300117</pub-id><pub-id pub-id-type="pmcid">PMC10231495</pub-id><pub-id pub-id-type="pmid">31563865</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0059"><title>Borobia 2021</title><ref id="CD015477-bib-0075"><mixed-citation id="cit75" publication-type="journal"><name name-style="western"><surname>Borobia</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Carcas</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>P&#233;rez-Olmeda</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Casta&#241;o</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bertran</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Garc&#237;a-P&#233;rez</surname><given-names>J</given-names></name>, et al. <article-title>Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>398</volume>(<issue>10295</issue>):<fpage>121</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01420-3</pub-id><pub-id pub-id-type="pmcid">PMC8233007</pub-id><pub-id pub-id-type="pmid">34181880</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0060"><title>Boutron 2020a</title><ref id="CD015477-bib-0076"><mixed-citation id="cit76" publication-type="journal"><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Meerpohl</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Hr&#243;bjartsson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Devane</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rada</surname><given-names>G</given-names></name>, et al. <article-title>The COVID-NMA Project: building an evidence ecosystem for the COVID-19 pandemic</article-title>. <source>Annals of Internal Medicine</source><year>2020</year>;<volume>173</volume>(<issue>12</issue>):<fpage>1015</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-5261</pub-id><pub-id pub-id-type="pmcid">PMC7518109</pub-id><pub-id pub-id-type="pmid">32931326</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0061"><title>Boutron 2020b</title><ref id="CD015477-bib-0077"><mixed-citation id="cit77" publication-type="journal"><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Meerpohl</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Hr&#243;bjartsson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Devane</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rada</surname><given-names>G</given-names></name>, et al. <article-title>Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review</article-title>. <source>Cochrane Database of Systematic Reviews</source><year>2020</year>, Issue <issue>11</issue>. Art. No: CD013769. [DOI: <pub-id pub-id-type="doi">10.1002/14651858.CD013769</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0062"><title>Bucci 2021</title><ref id="CD015477-bib-0078"><mixed-citation id="cit78" publication-type="journal"><name name-style="western"><surname>Bucci</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Berkhof</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gillibert</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gopalakrishna</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Calogero</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Bouter</surname><given-names>LM</given-names></name>, et al. <article-title>Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>(<issue>10288</issue>):<fpage>1881</fpage>-<lpage>3</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00899-0</pub-id><pub-id pub-id-type="pmcid">PMC9751705</pub-id><pub-id pub-id-type="pmid">33991475</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0063"><title>Bueno 2021</title><ref id="CD015477-bib-0079"><mixed-citation id="cit79" publication-type="other"><name name-style="western"><surname>Bueno</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Abarca</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>G&#225;lvez</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Soto</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Duarte</surname><given-names>LF</given-names></name>, et al. <article-title>Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial</article-title>. <source>medRxiv</source> 2021 [Preprint].</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0064"><title>Cabanac 2021</title><ref id="CD015477-bib-0080"><mixed-citation id="cit80" publication-type="journal"><name name-style="western"><surname>Cabanac</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Oikonomidi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name>. <article-title>Day-to-day discovery of preprint-publication links</article-title>. <source>Scientometrics</source><year>2021</year>;<volume>126</volume>(<issue>6</issue>):<fpage>5285</fpage>-<lpage>304</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11192-021-03900-7</pub-id><pub-id pub-id-type="pmcid">PMC8053368</pub-id><pub-id pub-id-type="pmid">33897069</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0065"><title>Castagneto Gissey 2021</title><ref id="CD015477-bib-0081"><mixed-citation id="cit81" publication-type="other"><name name-style="western"><surname>Castagneto Gissey</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Panunzi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Maltese</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Russo</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Angelini</surname><given-names>G</given-names></name>, <name name-style="western"><surname>De Gaetano</surname><given-names>A</given-names></name>, et al. <article-title>Living systematic meta-analysis of COVID-19 vaccines and dose allocation strategies</article-title>. <source>SSRN</source> &#160;2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.2139/ssrn.3827806</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0066"><title>CDC 2021</title><ref id="CD015477-bib-0082"><mixed-citation id="cit82" publication-type="other"><collab>Centers for Disease Control and Prevention</collab>. <article-title>Understanding mRNA COVID-19 vaccines</article-title>. <source>www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0067"><title>Chaimani 2013</title><ref id="CD015477-bib-0083"><mixed-citation id="cit83" publication-type="journal"><name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Mavridis</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Spyridonos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name>. <article-title>Graphical tools for network meta-analysis in STATA</article-title>. <source>PLOS One&#160;</source><year>2013</year>;<volume>8&#160;</volume>(<issue>10</issue>):<fpage>e76654</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0076654</pub-id><pub-id pub-id-type="pmcid">PMC3789683</pub-id><pub-id pub-id-type="pmid">24098547</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0068"><title>Chaimani 2015</title><ref id="CD015477-bib-0084"><mixed-citation id="cit84" publication-type="journal"><name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name>. <article-title>Visualizing assumptions and results in network meta-analysis: the Network Graphs Package</article-title>. <source>Stata Journal</source><year>2015</year>;<volume>15</volume>(<issue>4</issue>):<fpage>905</fpage>-<lpage>50</lpage>.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0069"><title>Chaimani 2022</title><ref id="CD015477-bib-0085"><mixed-citation id="cit85" publication-type="other"><name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Caldwell</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name>. <article-title>Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022</article-title>. <source>Available from training.cochrane.org/handbook</source>.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0070"><title>Chappell 2021</title><ref id="CD015477-bib-0086"><mixed-citation id="cit86" publication-type="journal"><name name-style="western"><surname>Chappell</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Mordant</surname><given-names>FL</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wijesundara</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Ellenberg</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lackenby</surname><given-names>JA</given-names></name>, et al. <article-title>Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>10</issue>):<fpage>1383</fpage>-<lpage>94</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00200-0</pub-id><pub-id pub-id-type="pmcid">PMC8055208</pub-id><pub-id pub-id-type="pmid">33887208</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0071"><title>Che 2021</title><ref id="CD015477-bib-0087"><mixed-citation id="cit87" publication-type="journal"><name name-style="western"><surname>Che</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Pu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name>, et al. <article-title>Randomized, double-blinded, placebo-controlled Phase 2 trial of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in healthy adults</article-title>. <source>Clinical Infectious Diseases</source><year>2021</year>;<volume>73</volume>(<issue>11</issue>):<fpage>e3949</fpage>-<lpage>55</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa1703</pub-id><pub-id pub-id-type="pmcid">PMC7717222</pub-id><pub-id pub-id-type="pmid">33165503</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0072"><title>Chu 2021</title><ref id="CD015477-bib-0088"><mixed-citation id="cit88" publication-type="journal"><name name-style="western"><surname>Chu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>McPhee</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pajon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nestorova</surname><given-names>B</given-names></name>, et al. <article-title>A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine</article-title>. <source>Vaccine</source><year>2021</year>;<volume>39</volume>(<issue>20</issue>):<fpage>2791</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.02.007</pub-id><pub-id pub-id-type="pmcid">PMC7871769</pub-id><pub-id pub-id-type="pmid">33707061</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0073"><title>Dal&#8208;R&#233; 2021a</title><ref id="CD015477-bib-0089"><mixed-citation id="cit89" publication-type="journal"><name name-style="western"><surname>Dal-R&#233;</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bekker</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Gluud</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Holm</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jha</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Poland</surname><given-names>GA</given-names></name>, et al. <article-title>Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>11</issue>):<fpage>e342</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00263-2</pub-id><pub-id pub-id-type="pmcid">PMC8131060</pub-id><pub-id pub-id-type="pmid">34019801</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0074"><title>Dal&#8208;R&#233; 2021b</title><ref id="CD015477-bib-0090"><mixed-citation id="cit90" publication-type="journal"><name name-style="western"><surname>Dal-R&#233;</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Orenstein</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Caplan</surname><given-names>AL</given-names></name>. <article-title>Being fair to participants in placebo-controlled COVID-19 vaccine trials</article-title>. <source>Nature Medicine</source><year>2021</year>;<volume>27</volume>(<issue>6</issue>):<fpage>938</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01338-1</pub-id><pub-id pub-id-type="pmid">33903751</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0075"><title>DeZure 2016</title><ref id="CD015477-bib-0091"><mixed-citation id="cit91" publication-type="journal"><name name-style="western"><surname>DeZure</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Berkowitz</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Ledgerwood</surname><given-names>JE</given-names></name>. <article-title>Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus</article-title>. <source>Journal of Infectious Diseases</source><year>2016</year>;<volume>214</volume>(<issue>Suppl 5</issue>):<fpage>S497</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiw352</pub-id><pub-id pub-id-type="pmcid">PMC5137244</pub-id><pub-id pub-id-type="pmid">27920180</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0076"><title>Dias 2010</title><ref id="CD015477-bib-0092"><mixed-citation id="cit92" publication-type="journal"><name name-style="western"><surname>Dias</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Welton</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Caldwell</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Ades</surname><given-names>AE</given-names></name>. <article-title>Checking consistency in mixed treatment comparison meta-analysis</article-title>. <source>Statistics in Medicine</source><year>2010</year>;<volume>29</volume>(<issue>7-8</issue>):<fpage>932</fpage>-<lpage>44</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.3767</pub-id><pub-id pub-id-type="pmid">20213715</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0077"><title>Dong 2020</title><ref id="CD015477-bib-0093"><mixed-citation id="cit93" publication-type="journal"><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name>. <article-title>A systematic review of SARS-CoV-2 vaccine candidates</article-title>. <source>Signal Transduction and Targeted Therapy</source><year>2020</year>;<volume>5</volume>(<issue>1</issue>):<fpage>237</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00352-y</pub-id><pub-id pub-id-type="pmcid">PMC7551521</pub-id><pub-id pub-id-type="pmid">33051445</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0078"><title>Egger 1997</title><ref id="CD015477-bib-0094"><mixed-citation id="cit94" publication-type="journal"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname><given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source><year>1997</year>;<volume>315</volume>:<fpage>629</fpage>-<lpage>34</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.315.7109.629</pub-id><pub-id pub-id-type="pmcid">PMC2127453</pub-id><pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0079"><title>Ella 2020b</title><ref id="CD015477-bib-0095"><mixed-citation id="cit95" publication-type="other"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ganneru</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name>, et al. <article-title>Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report</article-title>. <source>medRxiv</source> &#160;2020 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2020.12.21.20248643</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0080"><title>Ella 2021a</title><ref id="CD015477-bib-0096"><mixed-citation id="cit96" publication-type="journal"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ganneru</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name>, et al. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomized, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomized phase 1 trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>7</issue>):<fpage>950</fpage>-<lpage>61</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00070-0</pub-id><pub-id pub-id-type="pmcid">PMC8221739</pub-id><pub-id pub-id-type="pmid">33705727</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0081"><title>Enjuanes 2016</title><ref id="CD015477-bib-0097"><mixed-citation id="cit97" publication-type="journal"><name name-style="western"><surname>Enjuanes</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zu&#241;iga</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Casta&#241;o-Rodriguez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gutierrez-Alvarez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Canton</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sola</surname><given-names>I</given-names></name>. <article-title>Molecular basis of coronavirus virulence and vaccine development</article-title>. <source>Advances in Virus Research</source><year>2016</year>;<volume>96</volume>:<fpage>245</fpage>-<lpage>86</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.aivir.2016.08.003</pub-id><pub-id pub-id-type="pmcid">PMC7112271</pub-id><pub-id pub-id-type="pmid">27712626</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0082"><title>Epistemonikos</title><ref id="CD015477-bib-0098"><mixed-citation id="cit98" publication-type="other">Epistemonikos. <article-title>Epistemonikos L&#183;OVE COVID-19 platform</article-title>. <source>Available at app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?utm=ile</source>.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0083"><title>FDA 2020a</title><ref id="CD015477-bib-0099"><mixed-citation id="cit99" publication-type="other">Food and Drug Administration. <article-title>Development and licensure of vaccines to prevent COVID-19. Guidance for industry; June 2020</article-title>. <source>www.fda.gov/media/139638/download</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0084"><title>FDA 2020b</title><ref id="CD015477-bib-0100"><mixed-citation id="cit100" publication-type="other">Food and Drug Administration. <article-title>FDA Briefing Document Moderna COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting December 17, 2020</article-title>. <source>www.fda.gov/media/144434/download</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0085"><title>FDA 2020c</title><ref id="CD015477-bib-0101"><mixed-citation id="cit101" publication-type="other">Food and Drug Administration. <article-title>FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020</article-title>. <source>www.fda.gov/media/144245/download</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0086"><title>FDA 2021</title><ref id="CD015477-bib-0102"><mixed-citation id="cit102" publication-type="other">Food and Drug Administration. <article-title>FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021</article-title>. <source>www.fda.gov/media/146217/download</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0087"><title>Feikin 2022</title><ref id="CD015477-bib-0103"><mixed-citation id="cit103" publication-type="journal"><name name-style="western"><surname>Feikin</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Higdon</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Araos</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Goldberg</surname><given-names>Y</given-names></name>, et al. <article-title>Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression</article-title>. <source>Lancet</source><year>2022</year>;<volume>399</volume>(<issue>10328</issue>):<fpage>924</fpage>-<lpage>44</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)00152-0</pub-id><pub-id pub-id-type="pmcid">PMC8863502</pub-id><pub-id pub-id-type="pmid">35202601</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0088"><title>Feng 2021</title><ref id="CD015477-bib-0104"><mixed-citation id="cit104" publication-type="other"><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Xing</surname><given-names>R</given-names></name>, et al. <article-title>Safety and Immunogenicity of Inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.08.06.21261696</pub-id>]<pub-id pub-id-type="pmcid">PMC8692079</pub-id><pub-id pub-id-type="pmid">34933684</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0089"><title>Folegatti 2020</title><ref id="CD015477-bib-0105"><mixed-citation id="cit105" publication-type="journal"><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Angus</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name>, et al. <article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title>. <source>Lancet</source><year>2020</year>;<volume>396</volume>:<fpage>467</fpage>-<lpage>78</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id><pub-id pub-id-type="pmid">32702298</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0090"><title>Formica 2021</title><ref id="CD015477-bib-0106"><mixed-citation id="cit106" publication-type="other"><name name-style="western"><surname>Formica</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mallory</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Plested</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>I</given-names></name>, et al, <collab>the 2019nCoV-101 Study Group</collab>. <article-title>Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.02.26.21252482</pub-id>]<pub-id pub-id-type="pmcid">PMC8486115</pub-id><pub-id pub-id-type="pmid">34597298</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0091"><title>Fuenmayor 2017</title><ref id="CD015477-bib-0107"><mixed-citation id="cit107" publication-type="journal"><name name-style="western"><surname>Fuenmayor</surname><given-names>J</given-names></name>, <name name-style="western"><surname>G&#242;dia</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cervera</surname><given-names>L</given-names></name>. <article-title>Production of virus-like particles for vaccines</article-title>. <source>New Biotechnology</source><year>2017</year>;<volume>39</volume>(<issue>Pt B</issue>):<fpage>174</fpage>-<lpage>80</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbt.2017.07.010</pub-id><pub-id pub-id-type="pmcid">PMC7102714</pub-id><pub-id pub-id-type="pmid">28778817</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0092"><title>Gavi 2020</title><ref id="CD015477-bib-0108"><mixed-citation id="cit108" publication-type="other">Gavi. <article-title>What are viral vector-based vaccines and how could they be used against COVID-19?</article-title><source>www.gavi.org/vaccineswork/what-are-viral-vector-based-vaccines-and-how-could-they-be-used-against-covid-19</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0093"><title>Gobeil 2021</title><ref id="CD015477-bib-0109"><mixed-citation id="cit109" publication-type="other"><name name-style="western"><surname>Gobeil</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pillet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>S&#233;guin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boulay</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Mahmood</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vinh</surname><given-names>DC</given-names></name>, et al. <article-title>Interim report of a Phase 2 randomized trial of a plant-produced virus-like particle vaccine for Covid-19 in healthy adults aged 18-64 and older adults aged 65 and older</article-title>. <source>medRxiv</source> &#160;2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.05.14.21257248</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0094"><title>Goepfert 2021</title><ref id="CD015477-bib-0110"><mixed-citation id="cit110" publication-type="journal"><name name-style="western"><surname>Goepfert</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chabanon</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Bonaparte</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Essink</surname><given-names>BJ</given-names></name>, et al. <article-title>Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>9</issue>):<fpage>1257</fpage>-<lpage>70</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00147-X</pub-id><pub-id pub-id-type="pmcid">PMC8055206</pub-id><pub-id pub-id-type="pmid">33887209</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0095"><title>GRADEpro GDT [Computer program]</title><ref id="CD015477-bib-0111"><mixed-citation id="cit111" publication-type="other"><article-title>GRADEpro GDT</article-title>. Version accessed 6 December 2021. Hamilton (ON): <collab>McMaster University (developed by Evidence Prime)</collab>. Available at gradepro.org.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0096"><title>Guyatt 2011</title><ref id="CD015477-bib-0112"><mixed-citation id="cit112" publication-type="journal"><name name-style="western"><surname>Guyatt</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Oxman</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Kunz</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Brozek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Alonso-Coello</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rind</surname><given-names>D</given-names></name>, et al. <article-title>GRADE guidelines 6. Rating the quality of evidence &#8211; imprecision</article-title>. <source>Journal of Clinical Epidemiology</source><year>2011</year>;<volume>64</volume>(<issue>12</issue>):<fpage>1283</fpage>-<lpage>93</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2011.01.012</pub-id><pub-id pub-id-type="pmid">21839614</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0097"><title>Harder 2021</title><ref id="CD015477-bib-0113"><mixed-citation id="cit113" publication-type="journal"><name name-style="western"><surname>Harder</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vygen-Bonnet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kulper-Schiek</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Pilic</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Reda</surname><given-names>S</given-names></name>, et al. <article-title>Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021</article-title>. <source>Eurosurveillance</source><year>2021</year>;<volume>26</volume>(<issue>28</issue>):<fpage>2100563</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2021.26.28.2100563</pub-id><pub-id pub-id-type="pmcid">PMC8284046</pub-id><pub-id pub-id-type="pmid">34269175</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0098"><title>Hayawi 2021</title><ref id="CD015477-bib-0114"><mixed-citation id="cit114" publication-type="journal"><name name-style="western"><surname>Hayawi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Shahriar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Serhani</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Alashwal</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Masud</surname><given-names>MM</given-names></name>. <article-title>Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review</article-title>. <source>Vaccines</source><year>2021</year>;<volume>9</volume>(<issue>11</issue>):<fpage>1305</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9111305</pub-id><pub-id pub-id-type="pmcid">PMC8622454</pub-id><pub-id pub-id-type="pmid">34835238</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0099"><title>Heath 2021&#160;</title><ref id="CD015477-bib-0115"><mixed-citation id="cit115" publication-type="other"><name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Galiza</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Boffito</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Browne</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Burns</surname><given-names>F</given-names></name>, et al. <article-title>Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.1.7 variant</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.05.13.21256639</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0100"><title>Higdon 2021</title><ref id="CD015477-bib-0116"><mixed-citation id="cit116" publication-type="other"><name name-style="western"><surname>Higdon</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Wahl</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Rosen</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Truelove</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Baidya</surname><given-names>A</given-names></name>, et al. <article-title>A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.17.21263549</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0101"><title>Higgins 2021</title><ref id="CD015477-bib-0117"><mixed-citation id="cit117" publication-type="other"><name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chandler</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cumpston</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Welch</surname><given-names>VA</given-names></name>, editor(s). <article-title>Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021</article-title>. <source>Available from training.cochrane.org/handbook/archive/v6.2</source>.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0102"><title>Hobernik 2018</title><ref id="CD015477-bib-0118"><mixed-citation id="cit118" publication-type="journal"><name name-style="western"><surname>Hobernik</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bros</surname><given-names>M</given-names></name>. <article-title>DNA vaccines &#8211; how far from clinical use?</article-title><source>International Journal of Molecular Sciences</source><year>2018</year>;<volume>19</volume>(<issue>11</issue>):<fpage>3605</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id><pub-id pub-id-type="pmid">30445702</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0103"><title>Hultcrantz 2017</title><ref id="CD015477-bib-0119"><mixed-citation id="cit119" publication-type="journal"><name name-style="western"><surname>Hultcrantz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rind</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Akl</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Treweek</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mustafa</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Iorio</surname><given-names>A</given-names></name>, et al. <article-title>The GRADE Working Group clarifies the construct of certainty of evidence</article-title>. <source>Journal of Clinical Epidemiology</source><year>2017</year>;<volume>87</volume>:<fpage>4</fpage>-<lpage>13</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2017.05.006</pub-id><pub-id pub-id-type="pmcid">PMC6542664</pub-id><pub-id pub-id-type="pmid">28529184</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0104"><title>Kirkham 2018</title><ref id="CD015477-bib-0120"><mixed-citation id="cit120" publication-type="journal"><name name-style="western"><surname>Kirkham</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Gamble</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dwan</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Williamson</surname><given-names>PR</given-names></name>. <article-title>Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews</article-title>. <source>BMJ</source><year>2018</year>;<volume>362</volume>:<fpage>k3802</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k3802</pub-id><pub-id pub-id-type="pmcid">PMC6161807</pub-id><pub-id pub-id-type="pmid">30266736</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0105"><title>Korang 2022</title><ref id="CD015477-bib-0121"><mixed-citation id="cit121" publication-type="journal"><name name-style="western"><surname>Korang</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Rohden</surname><given-names>E</given-names><prefix>von</prefix></name>, <name name-style="western"><surname>Veroniki</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ngalamika</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Siddiqui</surname><given-names>F</given-names></name>, et al. <article-title>Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials</article-title>. <source>PLOS One</source><year>2022</year>;<volume>17</volume>(<issue>1</issue>):<fpage>e0260733</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0260733</pub-id><pub-id pub-id-type="pmcid">PMC8782520</pub-id><pub-id pub-id-type="pmid">35061702</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0106"><title>Kow 2022</title><ref id="CD015477-bib-0122"><mixed-citation id="cit122" publication-type="journal"><name name-style="western"><surname>Kow</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Ramachandram</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Hasan</surname><given-names>SS</given-names></name>. <article-title>The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: a systematic review and meta-analysis</article-title>. <source>Journal of Medical Virology</source><year>2022</year>;<volume>94</volume>(<issue>5</issue>):<fpage>2269</fpage>-<lpage>74</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.27568</pub-id><pub-id pub-id-type="pmcid">PMC9015635</pub-id><pub-id pub-id-type="pmid">34978339</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0107"><title>Lazarus 2021</title><ref id="CD015477-bib-0123"><mixed-citation id="cit123" publication-type="other"><name name-style="western"><surname>Lazarus</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Taucher</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>C</given-names></name>, <name name-style="western"><surname>&#268;orbic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Danon</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dubischar</surname><given-names>K</given-names></name>, et al. <article-title>Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.08.13.21262021</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0108"><title>Li 2021b</title><ref id="CD015477-bib-0124"><mixed-citation id="cit124" publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>H</given-names></name>, et al. <article-title>Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study</article-title>. <source>Nature Medicine</source><year>2021</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1062</fpage>-<lpage>70</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01330-9</pub-id><pub-id pub-id-type="pmid">33888900</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0109"><title>Li 2021c</title><ref id="CD015477-bib-0125"><mixed-citation id="cit125" publication-type="other"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name>, et al. <article-title>A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.08.03.21261544</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0110"><title>Liu 2021</title><ref id="CD015477-bib-0126"><mixed-citation id="cit126" publication-type="other"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Greenland</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dinesh</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Provstgaard-Morys</surname><given-names>S</given-names></name>, et al. <article-title>Safety and immunogenicity report from the com-COV study &#8211; a single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine</article-title>. <source>SSRN</source> 2021 [Preprint].<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01694-9</pub-id><pub-id pub-id-type="pmcid">PMC8346248</pub-id><pub-id pub-id-type="pmid">34370971</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0111"><title>Low 2021</title><ref id="CD015477-bib-0127"><mixed-citation id="cit127" publication-type="other"><name name-style="western"><surname>Low</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Alwis</surname><given-names>R</given-names><prefix>de</prefix></name>, <name name-style="western"><surname>Chen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kalimuddin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Leong</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Mah</surname><given-names>TK</given-names></name>, et al. <article-title>A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.07.01.21259831</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0112"><title>Lv 2021</title><ref id="CD015477-bib-0128"><mixed-citation id="cit128" publication-type="journal"><name name-style="western"><surname>Lv</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>E</given-names></name>, et al. <article-title>Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review</article-title>. <source>Vaccines</source><year>2021</year>;<volume>9</volume>(<issue>10</issue>):<fpage>1102</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9101102</pub-id><pub-id pub-id-type="pmcid">PMC8539812</pub-id><pub-id pub-id-type="pmid">34696210</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0113"><title>Madhi 2021</title><ref id="CD015477-bib-0129"><mixed-citation id="cit129" publication-type="other"><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Koen</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cutland</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Baillie</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Padayachee</surname><given-names>SD</given-names></name>, et al. <article-title>ChAdOx1 nCoV-19 (AZD1222) vaccine in people living with and without HIV</article-title>. <source>Research Square</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.21203/rs.3.rs-322470/v1</pub-id>]<pub-id pub-id-type="pmcid">PMC8372504</pub-id><pub-id pub-id-type="pmid">34416193</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0114"><title>Makris 2021</title><ref id="CD015477-bib-0130"><mixed-citation id="cit130" publication-type="journal"><name name-style="western"><surname>Makris</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pavord</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lester</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Scully</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hunt</surname><given-names>B</given-names></name>. <article-title>Vaccine-induced immune thrombocytopenia and thrombosis (VITT)</article-title>. <source>Research and Practice in Thrombosis and Haemostasis</source><year>2021</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e12529</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rth2.12529</pub-id><pub-id pub-id-type="pmcid">PMC8178610</pub-id><pub-id pub-id-type="pmid">34136745</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0115"><title>Mammen 2021</title><ref id="CD015477-bib-0131"><mixed-citation id="cit131" publication-type="other">Mammen MP Jr, <name name-style="western"><surname>Tebas</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Agnes</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Giffear</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kraynyak</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Blackwood</surname><given-names>E</given-names></name>, et al. <article-title>Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.05.07.21256652</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0116"><title>Marshall 2020</title><ref id="CD015477-bib-0132"><mixed-citation id="cit132" publication-type="journal"><name name-style="western"><surname>Marshall</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Murthy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Diaz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Adhikari</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Arabi</surname><given-names>YM</given-names></name>, et al. <article-title>A minimal common outcome measure set for COVID-19 clinical research</article-title>. <source>Lancet Infectious Diseases</source><year>2020</year>;<volume>20</volume>(<issue>8</issue>):<fpage>e192</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30483-7</pub-id><pub-id pub-id-type="pmcid">PMC7292605</pub-id><pub-id pub-id-type="pmid">32539990</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0117"><title>Mavridis 2014</title><ref id="CD015477-bib-0133"><mixed-citation id="cit133" publication-type="journal"><name name-style="western"><surname>Mavridis</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Welton</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name>. <article-title>A selection model for accounting for publication bias in a full network meta-analysis</article-title>. <source>Statistics in Medicine</source><year>2014</year>;<volume>33</volume>(<issue>30</issue>):<fpage>5399</fpage>-<lpage>412</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.6321</pub-id><pub-id pub-id-type="pmid">25316006</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0118"><title>Meng 2021b</title><ref id="CD015477-bib-0134"><mixed-citation id="cit134" publication-type="journal"><name name-style="western"><surname>Meng</surname><given-names>FY</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>XH</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>JX</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>XL</given-names></name>, et al. <article-title>Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials</article-title>. <source>Signal Transduction and Targeted Therapy</source><year>2021</year>;<volume>6</volume>(<issue>1</issue>):<fpage>271</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00692-3</pub-id><pub-id pub-id-type="pmcid">PMC8281021</pub-id><pub-id pub-id-type="pmid">34267185</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0119"><title>Mortola 2004</title><ref id="CD015477-bib-0135"><mixed-citation id="cit135" publication-type="journal"><name name-style="western"><surname>Mortola</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>P</given-names></name>. <article-title>Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system</article-title>. <source>FEBS Letters</source><year>2004</year>;<volume>576</volume>(<issue>1-2</issue>):<fpage>174</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.febslet.2004.09.009</pub-id><pub-id pub-id-type="pmcid">PMC7126153</pub-id><pub-id pub-id-type="pmid">15474033</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0120"><title>Mulligan 2020</title><ref id="CD015477-bib-0136"><mixed-citation id="cit136" publication-type="journal"><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name>, et al. <article-title>Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults</article-title>. <source>Nature</source><year>2020</year>;<volume>586</volume>(<issue>7830</issue>):<fpage>589</fpage>-<lpage>93</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2639-4</pub-id><pub-id pub-id-type="pmid">32785213</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0121"><title>Nguyen 2021</title><ref id="CD015477-bib-0137"><mixed-citation id="cit137" publication-type="other"><name name-style="western"><surname>Nguyen</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Do</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Phan</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Dinh</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Khong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hoang</surname><given-names>LV</given-names></name>, et al. <article-title>Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.07.22.21260942</pub-id>]<pub-id pub-id-type="pmcid">PMC9108376</pub-id><pub-id pub-id-type="pmid">35602004</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0122"><title>Nikolakopoulou 2020</title><ref id="CD015477-bib-0138"><mixed-citation id="cit138" publication-type="journal"><name name-style="western"><surname>Nikolakopoulou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Papakonstantinou</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Del Giovane</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, et al. <article-title>CINeMA: an approach for assessing confidence in the results of a network meta-analysis</article-title>. <source>PLOS Medicine</source><year>2020</year>;<volume>17&#160;</volume>(<issue>4</issue>):<fpage>e1003082</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1003082</pub-id><pub-id pub-id-type="pmcid">PMC7122720</pub-id><pub-id pub-id-type="pmid">32243458</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0123"><title>Oikonomidi 2020</title><ref id="CD015477-bib-0139"><mixed-citation id="cit139" publication-type="journal"><name name-style="western"><surname>Oikonomidi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Pierre</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Cabanac</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ravaud</surname><given-names>P</given-names></name>, <collab>COVID-19 NMA Consortium</collab>. <article-title>Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study</article-title>. <source>BMC Medicine</source><year>2020</year>;<volume>18</volume>(<issue>1</issue>):<fpage>402</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-020-01880-8</pub-id><pub-id pub-id-type="pmcid">PMC7745199</pub-id><pub-id pub-id-type="pmid">33334338</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0124"><title>Ostrowski 2021</title><ref id="CD015477-bib-0140"><mixed-citation id="cit140" publication-type="journal"><name name-style="western"><surname>Ostrowski</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>S&#248;gaard</surname><given-names>OS</given-names></name>, <name name-style="western"><surname>Tolstrup</surname><given-names>M</given-names></name>, <name name-style="western"><surname>St&#230;rke</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>Lundgren</surname><given-names>J</given-names></name>, <name name-style="western"><surname>&#216;stergaard</surname><given-names>L</given-names></name>, et al. <article-title>Inflammation and platelet activation after COVID-19 vaccines &#8211; possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis</article-title>. <source>Frontiers in Immunology</source><year>2021</year>;<volume>12</volume>:<fpage>779453</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.779453</pub-id><pub-id pub-id-type="pmcid">PMC8649717</pub-id><pub-id pub-id-type="pmid">34887867</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0125"><title>Ouzzani 2016</title><ref id="CD015477-bib-0141"><mixed-citation id="cit141" publication-type="journal"><name name-style="western"><surname>Ouzzani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hammady</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fedorowicz</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Elmagarmid</surname><given-names>A</given-names></name>. <article-title>Rayyanv &#8211; a web and mobile app for systematic reviews</article-title>. <source>Systematic Reviews</source><year>2016</year>;<volume>5</volume>(<issue>1</issue>):<fpage>210</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13643-016-0384-4</pub-id><pub-id pub-id-type="pmcid">PMC5139140</pub-id><pub-id pub-id-type="pmid">27919275</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0126"><title>Oxford Vaccine Group 2020</title><ref id="CD015477-bib-0142"><mixed-citation id="cit142" publication-type="other"><collab>Oxford Vaccine Group</collab>. <article-title>Vaccine Knowledge Project: independent information about vaccines and infectious diseases</article-title>. <source>vk.ovg.ox.ac.uk/vk</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0127"><title>Page 2021</title><ref id="CD015477-bib-0143"><mixed-citation id="cit143" publication-type="journal"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></name>, et al. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source><year>2021</year>;<volume>372</volume>:<fpage>n71</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id><pub-id pub-id-type="pmid">33782057</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0128"><title>Pajon 2021</title><ref id="CD015477-bib-0144"><mixed-citation id="cit144" publication-type="other"><name name-style="western"><surname>Pajon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Paila</surname><given-names>YD</given-names></name>, <name name-style="western"><surname>Girard</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dixon</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kacena</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name>, et al. <article-title>Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.28.21264252</pub-id>]<pub-id pub-id-type="pmcid">PMC9018421</pub-id><pub-id pub-id-type="pmid">35145311</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0129"><title>Pan 2021a</title><ref id="CD015477-bib-0145"><mixed-citation id="cit145" publication-type="other"><name name-style="western"><surname>Pan</surname><given-names>HX</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>BY</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>XY</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>YF</given-names></name>, et al. <article-title>Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (KCONVAC) in healthy adults: two randomized, double-blind, and placebo-controlled Phase 1/2 clinical trials</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.04.07.21253850</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0130"><title>Pan 2021b</title><ref id="CD015477-bib-0146"><mixed-citation id="cit146" publication-type="other"><name name-style="western"><surname>Pan</surname><given-names>HX</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>QH</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>XW</given-names></name>, &#160;et al. <article-title>Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18&#8211;59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.07.23.21261026</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0131"><title>P&#233;rez&#8208;Rodr&#237;guez 2021</title><ref id="CD015477-bib-0147"><mixed-citation id="cit147" publication-type="other"><name name-style="western"><surname>P&#233;rez-Rodr&#237;guez</surname><given-names>S</given-names></name>, <name name-style="western"><surname>la Caridad Rodr&#237;guez-Gonz&#225;lez</surname><given-names>M</given-names><prefix>de</prefix></name>, <name name-style="western"><surname>Ochoa-Azze</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Climent-Ruiz</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Alberto Gonz&#225;lez-Delgado</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Paredes-Moreno</surname><given-names>B</given-names></name>, et al. <article-title>A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.10.04.21264522</pub-id>]<pub-id pub-id-type="pmcid">PMC8823954</pub-id><pub-id pub-id-type="pmid">35164986</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0132"><title>Pitisuttithum 2021</title><ref id="CD015477-bib-0148"><mixed-citation id="cit148" publication-type="other"><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Luvira</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lawpoolsri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Muangnoicharoen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kamolratanakul</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sivakorn</surname><given-names>C</given-names></name>, et al. <article-title>Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, Phase 1/2 trial</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.17.21263758</pub-id>]<pub-id pub-id-type="pmcid">PMC8903824</pub-id><pub-id pub-id-type="pmid">35284808</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0133"><title>Polack 2020</title><ref id="CD015477-bib-0149"><mixed-citation id="cit149" publication-type="journal"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name>, et al. <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title>. <source>New England Journal of Medicine</source><year>2020</year>;<volume>383</volume>(<issue>27</issue>):<fpage>2603</fpage>-<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0134"><title>Pollard 2021</title><ref id="CD015477-bib-0150"><mixed-citation id="cit150" publication-type="journal"><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Bijker</surname><given-names>EM</given-names></name>. <article-title>A guide to vaccinology: from basic principles to new developments</article-title>. <source>Nature Reviews Immunology</source><year>2021</year>;<volume>21</volume>(<issue>2</issue>):<fpage>83</fpage>-<lpage>100</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-00479-7</pub-id><pub-id pub-id-type="pmcid">PMC7754704</pub-id><pub-id pub-id-type="pmid">33353987</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0135"><title>Pu 2021</title><ref id="CD015477-bib-0151"><mixed-citation id="cit151" publication-type="journal"><name name-style="western"><surname>Pu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>Q</given-names></name>, et al. <article-title>The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18&#8211;59 years: a phase I randomized, double-blinded, controlled trial</article-title>. <source>Vaccine</source><year>2021</year>;<volume>39</volume>(<issue>20</issue>):<fpage>2746</fpage>-<lpage>54</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.04.006</pub-id><pub-id pub-id-type="pmcid">PMC8040531</pub-id><pub-id pub-id-type="pmid">33875266</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0136"><title>Qiao 2020</title><ref id="CD015477-bib-0152"><mixed-citation id="cit152" publication-type="journal"><name name-style="western"><surname>Qiao</surname><given-names>J</given-names></name>. <article-title>What are the risks of COVID-19 infection in pregnant women?</article-title><source>Lancet</source><year>2020</year>;<volume>395</volume>(<issue>10226</issue>):<fpage>760</fpage>-<lpage>2</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30365-2</pub-id><pub-id pub-id-type="pmcid">PMC7158939</pub-id><pub-id pub-id-type="pmid">32151334</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0137"><title>Ramasamy 2020</title><ref id="CD015477-bib-0153"><mixed-citation id="cit153" publication-type="journal"><name name-style="western"><surname>Ramasamy</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Flaxman</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Owens</surname><given-names>DR</given-names></name>, et al. <article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial</article-title>. <source>Lancet</source><year>2020</year>;<volume>396</volume>(<issue>10267</issue>):<fpage>1979</fpage>-<lpage>93</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id><pub-id pub-id-type="pmid">33220855</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0138"><title>Richmond 2021</title><ref id="CD015477-bib-0154"><mixed-citation id="cit154" publication-type="journal"><name name-style="western"><surname>Richmond</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hatchuel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Smolenov</surname><given-names>I</given-names></name>, et al. <article-title>Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomized, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>(<issue>10275</issue>):<fpage>682</fpage>-<lpage>94</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00241-5</pub-id><pub-id pub-id-type="pmcid">PMC7906655</pub-id><pub-id pub-id-type="pmid">33524311</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0139"><title>Riley 2011</title><ref id="CD015477-bib-0155"><mixed-citation id="cit155" publication-type="journal"><name name-style="western"><surname>Riley</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Deeks</surname><given-names>JJ</given-names></name>. <article-title>Interpretation of random effects meta-analyses</article-title>. <source>BMJ</source><year>2011</year>;<volume>342</volume>:<fpage>d549</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.d549</pub-id><pub-id pub-id-type="pmid">21310794</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0140"><title>Rizk 2021</title><ref id="CD015477-bib-0156"><mixed-citation id="cit156" publication-type="journal"><name name-style="western"><surname>Rizk</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sardar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Henry</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Lewin</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name>, et al. <article-title>Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review</article-title>. <source>JAMA Cardiology</source><year>2021</year>;<volume>6</volume>(<issue>12</issue>):<fpage>1451</fpage>-<lpage>60</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamacardio.2021.3444</pub-id><pub-id pub-id-type="pmid">34374713</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0141"><title>Roozen 2021</title><ref id="CD015477-bib-0157"><mixed-citation id="cit157" publication-type="other"><name name-style="western"><surname>Roozen</surname><given-names>GV</given-names></name>, <name name-style="western"><surname>Prins</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Binnendijk</surname><given-names>R</given-names><prefix>van</prefix></name>, <name name-style="western"><surname>den Hartog</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kuiper</surname><given-names>VP</given-names></name>, <name name-style="western"><surname>Prins</surname><given-names>C</given-names></name>, et al. <article-title>Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.07.27.21261116</pub-id>]</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0142"><title>Roper 2009</title><ref id="CD015477-bib-0158"><mixed-citation id="cit158" publication-type="journal"><name name-style="western"><surname>Roper</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Rehm</surname><given-names>KE</given-names></name>. <article-title>SARS vaccines: where are we?</article-title><source>Expert Review of Vaccines</source><year>2009</year>;<volume>8</volume>(<issue>7</issue>):<fpage>887</fpage>-<lpage>98</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.09.43</pub-id><pub-id pub-id-type="pmcid">PMC7105754</pub-id><pub-id pub-id-type="pmid">19538115</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0143"><title>Rotshild 2021</title><ref id="CD015477-bib-0159"><mixed-citation id="cit159" publication-type="journal"><name name-style="western"><surname>Rotshild</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Hirsh-Raccah</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Miskin</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Muszkat</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Matok</surname><given-names>I</given-names></name>. <article-title>Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis</article-title>. <source>Scientific Reports</source><year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>22777</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-02321-z</pub-id><pub-id pub-id-type="pmcid">PMC8611039</pub-id><pub-id pub-id-type="pmid">34815503</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0144"><title>Rubin 2013</title><ref id="CD015477-bib-0160"><mixed-citation id="cit160" publication-type="journal"><name name-style="western"><surname>Rubin</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Levin</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Ljungman</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Avery</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tomblyn</surname><given-names>M</given-names></name>, et al. <article-title>2013 IDSA clinical practice guideline for vaccination of the immunocompromized host</article-title>. <source>Clinical Infectious Diseases</source><year>2013</year>;<volume>58</volume>(<issue>3</issue>):<fpage>e44</fpage>-<lpage>e100</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cit684</pub-id><pub-id pub-id-type="pmid">24311479</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0145"><title>Rucker 2013</title><ref id="CD015477-bib-0161"><mixed-citation id="cit161" publication-type="other"><name name-style="western"><surname>Rucker</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schwarzer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>R&#252;cker</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schwarzer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Krahn</surname><given-names>U</given-names></name>, <name name-style="western"><surname>K&#246;nig</surname><given-names>J</given-names></name>. <article-title>Network meta-analysis using frequentist methods &#8211; package netmeta</article-title>. <source>cran.r&#8211;project.org</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0146"><title>Ryzhikov 2021</title><ref id="CD015477-bib-0162"><mixed-citation id="cit162" publication-type="journal"><name name-style="western"><surname>Ryzhikov</surname><given-names>AB</given-names></name>, Ryzhikov &#1045;&#1040;, <name name-style="western"><surname>Bogryantseva</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Usova</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Danilenko</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Nechaeva</surname><given-names>EA</given-names></name>, et al. <article-title>A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" vaccine for the prevention of COVID-19</article-title>. <source>Russian Journal of Infection and Immunity</source><year>2021</year>;<volume>11</volume>(<issue>2</issue>):<fpage>283</fpage>-<lpage>96</lpage>.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0147"><title>Sadoff 2020c</title><ref id="CD015477-bib-0163"><mixed-citation id="cit163" publication-type="other"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Heerwegh</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Truyers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Groot</surname><given-names>AM</given-names><prefix>de</prefix></name>, et al. <article-title>Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial</article-title>. <source>MedRxiv</source> 2020 [Preprint].</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0148"><title>Salanti 2011</title><ref id="CD015477-bib-0164"><mixed-citation id="cit164" publication-type="journal"><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ades</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Ioannidis</surname><given-names>JP</given-names></name>. <article-title>Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial</article-title>. <source>Journal of Clinical Epidemiology</source><year>2011</year>;<volume>64</volume>(<issue>2</issue>):<fpage>163</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2010.03.016</pub-id><pub-id pub-id-type="pmid">20688472</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0149"><title>Sch&#252;nemann 2021</title><ref id="CD015477-bib-0165"><mixed-citation id="cit165" publication-type="other"><name name-style="western"><surname>Sch&#252;nemann</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Vist</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Glasziou</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Akl</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Skoetz</surname><given-names>N</given-names></name>, et al. <article-title>Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021</article-title>. <source>Available from training.cochrane.org/handbook/archive/v6.2</source>.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0150"><title>Sharifian&#8208;Dorche 2021</title><ref id="CD015477-bib-0166"><mixed-citation id="cit166" publication-type="journal"><name name-style="western"><surname>Sharifian-Dorche</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bahmanyar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sharifian-Dorche</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mohammadi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nomovi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mowla</surname><given-names>A</given-names></name>. <article-title>Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review</article-title>. <source>Journal of the Neurological Sciences</source><year>2021</year>;<volume>428</volume>:<fpage>117607</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2021.117607</pub-id><pub-id pub-id-type="pmcid">PMC8330139</pub-id><pub-id pub-id-type="pmid">34365148</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0151"><title>Shinde 2021</title><ref id="CD015477-bib-0167"><mixed-citation id="cit167" publication-type="other"><name name-style="western"><surname>Shinde</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bhikha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hoosain</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Archary</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bhorat</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name>, et al, <collab>for the 2019nCoV-501 Study Group</collab>. <article-title>Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant</article-title>. <source>medRxiv</source> 2021 [Preprint].<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2103055</pub-id><pub-id pub-id-type="pmcid">PMC8091623</pub-id><pub-id pub-id-type="pmid">33951374</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0152"><title>Shu 2021</title><ref id="CD015477-bib-0168"><mixed-citation id="cit168" publication-type="journal"><name name-style="western"><surname>Shu</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>He</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>He</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>ZH</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>SM</given-names></name>, et al. <article-title>Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial</article-title>. <source>Chinese Medical Journal</source><year>2021</year>;<volume>134</volume>(<issue>16</issue>):<fpage>1967</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000001702</pub-id><pub-id pub-id-type="pmcid">PMC8382383</pub-id><pub-id pub-id-type="pmid">34310400</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0153"><title>Sridhar 2021</title><ref id="CD015477-bib-0169"><mixed-citation id="cit169" publication-type="other"><name name-style="western"><surname>Sridhar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Joaquin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bonaparte</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Bueso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chabanon</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>A</given-names></name>, et al. <article-title>Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.10.08.21264302</pub-id>]<pub-id pub-id-type="pmcid">PMC8789245</pub-id><pub-id pub-id-type="pmid">35090638</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0154"><title>Stephenson 2021</title><ref id="CD015477-bib-0170"><mixed-citation id="cit170" publication-type="journal"><name name-style="western"><surname>Stephenson</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Groot</surname><given-names>AM</given-names><prefix>de</prefix></name>, <name name-style="western"><surname>Heerwegh</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Truyers</surname><given-names>C</given-names></name>, et al. <article-title>Immunogenicity of the Ad26.COV2.S vaccine for COVID-19</article-title>. <source>JAMA</source><year>2021</year>;<volume>325</volume>(<issue>15</issue>):<fpage>1535</fpage>-<lpage>44</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.3645</pub-id><pub-id pub-id-type="pmcid">PMC7953339</pub-id><pub-id pub-id-type="pmid">33704352</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0155"><title>Sterne 2019</title><ref id="CD015477-bib-0171"><mixed-citation id="cit171" publication-type="journal"><name name-style="western"><surname>Sterne</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Savovi&#263;</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Elbers</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Blencowe</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name>, et al. <article-title>RoB 2: a revised tool for assessing risk of bias in randomized trials</article-title>. <source>BMJ</source><year>2019</year>;<volume>366</volume>:<fpage>l4898</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.l4898</pub-id><pub-id pub-id-type="pmid">31462531</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0156"><title>Thomas 2021</title><ref id="CD015477-bib-0172"><mixed-citation id="cit172" publication-type="other"><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Moreira</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name>, et al. <article-title>Six month safety and efficacy of the BNT162b2 Mrna Covid-19 vaccine</article-title>. <source>medRxiv</source> 2021 [Preprint].<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2110345</pub-id><pub-id pub-id-type="pmcid">PMC8461570</pub-id><pub-id pub-id-type="pmid">34525277</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0157"><title>Turner 2012</title><ref id="CD015477-bib-0173"><mixed-citation id="cit173" publication-type="journal"><name name-style="western"><surname>Turner</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Davey</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Clarke</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>. <article-title>Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews</article-title>. <source>International Journal of Epidemiology</source><year>2012</year>;<volume>41</volume>(<issue>3</issue>):<fpage>818</fpage>-<lpage>27</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dys041</pub-id><pub-id pub-id-type="pmcid">PMC3396310</pub-id><pub-id pub-id-type="pmid">22461129</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0158"><title>van Riel 2020</title><ref id="CD015477-bib-0174"><mixed-citation id="cit174" publication-type="journal"><name name-style="western"><surname>Riel</surname><given-names>D</given-names><prefix>van</prefix></name>, <name name-style="western"><surname>Wit</surname><given-names>E</given-names><prefix>de</prefix></name>. <article-title>Next-generation vaccine platforms for COVID-19</article-title>. <source>Nature Materials</source><year>2020</year>;<volume>19</volume>(<issue>8</issue>):<fpage>810</fpage>-<lpage>2</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41563-020-0746-0</pub-id><pub-id pub-id-type="pmid">32704139</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0159"><title>Viechtbauer 2010</title><ref id="CD015477-bib-0175"><mixed-citation id="cit175" publication-type="journal"><name name-style="western"><surname>Viechtbauer</surname><given-names>W</given-names></name>. <article-title>Conducting meta-analyses in R with the metafor package</article-title>. <source>Journal of Statistical Software</source><year>2010</year>;<volume>36</volume>(<issue>3</issue>):<fpage>1</fpage>-<lpage>48</lpage>.</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0160"><title>Voysey 2021b</title><ref id="CD015477-bib-0176"><mixed-citation id="cit176" publication-type="journal"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Costa Clemens</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name>, <name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name>, et al. <article-title>Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomized trials</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>(<issue>10277</issue>):<fpage>881</fpage>-<lpage>91</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00432-3</pub-id><pub-id pub-id-type="pmcid">PMC7894131</pub-id><pub-id pub-id-type="pmid">33617777</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0161"><title>Walsh 2021</title><ref id="CD015477-bib-0177"><mixed-citation id="cit177" publication-type="other"><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Frenck</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name>, et al. <article-title>RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study</article-title>. <source>medRxiv</source> 2021 [Preprint].</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0162"><title>Ward 2021b</title><ref id="CD015477-bib-0178"><mixed-citation id="cit178" publication-type="journal"><name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Gobeil</surname><given-names>P</given-names></name>, <name name-style="western"><surname>S&#233;guin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Atkins</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Boulay</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Charbonneau</surname><given-names>PY</given-names></name>, et al. <article-title>Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19</article-title>. <source>Nature Medicine</source><year>2021</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1071</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01370-1</pub-id><pub-id pub-id-type="pmcid">PMC8205852</pub-id><pub-id pub-id-type="pmid">34007070</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0163"><title>White 2008</title><ref id="CD015477-bib-0179"><mixed-citation id="cit179" publication-type="journal"><name name-style="western"><surname>White</surname><given-names>IR</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>AM</given-names></name>. <article-title>Allowing for uncertainty due to missing data in meta-analysis &#8211; part 1: two-stage methods</article-title>. <source>Statistics in Medicine</source><year>2008</year>;<volume>27</volume>(<issue>5</issue>):<fpage>711</fpage>-<lpage>27</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.3008</pub-id><pub-id pub-id-type="pmid">17703496</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0164"><title>WHO 2020a</title><ref id="CD015477-bib-0180"><mixed-citation id="cit180" publication-type="other"><collab>World Health Organization</collab>. <article-title>Coronavirus disease 2019 (COVID-19). Situation report &#8211; 51</article-title>. <source>apps.who.int/iris/handle/10665/331475</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0165"><title>WHO 2020b</title><ref id="CD015477-bib-0181"><mixed-citation id="cit181" publication-type="other"><collab>World Health Organization</collab>. <article-title>Considerations for evaluation of COVID19 vaccines. Points to consider for manufacturers of COVID-19 vaccines. Version 24 September 2020</article-title>. <source>www.who.int/docs/default-source/in-vitro-diagnostics/covid19/who-evaluation-covid-vaccine-w-lines.pdf?sfvrsn=701d3a65_2</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0166"><title>WHO 2020c</title><ref id="CD015477-bib-0182"><mixed-citation id="cit182" publication-type="other"><collab>World Health Organization</collab>. <article-title>WHO target product profiles for COVID-19 vaccines. Version 3 &#8211; 29 April 2020</article-title>. <source>www.who.int/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0167"><title>WHO 2022a</title><ref id="CD015477-bib-0183"><mixed-citation id="cit183" publication-type="other"><collab>World Health Organization</collab>. <article-title>Tracking SARS-CoV-2 variants</article-title>. <source>www.who.int/activities/tracking-SARS-CoV-2-variants</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0168"><title>WHO 2022b</title><ref id="CD015477-bib-0184"><mixed-citation id="cit184" publication-type="other"><collab>World Health Organization</collab>. <article-title>COVID-19 vaccine tracker and landscape</article-title>. <source>www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0169"><title>WHO Ad Hoc Expert Group 2021</title><ref id="CD015477-bib-0185"><mixed-citation id="cit185" publication-type="journal"><collab>WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation</collab>. <article-title>Placebo-controlled trials of covid-19 vaccines &#8211; why we still need them</article-title>. <source>New England Journal of Medicine</source><year>2021</year>;<volume>384</volume>:<fpage>e2</fpage>. [DOI: <pub-id pub-id-type="doi">10.1056/NEJMp2033538</pub-id>]<pub-id pub-id-type="pmid">33264543</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0170"><title>Worldometer 2022</title><ref id="CD015477-bib-0186"><mixed-citation id="cit186" publication-type="other">Worldometer. <article-title>COVID-19 coronavirus pandemic</article-title>. <source>www.worldometers.info/coronavirus/#countries</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0171"><title>Wu 2021c</title><ref id="CD015477-bib-0187"><mixed-citation id="cit187" publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>H</given-names></name>, et al. <article-title>Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1654</fpage>-<lpage>64</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00396-0</pub-id><pub-id pub-id-type="pmcid">PMC8313090</pub-id><pub-id pub-id-type="pmid">34324836</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0172"><title>Xia 2020</title><ref id="CD015477-bib-0188"><mixed-citation id="cit188" publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name>, et al. <article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title>. <source>JAMA</source><year>2020</year>;<volume>324</volume>(<issue>10</issue>):<fpage>951</fpage>-<lpage>60</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.15543</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id><pub-id pub-id-type="pmid">32789505</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0173"><title>Yang 2021</title><ref id="CD015477-bib-0189"><mixed-citation id="cit189" publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>He</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, et al. <article-title>Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomized, double-blind, placebo-controlled, phase 1 and 2 trials</article-title>. <source>Lancet Infectious Diseases</source><year>2021</year>;<volume>21</volume>(<issue>8</issue>):<fpage>1107</fpage>-<lpage>19</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00127-4</pub-id><pub-id pub-id-type="pmcid">PMC7990482</pub-id><pub-id pub-id-type="pmid">33773111</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0174"><title>Yepes&#8208;Nu&#241;ez 2019</title><ref id="CD015477-bib-0190"><mixed-citation id="cit190" publication-type="journal"><name name-style="western"><surname>Yepes-Nu&#241;ez</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Guyatt</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Jack</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Brozek</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Beyene</surname><given-names>J</given-names></name>, et al. <article-title>Development of the summary of findings table for network meta-analysis</article-title>. <source>Journal of Clinical Epidemiology</source><year>2019</year>;<volume>115</volume>:<fpage>1</fpage>-<lpage>13</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2019.04.018</pub-id><pub-id pub-id-type="pmid">31055177</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0175"><title>Zakarya 2021</title><ref id="CD015477-bib-0191"><mixed-citation id="cit191" publication-type="journal"><name name-style="western"><surname>Zakarya</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kutumbetov</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Orynbayev</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Abduraimov</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sultankulova</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kassenov</surname><given-names>M</given-names></name>, et al. <article-title>A single-centre, randomized, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan</article-title>. <source>EClinicalMedicine</source><year>2021</year>;<volume>39</volume>:<fpage>101078</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101078</pub-id><pub-id pub-id-type="pmcid">PMC8363482</pub-id><pub-id pub-id-type="pmid">34414368</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0176"><title>Zeng 2021a</title><ref id="CD015477-bib-0192"><mixed-citation id="cit192" publication-type="journal"><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Brignardello-Petersen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hultcrantz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Siemieniuk</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Santesso</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Traversy</surname><given-names>G</given-names></name>, et al. <article-title>GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings</article-title>. <source>Journal of Clinical Epidemiology</source><year>2021</year>;<volume>137</volume>:<fpage>163</fpage>-<lpage>75</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2021.03.026</pub-id><pub-id pub-id-type="pmid">33857619</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0177"><title>Zeng 2021b</title><ref id="CD015477-bib-0193"><mixed-citation id="cit193" publication-type="other"><name name-style="western"><surname>Zeng</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>F</given-names></name>. <article-title>Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis</article-title>. <source>medRxiv</source> 2021 [Preprint]. [DOI: <pub-id pub-id-type="doi">10.1101/2021.09.23.21264048</pub-id>]<pub-id pub-id-type="pmcid">PMC9126103</pub-id><pub-id pub-id-type="pmid">35606843</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0178"><title>Zhang 2021b</title><ref id="CD015477-bib-0194"><mixed-citation id="cit194" publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>R</given-names></name>, et al. <article-title>Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial</article-title>. <source>Emerging Microbes &amp; Infections</source><year>2021</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1589</fpage>-<lpage>97</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2021.1951126</pub-id><pub-id pub-id-type="pmcid">PMC8366678</pub-id><pub-id pub-id-type="pmid">34197281</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0179"><title>Zhu 2020</title><ref id="CD015477-bib-0195"><mixed-citation id="cit195" publication-type="journal"><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>LH</given-names></name>, et al. <article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial</article-title>. <source>Lancet</source><year>2020</year>;<volume>396</volume>(<issue>10249</issue>):<fpage>479</fpage>-<lpage>88</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id><pub-id pub-id-type="pmid">32702299</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0180"><title>Zhu 2021a</title><ref id="CD015477-bib-0196"><mixed-citation id="cit196" publication-type="other"><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>H</given-names></name>, et al. <article-title>Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomized, double-blind, placebo-controlled, phase 2b trial</article-title>. <source>Clinical Infectious Diseases</source><year>2022</year>;<volume>75</volume>(<issue>1</issue>):<fpage>e783</fpage>-<lpage>91</lpage>. [DOI: <pub-id pub-id-type="doi">10.1093/cid/ciab845</pub-id>]<pub-id pub-id-type="pmcid">PMC8522421</pub-id><pub-id pub-id-type="pmid">34551104</pub-id></mixed-citation></ref></ref-list><ref-list id="CD015477-bbs2-0181"><title>Zhu 2022</title><ref id="CD015477-bib-0197"><mixed-citation id="cit197" publication-type="journal"><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>H</given-names></name>, et al. <article-title>Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomized, double-blind, placebo-controlled, phase 2b trial</article-title>. <source>Clinical Infectious Diseases</source><year>2022</year>;<volume>75</volume>(<issue>1</issue>):<fpage>e783</fpage>-<lpage>91</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciab845</pub-id><pub-id pub-id-type="pmcid">PMC8522421</pub-id><pub-id pub-id-type="pmid">34551104</pub-id></mixed-citation></ref></ref-list></ref-list><ref-list id="CD015477-bbs1-0004"><title>References to other published versions of this review</title><ref-list id="CD015477-bbs2-0182"><title>Grana 2021</title><ref id="CD015477-bib-0198"><mixed-citation id="cit198" publication-type="other"><name name-style="western"><surname>Grana</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ghosn</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name>. <article-title>Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis. PROSPERO 2021 CRD42021271897</article-title>. <source>www.crd.york.ac.uk/prospero/display_record.php?RecordID=271897</source> (accessed prior to 1 November 2022).</mixed-citation></ref></ref-list></ref-list></ref-list></back></article></pmc-articleset>